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Supplement
Abstract: The 2020 Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline on the Evaluation and 
Management of Candidates for Kidney Transplantation is intended to assist health care professionals worldwide who evaluate 
and manage potential candidates for deceased or living donor kidney transplantation. This guideline addresses general candidacy 
issues such as access to transplantation, patient demographic and health status factors, and immunological and psychosocial 
assessment. The roles of various risk factors and comorbid conditions governing an individual’s suitability for transplantation such 
as adherence, tobacco use, diabetes, obesity, perioperative issues, causes of kidney failure, infections, malignancy, pulmonary 
disease, cardiac and peripheral arterial disease, neurologic disease, gastrointestinal and liver disease, hematologic disease, and 
bone and mineral disorder are also addressed. This guideline provides recommendations for evaluation of individual aspects of a 
candidate’s profile such that each risk factor and comorbidity are considered separately. The goal is to assist the clinical team to 
assimilate all data relevant to an individual, consider this within their local health context, and make an overall judgment on candi-
dacy for transplantation. The guideline development process followed the Grades of Recommendation Assessment, Development, 
and Evaluation (GRADE) approach. Guideline recommendations are primarily based on systematic reviews of relevant studies and 
our assessment of the quality of that evidence, and the strengths of recommendations are provided. Limitations of the evidence 
are discussed with differences from previous guidelines noted and suggestions for future research are also provided.
Keywords: albuminuria; adherence; bone and mineral metabolism; candidates; CKD-MBD; clinical practice guideline; 
cancer; cardiac disease; compatibility; diabetes mellitus; end-stage kidney disease; evidence-based recommendation; gas-
trointestinal disease; genetic kidney disease; hematuria; hematological disorders; HLA; immunological assessment; infec-
tious diseases; KDIGO; kidney transplantation; liver disease; malignancy; mineral and bone disorder; neurologic disease; 
obesity; pediatric; perioperative; peripheral arterial disease; pulmonary disease; psychosocial; systematic review; tobacco
(Transplantation 2020;104: S1–S103)
In citing this document, the following format should be used: Kidney Disease: Improving Global Outcomes (KDIGO) Kidney 
Transplant Candidate Work Group. KDIGO Clinical Practice Guideline on the Evaluation and Management of Candidates for 
Kidney Transplantation. Transplantation. 2020;104: S1–S103.
SUMMARY OF RECOMMENDATION STATEMENTS
SECTION 1: ACCESS TO TRANSPLANTATION
 1.1: We recommend that all patients with chronic kidney dis-
ease (CKD) G4-G5 (glomerular filtration rate [GFR] < 
30 ml/min/1.73 m2) who are expected to reach end-stage 
kidney disease (ESKD) (excluding those listed in Rec 
1.1.3) be informed of, educated about, and considered 
for kidney transplantation regardless of socioeconomic 
status, sex, gender identity, or race/ethnicity (1D).
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 1.1.1: Refer potential kidney transplant candidates for 
evaluation at least 6 to 12 months before antici-
pated dialysis initiation to facilitate identification/
work-up of living donors and plan for possible 
pre-emptive transplantation (Not Graded).
 1.1.2: Refer potential candidates already on dialy-
sis when medically stable and kidney failure 
deemed irreversible (Not Graded).
 1.1.3: We recommend not referring patients for kid-
ney alone transplant evaluation with the fol-
lowing conditions (1D):
 • Multiple myeloma (Rec 9.13.1.1), light 
chain deposition disease or heavy chain 
deposition disease (Recs 9.13.2.1, 9.13.2.2 
and 9.13.2.3) unless they have received a 
potentially curative treatment regimen and 
are in stable remission;
 • AL amyloidosis with significant extrarenal 
involvement (Recs 9.13.3.1 and 13.8);
 • Decompensated cirrhosis (consider for 
combined liver-kidney transplant; Recs 
10.5.2.4.2, 16.7.2);
 • Severe irreversible obstructive or restrictive 
lung disease (Rec 12.5);
 • Severe uncorrectable and symptomatic car-
diac disease that is deemed by a cardiolo-
gist to preclude transplantation (Rec 13.7);
 • Progressive central neurodegenerative dis-
ease (Rec 15.4).
 1.1.3.1: Document the reason(s) for not refer-
ring patients for transplant evalua-
tion (Not Graded).
 1.1.3.2: Inform patients about the reason(s) 
for not referring for transplant evalu-
ation (Not Graded).
 1.1.4 We recommend delaying transplant evalua-
tion in patients with the following conditions 
until properly managed (1D):
 • An unstable psychiatric disorder that 
affects decision-making or puts the candi-
date at an unacceptable level of post-trans-
plant risk (Rec 4.2);
 • Ongoing substance use disorder that affects 
decision-making or puts the candidate at 
an unacceptable level of post-transplant 
risk (Rec 4.3);
 • Ongoing, health-compromising nonadher-
ent behavior despite education and adher-
ence-based counseling (Rec 5.4);
 • Active infection (excluding hepatitis C 
virus infection) that is not properly treated 
(Rec 10.1.1);
 • Active malignancy except for those with 
indolent and low-grade cancers such as 
prostate cancer (Gleason score ≤ 6), and 
incidentally detected renal tumors (≤ 1 cm 
in maximum diameter) (Rec 11.2.1);
 • Active symptomatic cardiac disease (eg, 
angina, arrhythmia, heart failure, valvular 
heart disease) that has not been evaluated 
by a cardiologist (Rec 13.2);
 • Active symptomatic peripheral arterial dis-
ease (Rec 14.5);
 • Recent stroke or transient ischemic attack 
(Rec 15.1);
 • Active symptomatic: peptic ulcer disease 
(Rec 16.2.2); diverticulitis (Rec 16.3.1), 
acute pancreatitis (Rec 16.4.1), gallstone/
gallbladder disease (16.5.1), inflammatory 
bowel disease (Rec 16.6.1);
 • Acute hepatitis (Rec 16.7.2);
 • Severe hyperparathyroidism (Rec 18.2).
 1.2: Use a multidisciplinary team, which includes at a 
minimum a transplant physician, transplant sur-
geon and a health care professional experienced in 
the psychosocial aspects of transplantation, to eval-
uate and decide about suitability for kidney trans-
plantation (Not Graded).
 1.3: Approve patients for kidney transplantation that 
have an estimated survival which is acceptable 
according to national standards (Not Graded).
 1.3.1: Inform patients of their option to seek a sec-
ond opinion from another transplant center if 
they are declined (Not Graded).
 1.4: We recommend pre-emptive transplantation with a 
living kidney donor as the preferred treatment for 
transplant-eligible CKD patients (1A).
 1.4.1: We recommend pre-emptive transplantation 
(living or deceased donor) in adults when the 
estimated glomerular filtration rate (eGFR) 
is < 10 ml/min/1.73 m2 or earlier with symp-
toms (1D).
 1.4.2: We recommend pre-emptive transplantation 
(living or deceased donor) in children when 
the eGFR is < 15 ml/min/1.73 m2 or earlier 
with symptoms (1D).
SECTION 2: AGE
 2.1: Consider age in the context of other comorbidities, 
including frailty, that may impact outcome when 
deciding about suitability for kidney transplanta-
tion (Not Graded).
 2.1.1: We recommend not excluding patients from kid-
ney transplantation because of age alone (1A).
SECTION 3: PEDIATRIC ISSUES
 3.1: We suggest performing a neurocognitive assessment 
in pediatric candidates who experienced end-stage 
kidney disease before the age of 5 years (2D).
 3.2: We suggest performing an academic assessment in 
pediatric candidates of school age who are experi-
encing academic difficulties (2D).
SECTION 4: PSYCHOSOCIAL ASSESSMENT
 4.1: We suggest performing a psychosocial assessment in 
all candidates (2D).
 4.1.1: Refer candidates to a health care professional 
experienced in the psychosocial aspects of kidney 
transplantation (eg, social worker, psychologist, 
psychiatrist, psychiatric nurse/nurse practitioner) 
to perform this assessment (Not Graded).
 4.1.2: Use measurement tools completed by the 
patient and/or evaluating clinician to supple-
ment the assessment (Not Graded).
 4.1.2.1: We suggest not using measurement 
tools in isolation to determine trans-
plant candidacy (2D).
 4.1.3: Refer candidates with a diagnosable psychiat-
ric or psychological condition, substance use 
disorder or nonadherence for pre-transplant 
counseling and services to enhance the likeli-
hood of a favorable post-transplant outcome 
(Not Graded).
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 4.2: We recommend not transplanting patients with an 
unstable psychiatric disorder that affects decision-
making or puts the candidate at an unacceptable 
level of post-transplant risk (1C).
 4.3: We recommend not transplanting patients with 
ongoing substance use disorder that affects deci-
sion-making or puts the candidate at an unaccepta-
ble level of post-transplant risk (1C).
 4.4: We suggest that patients without current social sup-
port be considered for kidney transplantation if they 
are able to care for themselves and have an identified 
support plan in place prior to transplantation (2D).
SECTION 5: ADHERENCE
 5.1: Assess adherence and adherence barriers pre-trans-
plantation to allow for appropriate education, coun-
seling and post-transplant surveillance (Not Graded).
 5.2: Refer candidates with a history of health-compro-
mising nonadherent behavior or identified adher-
ence barriers for adherence-based education and 
counseling pre-transplant (Not Graded).
 5.3: We suggest that candidates with a history of graft 
loss due to nonadherence undergo adherence-based 
counseling prior to re-transplantation (2D).
 5.4: We recommend that candidates with a history of 
nonadherence be considered for transplantation 
unless there is ongoing, health-compromising non-
adherent behavior (1D).
SECTION 6: TOBACCO
 6.1: Assess past and present use of tobacco products by 
candidates at transplant evaluation and while on 
the waiting list (Not Graded).
 6.2: We recommend counseling all candidates to avoid 
tobacco products before and indefinitely after trans-
plantation (1B).
 6.3: We recommend offering a tobacco cessation program 
to candidates who are using tobacco products (1B).
 6.4: We recommend that candidates abstain from 
tobacco use, at a minimum 1 month prior to wait-
listing or living donor transplantation (1B).
 6.5: We suggest chest computed tomography (CT) for 
current or former heavy tobacco users (≥ 30 pack-
years) as per local guidelines to screen for occult 
lung cancer (2C).
SECTION 7: SURGICAL ISSUES INCLUDING 
OBESITY
 7.1: We recommend candidates to have their body habi-
tus examined by a transplant surgeon at the time of 
evaluation and while on the waiting list (1B).
 7.1.1: We suggest that candidates not be excluded from 
transplantation because of obesity (as defined by 
body mass index or waist-to-hip ratio) (2B).
 7.1.2: We suggest weight loss interventions be 
offered to candidates with obesity prior to 
transplantation (2D).
 7.2: We suggest that candidates be assessed for frailty at 
the time of evaluation and while on the waitlist to 
inform post-transplant risk and enable optimization 
strategies, such as pre-operative rehabilitation (2C).
 7.3: We suggest that candidates be assessed for medi-
cal conditions that inhibit wound healing, includ-
ing obesity, undernutrition, tobacco use, and prior 
abdominal surgeries, to inform risks of delayed 
wound healing and hernia formation (2B).
 7.4: Candidates should not be excluded from consideration 
for kidney transplantation because of their need for 
anticoagulation, antiplatelet therapy or a history of hep-
arin-induced thrombocytopenia (HIT) (Not Graded).
 7.4.1: Single antiplatelet agents (eg, aspirin, clopi-
dogrel, ticagrelor) can be continued while wait-
ing for deceased donor transplant (Not Graded).
 7.4.2: Delay transplantation for the mandated period 
of treatment with dual antiplatelet therapy (eg, 
aspirin plus clopidogrel) when the risk of stop-
ping medication (eg, stent thrombosis) or oper-
ating while on treatment (eg, surgical bleeding) 
exceeds the anticipated benefit of transplanta-
tion (Not Graded).
 7.4.2.1: Antiplatelet agents (except aspirin) 
should be stopped 5 days prior to liv-
ing donor transplantation (unless ces-
sation is contraindicated) and during 
the perioperative period for deceased 
donor transplantation (Not Graded).
 7.4.3: Do not transplant patients on direct-acting 
oral anticoagulants (DOACs; eg, apixaban, 
rivaroxaban) except when there is specific 
expertise using DOACs perioperatively and 
access to DOAC reversal agents (Not Graded).
 7.4.3.1: Switch to an alternative anticoagulant 
(eg, warfarin) prior to waitlisting or 
living donor transplantation if recom-
mended by a thrombosis expert/hema-
tologist or if there is no expertise using 
DOACs perioperatively or access to 
DOAC reversal agents (Not Graded).
 7.4.4: Use non-heparin based agents for periopera-
tive anticoagulation in candidates with a his-
tory of HIT (Not Graded).
 7.5: Assess vascular anatomy and patency for patients 
with significant peripheral arterial disease (Section 
14), prior transplant procedures, venous dialysis 
catheters, pelvic surgery, or deep venous thrombosis 
(Not Graded).
 7.6: Evaluate native kidney size in patients with polycys-
tic kidney disease (Not Graded).
 7.6.1: We suggest staged or simultaneous native 
nephrectomy and transplantation for candidates 
with polycystic kidney disease that is sympto-
matic (eg, recurrent pain, recurrent infection), 
a suspicion of malignancy, or if the patient has 
insufficient room for a transplant (2D).
 7.7: Refer to a urologist experienced in transplant issues 
for patients at increased risk for or those with a his-
tory of urologic malignancy, recurrent urinary tract 
infections, dysfunctional voiding, prior bladder 
augmentation/division, an ileal conduit, significant 
structural anomalies of the kidneys or urinary tract, 
or nephrolithiasis (Not Graded).
 7.7.1: We suggest cystoscopy to screen for bladder car-
cinoma in candidates at increased risk, such as 
those with high-level exposure to cyclophospha-
mide or heavy smoking (≥ 30 pack-years) (2D).
 7.7.2: We suggest that pre-transplant unilateral or 
bilateral nephrectomy be considered for pedi-
atric candidates with high urine volumes (> 
2.5 ml/kg/hour) or heavy proteinuria associ-
ated with hypoalbuminemia (2D).
SECTION 8: DIABETES
 8.1: We recommend that candidates with type 1 or type 
2 diabetes mellitus (DM) be considered for kidney 
transplantation (1B).
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 8.1.1: We suggest candidates with ESKD and type 
1 DM be considered for simultaneous pan-
creas-kidney transplantation in regions where 
this procedure is available (2A).
 8.2: We suggest testing for abnormal glucose metabolism 
by oral glucose tolerance test in candidates who are 
not known to have diabetes (2A).
SECTION 9: CAUSE OF END-STAGE KIDNEY 
DISEASE (ESKD)
 9.1 Cause of ESKD and kidney transplantation
 9.1.1: We recommend that the cause of ESKD in 
candidates be determined, where possible, to 
inform risks and management after kidney 
transplantation (1A).
 9.1.2: Advise candidates about the disease-specific 
risk of recurrence and resultant risk of graft 
loss (Not Graded).
 9.2 Focal segmental glomerulosclerosis (FSGS)
 9.2.1: We recommend not excluding candidates with 
primary FSGS from kidney transplantation; 
however, the risk of recurrence should be con-
sidered and discussed with the candidate (1B).
 9.2.1.1: Loss of a prior graft due to recurrent 
FSGS indicates a high risk of recurrence 
upon subsequent transplantation and this 
factor should be a major consideration in 
determining candidacy (Not Graded).
 9.2.2: We suggest genetic testing (eg, for podocin 
and nephrin gene mutations, among others) 
be performed in children and young adults 
with a clinical course consistent with genetic 
FSGS to inform the risk of recurrence (2C).
 9.2.3: We suggest avoiding routine use of pre-trans-
plant plasma exchange or rituximab to reduce 
the risk of recurrent FSGS (2D).
 9.3 Membranous nephropathy (MN)
 9.3.1: We recommend not excluding candidates 
with MN from kidney transplantation; how-
ever, the risk of recurrence should be consid-
ered and discussed with the candidate (1B).
 9.3.1.1: We suggest not excluding candidates 
with prior graft loss due to MN; how-
ever, the risk of recurrence should be 
considered and discussed with the 
candidate (2D).
 9.3.2: We suggest that autoantibodies to phospholi-
pase A2 receptor (PLA2R) be measured pre-
transplant to inform the risk of recurrence in 
patients with MN (2C).
 9.3.3: We suggest not routinely using rituximab or 
alkylating agents to reduce the risk of recur-
rent MN (2D).
 9.4 IgA nephropathy (IgAN)
 9.4.1: We recommend not excluding candidates with 
IgAN from kidney transplantation; however, 
the risk of recurrence should be considered and 
discussed with the candidate (1B).
 9.5 IgA vasculitis
 9.5.1: We recommend not excluding candidates 
with IgA vasculitis from kidney transplanta-
tion; however, the risk of recurrence should 
be considered and discussed with the candi-
date (1B).
 9.6 Immune complex-mediated membranoproliferative 
glomerulonephritis (IC-MPGN) and C3 glomeru-
lopathy (C3G)
 9.6.1 IC-MPGN
 9.6.1.1: We recommend not excluding can-
didates with IC-MPGN from kidney 
transplantation; however, the risk of 
recurrence should be considered and 
discussed with the candidate (1B).
 9.6.1.2: We recommend investigation for an 
infective, autoimmune, or parapro-
tein-mediated cause of IC-MPGN 
prior to transplantation to guide 
treatment and inform risk of recur-
rence (1C).
 9.6.1.3: We suggest that, when possible, the 
cause of the IC-MPGN be treated 
prior to transplantation (2C).
 9.6.2 C3G, including dense deposit disease (DDD) 
and C3 glomerulonephritis (C3GN)
 9.6.2.1: We recommend not excluding can-
didates with C3G from kidney 
transplantation; however, the risk of 
recurrence should be considered and 
discussed with the candidate (1B).
 9.6.2.2: We suggest that candidates with C3G 
be screened for genetic or acquired 
causes for the dysregulation of the 
complement alternative pathway to 
guide treatment and inform risk of 
recurrence (2C).
 9.6.2.3: Loss of a prior graft due to recurrent 
C3G indicates a high risk of recur-
rence upon subsequent transplanta-
tion and this factor should be a major 
consideration in determining candi-
dacy (Not Graded).
 9.7 Lupus nephritis (LN)
 9.7.1: We recommend not excluding candidates with 
LN from kidney transplantation; however, the 
risk of recurrence should be considered and dis-
cussed with the candidate (1B).
 9.7.2: We recommend that lupus activity should be 
clinically quiescent on no or minimal immu-
nosuppression prior to transplantation (1D).
 9.7.3: We recommend evaluation for secondary 
antiphospholipid antibodies prior to trans-
plantation to inform perioperative manage-
ment (1C).
 9.8 Antiphospholipid syndrome (APS)
 9.8.1: We recommend not excluding candidates 
with APS from kidney transplantation; how-
ever, the risks of post-transplant thrombosis 
and perioperative anticoagulant therapies 
should be considered and discussed with the 
candidate (1B).
 9.8.2: We suggest that APS should be clinically qui-
escent prior to transplantation (2D).
 9.8.3: Continue anticoagulation (eg aspirin, warfa-
rin) at the time of activation on the transplant 
waitlist (Not Graded).
 9.9 Anti-neutrophil cytoplasmic antibody (ANCA)-
associated vasculitis
 9.9.1: We recommend not excluding candidates 
with ANCA-associated vasculitis from kidney 
transplantation; however, the risk of recur-
rence should be considered and discussed 
with the candidate (1B).
 9.9.2: We suggest that ANCA-vasculitis should be 
clinically quiescent prior to transplantation 
(2D).
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 9.10 Anti-glomerular basement membrane (anti-GBM) 
disease
 9.10.1: We recommend not excluding candidates 
with anti-GBM disease from kidney trans-
plantation (1B).
 9.10.2: We recommend that anti-GBM antibody 
titers be measured in candidates and that 
transplantation is only performed when 
 antibodies are undetectable (1D).
 9.11 Hemolytic uremic syndrome (HUS)
 9.11.1: We recommend not excluding candidates 
with HUS due to infection with a Shiga-toxin 
producing organism, usually E. coli (STEC-
HUS), from kidney transplantation (1A).
 9.11.2: We recommend assessment of candidates 
with suspected atypical HUS (aHUS) for a 
genetic or acquired defect in complement 
regulation or other genetic causes of aHUS 
to inform risk of recurrence (1B).
 9.11.3: We recommend not excluding candidates with 
aHUS from kidney transplantation; however, 
the risk of recurrence should be considered 
and discussed with the candidate (1B).
 9.11.3.1: We recommend that if the can-
didate has an abnormality in 
complement regulation placing 
them at high risk of recurrence, 
kidney transplantation should 
not proceed unless a complement 
inhibitor can be administered or 
combined liver-kidney transplant 
can be performed (1B).
 9.12 Systemic sclerosis
 9.12.1: We recommend not excluding candi-
dates with systemic sclerosis from kidney 
transplantation in the absence of severe 
pulmonary, gastrointestinal, or other life-
threatening extrarenal disease (1C).
 9.13 Plasma cell dyscrasias (PCDs)
Please consult Section 17.6 Hematologic Disorders for 
recommendations related to monoclonal gammopathy 
of undetermined significance (MGUS)
 9.13.1 Multiple myeloma
 9.13.1.1: We suggest that candidates with 
multiple myeloma be excluded 
from kidney transplantation 
unless they have received a poten-
tially curative treatment regimen 
and are in stable remission (2D).
 9.13.2 Monoclonal immunoglobulin deposition 
disease (MIDD)
 9.13.2.1: We suggest that candidates with 
light chain deposition disease 
(LCDD) be excluded from kidney 
transplantation unless they have 
received a potentially curative 
treatment regimen and are in sta-
ble remission (2D).
 9.13.2.2: We suggest that candidates with 
heavy chain deposition disease 
(HCDD) be excluded from kid-
ney transplantation unless they 
have received a potentially cura-
tive treatment regimen and are in 
stable remission (2D).
 9.13.2.3: We suggest that candidates with 
light and heavy chain deposition 
disease (LHCDD) be excluded 
from kidney transplantation 
unless they have received a poten-
tially curative treatment regimen 
and are in stable remission (2D).
 9.13.3 AL amyloidosis
 9.13.3.1: We suggest that candidates with 
AL amyloidosis be excluded from 
kidney transplantation unless they 
have  minimal extrarenal disease 
(eg, cardiac amyloid), have received 
a potentially curative treatment 
regimen and are in stable remission 
(2D).
 9.14 AA amyloidosis
 9.14.1: We recommend not excluding candidates 
with AA amyloidosis from kidney trans-
plantation after adequate treatment of the 
underlying cause and in the absence of 
severe extrarenal organ involvement (1D).
 9.15 Fibrillary/immunotactoid glomerulonephritis
 9.15.1: We recommend not excluding candi-
dates with fibrillary or immunotactoid 
glomerulonephritis from kidney trans-
plantation; however, the risk of recur-
rence should be considered and discussed 
with the candidate (1D).
 9.16 Hyperoxaluria (oxalosis), primary and secondary
 9.16.1: We suggest that candidates with primary 
hyperoxaluria type 1 be considered for 
combined or sequential liver-kidney trans-
plantation (2C).
 9.16.2: We suggest genetic testing to identify the 
cause of primary hyperoxaluria to inform 
treatment decisions (2C).
 9.16.3: We suggest not excluding candidates with 
correctable hyperoxaluria—pyridoxine-
responsive or secondary—from kidney 
transplantation alone; however, the risk of 
recurrence should be considered and dis-
cussed with the candidate (2D).
 9.16.4: We recommend the use of strategies to 
lower total body oxalate burden prior to 
transplantation in patients with hyper-
oxaluria, including intensive dialysis, diet 
modification, and pyridoxine treatment as 
appropriate on a case-by-case basis (1D).
 9.17 Cystinosis
 9.17.1: We recommend not excluding candidates 
with cystinosis from kidney transplanta-
tion in the absence of severe extrarenal 
manifestations (1C).
 9.18 Fabry disease
 9.18.1: We recommend not excluding candidates 
with Fabry disease from kidney transplanta-
tion in the absence of severe cardiac or other 
systemic extrarenal organ involvement (1C).
 9.19 Sickle cell disease
 9.19.1: We recommend not excluding candidates 
with sickle cell disease from kidney trans-
plantation in the absence of active, severe 
extrarenal sickle cell disease (1C).
 9.20 Sarcoidosis
 9.20.1: We recommend not excluding candidates 
with renal sarcoidosis from kidney trans-
plantation in the absence of severe extrare-
nal disease (1C).
 9.21 Alport syndrome
 9.21.1: We recommend not excluding candidates 
with Alport syndrome from kidney trans-
plantation (1C).
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SECTION 10: INFECTIONS
 10.1 Active infections
 10.1.1: We recommend that kidney transplantation 
be delayed until active infections (bacterial, 
fungal, viral [except hepatitis C], parasitic) 
are treated (1C).
 10.2 Colonization
 10.2.1: Follow local protocols for detection and 
management of colonization with drug-
resistant organisms (Not Graded).
 10.2.2: We recommend not excluding patients from 
kidney transplantation with asymptomatic 
bacterial, parasitic or fungal colonization 
(1C).
 10.3 Specific Infections
10.3.1 Urinary tract infections (UTIs)
 10.3.1.1: We recommend treating sympto-
matic UTIs prior to kidney trans-
plantation (1B).
 10.3.1.2: We suggest not routinely perform-
ing prophylactic nephrectomy for 
recurrent pyelonephritis or cyst 
infections (2D).
10.3.2 Tuberculosis (TB)
 10.3.2.1: We suggest complete treatment of 
active TB prior to kidney trans-
plantation, as per World Health 
Organization or local guidelines 
(2C).
 10.3.2.2: We recommend screening for 
latent TB at the time of candidate 
evaluation in low TB prevalence 
areas with a chest radiograph 
along with a purified protein 
derivative (PPD) skin test or inter-
feron-gamma release assay (1C).
 10.3.2.3: We suggest starting treatment of 
latent TB prior to or immediately 
following kidney transplantation 
in low TB prevalence areas (2C).
 10.3.2.4: We suggest screening for latent 
TB at the time of candidate evalu-
ation as per local guidelines in 
intermediate and high TB preva-
lence areas with post-transplanta-
tion vigilance for active TB (2C).
 10.4 Screening for periodontal disease
 10.4.1: We suggest dental evaluation, as per local 
general population guidelines, to screen for 
dental/periodontal disease prior to kidney 
transplantation (2C).
 10.5 Screening for viral infections (see Table 11)
 10.5.1 Human immunodeficiency virus (HIV)
 10.5.1.1: We recommend screening all 
patients for HIV infection, using 
HIV serology (1A).
 10.5.1.2: We recommend not excluding 
patients with controlled HIV 
infection from kidney transplan-
tation (1C).
 10.5.1.3: Kidney transplant candidates 
with HIV should be managed in a 
center with experience in this area 
(Not Graded).
 10.5.2 Hepatitis C virus (HCV) [This section 
is adapted from 2018 KDIGO HCV 
Guideline]
 10.5.2.1: We recommend screening all 
patients for HCV infection 
(1A). (KDIGO HCV Guideline 
Recommendation 1.1.4)
 10.5.2.2: We recommend using an immunoas-
say followed by nucleic acid testing 
(NAT) if immunoassay is positive 
(1A). (KDIGO HCV Guideline 
Recommendation 1.1.1.1)
 10.5.2.3: We recommend kidney trans-
plantation as the best therapeutic 
option for patients with CKD G5 
irrespective of presence of HCV 
infection (1A). (KDIGO HCV 
Guideline Recommendation 4.1.1)
 10.5.2.4: We suggest that all candidates 
with HCV infection be evaluated 
for severity of liver disease and 
presence of portal hypertension (if 
indicated) prior to acceptance for 
kidney transplantation (Figure 3) 
(2D). (KDIGO HCV Guideline 
Recommendation 4.1.2)
  10.5.2.4.1: We recommend that 
patients with HCV and 
compensated cirrhosis 
(without portal hyperten-
sion) undergo isolated kid-
ney transplantation (1B). 
(KDIGO HCV Guideline 
Recommendation 4.1.2.1)
  10.5.2.4.2: We recommend refer-
ring patients with HCV 
and decompensated cir-
rhosis for combined 
liver-kidney transplanta-
tion (1B) and deferring 
HCV treatment until after 
transplantation (1D). 
(KDIGO HCV Guideline 
Recommendation 4.1.2.2)
 10.5.2.5: Timing of HCV treatment in rela-
tion to kidney transplantation 
(before vs. after) should be based 
on donor type (living vs. deceased 
donor), waitlist times by donor 
type, center-specific policies gov-
erning the use of kidneys from 
HCV-infected deceased donors, 
HCV genotype, and severity 
of liver fibrosis (Not Graded). 
(KDIGO HCV Guideline 
Recommendation 4.1.3)
  10.5.2.5.1: We recommend that all 
patients with HCV who 
are candidates for kid-
ney transplantation be 
considered for direct-
acting antiviral (DAA) 
therapy, either before or 
after transplantation (1A). 
(KDIGO HCV Guideline 
Recommendation 4.1.3.1)
  10.5.2.5.2: We suggest that candidates 
with HCV with a living kid-
ney donor can be consid-
ered for treatment before 
or after transplantation 
according to HCV genotype 
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and anticipated timing 
of transplantation (2B). 
(KDIGO HCV Guideline 
Recommendation 4.1.3.2)
  10.5.2.5.3: We suggest that if receiv-
ing a kidney from an HCV-
positive donor improves 
the chances for transplanta-
tion, the HCV NAT-positive 
patient can undergo trans-
plantation with an HCV-
positive kidney and be 
treated for HCV infection 
after transplantation (2B). 
(KDIGO HCV Guideline 
Recommendation 4.1.3.3)
 10.5.3 Hepatitis B virus (HBV) [See Section 10.7 
for related recommendations on HBV 
vaccinations]
 10.5.3.1: We recommend screening for 
HBV infection with HBsAg, anti-
HBs, and anti-HBc (1A).
 10.5.3.2: We recommend screening with 
HBV DNA for patients with a 
positive HBsAg or anti-HBc (1A).
 10.5.3.3: We recommend that patients 
from hepatitis D virus (HDV) 
endemic areas be screened with 
HDV serology if they are positive 
for HBsAg or anti-HBc (1A).
 10.5.3.4: We recommend that HBsAg posi-
tive and/or HBV DNA positive 
candidates be referred to a spe-
cialist with expertise in the man-
agement of liver disease and HBV 
infection to determine appropri-
ate antiviral treatment (1D).
  10.5.3.4.1: We recommend that HBsAg 
positive and/or HBV DNA 
positive candidates undergo 
isolated kidney transplan-
tation if they do not have 
decompensated cirrhosis 
and are stable on antiviral 
therapy after specialist eval-
uation (1B).
 10.5.3.5: We recommend not exclud-
ing anti-HBc antibody positive 
(HBsAg negative) patients from 
kidney transplantation (1C).
  10.5.3.5.1: We recommend that anti-
HBc antibody positive 
(HBsAg negative) patients 
not receive antiviral proph-
ylaxis given that the risk of 
reactivation is low (1D).
  10.5.3.5.2: We suggest that anti-HBc 
antibody positive (HBsAg 
negative) patients have 
a plan in place for post-
transplant monitoring of 
HBsAg and HBV DNA for 
a minimum of 1-year post-
transplantation (2C).
 10.5.4 Cytomegalovirus (CMV)
 10.5.4.1: We recommend screening for 
CMV with CMV IgG (1C).
 10.5.5 Epstein-Barr virus (EBV)
 10.5.5.1: We recommend screening for EBV 
with EBV viral capsid antigen 
(VCA) IgG and/or EBV nuclear 
antigen (EBNA) IgG (1C).
 10.5.6 Herpes simplex virus (HSV)
 10.5.6.1: We suggest screening for HSV 
with HSV IgG (2C).
 10.5.7 Varicella-zoster virus (VZV)
 10.5.7.1: We recommend screening for 
VZV with VZV IgG (1C).
  10.5.7.1.1: We recommend varicella 
immunization for VZV 
seronegative candidates 
at least 4 weeks prior to 
transplantation (1C).
 10.5.8 Measles, mumps, and rubella (MMR)
 10.5.8.1: We suggest screening for MMR 
using IgG serology (2C).
  10.5.8.1.1: We suggest MMR immuni-
zation for MMR seronega-
tive candidates at least 4 
weeks prior to transplanta-
tion (2C).
 10.5.9 BK virus
 10.5.9.1: We recommend not screening for 
BK virus infection in candidates 
(1C).
  10.5.9.1.1: We recommend not exclud-
ing patients for repeat 
transplantation if a previ-
ous graft was lost due to 
BK nephropathy (1C).
 10.5.10 Human T-cell lymphotropic virus (HTLV)
 10.5.10.1: We recommend screening for 
HTLV 1/2 with IgG serology in 
candidates from endemic areas as 
per World Health Organization 
(1C).
 10.6 Screening for non-viral infections
 10.6.1 Syphilis
 10.6.1.1: We recommend screening for 
syphilis (Treponema pallidum) 
with serology at the time of can-
didate evaluation and treatment 
prior to transplantation if infec-
tion is identified (1C).
 10.6.2 Strongyloides
 10.6.2.1: We suggest screening for strongy-
loidiasis with serology at the time 
of evaluation in candidates from 
endemic areas, and treatment 
prior to transplantation if infec-
tion is identified (2C).
 10.6.3 Chagas disease
 10.6.3.1: We recommend screening for 
Chagas disease with serology at 
the time of evaluation in candi-
dates from endemic areas, and 
treatment prior to transplantation 
if infection is identified (1C).
 10.6.4 Malaria
 10.6.4.1: We recommend screening for 
malaria with a malaria blood 
smear at the time of evaluation 
in candidates who have recently 
travelled to endemic areas, and 
treatment prior to transplantation 
if infection is identified (1C).
 10.7 Vaccinations
 10.7.1: We recommend that the vaccination 
series be commenced using an acceler-
ated schedule, if necessary, prior to kidney 
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transplantation for any inactivated vac-
cines (Table 12) (1B).
 10.7.1.1: We suggest not excluding can-
didates who do not complete an 
inactivated vaccine series prior to 
kidney transplantation (2D).
 10.7.2: We recommend that the vaccination series 
be completed prior to kidney transplan-
tation for any live attenuated vaccines 
(Table 12) (1B).
 10.7.2.1: We recommend a 4-week delay 
in kidney transplantation if a 
live vaccine is administered (eg, 
MMR, VZV, shingles, yellow 
fever, oral typhoid, oral polio vac-
cine) (1B).
 10.7.3: We recommend that splenectomized can-
didates or those at increased risk for 
post-transplant splenectomy receive pre-
transplant pneumococcal, hemophilus, and 
meningococcal vaccination (1B).
 10.7.4: We recommend that candidates requiring 
complement inhibitors perioperatively or 
post-transplant undergo meningococcal 
vaccination (1B).
 10.7.5: We suggest administering the following 
vaccines to candidates who, due to age, 
direct exposure, residence or travel to 
endemic areas, or other epidemiological 
risk factors, are at increased risk for the 
specific diseases:
 • Rabies (2D)
 • Tick-borne meningoencephalitis (2D)
 • Japanese encephalitis (inactivated) (2D)
 • Meningococcus (2D)
 • Salmonella typhi (inactivated) (2D)
 • Yellow fever (2D)
SECTION 11: MALIGNANCY
 11.1 Cancer screening
 11.1.1: We recommend candidates undergo 
routine cancer screening, as per local 
guidelines for the general population 
(Table 13) (1D).
 11.1.1.1: We suggest chest imaging prior to 
transplantation in all candidates 
(2C). (Same as Rec 12.2)
 11.1.1.2: We suggest chest CT for current 
or former heavy tobacco users 
(≥ 30 pack-years) as per local 
guidelines, and chest radiograph 
for other candidates (2C). (Same 
as Rec 12.2.1)
 11.1.2: Screen candidates at increased risk for renal 
cell carcinoma (eg ≥ 3 years dialysis, family 
history of renal cancer, acquired cystic dis-
ease or analgesic nephropathy) with ultra-
sonography (Not Graded).
 11.1.3: We suggest cystoscopy to screen for blad-
der carcinoma in candidates at increased 
risk, such as those with high-level exposure 
to cyclophosphamide or heavy smoking (≥ 
30 pack-years) (2D).
 11.1.4: We recommend screening for hepatocellu-
lar carcinoma in candidates with cirrhosis 
prior to transplantation using techniques 
(eg, ultrasound, α-fetoprotein) and fre-
quency as per local guidelines (1C).
 11.1.5: We recommend screening for bowel cancer 
in candidates with inflammatory bowel dis-
ease as per local guidelines (1C).
 11.2 Potential kidney transplant candidates with a prior 
cancer
 11.2.1: We recommend that candidates with active 
malignancy be excluded from kidney trans-
plantation except for those with indolent 
and low-grade cancers such as prostate 
cancer (Gleason score ≤ 6), superficial non-
melanoma skin cancer, and incidentally 
detected renal tumors (≤ 1 cm in maximum 
diameter) (1B).
 11.2.2: Timing of kidney transplantation after 
potentially curative treatment for cancer is 
dependent on the cancer type and stage at 
initial diagnosis (Not Graded).
 11.2.3: We recommend no waiting time for candi-
dates with curatively treated (surgically or 
otherwise) non-metastatic basal cell and 
squamous cell carcinoma of the skin; mela-
noma in situ; small renal cell carcinoma (< 
3 cm); prostate cancer (Gleason score ≤ 6); 
carcinoma in situ (ductal carcinoma in situ, 
cervical, others); thyroid cancer (follicular/
papillary < 2 cm of low grade histology); 
and superficial bladder cancer (1C).
 11.2.3.1: For other cancers, we suggest fol-
lowing waiting time parameters 
as outlined in Table 14 (2D).
 11.2.3.2: We suggest that the recommended 
waiting time from cancer to kid-
ney transplantation begins upon 
completion of potentially curative 
treatment (2D).
 11.2.4: Decisions about transplantation for can-
didates in remission from cancer should 
be made collaboratively with oncologists, 
transplant nephrologists, patients, and 
their caregivers (Not Graded).
 11.2.4.1: For relevant cancers, supple-
ment estimates of prognosis using 
genomic profiling, other molecu-
lar genomic tests, and pheno-
typing in consultation with the 
patient’s oncologist (Not Graded).
 11.2.5: We recommend not excluding candidates with 
a history of metastatic cancer provided that 
potentially curative therapy has been adminis-
tered and complete remission achieved; how-
ever, the risk of recurrence should be a major 
consideration and discussed with the candi-
date and their oncologist (1D).
 11.3 Hematologic malignancy (See Sections 17.7, 17.8 
and 17.9)
 11.3.1: Acute leukemia and high-grade lymphoma, 
including post-transplant lymphoproliferative 
disease
 11.3.1.1: Avoid transplanting patients with 
leukemia or lymphoma until they 
have received curative therapy, 
achieved remission and remained 
cancer free for a period to be 
determined in consultation with 
the patient, a hematologist/oncol-
ogist and the transplant program 
(Not Graded).
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 11.3.2: Myelodysplasias, chronic leukemia and 
chronic/low-grade lymphoma
 11.3.2.1: Decisions about kidney trans-
plantation in patients with mye-
lodysplasia should be made in 
collaboration with a hematologist 
(Not Graded).
 11.3.2.2: Advise consultation with a hema-
tologist with transplant experi-
ence in determining transplant 
candidacy since many lesions may 
be deemed to be at high risk of 
accelerated progression or trans-
formation post-transplant (Not 
Graded).
 11.3.3: Decisions about kidney transplantation 
in patients with a prior history of hema-
tologic malignancy who are now in remis-
sion should be made in collaboration with 
a hematologist (Not Graded).
SECTION 12: PULMONARY DISEASE
 12.1: Assess candidates with lung disease in collabora-
tion with a pulmonary specialist to determine suit-
ability for transplantation (Not Graded).
 12.2: We suggest chest imaging prior to transplantation 
in all candidates (2C). (Same as Rec 11.1.1.1)
 12.2.1 We suggest chest CT for current or former 
heavy tobacco users (≥ 30 pack-years) as 
per local guidelines, and chest radiograph 
for other candidates (2C). (Same as Rec 
11.1.1.2)
 12.3: We recommend pulmonary function testing in can-
didates with impaired functional capacity, respira-
tory symptoms, or known pulmonary disease (1C).
 12.4: We recommend counseling all candidates to avoid 
tobacco products before and indefinitely after 
transplantation (1B). (Same as Rec 6.2)
 12.5: We recommend excluding patients with severe 
irreversible obstructive or restrictive lung disease 
from kidney transplantation (1C).
SECTION 13: CARDIAC DISEASE
 13.1: Evaluate all candidates for the presence and 
severity of cardiac disease with history, physical 
examination, and electrocardiogram (ECG) (Not 
Graded).
 13.2: Patients with signs or symptoms of active car-
diac disease (eg, angina, arrhythmia, heart fail-
ure, symptomatic valvular heart disease) should 
undergo assessment by a cardiologist and be man-
aged according to current local cardiac guidelines 
prior to further consideration for a kidney trans-
plant (Not Graded).
 13.3: We suggest that asymptomatic candidates at high 
risk for coronary artery disease (CAD) (eg, diabe-
tes, previous CAD) or with poor functional capac-
ity undergo non-invasive CAD screening (2C).
  13.3.1: We recommend that asympto-
matic candidates with known CAD not be 
revascularized exclusively to reduce perio-
perative cardiac events (1B).
 13.3.2: We suggest that patients with asymp-
tomatic, advanced triple vessel coro-
nary disease be excluded from kidney 
transplantation unless they have an esti-
mated survival which is acceptable accord-
ing to national standards (2D).
 13.4: We suggest that asymptomatic candidates who 
have been on dialysis for at least two years or have 
risk factors for pulmonary hypertension (eg, portal 
hypertension, connective tissue disease, congenital 
heart disease, chronic obstructive pulmonary dis-
ease) undergo echocardiography (2D).
 13.5: Patients with an estimated pulmonary systolic 
pressure greater than 45 mm Hg by echocardio-
graphic criteria should be assessed by a cardiolo-
gist (Not Graded).
 13.5.1: We recommend not excluding candidates 
with uncorrectable pulmonary artery sys-
tolic pressure greater than 60 mm Hg 
(obtained from right heart catherization) 
from kidney transplantation; however, the 
risks of sudden deterioration or progres-
sion after transplantation should be a key 
consideration and the patient should have 
an estimated survival which is acceptable 
according to national standards (1C).
 13.6: Patients with severe valvular heart disease should 
be evaluated and managed by a cardiologist accord-
ing to local cardiac guidelines (Not Graded).
 13.7: We suggest that patients with uncorrectable, symp-
tomatic New York Heart Association (NYHA) 
Functional Class III/IV heart disease [severe CAD; 
left ventricular dysfunction (ejection fraction < 
30%); severe valvular disease] be excluded from 
kidney transplantation unless there are mitigating 
factors that give the patient an estimated survival 
which is acceptable according to national stand-
ards (2D).
 13.7.1: Patients with severe heart failure (NYHA 
III/IV) who are otherwise suitable for kid-
ney transplantation should be assessed by a 
cardiologist and considered for combined/
simultaneous heart and kidney transplan-
tation (Not Graded).
 13.8: Perform cardiac imaging in patients with systemic 
amyloidosis. Exclude such patients from kidney 
transplantation if significant cardiac amyloid is 
confirmed (Not Graded). (see Rec 9.13.3.1)
 13.9: We suggest that candidates who have a myocardial 
infarction be assessed by a cardiologist to deter-
mine whether further testing is warranted and 
when they can safely proceed with kidney trans-
plantation (2B).
 13.10: We suggest that transplantation be delayed an 
appropriate amount of time after placement of a 
coronary stent as recommended by the patient’s car-
diologist (2B).
 13.11: We suggest that maintenance aspirin, β-blockers, 
and statins be continued while on the waiting list and 
perioperatively, according to local cardiac guidelines 
(2A).
SECTION 14: PERIPHERAL ARTERIAL  
DISEASE (PAD)
 14.1: Evaluate all candidates for presence and severity of 
peripheral arterial disease (PAD) with history and 
physical examination (Not Graded).
 14.2: We suggest that candidates without clinically 
apparent PAD, but who are at high risk for PAD, 
undergo non-invasive vascular testing (2D).
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 14.3: Candidates with clinically apparent PAD should 
undergo imaging and management of their PAD 
in consultation with a vascular surgeon prior to 
transplantation (Not Graded).
 14.4: We suggest that candidates with clinically appar-
ent PAD, abnormal non-invasive testing, or prior 
vascular procedures, undergo non-contrast CT 
imaging of the abdomen/pelvis to evaluate arterial 
calcification and improve operative planning (2D).
 14.5: Exclude candidates with non-healing extremity 
wounds with active infection from transplantation 
until the infection is resolved (Not Graded).
 14.6: We suggest not excluding patients with prior 
aorto-iliac procedures including iliac artery stent 
placement from kidney transplantation if there 
is sufficient native artery available for vascular 
anastomosis (2D).
 14.7: We suggest not excluding patients with severe 
aorto-iliac disease or distal vascular disease 
from kidney transplantation; however, the risk 
of progression after transplantation should be a 
key consideration and the patient should have an 
estimated survival which is acceptable according 
to national standards (2D).
SECTION 15: NEUROLOGIC DISEASE
 15.1: We suggest waiting at least 6 months after a stroke 
or 3 months after a transient ischemic attack (TIA) 
before kidney transplantation (2D).
 15.2: We recommend not screening asymptomatic can-
didates for carotid artery disease (1D).
 15.3: We suggest screening candidates with autosomal 
dominant polycystic kidney (ADPKD) disease for 
intracranial aneurysms only if they are at high risk 
due to prior history of or a family history of suba-
rachnoid hemorrhage (2D).
 15.4: Patients with progressive central neurodegen-
erative disease should not undergo kidney trans-
plantation if survival and quality of life are not 
expected to be substantially improved by trans-
plantation (Not Graded).
 15.5: Assess mental status in candidates with known or 
suspected cognitive impairment (Not Graded).
 15.5.1: We recommend not excluding candidates 
from kidney transplantation because of 
non-progressive intellectual, developmen-
tal, or cognitive disability (1D).
 15.6: Patients with symptomatic peripheral neu-
ropathy should be assessed by a neurologist 
(Not Graded).
 15.6.1: We suggest people with progressive periph-
eral neuropathy attributed to uremia be 
considered for urgent kidney transplanta-
tion, if available (2D).
 15.6.2: We recommend not excluding candidates 
from kidney transplantation because of 
peripheral neuropathy (1D).
SECTION 16: GASTROINTESTINAL AND 
LIVER DISEASE
 16.1: Evaluate all candidates for the presence of gas-
trointestinal disease, including liver disease, with 
a targeted history and physical examination (Not 
Graded).
 16.2 Peptic ulcer disease
 16.2.1: We recommend that candidates with symp-
toms suggestive of active peptic ulcer dis-
ease undergo esophagogastroscopy and H. 
pylori testing prior to kidney transplanta-
tion (1C).
 16.2.2: Delay kidney transplantation in candidates 
with endoscopically-proven peptic ulcer 
disease until symptoms have resolved (Not 
Graded).
 16.2.3: We recommend not screening candidates 
with a history of peptic ulcer disease with 
esophagogastroscopy (1C).
 16.2.4: We recommend not excluding candidates 
with a history of peptic ulcer disease from 
kidney transplantation (1D).
 16.3 Diverticulitis
 16.3.1: Delay kidney transplantation in candidates 
with active diverticulitis until symptoms 
have resolved (Not Graded).
 16.3.2: We recommend not screening asympto-
matic candidates for diverticulosis (1C).
 16.3.3: We recommend not performing prophy-
lactic colectomy in patients with a history 
of diverticulitis or asymptomatic diver-
ticulosis (1C).
 16.3.4: We recommend not excluding candidates 
with a history of diverticulitis from kidney 
transplantation (1C).
 16.4 Pancreatitis
 16.4.1: Delay kidney transplantation in candidates 
with acute pancreatitis a minimum of three 
months after symptoms have resolved (Not 
Graded).
 16.4.2: We suggest not excluding candidates with 
a history of acute or chronic pancreatitis 
from kidney transplantation (2C).
 16.5 Cholelithiasis
 16.5.1: Delay kidney transplantation in candidates 
with symptomatic gallstone or gallbladder 
disease until symptoms have resolved (Not 
Graded).
 16.5.2: We recommend that candidates with a his-
tory of cholecystitis undergo cholecystec-
tomy before kidney transplantation (1C).
 16.5.3: We recommend not screening asympto-
matic candidates for cholelithiasis (1C).
 16.5.4: We recommend not performing prophy-
lactic cholecystectomy in candidates with 
asymptomatic cholelithiasis (1C).
 16.5.5: We recommend not excluding candidates 
with asymptomatic cholelithiasis from kid-
ney transplantation (1A).
 16.6 Inflammatory bowel disease
 16.6.1: Delay kidney transplantation in candidates 
with active symptomatic inflammatory 
bowel disease (Not Graded).
 16.6.1.1: Determine timing of transplanta-
tion for such patients in consul-
tation with a gastroenterologist 
(Not Graded).
 16.6.2: We recommend screening for bowel cancer 
in candidates with inflammatory bowel dis-
ease as per local guidelines (1C). (Same as 
Rec 11.1.5).
 16.6.3: We recommend not excluding candidates 
with a history of inflammatory bowel dis-
ease from kidney transplantation (1D).
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 16.7 Liver disease
 16.7.1: Screen kidney transplant candidates for 
liver disease with a total bilirubin, alanine 
aminotransferase, international normalized 
ratio, and albumin (Not Graded).
 16.7.2: Delay kidney transplantation until acute 
hepatitis, of any cause, has resolved and a 
long-term strategy for managing liver dis-
ease has been implemented (Not Graded).
 16.7.3: We recommend that candidates with cir-
rhosis or suspected cirrhosis be referred 
to a specialist with expertise in combined 
liver-kidney transplantation for evaluation 
(1B).
 16.7.3.1: We recommend that patients 
undergo isolated kidney trans-
plantation if deemed to have com-
pensated cirrhosis after specialist 
evaluation (1B).
For liver disease associated with HBV or HCV infection, 
see Sections 10.5.2 and 10.5.3
 16.7.4: We recommend screening for hepatocellu-
lar carcinoma in candidates with cirrhosis 
prior to transplantation using techniques 
(eg, ultrasound, alpha-fetoprotein) and fre-
quency as per local guidelines (1C). (Same 
as Rec 11.1.4).
SECTION 17: HEMATOLOGIC DISORDERS
 17.1: We recommend not routinely screening for throm-
bophilia in candidates (1C).
 17.1.1: We suggest screening for thrombophilia 
only in candidates who have experienced 
a venous thromboembolic event, recurrent 
arteriovenous access thromboses, non-ath-
erosclerotic arterial thrombosis, or family 
history of venous thromboembolism to 
identify candidates at higher risk of graft 
thrombosis (2C).
 17.2: We suggest testing for antiphospholipid antibod-
ies (APLAs) in patients with systemic lupus erythe-
matosus or features of antiphospholipid syndrome 
(APS) (2C).
 17.3: Candidates should not be excluded from consid-
eration for kidney transplantation because of their 
need for anticoagulation, antiplatelet therapy or a 
history of HIT (Not Graded). [same as Rec 7.4]
 17.3.1: Single antiplatelet agents (eg, aspirin, clopi-
dogrel, ticagrelor) can be continued while 
waiting for deceased donor transplant (Not 
Graded). [same as Rec 7.4.1]
 17.3.2: Delay transplantation for the mandated 
period of treatment with dual antiplatelet 
therapy (eg, aspirin plus clopidogrel) when 
the risk of stopping medication (eg, stent 
thrombosis) or operating while on treat-
ment (eg, surgical bleeding) exceeds the 
anticipated benefit of transplantation (Not 
Graded). [same as Rec 7.4.2]
 17.3.2.1: Antiplatelet agents (except aspirin) 
should be stopped 5 days prior to 
living donor transplantation (unless 
cessation is contraindicated) and 
during the perioperative period for 
deceased donor transplantation 
(Not Graded). [same as Rec. 7.4.2.1]
 17.3.3: Do not transplant patients on direct-acting 
oral anticoagulants (DOACs; eg, apixaban, 
rivaroxaban) except when there is specific 
expertise using DOACs perioperatively 
and access to DOAC reversal agents (Not 
Graded). [same as Rec 7.4.3]
 17.3.3.1:  Switch to an alternative anticoagu-
lant (eg warfarin) prior to waitlist-
ing or living donor transplantation 
if recommended by a thrombosis 
expert/hematologist or if there is 
no expertise using DOACs periop-
eratively or access to DOAC reversal 
agents (Not Graded). [same as Rec. 
7.4.3.1]
 17.3.4: Use non-heparin based agents for periop-
erative anticoagulation in candidates with 
a history of HIT (Not Graded). [same as 
Rec. 7.4.4]
 17.4: Evaluate transplant suitability of patients with 
significant cytopenias based on cause and severity 
(Not Graded).
 17.5: We recommend that candidates with sickle cell dis-
ease or thalassemia not be excluded from kidney 
transplantation [see sections on recurrent disease: 
Section 9.19: sickle cell disease]. (1C)
17.6  Monoclonal gammopathy of undetermined signifi-
cance (MGUS)
 17.6.1: We suggest not excluding candidates 
with MGUS from kidney transplantation; 
however, a higher risk of post-transplant 
lymphoproliferative disease and other 
hematological malignancies should be 
considered and discussed with candidates 
(2D).
 17.6.2: We suggest not excluding candidates with 
smouldering multiple myeloma from kidney 
transplantation; however, a significant risk of 
transformation into multiple myeloma should 
be considered and discussed with candidates 
(2D).
 17.6.3: We recommend careful evaluation of 
candidates with MGUS for other types 
of plasma cell disorders prior to kidney 
transplantation (1D).
 17.7 Acute leukemia and high-grade lymphoma, includ-
ing post-transplant lymphoproliferative disease 
(Same as Section 11.3.1)
 17.7.1: Avoid transplanting patients with leuke-
mia or lymphoma until they have received 
curative therapy, achieved remission 
and remained cancer free for a period to 
be determined in consultation with the 
patient, a hematologist/oncologist and the 
transplant program (Not Graded).
 17.8 Myelodysplasias, chronic leukemia and chronic/
low-grade lymphoma (Same as Section 11.3.2)
 17.8.1: Decisions about kidney transplantation 
in patients with myelodysplasia should be 
made in collaboration with a hematologist 
(Not Graded).
 17.8.2: Advise consultation with a hematologist 
with transplant experience in determining 
transplant candidacy since many lesions 
may be deemed to be at high risk of accel-
erated progression or transformation post-
transplant (Not Graded).
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 17.9: Decisions about kidney transplantation in patients 
with a prior history of hematological malignancy 
who are now in remission should be made in col-
laboration with a hematologist (Not Graded) 
(Same as Rec 11.3.3).
SECTION 18: BONE AND MINERAL METABOLISM
 18.1: Measure serum parathyroid hormone (PTH) at the 
time of transplant evaluation (Not Graded).
 18.2: We suggest not transplanting patients with severe 
hyperparathyroidism until they are adequately 
treated (medically or surgically) as per KDIGO 
Chronic Kidney Disease-Mineral and Bone 
Disorder (CKD-MBD) guideline (2D).
 18.3: Bone mineral density (BMD) should not be meas-
ured as part of the transplant evaluation (Not 
Graded).
SECTION 19: IMMUNOLOGICAL ASSESSMENT
 19.1: Communicate all sensitizing events (eg, blood 
product transfusion, including platelets, pregnancy 
or miscarriage) or clinical events that can impact 
panel reactive antibody (PRA) (eg, vaccination, 
withdrawal of immunosuppression, transplant 
nephrectomy, significant infection) to the human 
leukocyte antigen (HLA) laboratory (Not Graded).
 19.2: Perform HLA antibody testing at transplant evalu-
ation, at regular intervals prior to transplantation 
and after a sensitizing event or a clinical event that 
can impact PRA (Not Graded).
 19.3: We recommend that HLA antibody testing be per-
formed using solid phase assays (1B).
 19.4: We recommend HLA typing of candidates at 
evaluation using molecular methods, optimally 
at all loci (1D).
 19.5: We suggest not routinely testing candidates for 
non-HLA antibodies (2C).
 19.6: We suggest not routinely testing candidates for 
complement-binding HLA antibodies (2C).
 19.7: We suggest informing candidates about their 
access to transplantation based on blood type and 
histocompatibility testing results (2C).
 19.7.1: We recommend offering candidates with 
immunologically-reduced access to trans-
plant access to a larger deceased donor 
pool, kidney exchange programs, and/or 
desensitization (1C).
 19.7.2: We suggest that antibody avoidance (eg, 
kidney exchange programs or deceased 
donor acceptable mismatch allocation) be 
considered before desensitization (2C).
METHODS FOR GUIDELINE DEVELOPMENT
AIM
The overall aim of this project was to develop an evi-
dence-based clinical practice guideline for the management 
of patients being evaluated for kidney transplantation. The 
guideline consists of recommendation statements, ration-
ale text, and a summary of systematically generated evi-
dence on relevant pre-defined clinical topics. The general 
guideline development method is described below.
OVERVIEW OF PROCESS
The development process for the KDIGO 2020 Clinical 
Practice Guideline on the Evaluation and Management of 
Candidates for Kidney Transplantation included the fol-
lowing steps:
 • Appointing Work Group members and the evidence 
review team (ERT)
 • Discussing process, methods, and results
 • Developing and refining topics
 • Identifying populations, interventions or predictors, and 
outcomes of interest
 • Selecting topics for systematic evidence review
 • Standardizing quality assessment methodology
 • Developing and implementing literature search strategies
 • Screening abstracts and retrieving full-text articles on 
the basis of pre-defined eligibility criteria
 • Creating data extraction forms
 • Extracting data and performing critical appraisal of the 
literature
 • Grading the methodology and outcomes in individual 
studies
 • Tabulating data from individual studies into summary 
tables
 • Grading quality of evidence for each outcome across 
studies, and assessing the overall quality of evidence 
across outcomes with the aid of evidence profiles
 • Grading the strength of recommendations on the basis 
of the quality of evidence and other considerations
 • Finalizing guideline recommendations and supporting 
rationale
 • Sending the guideline draft for public review in October 
2018
 • Editing the guideline
 • Publishing the final version of the guideline
The overall process for conducting the systematic 
reviews and developing the clinical practice guideline 
follow international standards, including those from the 
Institute of Medicine (now known as Health and Medicine 
Division, National Academies of Sciences, United States 
[US]).4,5
The Work Group Co-Chairs and ERT met for a two-
day meeting to review the guideline development process, 
evidence review topics, and systematic review findings. 
Following this, the Work Group, ERT, and KDIGO sup-
port staff met for two separate meetings to review the 
available evidence, formulate recommendation statements, 
evaluate the quality of the evidence and strength of rec-
ommendations, deliberate on rationale for recommenda-
tions, and develop consensus. The draft clinical practice 
guideline underwent public review, after which revisions to 
recommendations and text were made where appropriate.
Commissioning of Work Group and ERT
The KDIGO Co-Chairs appointed the Work Group 
Co-Chairs, who then assembled the Work Group of domain 
experts, including individuals with expertise in adult and 
pediatric nephrology, transplant nephrology, transplanta-
tion surgery, transplantation medicine, transplant immu-
nology, and cancer epidemiology. The Brown University 
Center for Evidence Synthesis in Health in Providence, 
Rhode Island, USA, was contracted as the ERT to con-
duct systematic evidence review and provide expertise in 
guideline development methodology. The ERT consisted of 
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physician–methodologists and experienced research asso-
ciates with expertise in nephrology and evidence-based 
clinical practice guideline development.
Defining scope and topics
The Work Group Co-Chairs and the ERT defined the 
overall scope and goals of the guideline including lists of 
populations, interventions, predictors, comparators, out-
comes, and analyses of interest. Together, they then drafted 
a preliminary list of topics and key clinical questions. The 
Work Group and the ERT further developed and refined 
each topic and specified screening criteria, literature search 
strategies, and data extraction forms.
Establishing the process for guideline 
development
The ERT performed systematic literature searches and 
organized abstract and article screening. The ERT also coor-
dinated the methodological and analytical processes and 
defined and standardized the methodology for performing 
literature searches, data extraction, and summarizing the 
evidence. The Work Group took the primary role of writing 
and grading the recommendation statements and rationale 
text and retained final responsibility for their content.
Formulating questions of interest
Questions of interest were formulated according to 
the PICOTS criteria (Population, Intervention/Predictor, 
Comparator, Outcome, Timing, and Study Design). Details 
of the PICOTS criteria are presented in Table 1.
Ranking of outcomes
The Work Group ranked outcomes of interest on the 
basis of their importance for informing clinical decision 
making (Table 2).
Literature searches and article selection
Systematic search strategies were developed by the ERT 
with input from the Work Group Co-Chairs. Modules 
were created for kidney transplantation, study designs, and 
terms for each of the systematic review topics. Separate 
searches were conducted for each topic (or sets of related 
topics). Searches were conducted in Medline (via PubMed), 
EMBASE, Cochrane Central Register of Controlled Trials, 
and Cochrane Database of Systematic Reviews. No date or 
language restrictions were entered into the searches. The full 
literature search strategies are provided in the Supplemental 
Appendix A. The final searches were conducted in August 
2017. The search for gammopathies was conducted in May 
2019. Searches were supplemented by articles provided by 
Work Group members through September 2019.
For selection of studies, all members of the ERT screened 
each set of abstracts in duplicate using an open-source, on-
line screening program Abstrackr (http://abstrackr.cebm.
brown.edu/). To establish relevance and consensus among 
reviewers, the entire team screened and achieved consensus 
on a series of initial batches of 100 abstracts. A total of 
45,914 citations were screened (Figure 1). Journal articles 
reporting original data or systematic reviews were selected 
for evidence review, based on a priori criteria for eligible 
evidence. Of these, 762 were selected for consideration for 
inclusion. After review of the full-text articles, 190 were 
included, as enumerated in Table 3.
Data extraction
Data extraction was done by ERT research associates. 
Extracted data from each study was reviewed by another 
ERT member to confirm accuracy. The ERT designed 
forms to capture data on design, methodology, eligibility 
criteria, study participant characteristics, interventions, 
comparators, predictors, outcomes, and results of indi-
vidual studies. Methodology and outcomes were also sys-
tematically assessed for risk of bias (see the section on risk 
of bias assessment below) and recorded during the data 
extraction process.
Summary tables
Summary tables were developed for each reviewed topic 
with eligible studies. Summary tables contain outcomes of 
interest, relevant population characteristics, description of 
intervention and comparator (or predictor), results, and 
quality grading for each outcome. Categorical and con-
tinuous outcomes were tabulated separately.
Work Group members reviewed and confirmed all sum-
mary table data and quality assessments. Summary tables 
are available at www.kdigo.org.
Evidence profiles
Evidence profiles were constructed to assess the qual-
ity and record quality grades and descriptions of effect 
(or association) for each outcome across studies, as well 
as the quality of overall evidence and description of net 
benefits or harms of the intervention or comparator across 
all outcomes. These profiles aim to make the evidence syn-
thesis process transparent. Decisions in the evidence pro-
files were based on data from the primary studies listed in 
corresponding summary tables and on judgments of the 
ERT and Work Group. Each evidence profile was initially 
constructed by the ERT and then reviewed, edited, and 
confirmed by the Work Group and/or Work Group Chairs. 
The work products created by the ERT for summarizing 
the evidence base are listed in Table 3, together with the 
number of included studies.
Grading of quality of evidence for outcomes of 
individual studies
Methodological quality (internal validity) refers to the 
design, conduct, and reporting of outcomes of a clinical 
study. A previously devised three-level classification system 
for quality assessment was used to grade the overall study 
quality and quality of all relevant outcomes in the study 
(Table 4). Grading of individual studies was done by one 
of the reviewers, then confirmed by another, with discrep-
ancies discussed in conference.
We based the methodological quality of each study 
on predefined criteria. For randomized controlled tri-
als (RCTs) and other comparative studies, the ERT used 
the Cochrane risk of bias tool,6 which asks about risk of 
selection bias, performance bias, detection bias, attrition 
bias, reporting bias, and other potential biases. For obser-
vational studies, we also used selected questions from the 
Newcastle Ottawa Scale about comparability of cohorts, 
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TABLE 1.
Systematic review topics and screening criteria
Clinical outcomes: Transpant vs. continued waitlist
Population Adult or child eligible for potential kidney transplant
Intervention Kidney transplantation (de novo, retransplant, any donor)
Comparator Continuation on waitlist for kidney transplantation.
 Exclude if include patients not on transplant waitlist (not awaiting transplantation).
Predictors Age subgroups, obesity subgroups, HIV, HBV
Outcome Mortality (all cause), HIV or HBV outcomes as relevant
Study design Multivariate (adults, HBV), any design (pediatrics, HIV)
Minimum duration of follow-up None
Minimum N of Subjects 100 (adults), Any (pediatrics)
Prediction model studies
Population Received kidney transplant, in large registry or national database or equivalent.
 Exclude multi-organ transplantation.
Predictors Pre-transplantation (or at time of transplant) variables only: eGFR, albumin, BMI (particularly at 
extremes), SGA or other nutrition markers, malnutrition, age (particularly at extremes), tobacco 
use, PRA, history of cardiac disease, heart disease status/measures, diabetes, aortoiliac 
disease, diabetic peripheral vascular disease, pulmonary disease, specific CKD, cancer history, 
morbidity indexes, substance use disorder, intellectual disability. Exclude organ donor factors.
Outcome All predictors: Mortality (all cause), graft failure/loss
 Predictor-specific: Mortality (cause-specific), cancer recurrence, new-onset diabetes
Design Registry study (or equivalent), multivariable analyses
Minimum N of subjects 100
Registry dates Latest enrollment in registry in or after 2007
CKD recurrence after transplantation
Population Kidney transplantation due to known, specific (listed) causes of CKD
Predictor Specific causes of CKD
Outcome CKD recurrence after transplantation (percentage with recurrence)
Design Longitudinal
Minimum duration of follow-up None
Minimum N of subjects Variable based on population frequency of specific causes of CKD
Prevention of CKD recurrence
Population Kidney transplantation due to FSGS, HUS, membranous nephropathy, or MPGN
Intervention Treatments for CKD at or around time of transplantation, including plasma exchange/plasma-
pheresis, rituximab, eculizumab, immunoabsorption, and immunosuppression
Outcome Mortality (all-cause), graft failure/loss, GFR, proteinuria, recurrent disease (by biopsy)
Design Longitudinal
Minimum duration of follow-up None
Minimum N of subjects None
Tuberculosis
Population CKD G4-G5 with active tuberculosis
Intervention Short course tuberculosis treatment
Comparator Long (typical) course tuberculosis treatment (or no comparator)
Outcome Mortality (all-cause and TB), TB reactivation, graft failure/loss
Study design Longitudinal
Minimum duration of follow-up None
Minimum N of Subjects 50
Nephrectomy (for recurrent UTI or BK virus)
Population CKD G4-G5 with recurrent UTI or
 Kidney transplant recipient with failed/failing graft due to BK virus
Intervention Nephrectomy (native or allograft kidney)
Comparator No nephrectomy (or no comparator)
Outcome Mortality (all-cause), graft failure/loss, GFR, recurrent UTI or BK nephropathy
Study design Any
Minimum duration of follow-up None
Minimum N of Subjects None
Continued
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HIV  
Population Kidney transplant candidates who receive transplants
Intervention HIV+
Comparator HIV-
Outcome Mortality (all-cause), graft failure/loss, HIV and infectious outcomes, GFR
Study design Comparative (HIV+ vs. HIV-)
Minimum duration of follow-up None
Minimum N of Subjects 100
Tuberculosis testing
Population CKD G4-G5 who receive transplants
Intervention Any TB test (pre-transplantation)
Outcome Test performance characteristics, Post-transplant TB outcomes
Study design Any
Minimum duration of follow-up None
Minimum N of Subjects 20
Vaccination
Population CKD G4-G5 who receive transplants
Intervention Vaccination for/with Pneumovax (Prevnar 13), influenza, HBV, measles, shingles
Outcome Immunogenicity, post-transplant vaccine effectiveness (disease incidence)
Study design Any
Minimum duration of follow-up None
Minimum N of Subjects 20
Prostate cancer
Population Kidney transplant candidate with non-metastatic prostate cancer who receive transplants
Intervention Prostatectomy (at time of kidney transplantation)
Comparator None needed
Outcome Mortality (all-cause), graft failure/loss, prostate cancer outcomes
Study design Longitudinal
Minimum duration of follow-up None
Minimum N of Subjects 10
Cancer, active
Population Kidney transplant candidates with known, specific, treated cancer who receive transplants
Predictor Wait-time for transplantation after cancer cure or treatment
Outcome Mortality (all-cause, cancer), graft failure/loss, cancer recurrence
Study design Longitudinal
Minimum duration of follow-up None
Minimum N of Subjects 100
Monoclonal gammopathy
Population Kidney transplant candidates who receive transplants
Predictor Testing for gammopathies
Outcome MGUS or MGRS (pre- or post-Txp), hematologic outcomes (post-Txp), kidney/graft outcomes 
(post-transplant), survival (post-Txp)
Study design Longitudinal
Minimum duration of follow-up None
Minimum N of Subjects None
Cancer screening
Population Kidney transplant candidates with no known cancer who receive transplants
Intervention Cancer screening (any cancer, method)
Outcome Mortality (all-cause, cancer), graft failure/loss, cancer
Study design Longitudinal
Minimum duration of follow-up None
Minimum N of Subjects 100
Echocardiography
Population Kidney transplant candidates asymptomatic for CHF, valvular disease, or other indications for 
echocardiography who receive transplants
Intervention Echocardiography measures
TABLE 1. (Continued ) 
Continued
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Outcome Mortality (all-cause, cardiac), graft failure/loss, cardiac disease, pulmonary hypertension, left 
ventricular function (overall or categorical, not specific measures)
Study design Longitudinal
Minimum duration of follow-up None
Minimum N of Subjects 100 (adults), any (pediatrics)
Cardiac revascularization
Population CKD G5 (dialysis) with severe CAD who receive transplants
Intervention Cardiac revascularization
Outcome Mortality (all-cause, cardiac), graft failure/loss
Study design Longitudinal
Minimum duration of follow-up None
Minimum N of Subjects 10
Cerebrovascular disease screening
Population CKD G4-G5 who receive transplants
Intervention Extracranial cerebrovascular testing (as screening)
Outcome Mortality (all-cause, cerebrovascular), graft failure/loss, stroke
Study design Longitudinal
Minimum duration of follow-up None
Minimum N of Subjects 100
ADPKD-related cerebral aneurysm screening
Population ADPKD
Intervention Intracranial aneurysm screen/test
Outcome Mortality (all-cause, cerebrovascular), stroke, intracranial aneurysm
Study design Any
Minimum duration of follow-up None
Minimum N of Subjects None
Hepatitis B treatment
Population CKD G5 (dialysis) with HBV who receive transplant
Intervention HBV treatment
Outcome HBV cure (HBV DNA-)
Study design Longitudinal
Minimum duration of follow-up None
Minimum N of Subjects 10
Perioperative testing, diabetes
Population Undergoing kidney transplantation
Intervention Diabetes testing (OGTT, FBG/FPG, RBG)
Outcome Perioperative complications, NODAT, change in perioperative management
Study design Any
Minimum duration of follow-up None
Minimum N of Subjects 100
Perioperative testing, thrombophilia
Population Kidney transplant candidates or CKD G5 (dialysis) with history of VTE, recurrent AV access throm-
bosis, or arterial thrombosis, or family history of VTE
Intervention Thrombophilia tests
Outcome Mortality (all-cause, thrombosis-related), graft loss/faiure, VTE, perioperative complications, 
change in perioperative management
Study design Any
Minimum duration of follow-up None
Minimum N of Subjects 200
Psychosocial testing
Population Kidney transplant candidates who receive transplants
Intervention Psychosocial scales/instruments, including: Psychosocial Assessment of Candidates for 
Transplantation (PACT), Stanford Integrated Psychosocial Assessment for Transplant (SIPAT), 
Transplant Evaluation Rating Scale (TERS)
Outcome Mortality (all-cause), graft failure/loss, adherence
TABLE 1. (Continued ) 
Continued
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Study design Longitudinal
Minimum duration of follow-up Any
Minimum N of Subjects 10
Retransplantation with history of nonadherence
Population History of graft failure/loss due to nonadherence
Intervention Retransplantation
Comparator None necessary
Outcome Mortality (all cause), graft failure/loss
Design Longitudinal
Minimum duration of follow-up None
Minimum N of subjects 100
Chest CT
Population CKD G4-G5
Intervention Low-radiation chest CT
Outcome Mortality (all-cause, lung cancer), lung cancer diagnosis
Study design Any
Minimum duration of follow-up Any
Minimum N of Subjects 10
Dual antiplatelet agents
Population Kidney transplant candidates who receive transplants
Intervention Dual antiplatelet treatment
Comparator Single antiplatelet treatment
Outcome Perioperative complications, Thombosis outcomes
Study design Comparative
Minimum duration of follow-up None
Minimum N of Subjects 10/arm
Hyperparathyroidism
Population Kidney transplant candidates who receive transplants with hyperparathyroidism (with or without 
hypercalcemia)
Intervention Parathyroidectomy
Comparator No surgery (or no comparator)
Outcome Mortality (all-cause), graft failure/loss, parathyroidectomy post-transplant
Study design Any
Minimum duration of follow-up None
Minimum N of Subjects 20
Peripheral artery disease testing
Population CKD G4-G5 with clinically-apparent PAD who receive transplant
Intervention Peripheral artery disease testing
Outcome Perioperative complications, Change in management, PAD post-transplantation
Study design Any
Minimum duration of follow-up Any
Minimum N of Subjects 10
ADPKD, autosomal dominant polycystic kidney disease; AV, arteriovenous; BMI, body mass index; CAD, coronary artery disease; CHF, congestive heart failure; CKD, chronic kidney disease; CT, computed 
tomography; eGFR, estimated glomerular filtration rate; FBG/FPG, fasting blood/plasma glucose; FSGS, focal segmental glomerulosclerosis; GFR, glomerular filtration rate; HBV, hepatitis B infection 
(DNA+, surface antigen +); HIV, human immunodeficiency virus infection; HUS, hemolytic uremic syndrome; MGRS, monoclonal gammopathy of renal significance; MGUS, monoclonal gammopathy of 
undetermined significance; MPGN, membranoproliferative glomerulonephritis; NODAT, new-onset diabetes after transplantation; OGTT, oral glucose tolerance test; PAD, peripheral artery testing; PRA, 
panel reactive antibodies; RBG, random blood glucose; SGA, subjective global assessment (nutrition assessment tool); TB, tuberculosis; UTI, urinary tract infection; VTE, venous thromboembolism.
TABLE 1. (Continued ) 
TABLE 2.
Hierarchy of outcomes
Hierarchy Outcome
Critical importance Mortality, graft loss, intracranial aneurysm rupture, stroke
High importance Graft loss (cause specific), cancer, infection, intracranial aneurysm, LV function, recurrent kidney disease
Moderate importance NODAT, nonadherence, uncomplicated UTI
LV, left ventrical; NODAT, new-onset diabetes after transplantation; UTI, urinary tract infection.
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representativeness of the population, and adjustment for 
different lengths of follow-up.7 Based on these characteris-
tics an overall assessment was made whether the study was 
of good, fair, or poor quality (Table 4).
Each reported outcome was then evaluated and given 
an individual grade depending on the quality of report-
ing and methodological issues specific to that outcome. 
However, the quality grade of an individual outcome could 
not exceed the quality grade for the overall study.
Grading the quality of evidence and the strength 
of a guideline recommendation
A structured approach, based on ‘Grades of 
Recommendation, Assessment, Development and 
Evaluation’ (GRADE)8–10 and facilitated by the use of evi-
dence profiles was used to grade the quality of the over-
all evidence and the strength of recommendations. For 
each topic, the discussion on grading of the quality of the 
Citations received from PubMed, Embase
and Cochrane databases
(32 individual searches: N = 45,914)
Full text articles retrieved
(762)
Excluded in
abstract screening
(45,152)
Excluded in
full text screening
(572)
Included studies: N = 190*
FIGURE 1. Search yield. *See Table 3 for enumeration by topic.
TABLE 3.
Work products for the guideline
Topics Topics Searched Citations Screened Included Studies, n Summary Tables / Evidence Profiles
1. Access to Transplantation Txp vs. WtL
Pre-emptive
1832
*
8
*
+
+
2. Age as a factor * * * *
3. Pediatric issues †  † †
4. Psychosocial assessment Psychosocial 449 2 +
5. Adherence issues Nonadherence 1137 1 +
6. Tobacco use Tobacco Cess’n 407 0 −
7. Obesity and related surgical issues Bariatric 2838 0 −
8. Diabetes Testing 738 7 +
9. Cause of ESKD Recurrence
Recur Tx
2285
231
86
0
+
−
10. Infection TB Tx
Nephrectomy
HIV
HBV
TB screen/Vac
925
1528
1138
622
1319
4
2
7
3
5
+
+
+
+
+
11. Malignancy Cancer Tx
Prostatectomy
Screening
1001
440
699
2
2
4
+
+
+
12. Pulmonary disease Chest CT 673 0 −
13. Cardiac disease Revasc
Echo
1144
2824
2
6
+
+
14. Peripheral artery disease PAD 1400 0 −
15. Neurologic disease ADPKD
Carotid Doppler
364
988
4
1
+
+
16. GI and liver disease −  0 −
17. Hematologic disorders Thrombophilia
Dual antiPlt
Gammopathies
546
3028
419
6
0
12
+
−
+
18. Bone and mineral metabolism PTx 1371 0 −
19. HLA testing Crossmatch 1342 0 −
Predictors of outcomes* Registries 3248 26 +
ADPKD, autosomal dominant polycystic kidney disease; antiPlt, antiplatelet drugs; Cess’n, cessation; CT, computed tomography; Echo, echocardiography; ESKD, end-stage kidney disease; GI, gas-
trointestinal; HBV, hepatitis B virus; HIV, human immunodeficiency virus; HLA, human leukocyte antigens; PAD, peripheral artery disease; PTx, parathyroidectomy; Recur, recurrence; Revasc, (cardiac) 
revascularization; TB, tuberculosis; Tx, treatment; Txp, (kidney) transplant; Vac, vaccination (all vaccinations); WtL, waitlist.
* Topics were covered by searches for registry studies.
† Covered within other topic searches and tables.
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evidence was led by the ERT, and the discussion regarding 
the strength of the recommendations was led by the Work 
Group Co-Chairs. The “strength of a recommendation” 
indicates the extent to which one can be confident that 
adherence to the recommendation will do more good than 
harm. The “quality of a body of evidence” refers to the 
extent to which our confidence in an estimate of effect is 
sufficient to support a particular recommendation.9
Grading the quality of evidence for each outcome 
across studies. Following GRADE, the quality of a body of 
evidence pertaining to a particular outcome of interest was 
initially categorized on the basis of study design. For each 
outcome, the potential grade for the quality of evidence 
for each intervention–outcome pair started at “high” but 
was then lowered if there were serious limitations to the 
methodological quality of the aggregate of studies, if there 
were important inconsistencies in the results across stud-
ies, if there was uncertainty about the directness of evi-
dence including limited applicability of the findings to 
the population of interest, if the data were imprecise (a 
low event rate [0 or 1 event] in either arm or a confidence 
interval [CI] spanning a range both <0.5 and >2) or sparse 
(only 1 study or total N < 500), or if there was thought to 
be a high likelihood of bias. The final grade for the qual-
ity of the evidence for an intervention–outcome pair could 
be one of the following four grades: “High”, “Moderate”, 
“Low” or “Very Low” (Table 5).
Grading the overall quality of evidence. The quality 
of the overall body of evidence was then determined on 
the basis of the quality grades for all outcomes of interest, 
taking into account explicit judgments about the relative 
importance of each outcome. The resulting four final cat-
egories for the quality of overall evidence were: “A”, “B”, 
“C” or “D” (Table 6).
Assessment of the net health benefit across all important 
clinical outcomes. The net health benefit was determined 
on the basis of the anticipated balance of benefits and 
harms across all clinically important outcomes (Table 7). 
The assessment of net benefit also involved the judgment 
of the Work Group and the ERT.
Developing the recommendations. Draft recommen-
dation statements were developed by the Work Group 
Co-Chairs and Work Group members. The health benefits, 
side effects, and risks associated with each recommenda-
tion were considered when formulating the guideline, as 
well as information on patient preferences when available. 
TABLE 4.
Classification of study quality
Good quality Low risk of bias and no obvious reporting errors; complete reporting of data. Must be prospective. If study of intervention, 
must be RCT.
Fair quality Moderate risk of bias, but problems with study or paper are unlikely to cause major bias. If study of intervention, must be 
prospective.
Poor quality High risk of bias or cannot rule out possible significant biases. Poor methods, incomplete data, reporting errors. Prospective 
or retrospective.
RCT, randomized controlled trial
TABLE 5.
GRADE system for grading quality of evidence
Step 1: Starting grade for 
quality of evidence based  
on study design Step 2: Reduce grade Step 3: Raise grade
Final grade for quality of evidence  
and definition
Randomized trials = High
Observational study = Low
 
Any other evidence = Very 
Low
Study quality −1 level if serious 
limitations −2 levels if very serious 
limitations
Consistency −1 level if important 
inconsistency
Directness −1 level if some uncertainty 
−2 levels if major uncertainty
Other −1 level if sparse or imprecise 
datac −1 level if high probability of 
reporting bias
Strength of association +1 level if 
stronga, no plausible confounders 
+2 levels if very strongb, no major 
threats to validity
Other +1 level if evidence of a 
dose–response gradient
+1 level if all residual plausible 
confounders would have reduced 
the observed effect
High = Further research is unlikely to 
change confidence in the estimate 
of the effect
Moderate = Further research is likely 
to have an important impact on 
confidence in the estimate of effect, 
and may change the estimate
Low = Further research is very likely 
to have an important impact on 
confidence in the estimate, and may 
change the estimate
Very Low = Any estimate of effect is 
very uncertain
  
  
  
GRADE, Grading of Recommendations Assessment, Development and Evaluation.
a Strong evidence of association is defined as “significant relative risk of >2 (<0.5)” based on consistent evidence from two or more observational studies, with no plausible confounders.
b Very strong evidence of association is defined as “significant relative risk of >5 (<0.2)” based on direct evidence with no major threats to validity.
c Sparse if there is only one study or if total N <500. Imprecise if there is a low event rate (0 or 1 event) in either arm or confidence interval spanning a range >1.
Adapted by permission from Uhlig K, Macleod A, Craig J et al.10
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Recommendation statements were revised in a multi-step 
process during face-to-face meetings and by subsequent 
drafts by email. All Work Group members provided feed-
back on initial and final drafts of the recommendation. A 
draft was then distributed for external public review and 
subsequently revised by the Work Group Co-Chairs and 
members based on this open feedback. Approval from all 
Work Group members must be received before publication 
of the final guideline.
Grading the strength of the recommendations. The 
strength of a recommendation is graded as level 1 or level 
2. Table  8 shows the KDIGO nomenclature for grading 
the strength of a recommendation and the implications 
of each level for patients, clinicians, and policy makers. 
Recommendations can be for or against doing something. 
Each recommendation includes an explicit link between 
the quality of the available evidence and the strength of 
that recommendation. However, Table  9 shows that the 
strength of a recommendation is determined not only by 
the quality of the evidence but also by other, often com-
plex judgments regarding the size of the net medical ben-
efit (potential risks vs benefit), values, and preferences, 
and costs. Formal decision analyses including cost analysis 
were not conducted.
Ungraded statements. This category was designed to 
allow the Work Group to issue general advice. Typically 
an ungraded statement meets the following criteria: it 
provides guidance based on common sense; it provides 
reminders of the obvious; and it is not sufficiently specific 
to allow for application of evidence to the issue and there-
fore it is not based on systematic evidence review. As such, 
ungraded statements may be considered to be relatively 
strong recommendations; they should not be interpreted as 
weak recommendations based on limited or poor evidence. 
Common examples include recommendations about fre-
quency of testing, referral to specialists, and routine 
medical care. We strove to minimize the use of ungraded 
recommendations.
This grading scheme, with two levels for the strength 
of a recommendation together with four levels of grad-
ing the quality of the evidence, as well as the option of an 
ungraded statement for general guidance, was adopted by 
the KDIGO Board in December 2008. The Work Group 
took on the primary role of writing the recommendations 
and rationale statements and retained final responsibility 
for the content of the guideline statements and the accom-
panying narrative. The ERT reviewed draft recommenda-
tions and grades for consistency with the conclusions of 
the evidence review.
Format for guideline recommendations. Each topic 
section contains one or more specific recommendations. 
Within each recommendation, the strength of recommen-
dation is indicated as level 1 or level 2 and the quality of 
TABLE 6.
Final grade for overall quality of evidence
Grade Quality of Evidence Meaning
A High We are confident that the true effect lies close to that of the estimate of the effect.
B Moderate The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.
C Low The true effect may be substantially different from the estimate of the effect.
D Very low The estimate of effect is very uncertain, and often will be far from the truth.
TABLE 7.
Balance of benefits and harms
When there was evidence to determine the balance of medical benefits 
and harms of an intervention to a patient, conclusions were categorized 
as follows:
• For statistically significant benefit or harm, report as “benefit [or harm] 
of intervention”.
• For non–statistically significant benefit or harm, report as “possible 
benefit [or harm] of intervention”.
• In instances where studies are inconsistent, report as “possible benefit 
[or harm] of intervention”.
• “No difference” can only be reported if a study is not imprecise.
• “Insufficient evidence” is reported if imprecision is a factor.
TABLE 8.
KDIGO nomenclature and description for grading recommendations
Grade* Implications
 Patients Clinicians Policy
Level 1
“We recommend”
Most people in your situation would 
want the recommended course of 
action and only a small proportion 
would not.
Most patients should receive the recom-
mended course of action.
The recommendation can be evaluated as 
a candidate for developing a policy or a 
performance measure.
Level 2
“We suggest”
The majority of people in your situa-
tion would want the recommended 
course of action, but many would not.
Different choices will be appropriate for 
different patients. Each patient needs 
help to arrive at a management deci-
sion consistent with her or his values 
and preferences.
The recommendation is likely to require 
substantial debate and involvement of 
stakeholders before policy can be deter-
mined.
*The additional category “Not Graded” is used, typically, to provide guidance based on common sense or where the topic does not allow adequate application of evidence. The most common examples 
include recommendations regarding monitoring intervals, counseling, and referral to other clinical specialists. Ungraded recommendations are generally written as simple declarative statements, but 
are not meant to be interpreted as being stronger recommendations than Level 1 or 2 recommendations.
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the supporting evidence is shown as A, B, C, or D. The rec-
ommendation statements and grades are followed by the 
rationale text summarizing the key points of the evidence 
base and the judgments supporting the recommendation. 
In relevant sections, considerations of the guideline state-
ments in international settings and suggested audit criteria 
are also provided where applicable. Important key points 
and research recommendations suggesting future research 
TABLE 9.
Determinants of strength of recommendation
Factor Comment
Balance between desirable and 
undesirable effects
The larger the difference between the desirable and undesirable effects, the more likely a level 1 recommendation 
is warranted. The narrower the gradient, the more likely a level 2 recommendation is warranted.
Quality of the evidence The higher the quality of evidence, the more likely a level 1 recommendation is warranted.
Values and preferences The more variability in values and preferences, or the more uncertainty in values and preferences, the more likely 
a level 2 recommendation is warranted. Values and preferences were obtained from the literature where pos-
sible or were assessed in the judgment of the Work Group when robust evidence was not identified.
Costs (resource allocation) The higher the costs of an intervention—that is, the more resources consumed—the less likely a level 1 recom-
mendation is warranted.
TABLE 10.
The Conference on Guideline Standardization (COGS) checklist for reporting clinical practice guidelines
Topic Topic Description How Topic Addressed
1. Overview material Provide a structured abstract that includes the guide-
line’s release date, status (original, revised, updated), 
and print and electronic sources.
Abstract and Executive Summary.
2. Focus Describe the primary disease/condition and interven-
tion/service/technology that the guideline addresses. 
Indicate any alternative preventative, diagnostic or 
therapeutic interventions that were considered during 
development.
ESKD, candidates for kidney transplantation. Interven-
tions and treatments to assess candidacy and prepare 
candidates for transplantation.
3. Goal Describe the goal that following the guideline is expected 
to achieve, including the rationale for development of 
a guideline on this topic.
This CPG is intended to assist the practitioner caring for 
patients with CKD who are potential candidates for 
transplantation, with the particular goals of minimizing 
graft loss and death while optimizing patients’ quality 
of life.
4. User/setting Describe the intended users of the guideline (eg, 
provider types, patients) and the settings in which the 
guideline is intended to be used.
Target audience is practicing nephrologists and other 
health care providers for adults and children with 
ESKD who are potential candidates for transplantation
5. Target population Describe the patient population eligible for guideline 
recommendations and list any exclusion criteria.
Adults and children with ESKD who are potential candi-
dates for transplantation
6. Developer Identify the organization(s) responsible for guideline 
development and the names/credentials/potential 
conflicts of interest of individuals involved in the 
guideline’s development.
Organization: KDIGO
Names/credentials/potential conflicts of interest of Work 
Group members involved in the guideline’s develop-
ment are disclosed in the Appendix: Biographic and 
Disclosure Information.
7. Funding source/sponsor Identify the funding source/sponsor and describe its role 
in developing and/or reporting the guideline. Disclose 
potential conflict of interest.
This guideline is funded by KDIGO.
8. Evidence collection Describe the methods used to search the scientific 
literature, including the range of dates and databases 
searched, and criteria applied to filter the retrieved 
evidence.
Topics were triaged either to a) systematic review, b) 
systematic search followed by narrative summary, 
or c) narrative summary. For systematic reviews, we 
searched PubMed, EMBASE, Cochrane Central Reg-
istry for trials, and Cochrane database of systematic 
reviews. Screening criteria for this and other topics 
are outlined in the Methods for Guideline Develop-
ment section. The search was updated through 
August 2017, with an additional search conducted in 
May 2019 and supplemented by articles identified by 
Work Group members through September 2019. We 
also searched for pertinent existing guidelines and 
systematic reviews.
Continued next page
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9. Recommendation 
 grading criteria
Describe the criteria used to rate the quality of evidence 
that supports the recommendations and the system 
for describing the strength of the recommenda-
tions. Recommendation strength communicates the 
importance of adherence to a recommendation and 
is based on both the quality of the evidence and the 
magnitude of anticipated benefits and harms.
Quality of individual studies was graded in a three-tiered 
grading system (see Table 4). Quality of evidence and 
strength of recommendations were graded following 
the GRADE approach (Tables 5, 6 and 8). The Work 
Group could provide general guidance in the form of 
ungraded statements.
10. Method for 
 synthesizing evidence
Describe how evidence was used to create recommen-
dations, eg, evidence tables, meta-analysis, decision 
analysis.
For systematic review topics, summary tables and 
evidence profiles were generated. For recommenda-
tions on interventions, the steps outlined by GRADE 
were followed.
11. Prerelease review Describe how the guideline developer reviewed and/or 
tested the guidelines prior to release.
The guideline has undergone external public review 
in October 2018. Public review comments were 
compiled and fed back to the Work Group, which 
considered comments in its revision of the guideline.
12. Update plan State whether or not there is a plan to update the 
guideline and, if applicable, an expiration date for this 
version of the guideline.
Following the publication of this guideline, requirement 
for updating will be assessed on a regular basis to 
determine if new evidence will lead to changes to the 
recommendations or may modify information provided 
herein.
13. Definitions Define unfamiliar terms and those critical to correct 
application of the guideline that might be subject to 
misinterpretation.
See Abbreviations and Acronyms.
14. Recommendations  
and rationale
State the recommended action precisely and the specific 
circumstances under which to perform it. Justify each 
recommendation by describing the linkage between 
the recommendation and its supporting evidence. 
Indicate the quality of evidence and the recommen-
dation strength, based on the criteria described in 
Topic 9.
Each guideline section contains recommendations for 
the management of potential kidney transplanta-
tion candidates. Each recommendation builds on a 
supporting rationale with evidence tables if available. 
The strength of the recommendation and the quality 
of evidence are provided in parenthesis within each 
recommendation.
15. Potential benefits and 
harms
Describe anticipated benefits and potential risks associ-
ated with implementation of guideline recommenda-
tions.
The benefits and harm for each comparison of interven-
tions are provided in summary tables and summarized 
in evidence profiles. The estimated balance between 
potential benefits and harm was considered when 
formulating the recommendations.
16. Patient preferences Describe the role of patient preferences when a recom-
mendation involves a substantial element of personal 
choice or values.
Recommendations that are level 2 or ”discretionary,” 
indicating a greater need to help each patient arrive 
at a management decision consistent with her or his 
values and preferences.
17. Algorithm Provide (when appropriate) a graphical description of the 
stages and decisions in clinical care described by the 
guideline.
See Figures 2 and 3.
18. Implementation 
 considerations
Describe anticipated barriers to application of the rec-
ommendations. Provide reference to any auxiliary 
documents for providers or patients that are intended 
to facilitate implementation. Suggest review criteria 
for measuring changes in care when the guideline is 
implemented.
These recommendations are global. Local versions of the 
guideline are anticipated to facilitate implementation 
and appropriate care. Review criteria were not sug-
gested because implementation with prioritization and 
development of review criteria have to proceed locally. 
Most recommendations are discretionary, requiring 
substantial discussion among stakeholders before 
they can be adopted as review criteria. The decision 
whether to convert any recommendations to review 
criteria will vary globally. Research recommendations 
were also outlined to address current gaps in the evi-
dence base.
CKD, chronic kidney disease; CPG, clinical practice guideline; ESKD, end-stage kidney disease; GRADE, Grading of Recommendations Assessment, Development and Evaluation; KDIGO, Kidney 
Disease: Improving Global Outcomes.
TABLE 10. (Continued )
Topic Topic Description How Topic Addressed
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to resolve current uncertainties are also outlined at the 
conclusion of each section.
Review of guideline development process
Several tools and checklists have been developed to 
assess the quality of the methodological process for sys-
tematic review and guideline development. These include 
the Appraisal of Guidelines for Research and Evaluation 
(AGREE 2) criteria, the Conference on Guideline 
Standardization (COGS) checklist,11 and the National 
Academy of Medicine’s (formerly known as Institute of 
Medicine) Standards for Systematic Reviews and Clinical 
Practice Guidelines We Can Trust.4,5 Table 10 shows the 
criteria which correspond to the COGS checklist and 
how each one is addressed in this guideline. Similarly, 
Supplemental Appendix B demonstrates the level of con-
currence with which this guideline corresponds to the 
National Academy of Medicine standards for systematic 
reviews and guidelines.4,5
SECTION 1: ACCESS TO TRANSPLANTATION
 1.1: We recommend that all patients with chronic kidney 
disease (CKD) G4-G5 (glomerular filtration rate 
[GFR] < 30 ml/min/1.73 m2) who are expected to 
reach end-stage kidney disease [ESKD] (excluding 
those listed in Rec 1.1.3) be informed of, educated 
about, and considered for kidney transplantation 
regardless of socioeconomic status, sex, gender 
identity, or race/ethnicity (1D).
 1.1.1: Refer potential kidney transplant candidates 
for evaluation at least 6 to 12 months before 
anticipated dialysis initiation to facilitate 
identification/work-up of living donors and 
plan for possible pre-emptive transplantation 
(Not Graded).
 1.1.2: Refer potential candidates already on dialy-
sis when medically stable and kidney failure 
deemed irreversible (Not Graded).
 1.1.3: We recommend not referring patients for kid-
ney alone transplant evaluation with the fol-
lowing conditions (1D):
 • Multiple myeloma (Rec 9.13.1.1), light 
chain deposition disease or heavy chain 
deposition disease (Recs 9.13.2.1, 9.13.2.2 
and 9.13.2.3) unless they have received a 
potentially curative treatment regimen and 
are in stable remission;
 • AL amyloidosis with significant extrarenal 
involvement (Recs 9.13.3.1 and 13.8);
 • Decompensated cirrhosis (consider for 
combined liver-kidney transplant; Recs 
10.5.2.4.2, 16.7.2);
 • Severe irreversible obstructive or restrictive 
lung disease (Rec 12.5);
 • Severe uncorrectable and symptomatic car-
diac disease that is deemed by a cardiolo-
gist to preclude transplantation (Rec 13.7);
 • Progressive central neurodegenerative dis-
ease (Rec 15.4).
 1.1.3.1: Document the reason(s) for not 
referring patients for transplant 
evaluation (Not Graded).
 1.1.3.2: Inform patients about the reason(s) 
for not referring for transplant 
evaluation (Not Graded).
 1.1.4 We recommend delaying transplant evalua-
tion in patients with the following conditions 
until properly managed (1D):
 • An unstable psychiatric disorder that 
affects decision-making or puts the candi-
date at an unacceptable level of post-trans-
plant risk (Rec 4.2);
 • Ongoing substance use disorder that affects 
decision-making or puts the candidate at 
an unacceptable level of post-transplant 
risk (Rec 4.3);
 • Ongoing, health-compromising nonadher-
ent behavior despite education and adher-
ence-based counseling (Rec 5.4);
 • Active infection (excluding hepatitis C 
virus infection) that is not properly treated 
(Rec 10.1.1);
 • Active malignancy except for those with 
indolent and low-grade cancers such as 
prostate cancer (Gleason score ≤ 6), and 
incidentally detected renal tumors (≤ 1 cm 
in maximum diameter) (Rec 11.2.1);
 • Active symptomatic cardiac disease (eg, 
angina, arrhythmia, heart failure, valvular 
heart disease) that has not been evaluated 
by a cardiologist (Rec 13.2);
 • Active symptomatic peripheral arterial dis-
ease (Rec 14.5);
 • Recent stroke or transient ischemic attack 
(Rec 15.1);
 • Active symptomatic: peptic ulcer disease 
(Rec 16.2.2), diverticulitis (Rec 16.3.1), 
acute pancreatitis (Rec 16.4.1), gallstone/
gallbladder disease (16.5.1), inflammatory 
bowel disease (Rec 16.6.1);
 • Acute hepatitis (Rec 16.7.2);
 • Severe hyperparathyroidism (Rec 18.2).
 1.2: Use a multidisciplinary team, which includes at a 
minimum a transplant physician, transplant sur-
geon and a health care professional experienced in 
the psychosocial aspects of transplantation, to eval-
uate and decide about suitability for kidney trans-
plantation (Not Graded).
 1.3: Approve patients for kidney transplantation that 
have an estimated survival which is acceptable 
according to national standards (Not Graded).
 1.3.1: Inform patients of their option to seek a sec-
ond opinion from another transplant center if 
they are declined (Not Graded).
 1.4: We recommend pre-emptive transplantation with a 
living kidney donor as the preferred treatment for 
transplant-eligible CKD patients (1A).
 1.4.1: We recommend pre-emptive transplantation 
(living or deceased donor) in adults when the 
estimated glomerular filtration rate (eGFR) is 
< 10 ml/min/1.73 m2 or earlier with symptoms 
(1D).
 1.4.2: We recommend pre-emptive transplantation 
(living or deceased donor) in children when 
the eGFR is < 15 ml/min/1.73 m2 or earlier 
with symptoms (1D).
BACKGROUND
For suitable candidates, kidney transplantation is the 
preferred form of kidney replacement therapy because 
it improves survival and quality of life and is less costly 
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than dialysis.2,12–15 Therefore, all patients with advanced 
chronic kidney disease (CKD) should be informed about 
options for kidney replacement therapy, including trans-
plantation. In most industrialized countries the majority 
of patients with end-stage kidney disease (ESKD) are older 
patients with many comorbidities. In most regions less than 
30% of prevalent dialysis patients are on the transplant 
waitlist but there is considerable variability.16,17 Given 
that demand for transplantable kidneys exceeds supply, it 
is reasonable to match patient survival with anticipated 
graft survival in order to avoid futility and maximize util-
ity. In fact, such an algorithm has been implemented for 
deceased donor kidney transplantation in some regions 
of the world.18,19 Therefore, a reasonable estimated life 
expectancy, according to national standards, should be 
considered a prerequisite in order to proceed with trans-
plant evaluation. The situation is different in living donor 
kidney transplantation. In this scenario, there is no wait-
ing-time, surgery is planned and ‘borderline’ recipients can 
be optimized pre-transplantation. The decision to proceed 
in such cases requires an open discussion with both the 
donor and recipient regarding anticipated outcomes.
RATIONALE
 • Kidney transplantation improves survival and quality of 
life and is less costly compared to dialysis.
 • Patients with advanced CKD who are expected to reach 
ESKD have the right to be informed of all available 
treatment options, including transplantation.
 • Demand for transplantable kidneys exceeds supply 
and thus candidacy for deceased donor transplantation 
needs careful evaluation.
 • Initiation of the transplant evaluation process depends 
on the patient’s subjective well-being, underlying kidney 
disease and rate of glomerular filtration rate (GFR) loss; 
number and severity of comorbid conditions; and the 
anticipated need for specialized testing (eg, coronary 
angiography).
 • Depending on the patient and region, the transplant 
evaluation process may take weeks to several months to 
complete.
 • Pre-emptive transplantation is the preferred treatment 
option but requires sufficient time to ensure a complete 
evaluation, and in many regions is restricted to those 
with a suitable living donor.
 • The timing of pre-emptive living donor transplantation 
needs individual decision making depending on patient’s 
symptoms and estimated GFR (eGFR).
 • Candidacy assessment is to some extent subjective; those 
declined should have the right to seek a second opinion.
Access to transplantation
Patients with progressive CKD (eg, CKD G4-G5) who 
are expected to reach ESKD should be informed about 
all available treatment options. This also includes the 
option of conservative management in cases with limited 
life expectancy or severe comorbidities. All patients have 
the right to be informed of all treatment options avail-
able, including transplantation, within their local health 
context and such discussions should occur regardless of 
the patient’s socioeconomic status, sex, age, gender iden-
tity, or race/ethnicity. Data demonstrate that on average, 
transplantation achieves superior medical outcomes (i.e., 
survival and quality of life) at lower cost as compared to 
dialysis, and transplantation is therefore considered to 
be the economically dominant and medically desirable 
therapy (Summary Tables: Kidney transplantation vs wait-
listing; Evidence Profiles: Kidney transplantation vs wait-
listing, Pre-emptive transplantation;).2 This does not mean 
that all CKD patients should be referred for transplant 
evaluation. Rather, patients should receive appropriate 
information to facilitate a discussion regarding transplan-
tation. Indeed, some factors such as progressive dementia, 
severe, uncorrectable cardiac dysfunction or certain can-
cers are common reasons for patients not to be considered 
for transplant evaluation.
Not all patients who may benefit from transplantation 
will actually receive a kidney transplant due to the short-
age of donor organs. Some regions have limited access to 
deceased donor kidney transplants based on anticipated 
survival.20–23 The threshold or estimated survival needed 
for transplant candidacy is not consistent,20–23 how-
ever prediction models have been created to guide clini-
cians.24–26 These tools, while not perfect, can be used to 
inform decision-making regarding eligibility for deceased 
donor transplantation. One of these prediction models24 
has been adopted for use in New Zealand.20 The United 
Kingdom (UK) Renal Association guidelines on trans-
plant eligibility state that patient survival must not be 
compromised by transplantation23 and that graft survival 
should not be limited by premature death (maximum 
benefit obtained from a limited resource).23 These state-
ments imply that clinical judgment, although subjective, is 
needed to ensure that appropriate candidates are referred 
for transplantation while those not likely to benefit should 
not proceed with evaluation.
Given the difficult decisions regarding candidacy in some 
patients, it is advisable to use a multidisciplinary team to 
evaluate and decide about suitability for transplantation. 
Since some comorbid conditions are only relative con-
traindications and can improve over time, a re-evaluation 
of patients initially denied may be advisable. Similarly, 
since much of this decision making is subjective in nature, 
patients should be informed of their option to seek a second 
opinion from another transplant center if they are declined.
There are many potential predictors of post-transplan-
tation outcomes for patients undergoing evaluation for 
kidney transplantation candidacy. In the following sections 
we discuss many of the factors separately. Numerous regis-
try studies have been analyzed to evaluate whether a host 
of risk factors may be predictors of post-transplantation 
outcomes. The registry studies are described in Summary 
Tables: Registry studies; Evidence Profiles: Pre-transplant 
predictors summarize the evidence regarding pre-transplan-
tation predictors of post-transplantation mortality, graft 
loss, and other outcomes.
Potential candidates should begin the evaluation pro-
cess at least 6 to 12 months before the anticipated start of 
kidney replacement therapy. Earlier evaluation may render 
some of the diagnostic tests outdated while a delay might 
lead to an incomplete work-up and miss the opportunity 
for pre-emptive transplantation. When a live donor is 
available or where pre-emptive deceased donor transplan-
tation is possible, cases should proceed when the eGFR is 
<10 ml/min/1.73 m2 (10 to 15 ml/min/1.73 m2 in pediat-
rics). Optimal timing, however, depends on factors other 
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than GFR such as the pace of renal decline, presence of 
symptoms and living donor preferences.
What prior guidelines recommend
Prior guidelines from Kidney Health Australia-Caring 
for Australasians with Renal Impairment (KHA-CARI) 
do not specifically address the topic of access to trans-
plantation.27 In the 2013 update, the KHA-CARI guide-
lines focused on the evaluation of pediatric patients and 
those with specific comorbidities (cardiovascular disease 
[CVD], diabetes mellitus [DM], viral infections, malignan-
cies, obesity). The American Society of Transplantation 
(AST) evaluation guideline does not have specific recom-
mendations on access to kidney transplantation.28 The 
Canadian Society of Transplantation (CST), however, has 
published consensus guidelines on eligibility for kidney 
transplantation in 2005.29 Similar to our current KDIGO 
guideline, the CST guideline strongly recommends (Grade 
A) to consider all ESKD patients without absolute con-
traindication for kidney transplantation. The European 
Renal Association-European Dialysis and Transplantation 
Association (ERA-EDTA) endorsed the 2009 KDIGO 
guidelines on management of the kidney transplant 
recipient but no specific statements are given regarding 
access or eligibility for kidney transplantation.30,31 The 
UK Renal Association guidelines have a detailed section 
on access to transplantation with several specific recom-
mendations, some of which are similar to this current 
guideline.23 Important recommendations include a state-
ment about equity of access to transplant regardless of 
gender or ethnicity; that all patients predicted to have an 
increased life expectancy with transplant should be evalu-
ated; all transplant programs should have written crite-
ria for transplant eligibility; and that patients should be 
active on the waitlist within six months of their antici-
pated dialysis start date.23
RESEARCH RECOMMENDATIONS
 • Randomized controlled trials (RCTs) should be con-
ducted on early versus late pre-emptive transplantation 
to determine whether important clinical outcomes are 
improved with earlier transplantation after accounting 
for lead-time bias.
 • RCTs should be conducted on prediction-model guided 
evaluation process versus usual care to determine if the 
proportion of appropriate candidates referred would 
increase with a reduction in inappropriate referrals and 
improvement in post-transplant survival.
RELEVANT SUPPLEMENTAL MATERIAL
Summary table: Kidney transplantation vs waitlisting
 Summary table: Kidney transplantation vs waitlisting 
(quality assessment)
Evidence profile: Kidney transplantation vs waitlisting
 Evidence profile: Effect of pre-emptive transplantation 
on post-transplant outcomes
Summary table of registry studies: Categorical outcomes
Summary table of registry studies: Quality assessment
 Evidence profile: Pre-transplant predictors of post-
transplant mortality
Evidence profile: Pre-transplant predictors of graft loss
 Evidence profile: Pre-transplant predictors of post-
transplant outcomes other than death and graft loss
SECTION 2: AGE
 2.1: Consider age in the context of other comorbidities, 
including frailty, that may impact outcome when 
deciding about suitability for kidney transplantation 
(Not Graded).
 2.1.1: We recommend not excluding patients from 
kidney transplantation because of age alone 
(1A).
RATIONALE
 • In adjusted analyses, kidney transplantation is associ-
ated with greater survival compared to similar patients 
on the waitlist – this is also true for elderly patients.
 • This survival advantage is maintained for elderly patients 
that receive advanced age donor kidneys, expanded-cri-
teria donor (ECD) kidneys or high kidney donor profile 
index (KDPI) kidneys.32
 • Estimated biological age together with several other risk 
factors for mortality should be taken into account when 
deciding about transplantation.
Patients aged 65 years and older represent the fastest 
growing group on the US waitlist with the numbers increas-
ing from 12.9% in 2003 to 21.2% of the waitlist in 2014.33 
This trend, although encouraging, fails to highlight the over-
all low rate of elderly patients waitlisted or transplanted. 
For instance, less than 5% of dialysis patients > 65 years are 
on the waiting list in the UK and only 10% are transplanted 
in the first 5 years.34 The elderly population brings with 
them a unique set of problems, including frailty, cognitive 
impairment, and comorbidities less commonly seen in the 
other age groups.35 All these factors have been associated 
with morbidity and mortality after transplantation,36–39 
although the trend has improved.40
Despite these issues, a number of studies have shown 
improvement in overall life expectancy (mortality risk 
40-60% lower) for those who have received a trans-
plant compared to similar waitlisted patients who have 
remained on dialysis.41–51 This survival advantage persists 
despite a significantly higher incidence of early mortal-
ity in some reports.40,41,45,46,52 A number of European and 
American studies53–72 have confirmed that transplanta-
tion in advanced age patients is associated with prolonged 
graft survival, since patient survival is often the limiting fac-
tor.53,55–59,62–64,66,67,69,70,73 On the contrary, other studies have 
shown higher mortality and worse death-censored graft sur-
vival in older recipients using ECD kidneys.34,54,59,61,68,71,74
Most elderly patients listed for transplantation will 
receive an ECD kidney, often from an older donor. 
Consequently, it is important to clarify if there is a survival 
advantage in using these kidneys compared to remaining 
on dialysis.41,42,44–50,52,75,76 In an attempt to minimize con-
founding factors, a paired-matched analysis has recently 
been published, comparing 823 recipients from donors 
over 65 years and counterparts listed with the same 
comorbidity.42 The risk for death was 2.66-fold higher 
in the dialysis group.42 In another analysis, the outcomes 
using donors ≥ 75 years were examined. Even using these 
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extreme aged kidneys, the survival benefit was clear with 
a 60% reduction in mortality for those transplanted com-
pared to the patients remaining on dialysis.47
What prior guidelines recommend
The CST eligibility guidelines state that advanced age 
per se is not a contraindication to kidney transplantation 
(Grade B level of evidence).29 The UK Renal Association 
guideline recommends that age is not a contraindication to 
transplantation but recognizes that age-related comorbid-
ity is an important limiting factor (1B level of evidence).23 
The AST,28 ERA-EDTA77 and KHA-CARI27 evaluation 
guidelines do not have specific recommendations regard-
ing age and access to kidney transplantation.
RESEARCH RECOMMENDATIONS
 • Tools for predicting the outcomes of transplantation 
for older candidates, and older candidates with multi- 
morbidity in particular, should be investigated.
 • Prospective studies to evaluate the utility of formally 
measuring fraility as part of the transplant evaluation 
process should be conducted.
SECTION 3: PEDIATRIC ISSUES
 3.1: We suggest performing a neurocognitive assessment 
in pediatric candidates who experienced end-stage 
kidney disease before the age of 5 years (2D).
 3.2: We suggest performing an academic assessment in 
pediatric candidates of school age who are experi-
encing academic difficulties (2D).
RATIONALE
Neurocognitive assessment evaluates all aspects of cog-
nitive function including global intelligence, language, 
problem-solving, visual-spatial perception, attention, 
memory, processing speed, motor function, emotion, and 
executive functions. This is distinguished from academic 
assessment, which evaluates academic performance in 
relation to expected performance based on age and on 
neurocognitive abilities. Neither neurocognitive nor aca-
demic assessments should be used to determine transplant 
eligibility. As noted in Recommendation 15.5.1, individu-
als should not be excluded from kidney transplantation 
because of non-progressive intellectual, developmental, or 
cognitive disability. Neurocognitive and academic assess-
ments are suggested for the following reasons:
 • Abnormalities in cognitive function and academic per-
formance are common in pediatric kidney transplant 
recipients, but may be unrecognized without formal 
testing.
 • Identification of cognitive and/or academic deficits will 
facilitate specialized services if needed.
 • Planning of transition to adult care and expectations 
for self-care may be modified by results of cognitive 
assessment.
Children with CKD are at high risk for abnormal neu-
rodevelopment due to a combination of factors includ-
ing the impact of uremic toxins on the developing brain, 
anemia, malnutrition, hypertension, and impaired inter-
actions with the environment due to illness and frequent 
medical procedures.78 Cognitive deficits result in impaired 
academic performance and may also influence self-care 
abilities. While the intelligence of the majority of pediat-
ric kidney transplant recipients is in the average range, a 
greater than expected proportion are in the impaired, bor-
derline, or low average range compared with healthy chil-
dren.79 Memory deficits have been reported consistently in 
the pediatric CKD population; attention problems are also 
common.78,80 However, cognitive deficits may be unrec-
ognized; the proportion of pediatric kidney transplant 
recipients receiving special educational services is lower 
than expected given the level of cognitive impairment.80 
Academic performance may be lower than expected for 
age for many reasons including frequent illnesses and 
school absences, chronic fatigue, and cognitive develop-
mental delays and dysfunction.
Assessment of cognitive and academic function will 
help set appropriate expectations for patients, parents, 
and educational professionals, and will guide provision of 
appropriate services, including accommodations and sup-
port.79 Furthermore, cognitive assessment may uncover 
deficits in executive functions (eg, planning, organization, 
problem-solving) that could influence the patient’s abil-
ity to engage in self-care behaviors such as medication 
adherence.79
The specific cognitive deficits identified in children 
with CKD and kidney transplants vary somewhat across 
studies. There are several potential reasons for these 
inconsistencies, including changes in the severity of defi-
cits over time due to improvements in care, heterogeneity 
of the populations studied, small sample sizes, and inclu-
sion or exclusion of children with comorbid neurologi-
cal conditions. Children with moderate to severe CKD 
pre- transplant have consistently shown poorer cognitive 
function than healthy children or sibling controls.78,81 
There is some evidence that cognitive function improves 
following kidney transplant.81–83 Kidney transplant 
recipients have better cognitive function than children 
with moderate to severe CKD pre-transplant,78,81,82 but 
still show deficits compared with healthy children.80,84 
Improvements in attention and memory following trans-
plant were observed in one longitudinal study.83 Younger 
age at onset of ESKD, longer duration of dialysis, and 
older age at transplant were associated with poorer cog-
nitive function.80,84
Neurocognitive and academic performance assess-
ment must be done by a qualified psychologist. Results 
are effort-dependent; assessment tools may not be avail-
able in all languages and some may be difficult to inter-
pret in children from non-Western cultural backgrounds. 
No studies have examined the impact of pre-transplant 
neurocognitive and/or academic performance assessment 
on long-term outcomes. Therefore, the value of such 
assessments in improving academic, occupational, qual-
ity of life or self-care (and therefore graft) outcomes is 
unknown.
What prior guidelines recommend
To our knowledge, no prior guidelines addressed the 
issue of neurocognitive or academic assessment in pediat-
ric candidates.
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RESEARCH RECOMMENDATION
 • Studies are needed to assess the frequency with which 
pre-transplant neurocognitive and academic assessments 
lead to implementation of specialized education pro-
grams, educational accommodations or modifications in 
self-care training or expectations, as well as whether pre-
transplant assessments lead to improved educational, 
vocational and graft outcomes. Economic analyses or 
cost-benefit studies would also be helpful, especially in 
resource-limited regions.
SECTION 4: PSYCHOSOCIAL ASSESSMENT
 4.1: We suggest performing a psychosocial assessment in 
all candidates (2D).
 4.1.1: Refer candidates to a health care professional 
experienced in the psychosocial aspects of 
kidney transplantation (eg, social worker, 
psychologist, psychiatrist, psychiatric nurse/
nurse practitioner) to perform this assessment 
(Not Graded).
 4.1.2: Use measurement tools completed by the 
patient and/or evaluating clinician to supple-
ment the assessment (Not Graded).
 4.1.2.1: We suggest not using measurement 
tools in isolation to determine trans-
plant candidacy (2D).
 4.1.3: Refer candidates with a diagnosable psychiat-
ric or psychological condition, substance use 
disorder or nonadherence for pre-transplant 
counseling and services to enhance the likeli-
hood of a favorable post-transplant outcome 
(Not Graded).
 4.2: We recommend not transplanting patients with an 
unstable psychiatric disorder that affects decision-
making or puts the candidate at an unacceptable 
level of post-transplant risk (1C).
 4.3: We recommend not transplanting patients with 
ongoing substance use disorder that affects deci-
sion-making or puts the candidate at an unaccepta-
ble level of post-transplant risk (1C).
 4.4: We suggest that patients without current social 
support be considered for kidney transplantation 
if they are able to care for themselves and have an 
identified support plan in place prior to transplanta-
tion (2D).
RATIONALE
The psychosocial assessment of potential kidney trans-
plant candidates typically occurs within a multidisci-
plinary context. It provides an opportunity to assess the 
patient’s psychological, behavioral health, and social 
network strengths and limitations that may facilitate or 
hinder adaptation to the complexities and challenges of 
chronic illness, transplantation, lifestyle modifications, and 
long-term survivorship. Moreover, a comprehensive psy-
chosocial assessment allows for identification of factors 
that may adversely impact the success of transplantation 
and for targeted interventions to be implemented, thereby 
enhancing the likelihood of a favorable outcome for the 
patient.
Published guidelines, consensus statements, trans-
plant center protocols, regulatory requirements, and 
clinical practice articles representing several countries 
were reviewed for content pertaining to the psychosocial 
assessment.27,28,77,85–93 While most guidelines stress the 
relative importance of a psychosocial assessment, we con-
cluded that there is wide variability in practice with respect 
to this component of the transplant evaluation process. 
Psychosocial evaluation is mandatory in some regions, at 
the discretion of transplant centers in other regions, or not 
performed in some parts of the world due to lack of quali-
fied mental health professionals. Additionally, even when a 
psychosocial assessment is performed as part of the trans-
plant evaluation, there is no empirical evidence on who 
should conduct the assessment, how the assessment should 
be conducted, what factors are most essential to evaluate, 
and how to handle psychosocial issues that are uncovered 
during the assessment.85–87 Recommendations regarding 
these elements of the psychosocial assessment are based 
on expert opinion. Evidence is limited and generally weak 
regarding the predictive role of pre-transplant psychoso-
cial factors on post-transplant outcomes. Consequently, 
recommendations put forth regarding the psychosocial 
assessment, like prior guidelines, are based largely on 
expert opinion.
Should all candidates have a psychosocial 
assessment?
Our suggestion is consistent with prior guidelines, 
regulations in some countries, and expert opinion, which 
describe the psychosocial assessment as an important and 
essential part of the evaluation of each potential transplant 
candidate.27,28,77,85–92 However, we recognize that in cer-
tain regions of the world, there may be limited or no quali-
fied health care professionals available to conduct such 
assessments on behalf of the transplant program.
Who should perform the psychosocial 
assessment?
The psychosocial assessment should be conducted by a 
qualified health care professional. The type of health care 
professional (eg, social worker, psychologist, psychiatrist, 
psychiatric nurse practitioner) may vary from center to 
center and region to region; however, the health care pro-
fessional should be knowledgeable of and experienced in 
the psychosocial aspects of transplantation.
How should the psychosocial assessment be 
performed?
There is considerable variability in how psychosocial 
assessments are performed across transplant programs and 
regions. The different formats of the psychosocial assess-
ment and their relationship to post-transplant outcomes 
have not been the focus of clinical investigation. However, 
consistent with sound clinical practice, the psychosocial 
assessment should be conducted face-to-face with the 
transplant candidate. In addition to conducting an inter-
view, it may be important in some instances to obtain col-
lateral or corroborating information from one or more 
members of the patient’s identified social network who 
will provide caregiving assistance throughout the trans-
plant process. In rare instances, it may not be possible to 
conduct a face-to-face interview assessment of the patient 
(eg, medically incapacitated and unable to participate 
reliably in interview), thus requiring the clinician to rely 
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heavily on collateral sources (eg, family member, primary 
care physician) for information to complete the psychoso-
cial assessment.
The psychosocial elements considered essential to 
examine in a transplant candidate also vary considerably 
based on availability of qualified mental health profes-
sionals, cultural factors, regulatory requirements, differ-
ent health care systems, and other factors. Elements of the 
psychosocial assessment should include: a mental status 
examination; cognitive evaluation to ensure valid decision-
making capacity and ability to provide informed consent 
for transplantation; understanding of the transplant pro-
cess; motivation for transplantation; expectations of the 
outcomes (including graft/patient survival, symptom relief, 
and quality of life); ability and willingness to form a col-
laborative relationship with the transplant team; past and 
current psychiatric/psychological disorders; past and cur-
rent substance use (eg, alcohol, tobacco, drugs); past and 
current adherence to recommendations regarding medical 
treatment and lifestyle modifications; social history (eg, 
education, occupation, financial resources, important rela-
tionships, living circumstances); cultural factors relevant 
to chronic illness and transplantation; and availability and 
stability of the social network as it pertains to meeting any 
caregiving needs of the patient. Assessment of these ele-
ments may allow the clinician to make an informed con-
ceptualization of the patient’s relative personal strengths 
and limitations that may be relevant to favorable psycho-
social adjustment throughout the transplant continuum of 
care.85–87,93–95
Clinician rating scales (eg, Psychosocial Assessment 
of Candidates for Transplantation, Stanford Integrated 
Psychosocial Assessment for Transplant, Transplant 
Evaluation Rating Scale, INTERMED, Psychosocial 
Assessment Tool, Psychosocial Transplant Evaluation 
Scale) may be used to supplement the psychosocial assess-
ment. These instruments aid in the identification of patient 
strengths and limitations as they pertain to psychosocial 
readiness for transplantation.96–103 However, we suggest 
that such tools not be used in isolation to determine can-
didacy for transplantation. There is insufficient evidence 
regarding their validity and reliability, and they may have 
limited applicability beyond the US.
What psychosocial criteria preclude listing for 
transplantation?
In our evidence review, we found limited and generally 
weak evidence regarding the utility of specific psychosocial 
elements in predicting post-transplant outcomes (psycho-
social or medical) (Summary Table and Evidence Profile: 
Psychosocial). While some prior reports and guidelines sug-
gest that certain psychiatric conditions, severe developmen-
tal disorders, substance use, lack of social support, and a 
history of nonadherence may be contraindications to trans-
plantation, the literature was very inconsistent about the 
presence of these factors pre-transplant and the association 
with poor post-transplant outcomes. Similarly, the absence 
of these psychosocial risk factors was not consistently asso-
ciated with favorable post-transplant outcomes.87,94,95 A 
history of affective disturbances such as anxiety or depres-
sion is not uncommon among transplant candidates.104–108 
While there is evidence that these affective disorders may be 
associated with graft function and mortality, such distress 
that occurs early post-transplant is more strongly associ-
ated with mortality than depression and anxiety that was 
present prior to transplantation.105,109–114 Therefore, we 
recommend that these affective conditions not necessarily 
exclude transplantation. Rather, identifying the presence of 
these factors provides the transplant center with an oppor-
tunity to recommend or provide appropriate treatment or 
additional support to remove these potential barriers and 
to optimize outcomes.
While the primary goal of the psychosocial assess-
ment is to identify areas necessitating additional sup-
port or intervention, some conditions may interfere with 
a patient’s ability to engage in self-care activities at a 
level necessary to achieve favorable transplant outcomes. 
Substance use disorder – which may include alcohol and/
or drugs – has been found to be an independent risk fac-
tor for medication nonadherence and associated graft fail-
ure.115–118 However, the definition of substance abuse or 
dependency, the duration and frequency of use, and the 
abstinence duration prior to transplantation have been 
variably applied in the literature. As such, there is weak 
evidence regarding which patients, if any, with a history 
of substance abuse should be precluded from transplanta-
tion. Moreover, while much has been written about the 
relationship between alcohol abuse and outcomes, very 
little is known about the association between drug use, 
abuse, or dependency (eg, marijuana, cocaine, prescrip-
tion drugs) and post-transplant psychosocial and medi-
cal outcomes. Patients with recent or current substance 
use disorder should be further evaluated by a substance 
abuse specialist and, as appropriate, offered or referred 
for counseling or treatment. Given the high relapse rate 
both in and beyond the transplant population, written 
policies regarding abstinence expectations, toxicology 
screening, and how relapses will be managed by the trans-
plant program while the patient is on the waiting list are 
advisable.119 We recommend that patients with ongoing 
substance use disorder (as defined in the Diagnostic and 
Statistical Manual of Mental Disorders)120 despite appro-
priate treatment, that adversely impacts decision-making 
or increases the level of post-transplant risk that is higher 
than acceptable to the transplant program not be accepted 
for transplantation.
An available and stable support system that provides 
patients with both instrumental and practical assistance 
throughout the transplant process is often considered an 
integral component of the evaluation process.28,91,92 While 
the presence of a caregiver is based on sound clinical judg-
ment, there is little evidence suggesting that the absence 
of social support is an absolute contraindication to trans-
plantation.121 However, in light of the complexities of pro-
gressive kidney failure, its treatment, and the associated 
demands of post-transplant recovery and rehabilitation, 
we recommend that patients who are unable to engage 
independently in self-care activities have an identified sup-
port system in place prior to transplantation.
What prior guidelines recommend
Prior guidelines from the CST and the AST suggest or 
recommend a psychosocial evaluation of all transplant can-
didates,28,29 while other guidelines are either silent about 
the need for such evaluation (KHA-CARI; Transplantation 
Society of Australia and New Zealand [TSANZ]) or fall 
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short of suggesting psychosocial assessment for all trans-
plant candidates (ERA-EDTA).27,88,90
The CST and AST guidelines indicate that mental illness 
alone is not a contraindication to transplantation and that 
patients with psychiatric or psychological disorders should 
be referred for treatment.28,29 The ERA-EDTA states that 
transplant candidates with a history of suicide attempt and 
psychosis are “poor candidates,” while the KHA-CARI 
and TSANZ guidelines are silent on evaluation and/or 
selection of candidates with a psychiatric or psychological 
disorder.27,88,90
All prior guidelines from the CST, AST, ERA-EDTA, 
KHA-CARI, and TSANZ considered ongoing or active 
substance abuse to be a contraindication to transplanta-
tion.27–29,88,90 The CST and AST guidelines further sug-
gested delaying transplantation until patients with a history 
of substance abuse have received appropriate treatment and 
achieved a minimum abstinence period of six months.28,29
The CST, AST, ERA-EDTA, and KHA-CARI guidelines 
are silent about the role of social support in determining 
transplant eligibility.27–29,88 The TSANZ guidelines suggest 
that patients with cognitive or neuropsychiatric deficits 
may not be appropriate transplant candidates if they do 
not have a caregiver to facilitate post-transplant medica-
tion adherence.90
RESEARCH RECOMMENDATIONS
 • RCTs are needed to examine the effectiveness of differ-
ent evaluation strategies designed to reliably identify 
psychosocial risk factors predictive of post-transplant 
outcomes.
 • Multicenter prospective studies are needed to assess the 
validity and reliability of existing and emerging clini-
cian rating scales for identifying psychosocial risk fac-
tors during the evaluation process.
 • Multicenter prospective studies and psychosocial risk- 
prediction modeling are needed to isolate the unique 
contribution of psychosocial factors on different post-
transplant outcomes (eg, psychosocial functioning, 
nonadherence, rehospitalization rates, complications, 
healthcare utilization, graft survival, patient survival).
 • RCTs are needed to test interventions given during the 
pre-transplant period that will reduce the risk of poor 
post-transplant psychosocial and medical outcomes.
RELEVANT SUPPLEMENTAL MATERIAL
Summary table: Psychosocial
Summary table: Psychosocial (quality assessment)
Evidence profile: Psychosocial testing
SECTION 5: ADHERENCE
 5.1: Assess adherence and adherence barriers pre- 
transplantation to allow for appropriate education, 
counseling and post-transplant surveillance (Not 
Graded).
 5.2: Refer candidates with a history of health-compro-
mising nonadherent behavior or identified adher-
ence barriers for adherence-based education and 
counseling pre-transplant (Not Graded).
 5.3: We suggest that candidates with a history of graft 
loss due to nonadherence undergo adherence-based 
counseling prior to re-transplantation (2D).
 5.4: We recommend that candidates with a history of 
nonadherence be considered for transplantation 
unless there is ongoing, health-compromising non-
adherent behavior (1D).
RATIONALE
Non-adherence is defined as “deviation from the pre-
scribed medication regimen sufficient to adversely influ-
ence the regimen’s intended effect.”122 Although the exact 
degree of deviation required to result in a poor outcome 
is unknown, even minor deviations have been linked to 
inferior outcomes among kidney transplant recipients.123 
Although some have suggested that a history of poor 
adherence should exclude patients from transplant candi-
dacy, our ability to predict future adherence behavior from 
past behavior is imperfect. Furthermore, not all adherence 
behaviors are equivalent; poor adherence in one domain 
(eg, dietary and fluid restriction) does not necessarily pre-
dict poor adherence in another (eg, medication adherence). 
In addition, adherence may change over time, particularly 
among developing adolescents and young adults. The rec-
ommendations provided are based on the following:
 • Poor adherence to immunosuppressive medication is 
one of the most important factors limiting graft survival.
 • Identification of patients at high risk for post-transplant 
non-adherence may allow more intensive monitoring 
and intervention to promote better adherence.
 • Identification of patients’ barriers to adherence before 
transplant may permit pre-transplant intervention to 
address these barriers.
 • Pre-transplant nonadherence modestly predicts post-
transplant nonadherence, but not all adherence behav-
iors are equivalent; evidence that nonadherence to 
dialysis treatments or dietary restrictions predicts post-
transplant medication nonadherence is lacking.
 • Adherence behavior may change over time.
 • Denying patients who admit non-adherence a chance 
for another transplant will ‘punish honesty’ and may 
lead to more covert non-adherence and undermine the 
therapeutic relationship
Pre-transplant adherence assessment
Medication non-adherence is estimated to be responsi-
ble for at least 15% of graft failures and about 50% of 
late acute rejections.124 Solid organ transplant recipients 
who reported pre-transplant non-adherence have been 
shown to have a 3.1 to 7.9 times higher likelihood of post-
t ransplant non-adherence than those who did not report 
nonadherence.121,125 However, these may represent over-
estimates of the ability of pre-transplant non-adherence 
to predict post-transplant non-adherence. Patients willing 
to report pre-transplant nonadherence may also be more 
likely to report post-transplant nonadherence.
Important stakeholders, including members of the gen-
eral community, patients, and transplant healthcare pro-
fessionals have expressed the view that adherence behavior 
should be considered in organ allocation decisions.126–128 
However, very few transplant centers have an objective 
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protocol in place to assess pre-transplant adherence. A 
survey of 79 US transplant centers found that only 51% of 
respondents had any knowledge of a protocol to evaluate 
pre-transplant adherence, and of these, only 10% used a 
standardized assessment questionnaire.129 The most com-
monly used means of assessing pre-transplant adherence 
was the number of missed hemodialysis sessions. However, 
it is not known if missed hemodialysis sessions predicts 
poor medication adherence post-transplant; transporta-
tion problems were reported as the most frequent reason 
for missing hemodialysis sessions.129 In contrast, the rea-
son for medication non-adherence post-transplant most 
frequently cited by survey respondents was an inability to 
pay for medications (73%). When assessing pre-transplant 
adherence, it is important to consider the likelihood that 
non-adherence in one domain of treatment will predict 
non-adherence in another. For example, failure to adhere 
to dietary and fluid restrictions (i.e., to NOT do some-
thing) may be a poor predictor of a patient’s ability to take 
medication on a strict schedule (i.e., to DO something). 
Furthermore, the complexity and burden of tasks required 
for self-care pre-transplant (eg, dietary and fluid restric-
tions, regular dialysis treatments, erythropoiesis stimulat-
ing agent injections, phosphate binders, numerous other 
medications three or more times per day) may be over-
whelming compared with the tasks post-transplant.
Pre-transplant adherence assessment should include not 
only evaluation of the patient’s adherence to treatment, but 
assessment of personal barriers to medication adherence, 
and identification of risk factors for poor adherence post-
transplant. Such a comprehensive assessment will permit 
identification of high risk patients for more intensive moni-
toring and potential interventions, and will allow care pro-
viders to address adherence barriers before problems arise.
Adherence as a criterion for transplant
Although pre-transplant non-adherence is a risk factor 
for post-transplant non-adherence,121,125 concordance is 
not perfect. A study of 924 kidney transplant recipients 
found 30% to have self-reported non-adherence pre-
transplant. The proportion reporting non-adherence at 
6 months post-transplant was only 10%, and at 3 years 
post-transplant was 20%.125 However, survival bias may 
have resulted in underestimation of the prevalence of 
non-adherence as non-adherent patients are likely to lose 
their grafts before adherent patients and therefore be less 
likely to contribute to the prevalence of non-adherence 
over time. Whether the patients exhibiting non-adherence 
post-transplant had also been non-adherent pre-transplant 
was not reported. It must also be recognized that accu-
rate adherence assessment is difficult; many patients with 
suboptimal adherence may not be detected. It would be 
difficult to base such a critical decision regarding access 
to transplantation on a questionable measure such as per-
ceived adherence. Furthermore, poor adherence does not 
universally lead to poor outcomes (Summary Table and 
Evidence Profile: Nonadherence). Patients with excellent 
human leukocyte antigen (HLA) matching may tolerate 
some non-adherence, and have shown outcomes similar to 
those of adherent patients with poorer HLA matching.130
Although we advise that pre-transplant non-adherence 
should not disqualify patients from transplant candidacy, 
we do not suggest that pre-transplant non-adherence be 
ignored. The preparation for and timing of transplanta-
tion should be carefully considered for patients at high risk 
for post-transplant non-adherence. Transplantation before 
adherence barriers are addressed, or before there is some 
evidence of willingness to adhere to treatment may not be 
in the patient’s best interest. Post-transplant non-adher-
ence will likely increase the risk of sensitization, limiting 
options for another transplant should one be needed. Non-
adherence post-transplant may also lead to repeated and 
intensive immunosuppression to treat rejection, increasing 
the risks of infectious and malignant complications. Patients 
should be informed of the substantial risks associated with 
post-transplant non-adherence, including limited opportu-
nity for another transplant due to sensitization. Preparation 
for transplant should include efforts to identify and address 
each patient’s personal barriers to adherence.
RE-TRANSPLANT FOLLOWING GRAFT LOSS DUE 
TO NON-ADHERENCE
Greater controversy surrounds the question of whether 
a patient who has lost a graft to non-adherence should 
be offered another transplant. The general community, 
patients, and transplant healthcare professionals often 
react strongly to non-adherent behavior, considering non-
adherent individuals less deserving of an organ than adher-
ent individuals.126–128 The scarcity of organs, along with 
the poorer outcomes observed following re-transplanta-
tion, has been cited as justification for denying repeat trans-
plants to patients who lost a graft to non-adherence.124 A 
strict utilitarian approach would exclude patients with 
prior graft loss due to non-adherence from re-transplan-
tation, directing organs preferentially to low risk patients 
with the longest potential graft survival. A comparison of 
35 patients re-transplanted after graft loss following overt 
non-adherence with 552 patients re-transplanted without 
non-adherence showed a trend towards poorer graft and 
patient survival for the non-adherent group.131 Although 
survival differences were not statistically significant, study 
power was limited. Such differences, if true, would support 
excluding non-adherent patients from re-transplant under 
utilitarianism. However, strict utilitarianism is not applied 
to other decisions regarding transplant candidacy. For 
example, patients at high risk of disease recurrence (such 
as focal segmental glomerulosclerosis [FSGS]), or at high 
immunologic risk, are routinely accepted for transplanta-
tion. If we are to be consistent in our decisions, strict utili-
tarianism cannot be applied to the non-adherent patients.
The difficulty in accurately identifying non-adherence also 
makes the exclusion from re-transplantation problematic. 
Only when a patient admits non-adherence can it be con-
firmed. An open dialogue between patients and healthcare 
professionals is critical to high quality care and is important 
to promoting good adherence. If patients fear that honesty 
about non-adherence will reduce their opportunities for re-
transplantation, they may be less likely to report it.
In a study of 114 kidney transplant recipients who lost 
a graft to non-adherence, adolescent issues and financial 
problems were the most common reasons given for non-
adherence; 29% were pediatric recipients, the majority of 
whom lost their grafts during adolescence or early young 
adulthood.131 Interestingly, pediatric recipients showed 
a lower rate of non-adherence after re-transplantation 
© 2020 Wolters Kluwer  S41
than adult recipients (38% vs 55%).131 These data show 
that behavior change is possible. Indeed, among pediatric 
recipients, behavior change is expected as a part of nor-
mal neurodevelopment. Neuroscientists hypothesize that 
the risk-taking behavior common among adolescents and 
young adults may reflect relatively rapid development of 
the limbic system (associated with reward-seeking and 
emotion) paired with slow maturation of the prefrontal 
cortex (associated with impulse control, planning, and 
organization).132 Brain development continues well into 
the twenties.133,134 The coincident decrease in graft fail-
ure risk after the age of about 25 years may reflect better 
adherence associated with brain maturity.135
Excluding patients who have lost a graft to non- 
adherence from re-transplant may particularly discrimi-
nate against pediatric recipients. Not only do pediatric 
recipients likely have a higher risk of non-adherence when 
they reach adolescence than other age groups – possibly 
due to brain immaturity – but they also require graft func-
tion for many more years than older recipients. Denying an 
individual who lost a graft to non-adherence during ado-
lescence any hope of re-transplant effectively condemns 
him or her to a dramatically shortened life expectancy and 
an inferior quality of life. Furthermore, such an approach 
would necessitate prolonged high-cost dialysis, rather than 
relatively economical transplant.
Proceeding with re-transplantation for a patient who 
has lost a graft to non-adherence should be undertaken 
carefully. A protocol for selective retransplantation was 
proposed in 2009 (Figure 2).131 Although there is no evi-
dence that this protocol results in better outcomes than 
would be seen without the protocol, the approach is rea-
sonable and has the potential to be beneficial.
What prior guidelines recommend
Prior guidelines from KHA-CARI,27 AST,28 CST,29 and 
ERA-EDTA88 all suggested a pre-transplant assessment 
aimed at identifying risk factors for nonadherence in order 
to target high-risk patients for adherence education and 
counselling. KHA-CARI guidelines specifically discussed 
adherence only in relation to pediatric patients, and did 
not recommend delaying transplant due to nonadher-
ence.27 The AST guidelines, which discussed adherence for 
both adult and pediatric candidates, suggested consider-
ing delaying transplant for patients who continue to dem-
onstrate poor adherence despite intervention.28 The CST 
guidelines were more specific, recommending that trans-
plantation be delayed until adherence has been demon-
strated for at least 6 months.29 Although the ERA-EDTA 
guidelines stated that those with a history of poor adher-
ence are poor candidates for transplant, the guidelines rec-
ommended against excluding those with a past history of 
nonadherence from repeat transplantation.88
RESEARCH RECOMMENDATIONS
 • Studies examining trajectories of adherence from pre- to 
post-transplant would be helpful in understanding the 
true value of pre-transplant non-adherence in predicting 
post-transplant non-adherence.
 • Clinical trials are needed to test the value of pre-trans-
plant adherence evaluation and selective re-transplant 
protocols, such as the one shown above, in improving 
clinical outcomes for those transplanted following graft 
failure due to non-adherence.
RELEVANT SUPPLEMENTAL MATERIAL
Summary table: Nonadherence
Summary table: Nonadherence (quality assessment)
Evidence profile: Nonadherence
SECTION 6: TOBACCO
 6.1: Assess past and present use of tobacco products by 
candidates at transplant evaluation and while on 
the waiting list (Not Graded).
 6.2: We recommend counseling all candidates to avoid 
tobacco products before and indefinitely after trans-
plantation (1B).
 6.3: We recommend offering a tobacco cessation pro-
gram to candidates who are using tobacco products 
(1B).
 6.4: We recommend that candidates abstain from 
tobacco use, at a minimum 1 month prior to wait-
listing or living donor transplantation (1B).
 6.5: We suggest chest computed tomography (CT) for cur-
rent or former heavy tobacco users (≥ 30 pack-years) 
as per local guidelines to screen for occult lung cancer 
(2C).
BACKGROUND
Smoking after transplantation is associated with poor 
outcomes in both the short and long term after kidney 
transplantation.
RATIONALE
 • There is high quality evidence that smokers have an 
increased risk of perioperative respiratory complications.
 • There is high quality evidence that people who smoke 
have an increased risk of CVD, non-skin malignancy, 
and death after kidney transplantation compared to 
non-smokers.
 • There is high quality evidence that smoking cessation 
programs are more likely to result in patients stopping 
smoking compared to no intervention.
 • There is moderate quality evidence that an annual low-
dose computed tomography (CT) scan of the chest ver-
sus a chest x-ray for 3 consecutive years reduces the risk 
of death from lung cancer and all-cause mortality in 
patients in the general population who have at least a 
30 pack-year history of smoking.
Current smokers have an increased risk of periopera-
tive respiratory complications with the risk depending on 
several factors including duration of smoking, the pres-
ence of respiratory symptoms and a history of chronic 
lung disease. Recent evidence has suggested that smoking 
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discontinuation as recently as 4 weeks prior to surgery can 
decrease post-operative complications.136
In the long-term there is an increased risk of CVD, non-
skin malignancies and death. A recent systematic review 
examined 43 studies of kidney transplant recipients137 and 
reported that younger individuals, males and those with a 
lower body mass index (BMI) were more likely to smoke. 
There was an increased risk of new CVD occurring after 
transplantation (odds ratio [OR] 1.41, 95% CI: 1.02-
1.95; P = 0.036) in smokers compared with non-smokers. 
Additionally there was a more than two-fold risk of non-
skin malignancies in smokers compared with non-smokers 
(OR 2.58, 95% CI: 1.26-5.29; P = 0.01) and a signifi-
cantly shorter survival time (OR 0.59, 95% CI: 0.44-0.79; 
P < 0.001) while patient mortality was significantly higher 
in smokers (OR 1.74, 95% CI: 1.21-2.48; P = 0.003). 
Other studies have shown similar results with an increase 
in malignancy and death in kidney transplant recipients 
who smoke in addition to reduced graft survival.138,139
Smoking cessation programs should be offered to 
patients who are current smokers. There is high quality 
evidence in the general population demonstrating effi-
cacy of smoking cessation measures compared with no 
intervention.140,141
Due to the increased mortality associated with smoking 
after transplantation, smoking may be considered an addi-
tional risk factor that along with other comorbidities, may 
preclude transplantation suitability.
The National Lung Screening Trial was a large RCT 
in which current and former smokers were randomized 
to annual screening for three years with either low-dose 
CT scans or a chest x-ray.142 53,454 individuals aged 
between 55 – 74 who had a history of cigarette smok-
ing of at least 30 pack-years, and, if former smokers, 
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had quit within the previous 15 years, were randomized 
to undergo 3 annual screenings with either CT or chest 
x-ray. Compared with a plain chest x-ray, CT reduced the 
risk of death from lung cancer by 20% and the overall 
risk of death by 6.7%.
However, there were a number of important issues raised 
in the study. Firstly there were a large number of false posi-
tive tests in the CT screening arm with around a quarter of 
patients having a positive finding on one of the CT scans – 
of these 96.4% were false positives. Hence screening did 
lead to increased follow up investigations with potential 
complications arising from these. Additionally individuals 
in this study were otherwise healthy and did not have kid-
ney failure.
Screening is recommended for high-risk smokers 
by a number of organizations including the American 
Association of Thoracic Surgery, American Cancer Society, 
American College of Chest Physicians/American Society of 
Clinical Oncology, the Canadian Task Force on the Periodic 
Health examination, the National Comprehensive Cancer 
Network and the US Preventative Services Task Force.
What prior guidelines recommend
The Work Group agrees with the European Renal Best 
Practice, UK Renal Association, AST, KHA-CARI and 
Canadian guidelines,23,27–29,143 all of which recommend 
smoking cessation prior to transplantation and recom-
mend the offering of a smoking cessation program to cur-
rent smokers. Canadian guidelines also argue that patients 
who continue to smoke may be eligible for kidney trans-
plantation with full informed consent regarding their 
increased risk.29
RESEARCH RECOMMENDATION
 • Further studies should examine the costs and benefits of 
screening for lung cancer in candidates.
SECTION 7: SURGICAL ISSUES INCLUDING 
OBESITY
 7.1: We recommend candidates to have their body habi-
tus examined by a transplant surgeon at the time of 
evaluation and while on the waiting list (1B).
 7.1.1: We suggest that candidates not be excluded 
from transplantation because of obesity (as 
defined by body mass index or waist-to-hip 
ratio) (2B).
 7.1.2: We suggest weight loss interventions be 
offered to candidates with obesity prior to 
transplantation (2D).
 7.2: We suggest that candidates be assessed for frailty at 
the time of evaluation and while on the waitlist to 
inform post-transplant risk and enable optimization 
strategies, such as pre-operative rehabilitation (2C).
 7.3: We suggest that candidates be assessed for medi-
cal conditions that inhibit wound healing, includ-
ing obesity, undernutrition, tobacco use, and prior 
abdominal surgeries, to inform risks of delayed 
wound healing and hernia formation (2B).
 7.4: Candidates should not be excluded from considera-
tion for kidney transplantation because of their need 
for anticoagulation, antiplatelet therapy or a history 
of heparin-induced thrombocytopenia (HIT) (Not 
Graded).
 7.4.1: Single antiplatelet agents (eg, aspirin, clopi-
dogrel, ticagrelor) can be continued while 
waiting for deceased donor transplant (Not 
Graded).
 7.4.2: Delay transplantation for the mandated 
period of treatment with dual antiplatelet 
therapy (eg, aspirin plus clopidogrel) when 
the risk of stopping medication (eg, stent 
thrombosis) or operating while on treatment 
(eg, surgical bleeding) exceeds the anticipated 
benefit of transplantation (Not Graded).
 7.4.2.1: Antiplatelet agents (except aspirin) 
should be stopped 5 days prior to liv-
ing donor transplantation (unless ces-
sation is contraindicated) and during 
the perioperative period for deceased 
donor transplantation (Not Graded).
 7.4.3: Do not transplant patients on direct-acting 
oral anticoagulants (DOACs; eg, apixaban, 
rivaroxaban) except when there is specific 
expertise using DOACs perioperatively 
and access to DOAC reversal agents (Not 
Graded).
 7.4.3.1: Switch to an alternative anticoagu-
lant (eg, warfarin) prior to waitlist-
ing or living donor transplantation 
if recommended by a thrombosis 
expert/hematologist or if there is no 
expertise using DOACs periopera-
tively or access to DOAC reversal 
agents (Not Graded).
 7.4.4: Use non-heparin based agents for periopera-
tive anticoagulation in candidates with a his-
tory of HIT (Not Graded).
 7.5: Assess vascular anatomy and patency for patients 
with significant peripheral arterial disease (Section 
14), prior transplant procedures, venous dialysis 
catheters, pelvic surgery, or deep venous thrombosis 
(Not Graded).
 7.6: Evaluate native kidney size in patients with polycys-
tic kidney disease (Not Graded).
 7.6.1: We suggest staged or simultaneous native 
nephrectomy and transplantation for candi-
dates with polycystic kidney disease that is 
symptomatic (eg, recurrent pain, recurrent 
infection), a suspicion of malignancy, or if the 
patient has insufficient room for a transplant 
(2D).
 7.7: Refer to a urologist experienced in transplant issues 
for patients at increased risk for or those with a his-
tory of urologic malignancy, recurrent urinary tract 
infections, dysfunctional voiding, prior bladder 
augmentation/division, an ileal conduit, significant 
structural anomalies of the kidneys or urinary tract, 
or nephrolithiasis (Not Graded).
 7.7.1: We suggest cystoscopy to screen for bladder 
carcinoma in candidates at increased risk, 
such as those with high-level exposure to 
cyclophosphamide or heavy smoking (≥ 30 
pack-years) (2D).
 7.7.2: We suggest that pre-transplant unilateral or 
bilateral nephrectomy be considered for pedi-
atric candidates with high urine volumes (> 
2.5 ml/kg/hour) or heavy proteinuria associ-
ated with hypoalbuminemia (2D).
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RATIONALE
Definitions
 • BMI is defined as weight in kilograms squared divided 
by the height in meters. Obesity is defined as a BMI 
≥ 30 kg/m2 and can be subdivided into classes I (BMI 
30-34.9), II (BMI 35-39.9) and III (≥ 40 kg/m2).
 • Waist-to-hip ratio is defined as the ratio of the circum-
ference of the waist to that of the hips. Waist-to-hip 
ratios > 0.85 for women or > 0.9 for men is considered 
obese by the World Health Organization.
 • Frailty is characterized by a loss of function in 5 
domains: (1)  shrinkage (unintentional weight loss and 
sarcopenia), (2) muscular weakness, (3) exhaustion and 
lack of endurance, (4) slow gait, and (5) physical inac-
tivity (refer to Frailty Index [FI]144,145).
Obesity
Obesity is highly prevalent across high-income countries 
and increasingly so across low- and low-middle income 
countries. In the US, nearly 70% of the adult population 
is overweight or obese, while 6.7% have class III obesity 
(BMI ≥ 40).146 Obesity in the context of metabolic syn-
drome is a strong risk factor for the development of ESKD. 
In the Reason for Geographic and Racial Differences in 
Stroke (REGARDS) study which prospectively evaluated 
30,239 black and white adults in the US, the overall inci-
dence of obesity (BMI ≥ 30 kg/m2) was 38%, of whom 
66% had metabolic syndrome. In the presence of meta-
bolic syndrome, obesity increased the risk of ESKD two-
fold. However, there was no independent association of 
obesity and ESKD in the absence of metabolic syndrome. 
Despite the clear association of obesity with peripheral 
vascular disease, coronary artery disease, and steatohepa-
titis, obesity is often associated with a lower risk of death 
among patients receiving maintenance dialysis.147,148
The impact of obesity on kidney transplant outcomes 
is complex. When compared to remaining on dialysis, 
obese patients who undergo kidney transplant experi-
ence prolonged survival.149,150 Among obese patients, 
Gill et al. demonstrated a 48% reduction in mortality 
after transplantation compared to remaining on dialy-
sis. However, a recent meta-analysis including more than 
200,000 recipients comparing outcomes in obese and 
non-obese recipients, demonstrated that obesity (BMI 
> 30 kg/m2) conveys an increased risk of death (relative 
risk [RR] 1.52), delayed graft function (RR 1.52), acute 
rejection (RR 1.17), wound infection (RR 3.13), dehis-
cence (RR 4.85), and prolonged hospital stay (2.31 days). 
Consequently, the Work Group recommends assessment 
of all candidates for obesity using either BMI or waist-
to-hip criteria. Obesity is a relative contraindication to 
kidney transplantation. Patients found to be obese or 
particularly those with class II or class III obesity (BMI ≥ 
35 kg/m2) should be considered for intervention such as 
dietary counseling or bariatric surgery. The Work Group 
did not establish a firm BMI cutoff, but encourages each 
transplant program to consider their own resources and 
skills in caring for this population. For example, early 
experience with robotically assisted transplantation 
has demonstrated improved outcomes among obese 
patients.151 Pre-transplant panniculectomy may be use-
ful in reducing BMI and improving wound outcomes 
following transplant.152 Transplantation in patients with 
a BMI ≥ 40 kg/m2 should be approached with caution; 
patients need to understand the increased risk of post-
operative complications in this situation.
Frailty
Frailty is a constellation of symptoms resulting in 
reduced physiological reserve which progresses with aging 
and chronic disease. In the ESKD population, the incidence 
of frailty in a European cohort increased from 27.5% in 
patients aged < 65 to 43.6% in patients > 65 as identified 
using the FI.144,145 Similar rates have been documented in 
the US using the FI. Frailty was 3.3 times more frequent in 
women and appears to increase over time among patients 
on dialysis. Higher FI has been associated with greater 
risks of mortality, morbidity, and hospitalization among 
ESKD patients.153
Recent prospective studies have evaluated the inde-
pendent impact of frailty on kidney transplant outcomes. 
Patients determined to be frail at the time of transplant 
have greater rates of delayed graft function, longer length 
of stay, and a greater incidence of risk adjusted graft loss 
and mortality.154 Furthermore, frailty appears to increase 
immediately after transplant, returning to baseline values 
after 3 months. Assessment of frailty at the time of listing 
is crucial to assess physiologic reserve and the potential 
for perioperative complications. However, frailty alone 
should not be a contraindication to transplantation as 
average survival after transplantation is superior to long-
term dialysis. The Work Group believes that patients with 
significant frailty should be referred for rehabilitation 
and conditioning prior to transplantation, although evi-
dence to support this strategy is currently not available. 
Frail patients should also be counselled regarding the 
risk of significant complications including perioperative 
mortality.
Wound healing and hernia management
All kidney transplant procedures have a risk of wound 
complications including infection and hernia formation 
due, in part, to the impact of immunosuppressive medi-
cations on wound healing. Comorbid conditions that 
increase this risk include diabetes, polycystic kidney dis-
ease, prior surgical procedures (including transplantation 
or hernia repairs), and tobacco use. The reported incidence 
of incisional hernia is approximately 7% at 10 years, and 
is increased 2-fold in patients who are active or former 
smokers.155–157 Technical factors that increase the rate of 
hernia include closure of the myofascial wall in one layer, 
the development of a lymphocele, need for re-exploration, 
or the development of a wound infection. Patients with 
risk factors for hernia formation should be advised of 
the potential need for surgical repair after transplant and 
tobacco cessation should be strongly advised.
Wound healing is also affected by the development 
of superficial and deep tissue infections. Risk factors for 
post-transplant wound infections include obesity, dia-
betes, peripheral vascular disease, rheumatologic condi-
tions (including lupus), and prior narcotic use disorder. 
Significant wound infections occur in approximately 15% 
of kidney transplant recipients. Perioperative antibiot-
ics and chlorhexidine-based skin preparation should be 
administered as per surgical guidelines.
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Collagen vascular disease/Ehlers-Danlos 
Syndrome
Collagen vascular diseases are an uncommon spectrum 
of disease that affect the formation and cross linking of 
collagen. Collagen vascular diseases contribute to trans-
plant morbidity including an elevated risk of hernia for-
mation.158 A history of collagen vascular diseases may 
be a contraindication to transplant in patients with other 
risks for poor wound healing. Ehlers-Danlos Syndrome 
(EDS), specifically, is the result of abnormal fibrillary col-
lagen formation due to inherited deficiencies in collagen-
processing enzymes, dominant negative effects of mutant 
collagen α-chains, and haploinsufficiency. Type IV or vas-
cular type EDS is an autosomal dominant defect in type III 
collagen synthesis. Affected individuals have an increased 
risk of arterial and hollow organ rupture, arterial dissec-
tion, and aneurysm formation resulting in an average life 
expectancy of less than 50 years. While endovascular tech-
niques have been used to prevent exsanguination, these 
arteries frequently fail to hold sutures, making vascular 
anastomoses quite treacherous. Alternative surgical tech-
niques can be considered including the use of pledgetted 
sutures, fibrin glue, and end-to-end anastomosis with the 
internal iliac artery rather than end-to-side to the com-
mon or external iliac. However, any vascular surgery in 
this population caries a high risk of morbidity and mortal-
ity. Pre-transplant diagnosis, discussion of risks and sur-
gical planning are advised in determining candidacy and 
approach to transplantation.
Anticoagulation
Patients with ESKD are frequently exposed to anticoag-
ulants during dialysis treatment, as treatment for comorbid 
conditions including atrial fibrillation, ischemic heart dis-
ease, peripheral arterial disease, prior thromboembolism 
and other pro-thrombotic states. Among dialysis patients, 
11.6% develop atrial fibrillation and many are placed on 
warfarin despite a lack of data confirming clinical benefit 
in the ESKD population.159,160 Given long waiting times 
and a high rate of comorbidities, the proportion of ESKD 
patients taking anticoagulation and antiplatelet agents is 
likely to increase.
The Work Group does not believe that the use of war-
farin, dipyridamole, or aspirin should be considered as a 
contraindication to proceeding with listing for or receiv-
ing a kidney transplant. In the case of living donor trans-
plant, most clinicians recommend stopping warfarin for a 
period of 5 days, dipyridamole for 7 days, and continu-
ing aspirin throughout the transplant period. For deceased 
donor transplantation, anticoagulation can be reversed 
successfully with prothrombin complex concentrate, fresh 
frozen plasma, vitamin K, and platelet transfusions prior 
to transplant or after reperfusion of the kidney. However, 
transplantation of patients receiving warfarin (OR 8.2, 
P < 0.001) or antiplatelet therapy (OR 2.9, P = 0.001) 
markedly increases the likelihood of receiving a blood 
transfusion when compared to patients on no therapy.161 
The impact of newer direct-acting oral anticoagulants 
(DOACs) on transplant outcomes has yet to be reported. 
Unlike warfarin-based therapy, they cannot be readily 
reversed with prothrombin complex concentrate or fresh 
frozen plasma. Unless there is specific expertise using 
DOACs perioperatively and access to DOAC reversal 
agents, these agents should be avoided in patients awaiting 
deceased donor transplantation. It is recommended that 
DOACs be stopped at least 48-72 hours prior to elective 
surgery, particularly in patients with kidney failure.162
The development of heparin-induced thrombocytope-
nia (HIT) is the result of immunization against soluble 
 heparin/platelet complexes which bind to protein platelet 
factor 4. There are only six published case reports of HIT 
in kidney transplantation, mostly demonstrating graft loss. 
In patients with established HIT, the use of heparin-free 
anticoagulation (eg, argatroban, hirudin) as a bridge to 
warfarin is recommended. In addition, in studies of other 
solid organ transplant recipients, the use of heparin during 
organ recovery did not appear to precipitate HIT recur-
rence in patients who were free from heparin for at least 
100 days.
Surgical planning
Kidney transplantation requires completion of vascu-
lar anastomoses to provide appropriate arterial inflow 
and venous outflow. The kidney transplant is tradition-
ally placed in the iliac fossa, which is extra-peritoneal, 
reducing risk of intra-abdominal infection and facilitating 
ureteral reconstruction given the shorter ureter and risk 
of ischemia due to a poor ureteral blood supply. Arterial 
inflow is generally obtained from the iliac artery (exter-
nal, common, internal) and venous outflow provided into 
the iliac vein. Alternative placement includes use of the 
distal aorta and vena cava, portal venous drainage, and 
an orthotopic transplant with recipient nephrectomy.163 
Significant peripheral vascular disease should be assessed 
and the surgical plan adjusted as described in Section 14. 
Patients with extensive past surgical interventions or vas-
cular procedures should be evaluated with cross-sectional 
imaging prior to listing.
Appropriate pre-transplant anatomic evaluation is cru-
cial to identify the optimal location for vascular anasto-
moses and plan for the recipient’s incision. In the case of 
prior kidney transplant, the optimal approach is generally 
to avoid previously violated tissue planes and not perform-
ing transplant nephrectomies if possible. For the initial re-
transplant procedure, this can be accomplished using the 
contralateral iliac fossa. Subsequent kidney transplant can 
be performed using a midline incision mobilizing the right 
colon, and using the distal aorta and inferior vena cava. 
Alternatively, the superior mesenteric vein can be used for 
drainage.
Prolonged exposure to hemodialysis has led to the 
exhaustion of upper extremity vascular access options for 
a growing population of ESKD patients. In these cases, 
lower extremity options for access, such as arteriovenous 
fistulas, arteriovenous grafts, and central venous catheters 
have been used.164 Ipsilateral lower extremity arterio-
venous fistula and arteriovenous graft may contribute to 
venous hypertension and potential graft dysfunction, but 
do not pose a contraindication to transplantation. In the 
case of hemodynamically significant venous hypertension, 
the arteriovenous graft/fistula should be ligated after the 
transplant procedure. Ipsilateral central venous catheters 
have a high incidence of femoral and iliac venous thrombo-
sis and infection. Patients with a history of dialysis access 
procedures in the lower extremity should have periopera-
tive imaging to confirm venous patency. Imaging options 
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include CT with intravenous contrast, magnetic resonance 
imaging with time-of-flight sequences, vascular Doppler 
ultrasonography, or venography. Transplantation using 
an iliac vein with an indwelling central venous catheter is 
generally contraindicated, especially without pre-operative 
imaging confirming patency of the vein.
Patients with polycystic kidney disease should undergo a 
non-contrast CT scan of the abdomen and pelvis to deter-
mine if they would benefit from simultaneous or staged 
native nephrectomy. The indications for pre-transplant 
nephrectomy include bleeding, recurrent infection, renal 
mass precluding safe transplant into the iliac fossa, sus-
picion of renal cell carcinoma, and constraint syndrome 
resulting in poor oral intake and pain. The options for sur-
gical interventions include pre-transplant bilateral laparo-
scopic nephrectomy, simultaneous bilateral  nephrectomy/
transplant, or post-transplant nephrectomy (open or lap-
aroscopic). Each approach can be performed safely, sug-
gesting that patient symptomatology, kidney size and local 
surgical expertise should dictate the timing and type of this 
procedure.165–167
Native nephrectomy for pediatric candidates
High urine output is relatively common among chil-
dren with ESKD because many of the conditions lead-
ing to ESKD involve significant tubular dysfunction (eg, 
renal hypoplasia, nephronophthisis, cystinosis). These high 
urine volumes from the native kidneys may persist follow-
ing transplantation making fluid management challenging. 
Infants and very young children in particular may have dif-
ficulty maintaining adequate perfusion of an adult donor 
kidney – which may result in a drop in GFR and accelerated 
fibrosis.168,169 Polyuria increases the risk of volume deple-
tion in the recipient. Some have advocated unilateral or 
bilateral native nephrectomy prior to transplant, or at the 
time of transplant, to facilitate maintenance of adequate 
volume status and improve perfusion of the graft.169,170
Heavy proteinuria has also been proposed as an indica-
tion for native nephrectomy pre-transplant due to the asso-
ciated increased risk of graft thrombosis among patients 
losing anti-thrombotic factors in the urine.169,171,172 
Pre-transplant nephrectomy for patients with nephrotic 
syndrome and persistent hypoalbuminemia may allow 
recovery of normal levels of anticoagulation factors prior 
to the transplant.169
What prior guidelines recommend
The AST guidelines suggest that a BMI ≥ 30 kg/m2 
should not be considered an absolute contraindication, 
though weight loss is recommended.28 The CST reviewed 
additional data from the US Renal Data System. While 
stopping short of declaring a high BMI as an absolute 
contraindication, the CST states, the increased risk of 
death post-transplant first becomes significant when BMI 
is 34-36 kg/m2.29 The relative risk for mortality is even 
greater when BMI at transplant is above 36 kg/m2. These 
data suggest that transplantation at this level of BMI may 
be associated with unacceptably higher risk and will need 
careful consideration. The CST further recommends moni-
tored weight loss programs and consideration of bariat-
ric surgical options to achieve a BMI < 30 kg/m2.29 The 
ERA-EDTA reports similar conclusions – they suggest 
that there is no clear evidence that denying obese patients 
transplant is in the best interest of the patient regardless 
of the the reduction in post-transplant outcomes.143 They 
suggest dietary modification and do not endorse pharma-
cologic or surgical weight loss interventions. Finally, the 
KHA-CARI guidelines27 suggest that a BMI < 40 kg/m2 not 
be considered a contraindication to transplant, provided 
the patient’s comorbid conditions are not prohibitive. In 
patients with a BMI > 40 kg/m2, the guideline appears to 
question the benefit of transplant compared to dialysis, 
given the risk of complications and graft loss.
RESEARCH RECOMMENDATIONS
 • Studies, ideally RCTs, should examine the impact of pre-
transplant rehabilitation on post-operative outcomes for 
frail patients who present for pre-transplant assessment.
 • Studies should investigate the impact of pre-transplant 
 bariatric surgery (eg, sleeve gastrectomy) on outcomes 
after kidney transplantation.
SECTION 8: DIABETES
 8.1: We recommend that candidates with type 1 or type 
2 diabetes mellitus (DM) be considered for kidney 
transplantation (1B).
 8.1.1: We suggest candidates with ESKD and type 
1 DM be considered for simultaneous pan-
creas-kidney transplantation in regions where 
this procedure is available (2A).
 8.2: We suggest testing for abnormal glucose metabolism 
by oral glucose tolerance test in candidates who are 
not known to have diabetes (2A).
RATIONALE
Diabetic nephropathy is the most common cause of 
ESKD globally. Candidates with type 1 and type 2 DM 
are, however, less likely to be listed for transplantation 
and less likely to be transplanted than people with ESKD 
from causes such as glomerulonephritis and polycystic kid-
ney disease, due to the higher prevalence of comorbidities 
among those with diabetes.173 Inferior patient and kidney 
survival rates for those with diabetes have been evident 
for many years, attributed to a higher burden of vascular, 
surgical and infective complications. Several single-center 
studies have reported substantial improvement in recent 
eras,174,175 however this was not matched in a recent reg-
istry analysis from Australia.176 Nonetheless, survival after 
kidney transplantation is superior to remaining on dialy-
sis for the majority of those candidates with ESKD due to 
diabetes.15 Therefore, diabetes per se should not be seen as 
a contraindication to transplantation, but rather an indica-
tion to closely evaluate and manage associated complica-
tions. For assessment of comorbidities commonly present 
in people with diabetes, please refer to the following sec-
tions of this Guideline on cardiac (section 13), vascular 
(section 14), obesity (section 7), wound healing (section 7) 
and frailty (sections 2 and 7) evaluations.
People with ESKD and type 1 DM may benefit more 
from simultaneous pancreas-kidney transplantation over 
kidney-alone transplantation. Discussion of the merits of 
simultaneous pancreas-kidney transplantation are beyond 
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the scope of this guideline, however referral to and evalu-
ation by a center with expertise in simultaneous pancreas-
kidney transplantation is warranted where available.
New-onset diabetes after transplantation (NODAT) is 
a common complication of kidney transplantation, occur-
ring in 10-40% of recipients.177 NODAT is associated with 
reduced survival after kidney transplantation, principally 
due to an increase in cardiovascular mortality, and an 
increase in comorbidity.177,178 Pre-transplant assessment 
of the risk of a candidate developing NODAT is therefore 
indicated to enable implementation of strategies to reduce 
risk, such as steroid minimization, choice of cyclosporine 
over tacrolimus or early post-transplant use of insulin, 
and to inform the candidate and their medical team of this 
risk.179–181 In addition to recognized risk factors for the 
development of NODAT, including obesity, family history 
of diabetes and older age, demonstration of impaired glu-
cose tolerance is strongly predictive.182–185
Screening for undiagnosed DM and impaired glucose tol-
erance may be performed by fasting blood glucose, glycated 
hemoglobin (HbA1c), or oral glucose tolerance test. Fasting 
blood glucose is an insensitive test for DM among ESKD 
patients and for the diagnosis of NODAT,186,187 however, 
elevated fasting blood glucose has been advocated as an 
indication for oral glucose tolerance test during candidate 
assessment. Performance characteristics of HbA1c for the 
diagnosis of DM or the prediction of NODAT development 
have not been formally assessed in transplant candidates, 
however the altered performance of HbA1c in advanced 
kidney disease and the poor sensitivity of HbA1c for 
NODAT imply the utility of this test is likely to be reduced 
in ESKD as compared to the general population.187–189 The 
use of oral glucose tolerance test to predict risk of NODAT 
has been assessed in several studies of moderate to good 
quality, which have found moderate to good performance 
characteristics for the prediction of NODAT (Summary 
Table and Evidence Profile: DM testing).182–185 Caillard et 
al. reported a cumulative incidence of NODAT of 50% (n 
= 11) among candidates with impaired glucose tolerance as 
compared to 20% (n = 20) candidates with normal glucose 
tolerance, as determined by pre-transplant oral glucose tol-
erance test. In that study, impaired glucose tolerance, older 
recipient age and autosomal dominant polycystic kidney 
disease (ADPKD) as cause of ESKD were significantly pre-
dictive of NODAT in a multivariate model. Thus use of oral 
glucose tolerance test may be considered the gold standard 
for demonstration of pre-transplant glucose metabolic sta-
tus and prediction of NODAT, despite the cost, inconven-
ience and potential for day-to-day variability of this test.182
What prior guidelines recommend
We concur with existing guidelines in their general rec-
ommendation that diabetes should not on its own pre-
clude a patient from kidney transplant candidacy. Most 
guidelines recommend screening for cardiovascular disease 
prior to and and regularly after listing for transplantation 
– here we have not addressed this requirement specifically 
in the section on diabetes, but captured it within Section 
13 on Cardiac Disease. We have been more circumspect as 
to the role of screening asymptomatic patients both before 
and after listing for transplantation, and discuss the evi-
dence available and required to enable firm recommenda-
tions to be made. Both the AST and KHA-CARI guidelines 
recommend assessing ischemic heart disease risk factors 
including diabetes.27,28 Given recent evidence, we have 
suggested screening for diabetes and impaired glucose tol-
erance by oral glucose tolerance test to enable assessment 
of risk of diabetes after transplant and to inform manage-
ment choices. We have made this a “suggestion,” acknowl-
edging the practical and economic limitations involved.
RESEARCH RECOMMENDATION
 • RCTs should be conducted to determine the impact of 
various interventions, including choice of immunosup-
pression, on development of NODAT for those found to 
have impaired glucose tolerance by pre-transplant oral 
glucose tolerance test.
RELEVANT SUPPLEMENTAL MATERIAL
Summary table: DM testing
Summary table: DM testing (quality assessment)
 Evidence profile: Glucose tolerance testing 
pre-transplantation
SECTION 9: CAUSE OF END-STAGE KIDNEY 
DISEASE (ESKD)
 9.1 Cause of ESKD and kidney transplantation
 9.1.1: We recommend that the cause of ESKD in 
candidates be determined, where possible, to 
inform risks and management after kidney 
transplantation (1A).
 9.1.2: Advise candidates about the disease-specific 
risk of recurrence and resultant risk of graft 
loss (Not Graded).
RATIONALE
Many causes of ESKD can recur after transplantation 
and affect the survival of the transplant and the patient. 
Primary disease can recur in up to 20% of transplants and 
has been reported as the cause of graft loss in 8.4% of 
grafts 10 years after transplantation, representing the third 
most common cause of graft loss.190 191 Despite the risk of 
recurrence, transplantation is the treatment of choice in 
eligible patients. However, patients should be made aware 
of the risk of recurrence of the primary disease and the 
implication this would have for transplant survival. There 
is a significant proportion of patients for whom the cause 
of ESKD is not known. One recent registry analysis sug-
gests the risk of recurrence in such patients is low.192
 9.2 Focal segmental glomerulosclerosis (FSGS)
 9.2.1: We recommend not excluding candidates 
with primary FSGS from kidney transplanta-
tion; however, the risk of recurrence should 
be considered and discussed with the candi-
date (1B).
 9.2.1.1: Loss of a prior graft due to recurrent 
FSGS indicates a high risk of recur-
rence upon subsequent transplanta-
tion and this factor should be a major 
consideration in determining candi-
dacy (Not Graded).
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 9.2.2: We suggest genetic testing (eg, for podocin 
and nephrin gene mutations, among others) 
be performed in children and young adults 
with a clinical course consistent with genetic 
FSGS to inform the risk of recurrence (2C).
 9.2.3: We suggest avoiding routine use of pre-trans-
plant plasma exchange or rituximab to reduce 
the risk of recurrent FSGS (2D).
RATIONALE
There is a significant risk of recurrence of primary FSGS 
after transplantation, reported in 10-56% of transplants 
(average 30%).193–196 When disease recurs, graft loss 
attributed to recurrence is reported in 30-50% of cases. 
Therefore, in candidates with primary FSGS, approxi-
mately 10-20% of grafts will be lost due to  recurrent dis-
ease, with a reported RR for graft loss of 2.03 (95% CI: 
1.19-3.44; p = 0.009) compared to other glomerular dis-
eases.190 In the ANZDATA (Australia and New Zealand 
Dialysis and Transplant) data, 5-year graft survival was 
52% in patients with recurrent FSGS compared to 83% 
in patients without recurrent disease.197
Factors associated with recurrence of FSGS include: 
young age, non-white ethnicity, living donor transplant, 
mesangial hypercellularity, rapid progression to ESKD, 
high levels of pre-transplant proteinuria and recurrence of 
FSGS in a previous graft.194,196,197 However, clinical assess-
ment of recurrence risk lacks specificity. Soluble urokinase 
plasminogen activator receptors have been proposed as a 
biomarker of recurrence, but this has not been confirmed 
in other studies.198,199
Despite living donation being an independent risk factor 
for disease recurrence, allograft survival is generally equiv-
alent to or superior to deceased donor grafts.197 Living 
donation is therefore not contraindicated. Registry data 
suggest that outcome is better in zero mismatched grafts.200
Most reports suggest that genetic forms of the disease 
have a lower rate of recurrence although recurrence has been 
reported.201–203 The low rate of recurrence reported by most 
authors would suggest that genetic screening is indicated 
to inform risk prior to transplantation in younger patients 
with a history of steroid resistant nephrotic syndrome.
The risk of recurrence in candidates who have previously 
lost a transplant due to recurrent disease is high, in the 
order of 80%.193 The benefits of re-transplantation with 
likely recurrence compared with long-term, maintenance 
dialysis should be considered on a case-by-case basis.
Plasma exchange is frequently used to treat recurrent dis-
ease. Case reports and case series have suggested efficacy of 
pre-transplant rituximab194,195 or plasma exchange196,204 
to prevent FSGS recurrence, however the absence of RCTs 
and the presence of negative case reports196,205 demonstrate 
uncertainty (Summary Table: Recurrence FSGS and Evidence 
Profile: Treatments to prevent kidney disease recurrence). 
Thus neither therapy can be recommended at this stage.194
 9.3 Membranous nephropathy (MN)
 9.3.1: We recommend not excluding candidates 
with MN from kidney transplantation; how-
ever, the risk of recurrence should be consid-
ered and discussed with the candidate (1B).
 9.3.1.1: We suggest not excluding candidates 
with prior graft loss due to MN; 
however, the risk of recurrence should 
be considered and discussed with the 
candidate (2D).
 9.3.2: We suggest that autoantibodies to phospholi-
pase A2 receptor (PLA2R) be measured pre-
transplant to inform the risk of recurrence in 
patients with MN (2C).
 9.3.3: We suggest not routinely using rituximab or 
alkylating agents to reduce the risk of recur-
rent MN (2D).
RATIONALE
There is a significant risk of recurrent primary 
 membranous nephropathy (MN) following trans-
plantation. The reported rate of recurrence is between 
10-50%.206–208 This wide range of reported recurrence rate 
is due to different follow-up periods and reporting of clini-
cal recurrence versus histological recurrence on ‘for cause’ 
or protocol biopsy.
The effect of recurrent primary MN on allograft out-
come is unclear with reports of worse or equivalent out-
comes in patients with recurrent primary MN.207,209 This 
difference may reflect whether disease is detected on pro-
tocol or ‘for cause’ biopsy and the use of newer treatment 
strategies. It is clear that recurrent primary MN can lead to 
graft failure and when it does recur, 50% of death-censored 
graft losses have been attributed to recurrent disease.207
Our understanding of the pathogenesis of primary 
MN has advanced significantly since the identification of 
autoantibodies to the phospholipase A2 receptor (PLA2R). 
Approximately 70% of patients with primary MN have 
anti-PLA2R antibodies. Patients who are anti-PLA2R 
antibody positive have a higher risk of recurrence (60-
83%) compared to those patients who are antibody nega-
tive (28-53%).207,210,211 Insufficient data are available to 
understand the relevance to transplantation of other auto-
antibodies. Heavy proteinuria prior to transplantation is 
also a risk factor for recurrence.207
There is accumulating evidence for the use of anti-
CD20 therapy for the treatment of recurrent primary MN. 
Complete or partial clinical remission has been reported 
in 80% of cases treated with rituximab.207,208,212 There 
is currently insufficient data to determine whether the 
presence of anti-PLA2R antibodies is predictive of the 
response to anti-CD20 treatment. Alkylating agents have 
also been used to treat recurrent primary MN similar to 
the treatment of native kidney disease. However, there is 
no evidence at present for the pre-emptive treatment of 
candidates with either rituximab or alkylating agents to 
prevent recurrent primary MN.
 9.4 IgA nephropathy (IgAN)
 9.4.1: We recommend not excluding candidates 
with IgAN from kidney transplantation; 
however, the risk of recurrence should 
be considered and discussed with the 
candidate (1B).
RATIONALE
There is significant variability in the reported rate of recur-
rence of IgA nephropathy (IgAN) after transplantation. 
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This relates to the criteria for biopsy (protocol or for 
cause) and the duration of follow-up. Clinical recurrence 
occurs in approximately 30% of cases.213 Histological 
recurrence is more common and probably occurs in 
> 50% of cases, with this percentage increasing the longer 
the period between transplantation and biopsy.193,214
Generally the outcome of transplantation for those with 
IgAN is equivalent to or better than other primary diag-
noses.213,215 However, despite good outcome overall in 
patients with IgAN, recurrence is associated with a higher 
risk of allograft failure.216 Early recurrence of IgAN is 
unusual but this may be more common in younger candi-
dates with rapidly progressive, crescentic disease in their 
native kidneys.217
 9.5 IgA vasculitis
 9.5.1: We recommend not excluding candidates 
with IgA vasculitis from kidney transplanta-
tion; however, the risk of recurrence should 
be considered and discussed with the candi-
date (1B).
RATIONALE
A primary diagnosis of IgA vasculitis, previously referred 
to as Henoch-Schönlein purpura, is associated with a simi-
lar death-censored graft survival compared to other diag-
noses.218 The risk of recurrence is lower than for IgAN 
with a rate of recurrence of 11.5% at 10 years reported in 
a multicenter European study.218 The proportion of graft 
losses attributed to recurrent disease was 7.5-13.6% in the 
European series and United Network for Organ Sharing 
(UNOS) database study.218,219
 9.6 Immune complex-mediated membranoproliferative 
glomerulonephritis (IC-MPGN) and C3 glomeru-
lopathy (C3G)
 9.6.1 IC-MPGN
 9.6.1.1: We recommend not excluding candidates 
with IC-MPGN from kidney transplan-
tation; however, the risk of recurrence 
should be considered and discussed with 
the candidate (1B).
 9.6.1.2: We recommend investigation for an infec-
tive, autoimmune, or paraprotein-mediated 
cause of IC-MPGN prior to transplanta-
tion to guide treatment and inform risk of 
recurrence (1C).
 9.6.1.3: We suggest that, when possible, the cause 
of the IC-MPGN be treated prior to trans-
plantation (2C).
 9.6.2 C3G, including dense deposit disease (DDD) 
and C3 glomerulonephritis (C3GN)
 9.6.2.1: We recommend not excluding candidates 
with C3G from kidney transplantation; 
however, the risk of recurrence should be 
considered and discussed with the candi-
date (1B).
 9.6.2.2: We suggest that candidates with C3G be 
screened for genetic or acquired causes for 
the dysregulation of the complement alter-
native pathway to guide treatment and 
inform risk of recurrence (2C).
 9.6.2.3:  Loss of a prior graft due to recurrent C3G 
indicates a high risk of recurrence upon 
subsequent transplantation and this factor 
should be a major consideration in deter-
mining candidacy (Not Graded).
RATIONALE
Recent progress in our understanding of the pathogene-
sis of membranoproliferative glomerulonephritis (MPGN) 
has led to a revision of the classification depending on the 
presence of immunoglobulin containing immune com-
plexes (IC-MPGN) or dominant C3 (C3G). The assess-
ment of the candidates and the risk of recurrent disease is 
dependent on the type of MPGN and therefore studies that 
do not differentiate between the different types of MPGN 
have to be interpreted with caution. Overall the rate of 
recurrence is high and recurrence is associated with infe-
rior graft outcomes.191,220,221
Using protocol biopsies, Lorenz and colleagues 
reported a risk of recurrent IC-MPGN of 41%, with a 
higher risk in those patients with monoclonal IgG deposi-
tion.220,222 Recurrence of MPGN with monoclonal depo-
sition is associated with a poor graft prognosis. Only a 
minority of patients will have a detectable paraprotein 
(30%) and there is a low risk of progression to multi-
ple myeloma. The risk of recurrent disease in cases with 
polyclonal IgG deposition, including secondary cryo-
globulinemia, is lower provided the underlying cause is 
adequately treated.
C3 glomerulopathy (C3G) is divided into two dis-
eases depending primarily on appearances under electron 
microscopy: dense deposit disease (DDD) and C3 glomer-
ulonephritis (C3GN). The rate of recurrence of both sub-
types of C3G is high, 70% in C3GN223–225 and 50-100% 
in DDD.223,225
Recurrence of C3G has a negative impact on transplant 
survival. A study using data from the North American 
Pediatric Renal Transplant Cooperative Study reported a 
5-year graft survival of only 50% in patients with a pri-
mary diagnosis of DDD compared with 74% for the data-
base as a whole.226 This 5-year survival is consistent with 
other reports in the literature.226,227 When DDD recurs, 
the proportion of graft losses attributable to recurrence is 
> 50%.227 A similar 5-year allograft survival is reported 
for patients with C3GN.223 Nevertheless, in patients 
with either C3GN or DDD 5-year survival of > 50% are 
expected, therefore transplantation is a realistic option for 
this patient cohort despite the risk of recurrence.
The cause of C3G should be determined when testing 
is available as it may affect future treatment in case of 
recurrence. Insufficient data are available to comment on 
whether the cause of complement dysregulation (genetic 
or acquired) predicts risk of recurrence. Several factors 
have been reported to predict a higher risk of recurrence 
and poor outcome including low complement (C3 and C4) 
levels at the time of transplant in some220,228 but not all 
reports,226,229 young age, heavy proteinuria and crescentic 
primary disease.226
 9.7 Lupus nephritis (LN)
 9.7.1: We recommend not excluding candidates with 
LN from kidney transplantation; however, 
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the risk of recurrence should be considered 
and discussed with the candidate (1B).
 9.7.2: We recommend that lupus activity should be 
clinically quiescent on no or minimal immu-
nosuppression prior to transplantation (1D).
 9.7.3: We recommend evaluation for secondary 
antiphospholipid antibodies prior to trans-
plantation to inform perioperative manage-
ment (1C).
RATIONALE
The reported incidence of systemic lupus erythemato-
sus recurrence after transplantation varies widely, ranging 
from 2.5-54%, depending on whether clinical or biopsy 
recurrence is reported.230–233 A retrospective analysis of the 
UNOS database suggested a low rate of clinical recurrence, 
affecting 2.4% of patients.234 This is in contrast to a recur-
rence rate of 54% in one study where surveillance biopsies 
were performed.235 Clinically relevant recurrence is likely 
to be in the range reported from registry data (< 5%).
From the UNOS data, the risk of graft failure is increased 
in patients who develop recurrence, four fold higher than 
patients without recurrence.234 However, only 7% of graft 
losses were attributed to recurrent disease. Although some 
studies have suggested that transplant outcome is worse 
in patients with LN,236 most studies report a low rate of 
graft loss due to recurrent LN and equivalent transplant 
survival in patients with LN compared to patients with 
other primary diseases.230,232,233,237,238
The UNOS data suggest that black race, female gender 
and young age increase the risk of recurrence.234 Similar 
risk factors are identified in other reports.
There are cases of successful transplantation in patients 
with serologically active lupus. However, the risk of 
recurrence is higher in patients with clinical or serologi-
cal disease activity at the time of transplantation.239,240 
Therefore, it is generally accepted that disease should be 
quiescent, or at least stable, on no or minimal immunosup-
pression prior to transplantation. There is no relationship 
between time on dialysis before transplantation and risk of 
recurrence.230 Although a period on dialysis prior to trans-
plantation has been suggested to reduce recurrence risk, 
there is insufficient evidence to support this.241
A proportion of patients with LN exhibit features of 
antiphospholipid syndrome (APS). Because of the implica-
tions of APS in kidney transplantation (see Section 9.8), we 
suggest that kidney transplant recipients with a primary 
diagnosis of LN be screened for the presence of antiphos-
pholipid antibodies (APLAs).
 9.8 Antiphospholipid syndrome (APS)
 9.8.1: We recommend not excluding candidates 
with APS from kidney transplantation; how-
ever, the risks of post-transplant thrombosis 
and perioperative anticoagulant therapies 
should be considered and discussed with the 
candidate (1B).
 9.8.2: We suggest that APS should be clinically qui-
escent prior to transplantation (2D).
 9.8.3: Continue anticoagulation (eg, aspirin, warfa-
rin) at the time of activation on the transplant 
waitlist (Not Graded).
RATIONALE
Primary or secondary APS (most commonly in associa-
tion with systemic lupus erythematosus) can cause intra-
renal vascular disease and thrombotic microangiopathy, 
ultimately leading to ESKD. A diagnosis of APS is associ-
ated with arterial and venous thrombosis and bleeding at 
the time of transplant, recurrence of nephropathy or casta-
trophic APS. Consequently the presence of APS is associated 
with worse allograft and patient survival, particularly in 
patients who have high level of pre-transplant antibodies.242 
However, the relevance of isolated positive antibody tests, 
particularly anti-cardiolipin, in the absence of clinical fea-
tures of APS, is less clear as anti-cardiolipin antiibodies can 
be found in up to one-third of dialysis patients. Although 
there are some reports that the presence of anti-phospho-
lipid antibodies increase the risk of early graft loss,243 other 
studies have not identified an increased thrombotic risk.244
 9.9 Anti-neutrophil cytoplasmic antibody (ANCA)-
associated vasculitis
 9.9.1: We recommend not excluding candidates 
with ANCA-associated vasculitis from kidney 
transplantation; however, the risk of recur-
rence should be considered and discussed with 
the candidate (1B).
 9.9.2: We suggest that ANCA-vasculitis should be 
clinically quiescent prior to transplantation 
(2D).
RATIONALE
The reported rate of relapse for ANCA-associated vas-
culitis varies from 9-36.8%245,246 with a pooled analy-
sis of reported cases finding that recurrence in the graft 
occurred in 17% of those transplanted.246 The variation 
may be explained by the different treatment regimens used 
to treat primary disease and the criteria used for diagnosis 
of recurrence. A more recent study, with patients on mod-
ern immunosuppression, reported a lower rate of recur-
rence (8.6%).247 The only relapses that occurred were 
extrarenal and no detrimental effect on graft function was 
identified.
Both allograft and patient survival is good in recipients 
with a primary diagnosis of ANCA-associated vasculitis, 
with 10-year patient and death-censored graft survival of 
87% and 70-84%, respectively.245,248,249
The risk of relapse is not influenced by the pattern of 
original disease (granulomatosis with polyangiitis or 
microscopic polyarteritis) or ANCA type.246 ANCA pos-
itivity at the time of transplant did not increase risk of 
allograft loss,246,249 but high titer antibodies at the time 
of transplant may be associated with early recurrence.250 
There is some evidence that the risk of relapse is increased 
if transplantation is performed within 1 year of clinical 
remission and therefore a period of 1 year of clinical remis-
sion prior to transplantation has been recommended in 
previous guidelines.29,249
 9.10 Anti-glomerular basement membrane (anti-GBM) 
disease
 9.10.1: We recommend not excluding candidates 
with anti-GBM disease from kidney trans-
plantation (1B).
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 9.10.2: We recommend that anti-GBM antibody 
titers be measured in candidates and that 
transplantation is only performed when 
antibodies are undetectable (1D).
RATIONALE
The exact rate of anti-glomerular basement membrane 
(anti-GBM) disease recurrence after transplantation is not 
known but is estimated to be < 10% and is more likely 
if anti-GBM antibodies are detectable at the time of 
transplantation.251 Therefore, to reduce the risk of recur-
rence, we suggest that serological remission be confirmed. 
Although 9-12 months of serological remission prior to 
transplantation has been suggested, there is insufficient 
evidence to recommend this.252
 9.11 Hemolytic uremic syndrome (HUS)
 9.11.1: We recommend not excluding candidates 
with HUS due to infection with a Shiga-
toxin producing organism, usually E. coli 
(STEC-HUS), from kidney transplantation 
(1A).
 9.11.2: We recommend assessment of candidates 
with suspected atypical HUS (aHUS) for a 
genetic or acquired defect in complement 
regulation or other genetic causes of aHUS 
to inform risk of recurrence (1B).
 9.11.3: We recommend not excluding candidates 
with aHUS from kidney transplantation; 
however, the risk of recurrence should be 
considered and discussed with the candi-
date (1B).
 9.11.3.1: We recommend that if the can-
didate has an abnormality in 
complement regulation placing 
them at high risk of recurrence, 
kidney transplantation should 
not proceed unless a complement 
inhibitor can be administered or 
combined liver-kidney transplant 
can be performed (1B).
RATIONALE
Hemolytic uremic syndrome (HUS) is most commonly 
due to infection with a Shiga-toxin producing E. coli 
(STEC-HUS, 90% of cases). STEC-HUS is a self-limiting 
illness that only rarely results in ESKD, although lesser 
degrees of CKD are common. STEC-HUS recurs very 
rarely after transplantation (0-1%) and therefore this diag-
nosis is not a contraindication to transplantation.253 The 
low rate of ESKD in patients with STEC-HUS raises the 
possibility of an alternative diagnosis when ESKD occurs, 
particularly an atypical, complement-mediated form of the 
disease. In this situation, consideration should be given to 
testing for of a genetic or acquired defect in complement 
regulation.254
When presumed STEC-HUS has recurred after trans-
plantation, again an alternative diagnosis such as atypical 
hemolytic uremic syndrome (aHUS) should be considered. 
Alberti et al. described genetic defects in complement 
regulation in 2 patients with recurrent HUS, despite evi-
dence of STEC infection during the initial presentation.254
Unlike STEC-HUS, the renal prognosis of aHUS is poor 
with 50% of patients developing ESKD.255 The risk of 
recurrence and subsequent graft loss is high. Patients with 
a pathological variant of Complement Factor H (CFH), 
Complement Factor I (CFI), C3, Complement Factor 
B (CFB) or high titer anti-CFH autoantibodies have an 
80-90% risk of recurrence and, without treatment with a 
complement inhibitor, most grafts are lost following recur-
rence.256,257 Patients with a variant Membrane Cofactor 
Protein or low titer of historical anti-CFH antibodies can 
be considered for transplantation as the recurrence risk is 
low.256,257 Candidates in whom no cause of aHUS is iden-
tified are at an intermediate risk of recurrent disease.258
Candidates at risk of recurrent aHUS should be counse-
led about the pre-emptive use of a complement inhibitor or 
the need to start treatment if aHUS occurs post-transplant 
(Summary Table: Recurrence aHUS and evidence pro-
file: Treatments to prevent kidney disease recurrence).259 
Transplant candidates with a genetic defect in proteins 
primarily synthesized in the liver (CFH, CFI, C3 and 
CFB) could be considered for combined liver and kidney 
transplantation.260
 9.12 Systemic sclerosis
 9.12.1: We recommend not excluding candi-
dates with systemic sclerosis from kidney 
transplantation in the absence of severe 
pulmonary, gastrointestinal, or other life-
threatening extrarenal disease (1C).
RATIONALE
Transplantation should be considered for candidates 
with systemic sclerosis as a cause of ESKD provided that 
the severity of extrarenal manifestation of the disease 
does not preclude transplantation. UNOS database stud-
ies suggested that although transplantation improved 
the outcome of patients with systemic sclerosis, sur-
vival was less favorable than for other kidney transplant 
candidates (68% 1-year graft survival).261,262 More 
recently a French Registry study reported the outcome 
of 36 transplants in 34 patients with a primary diagnosis 
of systemic sclerosis. Patient survival was 82.5% at 5 
years, with death-censored graft survival of 92.8% at 5 
years.263 There were 3 cases of renal crisis, and cardiac 
and gastrointestinal disease worsened in 45% and 26% 
of patients, respectively.
 9.13 Plasma cell dyscrasias (PCDs)
Please consult Section 17.6 Hematologic Disorders for 
recommendations related to monoclonal gammopathy 
of undetermined significance (MGUS)
 9.13.1 Multiple myeloma
 9.13.1.1: We suggest that candidates with 
multiple myeloma be excluded 
from kidney transplantation 
unless they have received a poten-
tially curative treatment regimen 
and are in stable remission (2D).
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 9.13.2 Monoclonal immunoglobulin deposition 
disease (MIDD)
 9.13.2.1: We suggest that candidates with 
light chain deposition disease 
(LCDD) be excluded from kidney 
transplantation unless they have 
received a potentially curative 
treatment regimen and are in sta-
ble remission (2D).
 9.13.2.2: We suggest that candidates with 
heavy chain deposition disease 
(HCDD) be excluded from kid-
ney transplantation unless they 
have received a potentially cura-
tive treatment regimen and are in 
stable remission (2D).
 9.13.2.3: We suggest that candidates with 
light and heavy chain deposition 
disease (LHCDD) be excluded 
from kidney transplantation 
unless they have received a poten-
tially curative treatment regimen 
and are in stable remission (2D).
 9.13.3 AL amyloidosis
 9.13.3.1: We suggest that candidates with 
AL amyloidosis be excluded from 
kidney transplantation unless 
they have minimal extrarenal dis-
ease (eg, cardiac amyloid), have 
received a potentially curative 
treatment regimen and are in sta-
ble remission (2D).
RATIONALE
Renal manifestations of plasma cell dyscrasias (PCDs) are 
common and are present in approximately 25% of cases 
at the time of presentation and in 50% of patients at some 
stage.264,265 The most common renal manifestations of PCD 
are cast nephropathy, monoclonal immunoglobulin deposi-
tion disease (MIDD) and AL amyloidosis. In patients with 
PCD, these are found in 40-63%, 19-26% and 7-30%, 
respectively. Patient survival is dependent on the type of kid-
ney disease present, with a median survival of 6, 48 and 22 
months for cast nephropathy, MIDD and AL amyloidosis, 
respectively, and secondly on kidney function at presenta-
tion, with impaired function predicting a poor survival.
There have been advances in the treatment of PCD 
which have led to a significant improvement in remission 
rates and survival. Hence, older reports should be inter-
preted with caution.
Multiple myeloma with cast nephropathy has been 
regarded as a contraindication to transplantation because 
of the high risk of recurrence and poor survival due to the 
underlying multiple myeloma.89 However, there are a num-
ber of case series and reports describing short and medium 
term survival after kidney transplantation in patients with 
multiple myeloma.266 In a series of nine patients with mul-
tiple myeloma who received a kidney transplant, patients 
survived between 14 and 114 months, though this is a 
report from 1996 prior to the introduction of new treat-
ment strategies.267 Three patients died of recurrent disease 
and 3 from sepsis. No graft was lost due to recurrent cast 
nephropathy. The ERA-EDTA registry identified 35 cases 
of patients with multiple myeloma undergoing transplan-
tation with a median survival of 9.6 years.268 There is no 
information about disease or patient characteristics, but 
this is likely to represent a highly selected group of patients. 
There is no evidence to inform the wait time between 
induction of multiple myeloma remission and transplanta-
tion. A multidisciplinary approach to transplant candidate 
with multiple myeloma, involving hematologists and neph-
rologists, is advised.
Successful outcomes have been reported after HLA 
matched, combined kidney and stem cell transplantation. 
In a series of 7 cases reported in 2011, 4 remained disease 
free after 4 years.269 Given the difficulties in finding well-
matched donors, an emerging strategy has been treatment 
with chemotherapy and stem cell transplant to obtain sta-
ble remission followed by kidney transplantation.270
Light chain deposition disease (LCDD) is the most com-
mon form of MIDD and has been considered as a con-
traindication to transplant.88 LCDD occurs in association 
with monoclonal gammopathy of undetermined signifi-
cance (MGUS, 20%) or multiple myeloma (60%) and, as 
with cast nephropathy, poor outcomes have been reported 
after kidney transplantation. In a series reported by Leung 
et al., 7 patients with LCDD received a transplant with a 
median allograft survival of 37 months. LCDD recurred in 
5 patients, 4 of whom died.271
Light and heavy chain deposition disease (LHCDD) is 
the second most common form of MIDD, representing 
10% of cases, but is still rare. As with LCDD, underly-
ing multiple myeloma is common, present in about 50% 
of cases. Heavy chain deposition disease (HCDD) is very 
rare with a review in 2013 identifying only 37 cases in 
the literature. Therefore, there is limited experience of kid-
ney transplantation in this patient group. Renal prognosis 
is poor, with case reports of response to corticosteroids 
and chemotherapy. The proportion of patients with mul-
tiple myeloma is lower than with LCDD (20%). Of two 
patients who received a kidney transplant, one developed 
recurrent disease.272
An updated series of 255 patients with MIDD, which 
includes patients with LCDD, HCDD and LHCDD, has 
recently been published.273 Patients received a variety of 
treatments including bortezomib and high dose melphalan 
followed by autologous stem cell transplantation. Twenty-
three patients received a kidney transplant. Consistent with 
previous literature, graft survival was poor in those who did 
not receive appropriate treatment pre-transplant. However, 
there was a subset of 14 patients who received a kidney 
transplant after achieving a hematological response. Disease 
recurrence occurred in 4 patients but only one sustained 
graft loss after 5 years. Therefore, in select patients who 
have achieved a remission, kidney transplantation appears 
to be a viable treatment option for patients with MIDD.
There have been a few series of patients with AL amy-
loidosis reporting kidney allograft survival in 41 patients 
from 18 to 72 months without evidence of disease recur-
rence. These patients had received treatment for their PCD 
consisting of chemotherapy with or without autologous 
stem cell transplant and had maintained good functional 
status without significant extrarenal amyloid deposition. A 
study from the UK National Amyloidosis Centre reported 
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outcome of 25 patients with AL amyloidosis who received 
a kidney transplant. Median patient survival was 7.3 years 
and median graft survival was 5.8 years. No graft was lost 
due to recurrent AL amyloidosis. Survival was improved if 
there was at least a partial response to treatment aimed at 
suppression of the precursor fibril load (median survival 
8.9 vs 5.2 years in those patients with no response).
A recent paper from the US analyzed 49 patients who 
underwent kidney transplantation with AL amyloidosis.274 
Eighty percent had received a stem cell transplant and 
were in stable remission before kidney transplantation. 
Although 33% had evidence of cardiac involvement, none 
of the patients had “clinically significant” amyloid heart 
disease. Unfortunately, the degree of cardiac involvement 
was not detailed further and anyone with “advanced” 
organ involvement was excluded. Median patient survival 
from kidney transplantation was 10.5 years with even 
better survival for those with a complete hematological 
response pre-transplant. The authors also found that those 
patients transplanted in the most recent era had a signifi-
cant improvement in survival. The authors concluded that 
carefully selected patients with amyloidosis can have good 
outcomes following kidney transplantation.274
Other manifestations of monoclonal deposition are 
considered in the sections on MPGN and fibrillary 
glomerulonephritis.
 9.14 AA amyloidosis
 9.14.1: We recommend not excluding candidates 
with AA amyloidosis from kidney trans-
plantation after adequate treatment of the 
underlying cause and in the absence of 
severe extrarenal organ involvement (1D).
RATIONALE
There are conflicting data on the outcome of kidney 
transplantation in candidates with a primary diagnosis of 
AA amyloidosis, with both equivalent and inferior graft 
and patient survival reported.275,276 A multicenter study 
reported inferior 10-year patient survival for AA amyloid 
versus non-amyloid ESKD (62% vs 83%) but equiva-
lent death-censored graft survival, suggesting an effect of 
extrarenal manifestations of AA amyloidosis on patient 
survival.277
 9.15 Fibrillary/immunotactoid glomerulonephritis
 9.15.1: We recommend not excluding candidates 
with fibrillary or immunotactoid glomeru-
lonephritis from kidney transplantation; 
however, the risk of recurrence should be 
considered and discussed with the candi-
date (1D).
RATIONALE
Fibrillary and immunotactoid glomerulonephritis can 
recur after transplantation.278 A case series reported recur-
rence of fibrillary glomerulonephritis in 43% of cases, 
and this was more common in patients with a monoclo-
nal gamopathy.279,280 Fibrillary glomerulonephritis with 
a monoclonal gammopathy is associated with a high risk 
of allograft loss suggesting that treatment of the underly-
ing PCD is required prior to kidney transplantation.280 A 
recent registry analysis found that patients with fibrillary 
glomerulonephritis had similar long term graft survival to 
other causes of ESKD.281 Although only four patients with 
immunotactoid glomerulonephritis were transplanted, 
there was 100% renal-allograft survival at 3.66 years.281
 9.16 Hyperoxaluria (oxalosis), primary and secondary
 9.16.1: We suggest that candidates with primary 
hyperoxaluria type 1 be considered for 
combined or sequential liver-kidney trans-
plantation (2C).
 9.16.2: We suggest genetic testing to identify the 
cause of primary hyperoxaluria to inform 
treatment decisions (2C).
 9.16.3: We suggest not excluding candidates with 
correctable hyperoxaluria—pyridoxine-
responsive or secondary—from kidney 
transplantation alone; however, the risk of 
recurrence should be considered and dis-
cussed with the candidate (2D).
 9.16.4: We recommend the use of strategies to 
lower total body oxalate burden prior to 
transplantation in patients with hyper-
oxaluria, including intensive dialysis, diet 
modification, and pyridoxine treatment as 
appropriate on a case-by-case basis (1D).
RATIONALE
Primary hyperoxaluria causes kidney injury due to crys-
tal deposition in the kidneys, and this can lead to ESKD. As 
kidney disease progresses, oxalate production exceeds excre-
tion and tissue accumulation occurs. This continues while on 
dialysis, which does not remove sufficient oxalate to prevent 
accumulation. After transplantation, in primary hyperoxalu-
ria the kidney is exposed to both new oxalate produced in 
the liver and tissue oxalate that is mobilized on restoration 
of kidney function, and this may cause early graft failure.
A study of the outcome of kidney transplantation in 
patients with primary hyperoxaluria published in 1990 
from the European Dialysis and Transplant Association 
registry reported a 3-year graft survival of 23% from living 
donors and 17% from deceased donors.282 More recently a 
publication from the International Primary Hyperoxaluria 
Registry reported a 5-year survival of 45%.283
Liver transplantation will reverse the metabolic abnor-
mality responsible for primary hyperoxaluria type 1. Less 
is known about the benefit in other types. Combined 
liver-kidney transplantation offers superior death-cen-
sored graft survival compared with kidney transplant 
alone.283,284 Although the metabolic defect is corrected, 
high oxalate levels may persist after transplantation due to 
mobilization of tissues stores.285 Sequential liver and kid-
ney transplantation can be performed in order to minimize 
oxalate accumulation in the transplanted kidney and may 
be considered.286 If this is not possible, strategies to reduce 
oxalate burden, including intensive dialysis and a low oxa-
late diet, should be started early, even with a GFR above 
20 ml/min/1.73 m2.282 Current early-phase trials of small 
interfering RNA (siRNA) strategies to prevent excess oxa-
late accumulation in people with primary hyperoxaluria 
type 1 have shown positive results. If more definitive trials 
are successful and the compound is made available, initia-
tion prior to transplantation may greatly reduce the risk of 
recurrence for such patients in the future.287,288
S54 Transplantation  ■  April 2020  ■ Volume 104  ■  Number 4S www.transplantjournal.com
 9.17 Cystinosis
 9.17.1: We recommend not excluding candidates 
with cystinosis from kidney transplanta-
tion in the absence of severe extrarenal 
manifestations (1C).
RATIONALE
Cystinosis does not recur in the kidney allograft and 
transplantation represents the best treatment for patients 
with cystinosis and ESKD, provided that extrarenal mani-
festations do not represent an unacceptable risk.289
 9.18 Fabry disease
 9.18.1: We recommend not excluding candidates 
with Fabry disease from kidney transplan-
tation in the absence of severe cardiac or 
other systemic extrarenal organ involve-
ment (1C).
RATIONALE
Fabry disease does not recur after transplantation.290 
Reports suggest that allograft and patient survival is 
good after transplantation in patients with Fabry disease, 
although perhaps worse than in patients with other pri-
mary diseases due to extrarenal disease.290–292 Therefore 
kidney transplantation is an option for most transplant 
candidates with Fabry disease. In some patients the sever-
ity of cardiac or cerebrovascular disease may preclude 
transplantation.
 9.19 Sickle cell disease
 9.19.1: We recommend not excluding candidates 
with sickle cell disease from kidney trans-
plantation in the absence of active, severe 
extrarenal sickle cell disease (1C).
RATIONALE
Sickle cell disease can recur in the allograft but currently 
there are insufficient data to determine the rate of recur-
rence.293 Earlier reports suggested poor allograft survival 
in patients with sickle cell disease, but more recent stud-
ies report similar graft and patient survival compared to 
patients with normal hemoglobin genotype.294 A review 
of US Renal Data System reported that transplant survival 
was similar at 1 year in patients with a primary diagnosis 
of sickle cell disease compared to black patients with other 
primary diagnoses.295 However, longer-term patient and 
allograft survival was inferior in sickle cell patients, with 
a RR of 1.60 for graft failure and 2.95 for death. Although 
mortality is higher in sickle cell patients after transplant, it 
is lower than in sickle cell patients who remain on dialy-
sis. There are insufficient data available to predict the effect 
of bone marrow transplantation on outcomes after kidney 
transplantation.
 9.20 Sarcoidosis
 9.20.1: We recommend not excluding candidates 
with renal sarcoidosis from kidney trans-
plantation in the absence of severe extrare-
nal disease (1C).
RATIONALE
Sarcoidosis can recur in the kidney allograft. There are 
case reports and one series of 18 kidney transplant can-
didates with sarcoidosis, 10 of whom had renal sarcoid 
diagnosed prior to transplantation. Sarcoidosis recurred in 
the grafts of 3 of the 10 patients who had renal sarcoid 
in their native kidneys.296,297 Graft loss was not seen in 
patients with recurrent renal sarcoid but kidney function 
was inferior.
 9.21 Alport syndrome
 9.21.1: We recommend not excluding candidates 
with Alport syndrome from kidney trans-
plantation (1C).
RATIONALE
The outcome of transplantation is equivalent to or bet-
ter in patients with Alport syndrome compared to other 
causes of ESKD. The development of post-transplant anti-
GBM disease has been recognized and occurs in 3-5% of 
recipients and candidates should be aware of this poten-
tial outcome. It is more likely to occur in patients with 
large gene deletions. This outcome was not seen in a 
recent report of 51 patients with Alport syndrome under-
going kidney transplant, suggesting that modern immu-
nosuppressive regimens may be protective against this 
occurrence.298
What prior guidelines recommend
We are in agreement with other guidelines that there 
are only a limited number of diseases causing ESKD that 
are a contraindication to transplantation. There have been 
changes in the classification of some disease, for example 
MPGN, and the current guidelines reflect these changes 
and therefore differ from previous guidelines. There have 
also been advances in the diagnostics which allow more 
accurate assessment of the risk of recurrence, eg, anti-
body status in membranous nephropathy. These tests are 
not included in previously published guidelines but will 
be addressed in the forthcoming KDIGO glomerulonp-
ehritis guideline update. Advances in treatments have also 
changed how some diseases are considered with respect to 
recurrence risk. Atypical HUS with certain causative muta-
tions had been considered a contraindication to transplan-
tation.299 The availability of complement inhibitors now 
allows kidney-only transplantation for these patients. 
However, it is important to recognize that new treat-
ments may not be universally available. Similarly, multiple 
myeloma and other plasma cell dyscrasias are considered 
absolute contraindications to transplantation in some 
guidelines27,29 but the availability of curative treatments 
allows successful kidney transplantation for a subgroup of 
patients.
RESEARCH RECOMMENDATIONS
 • Studies should evaluate the efficacy of pre- and post-
transplant interventions to prevent or treat post-trans-
plant FSGS recurrence.
 • Studies should evaluate the efficacy of pre-transplant 
rituximab to prevent recurrence of MN, including effect 
on anti-PLA2R positive and negative candidates.
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 • RCTs should compare pre-transplant complement inhi-
bition versus post-transplant therapy only on the pres-
ence of aHUS recurrence.
 • Further studies should assess the impact of new treat-
ments for PCD on kidney transplant outcomes.
 • The ability of pre- and post-transplant siRNA admin-
istration to prevent post-transplant recurrent oxalosis 
in people with primary hyperoxaluria type 1 should be 
examined.
RELEVANT SUPPLEMENTAL MATERIAL
Summary table: Recurrence aHUS
Summary table: Recurrence FSGS
 Evidence profile: Treatments to prevent kidney disease 
recurrence
SECTION 10: INFECTIONS
 10.1 Active infections
 10.1.1: We recommend that kidney transplantation 
be delayed until active infections (bacterial, 
fungal, viral [except hepatitis C], parasitic) 
are treated (1C).
RATIONALE
Patients awaiting kidney transplantation are at risk for 
a variety of infectious diseases due to underlying immuno-
logic abnormalities from CKD, diabetes, and the process 
of dialysis itself. All infections should be treated with the 
goal to cure. Clinical and radiologic improvement should 
occur before transplantation. Microbiologic eradication 
should be documented in situations where cultures can 
be obtained. Any active infection at the time of transplant 
surgery can increase the risk of sepsis and wound infection. 
In addition, the infection can also become more difficult to 
resolve due to post-transplant immunosuppression. Ideally, 
the patient should complete the full course of therapy for 
an active infection prior to transplantation. Although not 
ideal, transplantation can be considered prior to comple-
tion of the course of therapy as long as clinical improve-
ment has occurred, cultures have become negative and the 
patient will continue on the antimicrobials post-transplant.
Common infections in dialysis patients include central 
venous catheter-related, soft tissue and bloodstream infec-
tions. These infections are usually caused by Staphylococcus 
aureus or coagulase-negative Staphylococci although 
Gram-negative organisms and fungi can also be isolated. 
Infection source, such as catheters, should be removed 
especially in the case of bloodstream infections from 
Staphylococcus aureus, Candida spp., Pseudomonas spp., 
and other multidrug resistant Gram-negative bacteria 
where antimicrobial options are limited.300 Infection of the 
peritoneal dialysis catheter can also occur and lead to the 
development of peritonitis. Culture negativity, a decrease 
in peritoneal dialysis fluid leukocyte count as well as clini-
cal improvement should be documented before transplan-
tation. In some cases, infection of the peritoneal dialysis 
catheter can recur or become chronic. In such cases, infec-
tion is not possible to completely cure and transplanta-
tion with simultaneous removal of the catheter is the best 
treatment option. Skin and soft tissue infections in diabetic 
patients may develop in candidates and are often polymi-
crobial. In chronic infections or ulcers, an atypical organ-
ism (eg, Mycobacterium) or an underlying osteomyelitis 
should be considered and excluded. Surgical management 
may be necessary for severe cases prior to transplanta-
tion. In the ideal situation, an ulcer should not be actively 
infected and healing should be complete or nearing com-
pletion prior to transplantation.
 10.2 Colonization
 10.2.1: Follow local protocols for detection and 
management of colonization with drug-
resistant organisms (Not Graded).
 10.2.2: We recommend not excluding patients from 
kidney transplantation with asymptomatic 
bacterial, parasitic or fungal colonization 
(1C).
RATIONALE
Transplant candidates may harbor drug-resistant 
microbes. Knowledge of colonization with specific organ-
isms can help in management and selection of antimicrobi-
als for peri- and post-operative infections. Many healthcare 
facilities have implemented screening practices to detect 
and manage colonization with drug resistant organisms 
such as methicillin-resistant Staphylococcus aureus, vanco-
mycin-resistant enterococci, carbapenem-resistant entero-
bacteriaceae, etc. Although active screening for multidrug 
resistant organisms (MDROs) is not required for trans-
plantation, candidates may test positive during routine 
screening or have a prior history of MDRO infection. In 
such cases, consideration can be given to modification of 
perioperative and post-transplant prophylaxis to cover the 
organisms found during screening. Transplant candidates 
may have a history of fungal, parasitic or bacterial coloni-
zation. Colonization without evidence of infection is not a 
contraindication for transplant. However, there is greater 
risk of progression to infection and strategies to mitigate 
progression such as antimicrobial prophylaxis should be 
considered at the time of transplant.
 10.3 Specific Infections
10.3.1 Urinary tract infections (UTIs)
 10.3.1.1: We recommend treating sympto-
matic UTIs prior to kidney trans-
plantation (1B).
 10.3.1.2: We suggest not routinely perform-
ing prophylactic nephrectomy for 
recurrent pyelonephritis or cyst 
infections (2D).
RATIONALE
For transplant candidates with recurrent urinary tract 
infections (UTIs), anatomic abnormalities need to be ruled 
out. In the specific case of polycystic kidney disease, recur-
rent UTIs with the same organism may be indicative of 
a renal cyst infection. One study reported on 73 polycys-
tic kidney disease patients, 30 of whom underwent pre-
transplant nephrectomy while 43 did not. Complications, 
especially cyst infections, were more frequent in those 
without nephrectomy although the overall rate was not 
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significantly different.301 Some experts suggest native 
nephrectomy at the time of transplant in patients with a 
history of cyst infection although this has not shown to 
reduce post-transplant UTI or to reduce the risk of graft loss 
(Summary Table and Evidence Profile: Nephrectomy].302 
In select situations, patients with chronic pyelonephritis 
have also undergone nephrectomy prior to transplantation 
with significant post-operative complications.303,304 One 
study that determined the effect of bilateral nephrectomy 
in patients with vesicoureteral reflux showed no significant 
difference in the rates of UTIs at 3 years in those with or 
without nephrectomy.305
10.3.2 Tuberculosis (TB)
 10.3.2.1: We suggest complete treatment of 
active TB prior to kidney trans-
plantation, as per World Health 
Organization or local guidelines 
(2C).
 10.3.2.2: We recommend screening for 
latent TB at the time of candidate 
evaluation in low TB prevalence 
areas with a chest radiograph 
along with a purified protein 
derivative (PPD) skin test or inter-
feron-gamma release assay (1C).
 10.3.2.3: We suggest starting treatment of 
latent TB prior to or immediately 
following kidney transplantation 
in low TB prevalence areas (2C).
 10.3.2.4: We suggest screening for latent 
TB at the time of candidate evalu-
ation as per local guidelines in 
intermediate and high TB preva-
lence areas with post-transplanta-
tion vigilance for active TB (2C).
RATIONALE
One specific infection that may occur in persons with 
CKD is active tuberculosis (TB), especially in persons liv-
ing in endemic areas. Therapy for active TB involves a 
multidrug regimen for at least 6 months with longer dura-
tions for more complex disease.306,307 Overall, multid-
rug resistant TB makes up approximately 2-5% of cases; 
however, in some areas, resistance rates to the primary 
anti-tuberculous drugs may exceed 20%.307 The World 
Health Organization recommends at least 20 months of 
treatment for multidrug resistant TB. In a meta-analysis, 
cure rates for multidrug resistant-TB were only 65%.308 
Ideally, therapy for TB should be completed prior to trans-
plantation. However, studies have shown that transplan-
tation can successfully occur after 3-6 months of therapy 
for active TB with completion of therapy in the post-
transplant setting (Summary Table and Evidence Profile: 
TB treatment).309–312 At a minimum, the patient should be 
documented as culture-negative, and have clinical as well 
as radiologic improvement. In some situations, it may not 
be feasible to wait for therapy completion before trans-
plantation (eg, lack of access to dialysis); in such cases, the 
benefit of transplantation should be weighed against the 
risk of recurrent TB or non-completion of therapy.
Latent TB is a significant worldwide problem and it is 
estimated that 1 in 4 people are infected. Post-transplant, 
there is a 20-55 fold increase in the risk of TB reactivation 
compared to the general population. In many non-
endemic countries (< 20 cases per 100,000 population 
annually), public health measures such as contact tracing 
and ensuring completion of therapy are used to control 
transmission of TB. Therefore, many guidelines recom-
mend screening and subsequent treatment for latent TB. 
Screening can be performed using either purified pro-
tein derivative (PPD) skin test or an interferon-gamma 
release assay as well as a chest radiograph.313 One study 
showed that a positive PPD test and previously healed 
TB on chest radiograph were significant risk factors for 
post-transplant TB.314 Where TB screening is performed, 
it should be repeated annually if there is ongoing risk of 
exposure while awaiting transplantation. If the patient is 
determined to have latent TB, there are several treatment 
regimens that can be used.309,315,316 There is no consen-
sus as to the duration of treatment that needs to be com-
pleted prior to transplantation; however, it is reasonable 
that once the patient is clinically tolerating the therapy, 
transplantation can be performed. Since the majority of 
reactivation occurs within the first year post-transplant, 
therapy for latent TB should be instituted no later than 
1-2 weeks post-transplant if it was not started in the pre-
transplant period.317,318
While TB screening in low prevalence countries is gener-
ally performed, the same may not be feasible in intermedi-
ate or high prevalence countries where there is a high rate 
of positivity and resistance to first-line anti-tuberculous 
agents. Therefore, in TB-endemic regions, screening strate-
gies or universal therapy for latent TB may not prevent 
post-transplant TB since there is risk for ongoing exposure. 
In such situations, local screening guidelines should be fol-
lowed (Summary Table and Evidence Profile: TB testing). 
At a minimum, a chest radiograph should be performed to 
rule out active TB and the clinician should remain vigilant 
for the development of post-transplant TB.
 10.4 Screening for periodontal disease
 10.4.1: We suggest dental evaluation, as per local 
general population guidelines, to screen for 
dental/periodontal disease prior to kidney 
transplantation (2C).
RATIONALE
Dental screening is important prior to transplant in 
order to screen for and prevent post-transplant oral infec-
tions.319–321 Although not mandated prior to transplanta-
tion, a dental evaluation may be especially important in 
diabetics who appear to have a greater risk of periodontal 
disease.
 10.5 Screening for viral infections (see Table 11)
 10.5.1 Human immunodeficiency virus (HIV)
 10.5.1.1: We recommend screening all 
patients for HIV infection, using 
HIV serology (1A).
 10.5.1.2: We recommend not excluding 
patients with controlled HIV 
infection from kidney transplan-
tation (1C).
 10.5.1.3: Kidney transplant candidates 
with HIV should be managed in a 
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center with experience in this area 
(Not Graded).
 10.5.2 Hepatitis C virus (HCV) [This section 
is adapted from 2018 KDIGO HCV 
Guideline]
 10.5.2.1: We recommend screening all 
patients for HCV infection 
(1A). (KDIGO HCV Guideline 
Recommendation 1.1.4)
 10.5.2.2: We recommend using an immu-
noassay followed by nucleic acid 
testing (NAT) if immunoassay 
is positive (1A). (KDIGO HCV 
Guideline Recommendation 
1.1.1.1)
 10.5.2.3: We recommend kidney trans-
plantation as the best therapeutic 
option for patients with CKD G5 
irrespective of presence of HCV 
infection (1A). (KDIGO HCV 
Guideline Recommendation 
4.1.1)
 10.5.2.4: We suggest that all candidates 
with HCV infection be evaluated 
for severity of liver disease and 
presence of portal hypertension (if 
indicated) prior to acceptance for 
kidney transplantation (Figure 3) 
(2D). (KDIGO HCV Guideline 
Recommendation 4.1.2)
 10.5.2.4.1: We recommend that patients 
with HCV and compensated 
cirrhosis (without portal 
hypertension) undergo iso-
lated kidney transplanta-
tion (1B). (KDIGO HCV 
Guideline Recommendation 
4.1.2.1)
 10.5.2.4.2: We recommend referring 
patients with HCV and 
decompensated cirrhosis for 
combined liver-kidney trans-
plantation (1B) and defer-
ring HCV treatment until 
after transplantation (1D). 
(KDIGO HCV Guideline 
Recommendation 4.1.2.2)
 10.5.2.5: Timing of HCV treatment in rela-
tion to kidney transplantation 
(before vs. after) should be based 
on donor type (living vs. deceased 
donor), waitlist times by donor 
type, center-specific policies gov-
erning the use of kidneys from 
HCV-infected deceased donors, 
HCV genotype, and severity 
of liver fibrosis (Not Graded). 
(KDIGO HCV Guideline 
Recommendation 4.1.3)
 10.5.2.5.1: We recommend that all 
patients with HCV who are 
candidates for kidney trans-
plantation be considered for 
direct-acting antiviral (DAA) 
therapy, either before or 
after transplantation (1A). 
(KDIGO HCV Guideline 
Recommendation 4.1.3.1)
 10.5.2.5.2: We suggest that candidates 
with HCV with a living kid-
ney donor can be considered 
for treatment before or after 
transplantation according to 
HCV genotype and antici-
pated timing of transplanta-
tion (2B). (KDIGO HCV 
Guideline Recommendation 
4.1.3.2)
 10.5.2.5.3: We suggest that if receiving a 
kidney from an HCV-positive 
TABLE 11.
Recommendations for initial and follow-up screening of viral and non-viral pathogens in kidney transplant candidates.
Pathogen Test Repeat testing
Viral infections
 HIV IgG If negative, repeat annually and at time of transplant
 HCV IgG If negative, repeat annually and at time of transplant
 HBV Anti-HBs, Anti-HBc, HBsAg If negative, repeat annually and at time of transplant
 CMV IgG If negative, repeat at time of transplant
 EBV VCA IgG or EBNA IgG If negative, repeat at time of transplant
 HSV IgG If negative, repeat at time of transplant
 VZV IgG If negative, repeat at time of transplant and 4 weeks post-vaccination
 Measles, Mumps, Rubella IgG If negative, repeat at time of transplant and 4 weeks post-vaccination
 HTLV IgG None unless ongoing risk of exposure
Non-Viral infections
 Syphilis IgG with confirmatory testing if IgG positive None
 Strongyloides IgG None
 Chagas disease IgG None
 Tuberculosis
 (in low prevalence areas)
Tuberculin skin test or Interferon-gamma  
release assay (IGRA)
Annually if ongoing risk of exposure
 Malaria Blood smear if clinically indicated None
Anti-HBc, hepatitis B core antibody; Anti-HBs, hepatitis B surface antibody; CMV, cytomegalovirus; EBNA, EBV nuclear antigen; EBV, Epstein-Barr virus; HBV, hepatitis B virus; HBsAg, hepatitis B surface 
antigen; HCV, hepatitis C virus; HIV, human immunodeficiency virus; HSV, herpes simplex virus; HTLV, human T-lymphotropic virus; IgG, immunoglobulin G; VCA, viral capsid antigen; VZV, varicella zoster virus.
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donor improves the chances 
for transplantation, the HCV 
NAT-positive patient can 
undergo transplantation with 
an HCV-positive kidney and 
be treated for HCV infection 
after transplantation (2B). 
(KDIGO HCV Guideline 
Recommendation 4.1.3.3)
 10.5.3 Hepatitis B virus (HBV) [See Section 10.7 
for related recommendations on HBV 
vaccinations]
 10.5.3.1: We recommend screening for HBV 
infection with HBsAg, anti-HBs, 
and anti-HBc (1A).
 10.5.3.2: We recommend screening with 
HBV DNA for patients with a 
positive HBsAg or anti-HBc (1A).
 10.5.3.3: We recommend that patients 
from hepatitis D virus (HDV) 
endemic areas be screened with 
HDV serology if they are positive 
for HBsAg or anti-HBc (1A).
 10.5.3.4: We recommend that HBsAg posi-
tive and/or HBV DNA positive 
candidates be referred to a spe-
cialist with expertise in the man-
agement of liver disease and HBV 
infection to determine appropri-
ate antiviral treatment (1D).
 10.5.3.4.1: We recommend that HBsAg 
positive and/or HBV DNA 
positive candidates undergo 
isolated kidney transplan-
tation if they do not have 
decompensated cirrhosis and 
Living donor Deceased donor
HCV-infected candidates
for a kidney transplantation
Testing for liver fibrosis and
if indicated, portal hypertension
F0 to compensated cirrhosis
without portal hypertension
Decompensated
cirrhosis
SKLT before
treatment
Short time
to transplantation
< 24 weeks
Expected time
to transplantation
> 24 weeks
Treatment before
or after
transplantation
depending on
HCV genotype
and availability of
treatment regimens
Treatment after
transplantation
Possibility of
receiving an HCV+
kidney rapidly
No possibility of
receiving an HCV+
kidney rapidly
No treatment prior
to transplantation
Kidney from
HCV + or – donor
Treatment after
transplantation
Treatment before
transplantation
FIGURE 3. Algorithm for the evaluation of kidney transplant candidates with HCV Reproduced from KDIGO 2018 Clinical Practice 
Guideline on the Prevention, Diagnosis, Evaluation and Treatment of Hepatitis C in CKD.329 F0, no fibrosis; HCV, hepatitis C virus; SKLT, 
simultaneous kidney-liver transplantation.
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are stable on antiviral therapy 
after specialist evaluation 
(1B).
 10.5.3.5: We recommend not exclud-
ing anti-HBc antibody positive 
(HBsAg negative) patients from 
kidney transplantation (1C).
 10.5.3.5.1: We recommend that anti-HBc 
antibody positive (HBsAg 
negative) patients not receive 
antiviral prophylaxis given 
that the risk of reactivation is 
low (1D).
 10.5.3.5.2: We suggest that anti-HBc 
antibody positive (HBsAg 
negative) patients have a plan 
in place for post-transplant 
monitoring of HBsAg and 
HBV DNA for a minimum of 
1-year post-transplantation 
(2C).
 10.5.4 Cytomegalovirus (CMV)
 10.5.4.1: We recommend screening for 
CMV with CMV IgG (1C).
 10.5.5 Epstein-Barr virus (EBV)
 10.5.5.1: We recommend screening for EBV 
with EBV viral capsid antigen 
(VCA) IgG and/or EBV nuclear 
antigen (EBNA) IgG (1C).
 10.5.6 Herpes simplex virus (HSV)
 10.5.6.1: We suggest screening for HSV 
with HSV IgG (2C).
 10.5.7 Varicella-zoster virus (VZV)
 10.5.7.1: We recommend screening for 
VZV with VZV IgG (1C).
 10.5.7.1.1: We recommend varicella 
immunization for VZV seron-
egative candidates at least 4 
weeks prior to transplantation 
(1C).
 10.5.8 Measles, mumps, and rubella (MMR)
 10.5.8.1: We suggest screening for MMR 
using IgG serology (2C).
 10.5.8.1.1: We suggest MMR immuniza-
tion for MMR seronegative 
candidates at least 4 weeks 
prior to transplantation (2C).
 10.5.9 BK virus
 10.5.9.1: We recommend not screening for 
BK virus infection in candidates 
(1C).
 10.5.9.1.1: We recommend not excluding 
patients for repeat transplan-
tation if a previous graft was 
lost due to BK nephropathy 
(1C).
 10.5.10 Human T-cell lymphotropic virus (HTLV)
 10.5.10.1: We recommend screening for 
HTLV 1/2 with IgG serology in 
candidates from endemic areas as 
per World Health Organization 
(1C).
BACKGROUND
Viral infections are one of the most common opportun-
istic infections post-transplant. Therefore, pre-transplant 
risk stratification using viral serology can help to define 
post-transplant prophylaxis and pre-emptive strategies to 
mitigate infections (Table 11). Standard serologic testing 
is generally available for the following viruses: HIV, HCV, 
HBV, CMV, EBV, HSV, VZV, MMR, and HTLV. These 
serologies should be performed at the time the candidate 
is evaluated. Assays with sufficient sensitivity for testing 
in candidates should be used. If negative at initial screen-
ing, serology for HIV, HCV, and HBV should be repeated 
annually while on the waitlist and at the time of transplan-
tation. For other viruses such as CMV, EBV, HSV, MMR, 
and VZV, if initial serology is negative, then testing should 
be repeated at the time of transplantation (Table 11).
RATIONALE
If the candidate is HIV positive, this does not preclude 
transplantation (Summary Table and Evidence Profile: 
HIV).322–326 However, the patient will need further testing 
for viral load, T-cell counts and viral resistance to deter-
mine an appropriate immunosuppressive regimen and 
post-transplant anti-retrovirals. HIV positive transplant 
candidates should be considered if: (a) CD4+ T-cell count 
is ≥ 200/µl and stable for the past 3 months; (b) the viral 
load is undetectable; (c) no opportunistic infections in the 
past 6 months; (d) compliant with antiretroviral regimen; 
(e) no cognitive impairment; (f) no history of progressive 
multifocal leukoencephalopathy and (g) no history of cen-
tral nervous system lymphoma.327 Re-transplantation has 
been performed in HIV positive candidates but has been 
associated with an increased risk of death and graft loss.328 
Evaluation of HIV positive transplant candidates should 
be done in collaboration with an HIV specialist. Ideally, 
the candidate should be stabilized on an anti-retroviral 
regimen that minimizes risks of drug-drug interactions 
post-transplant.
If the candidate is HCV seropositive, this does not 
preclude transplantation. However, HCV RNA and liver 
imaging should be performed to rule out hepatocellular 
carcinoma. The patient should be assessed for chronic 
liver disease and treatment with direct-acting antivirals 
(DAAs) to eradicate HCV should be considered (Figure 3). 
Please consult the 2018 KDIGO HCV guideline for further 
details.329
The prevalence of HBV infections ranges from 0-7% 
of patients on hemodialysis.330,331 A positive hepatitis 
B serology (hepatitis B surface antigen [HBsAg] and/or 
antibody to hepatitis B core antigen [anti-HBc]) does not 
preclude transplantation but does require further evalua-
tion. Positivity of HBsAg denotes actively replicating virus 
and this should be further quantified using HBV DNA. In 
such cases, the patient should be assessed for chronic liver 
disease. Liver imaging should be performed to rule out 
hepatocellular carcinoma and expert consultation should 
be sought to determine antiviral therapy prior to trans-
plantation (Summary Table and Evidence Profile: HBV 
treatment). Positivity of hepatitis B core antibody (anti-
HBc) with a negative HBsAg is evidence of prior infection. 
Active replication should be ruled out with HBV DNA 
testing. Patients with isolated anti-HBc positivity (with or 
without a positive antibody to hepatitis B surface antigen 
[anti-HBs]) can undergo transplantation. There is a small 
risk of reactivation (< 5%) post-transplant and monitoring 
S60 Transplantation  ■  April 2020  ■ Volume 104  ■  Number 4S www.transplantjournal.com
of HBsAg and HBV DNA is required at regular intervals 
up to one year post-transplant.332,333 Since hepatitis D 
virus (HDV) can co-infect those with HBV, and HDV is 
endemic in Asia and Africa, transplant candidates from 
these regions who have serologic evidence of HBV infec-
tion should also have HDV serology performed.
If the candidate is CMV seronegative and receives a 
CMV seropositive donor kidney, this puts the patient at 
high risk for primary CMV infection. Another high risk 
group for CMV reactivation is the CMV seropositive 
recipient who receives anti-lymphocyte globulin. In such 
cases, a prophylactic or pre-emptive approach to prevent-
ing CMV is required.334 Transplant candidates who are 
CMV negative should have serology repeated at the time 
of transplantation.
Transplant candidates are at risk for primary herpes-
virus infection or reactivation of latent herpesviruses. 
Screening is therefore important in order to risk stratify 
and make decisions for post-transplant prevention. If the 
candidate is EBV seronegative and receives an EBV sero-
positive donor kidney, this increases the risk of primary 
EBV infection and post-transplant lymphoproliferative 
disease.335 If the candidate is VZV seronegative, varicella 
immunization is recommended. Since varicella vaccine is 
live-attenuated, the candidate should defer transplant for 
at least 4 weeks after immunization. Immunization should 
not occur pre-transplantation if patient is immunosup-
pressed for another indication (eg, treatment of underling 
kidney disease with steroids). If the candidate is HSV sero-
positive and corticosteroids are used, there is increased risk 
of local and disseminated HSV infection. There may also 
be risk for primary infection in HSV seronegative recipi-
ents of seropositive donors and antiviral prophylaxis may 
be indicated. HSV seropositivity should not be assumed 
as prevalence varies widely by geography and is falling in 
some regions.336
If the candidate is MMR seronegative, consideration 
should be given to MMR immunization prior to kidney 
transplant (Summary Table and Evidence Profile: Vaccines, 
vaccination, respectively). Those born after the introduc-
tion of MMR vaccine in their region may be seronegative 
since circulation of wild-type virus decreased. Since MMR 
vaccine is live-attenuated, the candidate should defer trans-
plant for at least 4 weeks after immunization. Similarly, 
live virus immunization should not occur pre-transplanta-
tion if patient is immunosuppressed for another indication 
(eg, treatment of underling kidney disease with steroids).
It is unknown whether BK viremia or viruria pre-trans-
plant affects graft outcomes post-transplant.337,338 There 
are also limited data on graft nephrectomy and the risk 
of subsequent BK nephropathy. In one study, 7 of 10 
patients that underwent retransplantation for BK virus-
associated nephropathy had nephroureterectomy of the 
first graft; only one patient had recurrent BK virus-asso-
ciated nephropathy (Summary Table and Evidence Profile: 
Nephrectomy].339 Another report suggested no benefit of 
transplant nephrectomy in the setting of retransplantation 
following BK nephropathy.340
HTLV is endemic in many parts of the world including 
the Caribbean, Japan and South America. If the candidate 
is HTLV seropositive, this does not preclude transplanta-
tion. However, the patient should be counseled as to the 
increased risk of HTLV-associated disease post-transplant 
such as T-cell leukemia and myelopathy/spastic parapare-
sis.341,342 In addition, there should be a high-index of sus-
picion for these conditions post-transplant.
Although the above recommendations describe estab-
lished viruses in the population, the clinician should be 
cognizant of emerging viral infections such as new res-
piratory viruses (eg, new coronaviruses), arboviruses (eg, 
Zika, Chikungunya virus) and hemorrhagic fever viruses 
(eg, Ebola), their incubation periods and disease manifes-
tations. Transplant candidates with symptomatic disease 
from these viruses should await resolution.
 10.6 Screening for non-viral infections
 10.6.1 Syphilis
 10.6.1.1: We recommend screening for 
syphilis (Treponema pallidum) 
with serology at the time of can-
didate evaluation and treatment 
prior to transplantation if infec-
tion is identified (1C).
 10.6.2 Strongyloides
 10.6.2.1: We suggest screening for strongy-
loidiasis with serology at the time 
of evaluation in candidates from 
endemic areas, and treatment 
prior to transplantation if infec-
tion is identified (2C).
 10.6.3 Chagas disease
 10.6.3.1: We recommend screening for 
Chagas disease with serology at 
the time of evaluation in candi-
dates from endemic areas, and 
treatment prior to transplantation 
if infection is identified (1C).
 10.6.4 Malaria
 10.6.4.1: We recommend screening for 
malaria with a malaria blood 
smear at the time of evaluation 
in candidates who have recently 
travelled to endemic areas, and 
treatment prior to transplantation 
if infection is identified (1C).
RATIONALE
Syphilis is often asymptomatic but could progress with 
cardiac and neurologic disease post-transplant. Therefore, 
serology should be routinely performed in patients await-
ing transplantation and the patient treated if a confirma-
tory test for syphilis is positive. Lumbar puncture can be 
done if neurologic or ocular involvement is suspected. The 
ideal treatment is three doses of benzathine penicillin, each 
one week apart. In penicillin-allergic patients, ceftriaxone 
or doxycycline can be used.
Testing for endemic infections and tropical diseases 
should only be done in transplant candidates at risk. The 
worldwide distribution of endemic zones for various infec-
tions is readily available on the World Health Organization 
website (www.who.int). Strongyloides infection may be 
asymptomatic and lead to hyperinfection post-transplant. 
Therefore, screening for strongyloides is recommended 
in those who have lived in or travelled to strongyloides 
endemic areas.343 Screening should be done using serol-
ogy and seropositive patients should be treated prior to, 
or at the time of, transplantation with ivermectin. Malaria 
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testing should be performed if a transplant candidate has 
returned within the past month from a malaria endemic 
area and did not use malaria prophylaxis. For patients liv-
ing in endemic areas, testing should be performed if clini-
cal symptoms suggest disease. Chagas disease is endemic 
in Latin America and is caused by the protozoan parasite, 
Trypanosoma cruzi. This infection is transmitted by an 
insect vector and can establish clinical latency for decades. 
After kidney transplantation, reactivation generally occurs 
in the first year as asymptomatic parasitemia or fever 
with skin, heart or brain involvement.344,345 Screening for 
Chagas disease is by serology. In the case of seropositivity, 
most experts recommend to monitor for reactivation post-
transplant using polymerase chain reaction rather than 
treatment of the asymptomatic phase. The clinical utility 
for detection of endemic fungal infection in an otherwise 
asymptomatic transplant candidate is low as the serology-
based tests lack sensitivity.346 Please see Table  11 for a 
summary of screenings for non-viral infections.
 10.7 Vaccinations
 10.7.1: We recommend that the vaccination series 
be commenced using an accelerated sched-
ule, if necessary, prior to kidney trans-
plantation for any inactivated vaccines 
(Table 12) (1B).
 10.7.1.1: We suggest not excluding can-
didates who do not complete an 
inactivated vaccine series prior to 
kidney transplantation (2D).
 10.7.2: We recommend that the vaccination series 
be completed prior to kidney transplan-
tation for any live attenuated vaccines 
(Table 12) (1B).
 10.7.2.1: We recommend a 4-week delay 
in kidney transplantation if a 
live vaccine is administered (eg, 
MMR, VZV, shingles, yellow 
fever, oral typhoid, oral polio vac-
cine) (1B).
 10.7.3: We recommend that splenectomized can-
didates or those at increased risk for 
post-transplant splenectomy receive pre-
transplant pneumococcal, hemophilus, and 
meningococcal vaccination (1B).
 10.7.4: We recommend that candidates requiring 
complement inhibitors perioperatively or 
post-transplant undergo meningococcal 
vaccination (1B).
 10.7.5: We suggest administering the following 
vaccines to candidates who, due to age, 
direct exposure, residence or travel to 
endemic areas, or other epidemiological 
risk factors, are at increased risk for the 
specific diseases:
 • Rabies (2D)
 • Tick-borne meningoencephalitis (2D)
 • Japanese encephalitis (inactivated) (2D)
 • Meningococcus (2D)
 • Salmonella typhi (inactivated) (2D)
 • Yellow fever (2D)
RATIONALE
Vaccine preventable diseases are an important cause 
of morbidity after kidney transplantation. Vaccine 
immunogenicity is generally reduced in both CKD and 
post-transplant settings. However, data suggest that 
some vaccines are more immunogenic when given pre-
transplant rather than post-transplant. In addition, 
live-attenuated vaccines should only be given prior to 
transplantation. Therefore, assessment of vaccination 
status is an integral part of the pre-transplant evalua-
tion. Childhood vaccinations should be updated as per 
local guidelines. Accelerated schedules can be used.347,348 
Inactivated vaccines can be given pre- or post-transplan-
tation (see KDIGO Care of Transplant Recipient guide-
line30). Vaccines should be updated as per local guidelines 
for diphtheria, polio, tetanus, pertussis, and Hemophilus 
influenzae. Transplant recipients have an increased risk 
for developing invasive pneumococcal disease. As such, 
kidney transplant candidates should receive the conju-
gated pneumococcal vaccine followed by the polysac-
charide pneumococcal vaccine at least 8 weeks later.349 
Transplant candidates should receive the influenza vac-
cine annually while awaiting transplantation. Depending 
on availability, the MF59 adjuvanted or the high-dose 
influenza vaccine can be used in transplant candidates 
≥  65 years of age. HBV vaccine is recommended for 
those with CKD (Summary Table: HBV vaccination).350 
A 40 µg preparation (‘dialysis dose’) should be used with 
a 3-dose interval.351,352 Anti-HBs titer should be meas-
ured 4-6 weeks after series completion. Titers of anti-
HBs should be checked at regular intervals as they may 
decline over time.353 If titers have declined to < 10 IU/ml, 
a repeat HBV vaccine series can be given. In endemic 
areas (www.who.int), hepatitis A vaccine should be given 
to all candidates before transplantation. Meningococcal 
conjugate vaccine should be given to children as per 
local guidelines. In adults, meningococcal conjugate vac-
cine should be given to those with risk factors including 
functional or anatomic asplenia, travelers to meningo-
coccus endemic areas (eg, sub-Saharan Africa, travelers 
for Hajj) or those likely to require complement inhibi-
tors perioperatively or post-transplant. In adults, two 
doses of quadrivalent vaccine at least 8 weeks apart can 
be given. In candidates who may receive eculizumab or 
other complement inhibitors, two doses of quadrivalent 
meningococcal vaccine (for serogroups A, C, Y, W-135) 
as well as meningococcal serogroup B vaccine should 
be administered. Human papillomavirus vaccine is also 
inactivated and can be given using the 3-dose schedule 
to males and females over age 9 years. A recombinant 
subunit inactivated vaccine is available to prevent her-
pes zoster and can be used in transplant candidates ≥ 
50 years of age. In the general population, efficacy of 
this vaccine is > 97% and it is recommended for those 
≥ 50 years;354 however, there are no specific data on its 
efficacy or effectiveness in those with CKD. Please refer 
to Table 12 for a summary of routine vaccinations for 
kidney transplant candidates.
For inactivated vaccines, no specific wait period is 
required pre-transplantation and candidates can remain 
active if on a deceased donor waitlist; however, at least 
two weeks is required for establishment of vaccine immu-
nity. Nevertheless, due to lack of data, there are no rec-
ommendations for reimmunization if transplantation 
occurs within days after vaccination. Vaccine series that 
are not completed pre-transplant can be generally resumed 
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post-transplant. Please refer to the KDIGO Care of the 
Transplant Recipient guideline for post-transplant guid-
ance on vaccination.30
Live attenuated vaccines include MMR, varicella, her-
pes zoster, yellow fever, oral typhoid and oral polio vac-
cine. Transplant candidates who do not have documented 
immunity to MMR and have not previously received 
MMR vaccine should receive MMR vaccination since 
the vaccine is immunogenic and immunity is shown to be 
retained post-transplant.355 Since viremia can occur after 
vaccination, transplantation should be delayed by at least 
4 weeks. Varicella vaccine is indicated for persons who are 
VZV IgG negative.356 Herpes zoster vaccine is effective for 
the prevention of shingles in those ≥ 50 years of age that 
are VZV IgG positive. Herpes zoster vaccine is beneficial 
in CKD and can reduce the risk of zoster by approximately 
2-fold.357 However, since this is a live-attenuated vaccine, 
a period of 4 weeks should elapse before transplantation 
occurs in order to clear the viremia. Limited data show that 
vaccine titers persist post-transplant although the duration 
of persistence is unclear. In general, the inactivated herpes 
zoster vaccine is preferred over the live zoster vaccine since 
its efficacy in the general population is higher than that of 
live vaccine and candidates can remain active on the wait-
list. Yellow fever vaccine is also a live-attenuated vaccine. 
For transplant candidates at increased risk of developing 
yellow fever, vaccination must be given at least 4 weeks 
before transplantation.
Transplant candidates should also receive specific travel 
vaccines if travel to endemic areas is anticipated. Based on 
exposure risk, transplant candidates can safely receive any 
travel vaccines including both inactivated and live vac-
cines. Further details on vaccination in transplant candi-
dates can be found in this recent review from the American 
Society of Transplantation Infectious Diseases Community 
of Practice.358
What prior guidelines recommend
Our KDIGO infection guidelines are largely consist-
ent with the 2019 AST infectious diseases guidelines in 
regards to kidney transplant candidate screening and vac-
cinations.358,359 Most prior guidelines recommend to delay 
transplantation in a candidate with an active infection. 
All guidelines also recommend screening for HIV, HCV, 
and HBV prior to transplantation.23,27,29,143,359 HIV infec-
tion is not a contraindication for transplant in all previous 
TABLE 12.
Summary of routine vaccinations for kidney transplant candidates
Routine Vaccines Dosing Guidelines* Comment
Inactive Vaccines
Diphtheria, Pertussis, Polio, Tetanus, HiB Generally given in childhood; Ensure these are 
up-to-date
 
Pneumococcal Vaccination:
PCV13, PPV23
One dose of PCV13 followed by one dose of 
PPV23 with a minimum of 8-week interval in 
between
One booster of PPV23 five years from previous 
PPV23
Influenza One dose annually  
Hepatitis B Three doses at 0, 1, 6 months Check anti-HBs titer
Monitor annually and give booster dose if titers 
decline <10 IUs/ml
Hepatitis A Two doses at 0, 2 months Check titers; If not immune, give vaccination again 
(i.e., repeat if no response to first series)
Human Papillomavirus Three doses in both males and females if not 
previously given (ages 9 to 45)
No boosters
Meningococcal quadrivalent conjugate
(Serogroups A,C,Y,W-135)
Two doses given 8 weeks apart; Indicated for 
travel to endemic areas, prior or planned 
splenectomy or planned use of eculizumab
Repeat one dose every five years in patients at risk
Meningococcal B vaccine One dose if planned use of eculizumab  
Shingles (Herpes Zoster Subunit) Two doses at 0, 2-6 months for those age ≥ 50 
years and VZV IgG positive
Unknown if benefit in less than 50 years of age
No boosters
Live Vaccines
Measles, Mumps, Rubella Two doses given 4 weeks apart. Considered 
immune after two doses regardless of 
seroconversion.
Check serology and provide vaccination if negative
Varicella Two doses given 4 weeks apart. Considered 
immune after two doses regardless of 
seroconversion.
Check serology and provide vaccination if negative
Shingles (Herpes Zoster Live)** One dose in those age ≥ 50 years and VZV IgG 
positive
Unknown if benefit in less than 50 years of age
No boosters
*Duration and doses are suggestive only as they may be variable in different regions. Please check your local guidelines.
**The herpes zoster subunit inactivated vaccine is preferred over the herpes zoster live vaccine. If the herpes zoster live vaccine has already been administered, the transplant candidate can be reim-
munized with the inactivated vaccine a minimum of one year after the live vaccine.
Anti-HBs, hepatitis B surface antibodies; HiB, hemophilus influenzae type b; IgG, immunoglobulin G; IU, international unit; PCV13, pneumococcal conjugate vaccine-13 valent; PPV23, pneumococcal 
polysaccharide vaccine-23 valent; VZV, varicella zoster virus.
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guidelines.23,27,29,143,359 Only the AST360 and CST29 guide-
lines address screening for TB and recommend that all 
transplant candidates be screened and treated. In the cur-
rent KDIGO guidelines, we recognize that treatment may 
not be feasible in TB-endemic countries performing kid-
ney transplants and therefore make separate recommen-
dations for regions with low and high TB prevalence. We 
address screening for geographically restricted infections 
(eg, strongyloides, Chagas disease, malaria) which are not 
addressed in most other guidelines. The AST,359 CST,29 and 
ERA-EDTA143 guidelines address pre-transplant immuni-
zation to varying extents. The AST358 recommends annual 
influenza vaccine, polysaccharide pneumococcal vaccine, 
and routine childhood immunizations whereas the CST 
guidelines29 additionally recommend hepatitis B and vari-
cella immunization. ERA-EDTA specifically addresses 
only pre-transplant varicella vaccination.143 Our KDIGO 
guideline recommendations address pre-transplant screen-
ing and immunizations in a comprehensive manner. The 
AST361 and CST29 guidelines also make a recommenda-
tion to consider retransplantation of kidney transplant 
candidates with prior BK nephropathy but do not outline a 
consensus on pre-transplant nephrectomy prior to retrans-
plantation for BK.
RESEARCH RECOMMENDATIONS
 • Studies should determine the post-transplant infection 
rates, morbidity, and mortality of transplant candidates 
colonized with MDROs.
 • Studies should determine newer strategies to increase 
the immunogenicity of vaccines in transplant candidates 
including influenza, shingles, pneumococcal, and hepati-
tis B vaccines. With newer high-dose influenza vaccines 
and adjuvanted influenza vaccines, comparative trials 
can be performed with immunogenicity or efficacy as an 
endpoint. Similarly, inactivated shingles vaccine should 
be evaluated in this population.
 • Studies should examine whether pre-transplant vacci-
nations affect the incidence of post-transplant disease, 
specifically where the disease outcome is measurable (eg, 
varicella zoster).
 • Studies should examine whether it is ideal to treat HCV-
positive transplant candidates pre- or post-transplant.
RELEVANT SUPPLEMENTAL MATERIAL
Summary table: Nephrectomy
Summary table: Nephrectomy (quality assessment)
 Evidence profile: Transplantation outcomes after pre-
transplant nephrectomy for UTI or BK-associated 
nephropathy
Summary table: TB testing
Summary table: TB testing (quality assessment)
Evidence profile: TB testing
Summary table: TB treatment
Summary table: TB treatment (quality assessment)
Evidence profile: TB treatment, short vs. full course
Summary table: HBV vaccination
Summary table: HBV vaccination (quality assessment)
Summary table: HBV treatment
Summary table: HBV treatment (quality assessment)
Evidence profile: HBV treatment (lamivudine)
Summary table: HIV
Summary table: HIV (quality assessment)
 Evidence profile: Transplantation outcomes in patients 
with HIV
Summary table: Vaccines measles
Summary table: Vaccines measles (quality assessment)
Evidence profile: Pre-transplant vaccination
SECTION 11: MALIGNANCY
 11.1 Cancer screening
 11.1.1: We recommend candidates undergo routine 
cancer screening, as per local guidelines for 
the general population (Table 13) (1D).
 11.1.1.1: We suggest chest imaging prior to 
transplantation in all candidates 
(2C). (Same as Rec 12.2)
 11.1.1.2: We suggest chest CT for current 
or former heavy tobacco users (≥ 
30 pack-years) as per local guide-
lines, and chest radiograph for 
other candidates (2C). (Same as 
Rec 12.2.1)
 11.1.2: Screen candidates at increased risk for renal 
cell carcinoma (eg ≥ 3 years dialysis, family 
history of renal cancer, acquired cystic dis-
ease or analgesic nephropathy) with ultra-
sonography (Not Graded).
 11.1.3: We suggest cystoscopy to screen for blad-
der carcinoma in candidates at increased 
risk, such as those with high-level exposure 
to cyclophosphamide or heavy smoking (≥ 
30 pack-years) (2D).
 11.1.4: We recommend screening for hepatocellu-
lar carcinoma in candidates with cirrhosis 
prior to transplantation using techniques 
(eg, ultrasound, α-fetoprotein) and fre-
quency as per local guidelines (1C).
 11.1.5: We recommend screening for bowel cancer 
in candidates with inflammatory bowel dis-
ease as per local guidelines (1C).
 11.2 Potential kidney transplant candidates with a prior 
cancer
 11.2.1: We recommend that candidates with active 
malignancy be excluded from kidney trans-
plantation except for those with indolent 
and low-grade cancers such as prostate 
cancer (Gleason score ≤ 6), superficial non-
melanoma skin cancer, and incidentally 
detected renal tumors (≤ 1 cm in maximum 
diameter) (1B).
 11.2.2: Timing of kidney transplantation after 
potentially curative treatment for cancer is 
dependent on the cancer type and stage at 
initial diagnosis (Not Graded).
 11.2.3: We recommend no waiting time for candi-
dates with curatively treated (surgically or 
otherwise) non-metastatic basal cell and 
squamous cell carcinoma of the skin; mela-
noma in situ; small renal cell carcinoma 
(< 3 cm); prostate cancer (Gleason score ≤ 
6); carcinoma in situ (ductal carcinoma in 
situ, cervical, others); thyroid cancer (fol-
licular/papillary < 2 cm of low grade histol-
ogy); and superficial bladder cancer (1C).
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 11.2.3.1: For other cancers, we suggest fol-
lowing waiting time parameters 
as outlined in Table 14 (2D).
 11.2.3.2: We suggest that the recommended 
waiting time from cancer to kid-
ney transplantation begins upon 
completion of potentially curative 
treatment (2D).
 11.2.4: Decisions about transplantation for can-
didates in remission from cancer should 
be made collaboratively with oncologists, 
transplant nephrologists, patients, and 
their caregivers (Not Graded).
 11.2.4.1: For relevant cancers, supple-
ment estimates of prognosis 
using genomic profiling, other 
TABLE 13.
Recommendations for cancer screening in the general population and potential transplant candidates
Cancer General population Potential transplant candidates
Breast • Women ages 40 to 49 should have the choice to start annual 
breast cancer screening if they wish to do so
• Biennial mammography is recommended for women age 50 and 
above
• Screening should continue as long as woman is in good health 
and is expected to live 10 more years or longer362
• As per general population363
Colorectal • Biennial fecal immunochemical testing (FIT) is recommended 
for all people age 50 years and above. Those with positive FIT 
should have full examination of the colon, preferably by colonos-
copy
• As per general population364,365
 • Flexible sigmoidoscopy (every 5 or 10 years) may also be con-
sidered for people age 50 years and above
• Screening can be stopped for people who are older than 75 
years or with life expectancy less than 10 years
 
Liver • Annual liver ultrasound and alpha-fetoprotein screening for 
those with known cirrhosis
• As per general population (see Rec 11.1.4)
Cervical • Papanicolaou (Pap) test is recommended for women starting 
at the age of 21 and screening should be done every 3 years. 
Alternately, screening using HPV testing should be done every 
5 years up to age 65 years. Women older than 65 should talk 
to their doctors about whether or not they need to have regular 
cervical screening. The decision to stop is often based on a 
woman’s history of having normal or negative Pap test results
• Women who had a previous total hysterectomy (removal of the 
uterus, including the cervix) do not require routine Pap screen
• As per general population366
Lung • Routine screening for lung cancer using chest radiography and 
low-dose computed tomography (LDCT) is not recommended for 
average risk individuals
• However, there is some evidence to suggest annual screening 
for people at high risk of lung cancer using LDCT. Individuals at 
high risk are adults aged 55 to 80 years who have a smoking 
history of at least 30 pack-years and currently smoke or have 
quit within the past 15 years367
• LDCT of the chest may be recommended for individuals 
who are at high risk of lung cancer, including a prolonged 
heavy smoking history (see Rec 11.1.1.2)
Prostate • Men between the ages of 55 to 69 can undergo periodic 
screening for prostate cancer using prostate specific antigen if 
they wish to do so after understanding risks and benefits
• Clinicians should not screen men who do not express a prefer-
ence for screening and screening should stop at the age of 70
• As per general population368
Kidney • Routine screening for renal cell cancer is not recommended for 
average risk individuals
• Ultrasonographic screening of the native kidneys may be 
recommended for individuals who have a family history 
of renal cancer, a personal history of acquired cystic 
disease, analgesic nephropathy, long-term smoking and/or 
prolonged waiting time on dialysis369 (see Rec 11.1.2)
Bladder • Routine screening for bladder cancer is not recommended for 
average risk individuals
• Urine cytology and cystoscopies may be recommended for 
individuals who had been previously exposed to chemo-
therapeutic agents such as cyclophosphamide, regular 
users of compound analgesics and for heavy smokers  
(≥ 30 pack-year history) (see Rec 11.1.3)
FIT, fecal immunochemical testing; HPV, human papillomavirus; LDCT, low-dose computed tomography.
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molecular genomic tests, and phe-
notyping in consultation with the 
patient’s oncologist (Not Graded).
 11.2.5: We recommend not excluding candidates with 
a history of metastatic cancer provided that 
potentially curative therapy has been admin-
istered and complete remission achieved; 
however, the risk of recurrence should be a 
major consideration and discussed with the 
candidate and their oncologist (1D).
 11.3 Hematologic malignancy (see Sections 17.7, 17.8, 
and 17.9)
 11.3.1 Acute leukemia and high-grade lymphoma, 
including post-transplant lymphoprolifera-
tive disease
 11.3.1.1: Avoid transplanting patients with 
leukemia or lymphoma until they 
have received curative therapy, 
achieved remission and remained 
cancer free for a period to be 
determined in consultation with 
the patient, a hematologist/oncol-
ogist and the transplant program 
(Not Graded).
 11.3.2 Myelodysplasias, chronic leukemia and 
chronic/low-grade lymphoma
 11.3.2.1: Decisions about kidney trans-
plantation in patients with mye-
lodysplasia should be made in 
collaboration with a hematologist 
(Not Graded).
 11.3.2.2: Advise consultation with a hema-
tologist with transplant experience 
in determining transplant candi-
dacy since many lesions may be 
deemed to be at high risk of accel-
erated progression or transforma-
tion post-transplant (Not Graded).
 11.3.3: Decisions about kidney transplantation in 
patients with a prior history of hematologic 
malignancy who are now in remission should 
be made in collaboration with a hematologist 
(Not Graded).
RATIONALE
Cancer screening
Cancer is common in patients with ESKD. Evidence from 
observational studies and registry data reported a 2-fold 
increase in overall cancer incidence among patients on 
dialysis, with kidney-related (such as urogenital cancers), 
endocrine-related malignancy such as thyroid cancer, and 
solid organ cancers such as colorectal cancer seen in excess 
compared to the general population.370,371 Cancer is also 
a major cause of mortality and morbidity in patients with 
advanced kidney disease (CKD G4-G5D). Registry and 
linked data analyses reported at least a 1.5-fold increase in 
risk of cancer related death in patients on dialysis compared 
to the age-matched general population.372 Early detection 
through screening and eradication of pre-cancerous lesions 
is one of the few strategies proven to reduce the risk of 
cancer-related morbidity and mortality in the general popu-
lation. Trials have reported significant reductions in cancer 
mortality, of at least 20% for solid organ cancers such as 
colorectal cancer, in the screened versus unscreened arms.373
Despite the increased risk of cancer and cancer-related 
death in potential transplant candidates, cancer screening 
uptake in those with ESKD is much lower than those without 
kidney disease.374 The rationale behind the reduced screen-
ing uptake is unclear, but may reflect patients’ preferences for 
preventive medicine in the context of chronic illness.375,376 
Also, potential candidates may experience a lower likelihood 
of benefits from screening even if cancer is diagnosed early 
because of the reduced life expectancy compared to the gen-
eral population. Prior modeling analyses reported the pro-
jected gains in life years to be gained by applying screening 
mammography, colorectal and cervical cancer screening of 
patients on dialysis were at least 50% less than expected in 
the general population, largely because of the risk of com-
peting events in this high-risk population including risk of 
death from CVD.369,377–381 Uncertainties also exist in the 
test performance characteristics of individual screening tests, 
patient preferences, and the choice of the screening tool.382 
Currently, there are no quality primary data to inform can-
cer screening practices specifically in the ESKD population 
(Summary Table and Evidence Profile: Cancer screening). 
TABLE 14.
Recommended waiting times between cancer remission 
and kidney transplantation91
Breast Early At least 2 years
 Advanced At least 5 years
Colorectal Dukes A/B At least 2 years
 Duke C 2-5 years
 Duke D At least 5 years
Bladder Invasive At least 2 years
Kidney Incidentaloma  
(< 3 cm)
Early
No waiting time
At least 2 years
 Large and invasive At least 5 years
Uterine Localized At least 2 years
 Invasive At least 5 years
Cervical Localized At least 2 years
 Invasive At least 5 years
Lung Localized 2-5 years
Testicular Localized At least 2 years
 Invasive 2-5 years
Melanoma Localized At least 5 years
 Invasive Contraindicated
Prostate Gleason ≤6
Gleason 7
Gleason 8-10
No waiting time
At least 2 years
At least 5 years
Thyroid Papillary/Follicular/
Medullary
Stage 1
Stage 2
Stage 3
Stage 4
Anaplastic
No waiting time
At least 2 years
At least 5 years
Contraindicated
Contraindicated
Hodgkin Lymphoma Localized
Regional
Distant
At least 2 years
3-5 years
At least 5 years
Non-Hodgkin 
 Lymphoma
Localized
Regional
Distant
At least 2 years
3-5 years
At least 5 years
Post-transplant 
 lymphoproliferative 
disease
Nodal
Extranodal and 
 cerebral
At least 2 years
At least 5 years
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As such, it would be appropriate for potential transplant 
candidates to follow the current cancer screening practices 
for common cancer types such as colorectal, breast, cervi-
cal, lung and prostate cancers as per the general population 
(Table 13).380,382 For other common cancer types that are 
specific to the ESKD populations, such as cancers of the 
urinary tract system, previous research has indicated some 
benefits of routine ultrasonographic screening for renal cell 
cancers and urinary cytology/cystoscopies for bladder can-
cers among high-risk individuals.369,383–385 It has been sug-
gested that screening for renal cell carcinoma be performed 
in those with three or more years of dialysis.384–387
Potential candidates with a prior cancer
Patients with ESKD and a cancer history in need of a 
transplant typically pose a challenge for transplant health 
professionals (Summary Table: Cancer recurrence risk; 
Evidence Profile: Cancer recurrence risk). While the long-
term overall risk of cancer recurrence after transplanta-
tion may be low (between 5-10%), cancer prognoses after 
recurrence are poor.388 A recent systematic review reported 
an increased risk of cancer-related mortality by at least 
3-fold in patients with a pre-transplant cancer history 
compared to recipients without prior cancers. Recipients 
with prior cancer also have an increased risk of developing 
de novo malignancy after transplantation.389
Although a prior cancer history is not an absolute con-
traindication for kidney transplantation,390 waiting time 
between two and five years for most cancer types has been 
recommended by clinical practice guidelines.91 This rec-
ommendation arises from several large registry analyses 
indicating that the risk of cancer recurrence was maximal 
within the first five years after kidney transplantation. The 
highest risk of recurrences occurs among symptomatic 
renal cell carcinomas, sarcomas, melanocytic skin can-
cers, invasive bladder cancers and multiple myeloma.391 
Consequently, a waiting period of five years or more 
between cancer remission and kidney transplantation has 
been recommended for these cancers. Other solid organ 
tumors such as breast, prostate and colorectal cancers con-
fer a lesser risk, with a recommended minimum waiting 
period before transplantation of 2 years. More recently, 
data from Norway found no association between waiting 
time and all-cause mortality after kidney transplantation 
for those with prior cancer. However, an increased risk of 
cancer-related death was observed among recipients with 
a prior history of kidney, prostate, breast, lung or plasma 
cell cancers compared to those without a cancer history.390 
Given the findings, the authors recommended a shorter 
waiting time (one year) to transplantation from disease 
remission, particularly for those with localized cancer. In 
a recent case series study, prostate cancer recurrence risks 
were shown to be related to the stage of disease at initial 
diagnosis, with the recurrence rates of stage I and II dis-
eases, 14% and 16% respectively, significantly lower than 
stage III disease at 33%, suggesting a longer waiting time 
may be necessary for advanced disease.392 Analyses using 
the ANZDATA registry found a much lower rate of cancer 
recurrence compared to the US study. Between the years 
1963 and 1999, the overall cancer recurrence rate in 210 
kidney transplant recipients with a prior cancer history was 
only 5%, with a much higher rate of death among those 
whose prior cancers were diagnosed after commencement 
of dialysis compared to those diagnosed before dialysis.391 
Differences between the two registries, probably due to 
selection bias of recipients, ascertainment bias of cancer 
diagnoses and unadjusted residual confounders, imply fur-
ther unbiased analyses are necessary to address these unre-
solved issues in detail.
Recent analyses from the ANZDATA registry reported 
the overall survival for recipients who developed cancer 
after transplantation was generally poor, with less than 
50% surviving five years after cancer diagnosis. For those 
who did not die from cancer, less than 20% survived more 
than 10 years after cancer diagnosis. Cancer of the digestive, 
respiratory and urinary tract systems were the three most 
common causes of cancer death regardless of cancer types 
(first cancer, recurrence and second primary). However, there 
were no significant differences in the risk of cancer-specific 
and all-cause mortality between patients who developed 
their first cancer after transplantation and those with cancer 
recurrence and those with second primary cancers.388
When considering the prospect of transplantation in 
potential candidates with a prior cancer, clinicians must 
balance the risk of death and associated morbidities 
against the reduced life expectancy and quality of life 
while waiting on dialysis instead of receiving a kidney 
transplant. To better define and stratify the risk of disease 
recurrence in a potential transplant candidate, genomic 
profiling may represent a novel application that distin-
guishes between breast cancers that are likely to result in 
early recurrence versus those that are unlikely to recur. 
Currently, there are two commercially available assays 
including the Oncotype DX Breast Recurrence Score 
(Genomic Health Inc., Redwood City, CA) and Mamma-
Print (Agendia, Amsterdam, Netherlands). These assays 
can calculate a Breast Cancer Recurrence Score that 
correlates with the risk of cancer recurrence 10 years 
after transplantation, thus representing a potentially 
effective prognostic tool to guide treatment and future 
management.393
What prior guidelines recommend
Most guidelines recommend that potential transplant 
candidates should undergo age- and sex-specific cancer 
screening consistent with what is recommended for the 
general population. For potential transplant recipients 
with a prior history of cancer, clinical guidelines generally 
recommend a waiting time of between two and five years 
prior to transplantation, largely due to the fear of recur-
rent disease.23,27,28,143
Instead of imposing a strict waiting time-period, we 
have provided a suggested list of waiting-time parameters 
in Table 14. These recommendations are based on previ-
ous studies which showed a reduction in cancer recurrence 
with time.391 Approximately 50% of cancer recurrences 
occurred in patients treated for cancer within 2 years of 
transplantation and only 13% in patients treated more 
than 5 years prior to transplantation.
Given the rapid advancement in cancer genome sequenc-
ing, we also suggest the use of genomic profiling assays, 
which may help to better assess potential transplant can-
didate’s risks of cancer recurrence and the timing of trans-
plant eligibility. Assays are now commercially available for 
early stage breast cancer and similar assays are also under 
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investigation for other cancers such as early colorectal can-
cer and lung cancer.
RESEARCH RECOMMENDATIONS
 • There is a lack of trial-based evidence of cancer screen-
ing in the transplant population; therefore, reliance has 
been placed on evidence from observational cohort and 
registry studies and modeling analyses. Given variations 
in the accuracy of screening tests in kidney transplant 
recipients and differing prognoses and life expectancies 
for individual transplant patients, future research that 
focuses on a personalized approach to shared-decision 
making for cancer screening, which takes into consid-
eration a patient’s individual risks of cancer, the com-
peting risks associated with other comorbidities and the 
patient’s preferences towards cancer screening should be 
encouraged.
 • Emerging evidence has shown that prior cancer site, his-
tology and stage are key factors that determine the risk 
of post-transplant cancer recurrence for most potential 
candidates with prior cancers. However, often the risk of 
death from cardiovascular causes or infection outweighs 
the projected risk of cancer recurrence. Future work is 
needed to model the tradeoff for early transplantation 
versus remaining on dialysis for these patients.
RELEVANT SUPPLEMENTAL MATERIAL
Summary table: Cancer screening
Summary table: Cancer screening (quality assessment)
Evidence profile: Cancer screening
Summary table: Cancer recurrence risk
 Summary table: Cancer recurrence risk (quality 
assessment)
Evidence profile: Cancer recurrence risk
SECTION 12: PULMONARY DISEASE
 12.1: Assess candidates with lung disease in collabora-
tion with a pulmonary specialist to determine suit-
ability for transplantation (Not Graded).
 12.2: We suggest chest imaging prior to transplantation 
in all candidates (2C). (Same as Rec 11.1.1.1)
 12.2.1 We suggest chest CT for current or former 
heavy tobacco users (≥ 30 pack-years) as 
per local guidelines, and chest radiograph 
for other candidates (2C). (Same as Rec 
11.1.1.2)
 12.3: We recommend pulmonary function testing in can-
didates with impaired functional capacity, respira-
tory symptoms, or known pulmonary disease (1C).
 12.4: We recommend counseling all candidates to avoid 
tobacco products before and indefinitely after 
transplantation (1B). (Same as Rec 6.2)
 12.5: We recommend excluding patients with severe 
irreversible obstructive or restrictive lung disease 
from kidney transplantation (1C).
RATIONALE
There are very little data on pre-transplant evaluation of 
patients with pulmonary disease. As such, the recommen-
dations are based on evidence from the general population 
who undergo preoperative pulmonary assessment for non-
transplant surgery.394,395 Post-operative pulmonary com-
plications prolong hospital stay and results in increased 
morbidity and mortality.28,396 Preoperative chest radio-
graphs have not been shown to be of benefit in routine 
non-pulmonary surgery.394,396 However, in kidney trans-
plant candidates a routine chest x-ray might demonstrate 
localized fluid collections or volume overload.397,398 The 
American Cancer Society recommends that patients who 
have at least a 30 pack-year smoking history and who cur-
rently smoke or have quit within the past 15 years undergo 
lung cancer screening with a chest CT.399 It seems reason-
able to apply these recommendations to transplant candi-
dates as well.
Pulmonary function tests are not needed in most trans-
plant candidates without significant pulmonary disease or 
symptoms given the lack of benefit seen with the use of 
these tests in the preoperative setting in the general popula-
tion. However, preoperative pulmonary function tests may 
offer benefit in patients with impaired functional capacity, 
known pulmonary disease, or unexplained dyspnea.
Cigarette smoking increases the risk of cancer and CVD 
in the general population. In kidney transplant recipi-
ents, a smoking history of more than 25 pack-years was 
associated with a 30% higher risk of graft failure (RR 
1.30, 95% CI: 1.04-1.63; P = 0.021), mainly due to an 
increased risk of death.400 For patients who quit smok-
ing > 5 years before transplantation, the RR for graft fail-
ure was reduced by 34% (RR 0.66, 95% CI: 0.52-0.85; 
P < 0.001). Given the evidence in the general population 
and transplant recipients, transplant candidates must be 
advised to stop smoking.400
Candidates with underlying pulmonary disease should be 
assessed and evaluated in collaboration with a pulmonary 
specialist. The benefit of kidney transplantation in patients 
with severe pulmonary disease will be offset by poor out-
comes related to their lung pathology.401,402 Given the poor 
prognosis, patients with the following conditions should 
not be candidates for kidney transplantation: lung disease 
requiring home oxygen therapy; uncontrolled asthma; 
severe cor pulmonale; irreversible moderate to severe pul-
monary hypertension; and severe chronic obstructive pul-
monary disease, pulmonary fibrosis or restrictive disease.89 
Patients with underlying bronchiectasis and previously 
treated pulmonary TB may need additional pulmonary 
assessments for consideration of impact of long-term 
immunosuppression on these diseases (see Section 10 on 
pre-transplant infectious disease assessment).
What prior guidelines recommend
The European Renal Best Practice and the UK Renal 
Association evaluation guideline recommend tobacco 
cessation pre-transplant but no other specific statements 
are made regarding pulmonary evaluation.23,143 In a 
review by Bunnapradist and Danovitch, they have rec-
ommended evaluation to include assessment for general 
anesthetic risk and cessation of smoking prior to trans-
plantation.403 Both the AST and the CST evaluation 
guidelines make several suggestions regarding pulmonary 
assessment that are very similar to our recommenda-
tions with no notable discrepancies.28,29 The KHA-CARI 
guidelines make no specific mention of pulmonary assess-
ment pre-transplantation.27
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RESEARCH RECOMMENDATIONS
 • Further studies should examine the costs and ben-
efits of screening for lung cancer in kidney transplant 
candidates.
 • Transplant outcome data are limited for patients with 
functional impairment due to pulmonary disease. 
However, a subset of these patients may benefit from 
kidney transplantation. Prospective cohort studies 
should be done assessing survival and quality of life in 
patients with pulmonary functional impairment who 
undergo transplant compared to those remaining on 
dialysis.
SECTION 13: CARDIAC DISEASE
 13.1: Evaluate all candidates for the presence and 
severity of cardiac disease with history, physical 
examination, and electrocardiogram (ECG) (Not 
Graded).
 13.2: Patients with signs or symptoms of active car-
diac disease (eg, angina, arrhythmia, heart fail-
ure, symptomatic valvular heart disease) should 
undergo assessment by a cardiologist and be man-
aged according to current local cardiac guidelines 
prior to further consideration for a kidney trans-
plant (Not Graded).
 13.3: We suggest that asymptomatic candidates at high 
risk for coronary artery disease (CAD) (eg, diabe-
tes, previous CAD) or with poor functional capac-
ity undergo non-invasive CAD screening. (2C)
 13.3.1: We recommend that asymptomatic can-
didates with known CAD not be revascu-
larized exclusively to reduce perioperative 
cardiac events (1B).
 13.3.2: We suggest that patients with asympto-
matic, advanced triple vessel coronary 
disease be excluded from kidney trans-
plantation unless they have an estimated 
survival which is acceptable according to 
national standards (2D).
 13.4: We suggest that asymptomatic candidates who 
have been on dialysis for at least two years or have 
risk factors for pulmonary hypertension (eg, portal 
hypertension, connective tissue disease, congenital 
heart disease, chronic obstructive pulmonary dis-
ease) undergo echocardiography (2D).
 13.5: Patients with an estimated pulmonary systolic 
pressure greater than 45 mm Hg by echocardio-
graphic criteria should be assessed by a cardiolo-
gist (Not Graded).
 13.5.1: We recommend not excluding candidates 
with uncorrectable pulmonary artery sys-
tolic pressure greater than 60 mm Hg 
(obtained from right heart catherization) 
from kidney transplantation; however, the 
risks of sudden deterioration or progres-
sion after transplantation should be a key 
consideration and the patient should have 
an estimated survival which is acceptable 
according to national standards (1C).
 13.6: Patients with severe valvular heart disease should 
be evaluated and managed by a cardiologist accord-
ing to local cardiac guidelines (Not Graded).
 13.7: We suggest that patients with uncorrectable, symp-
tomatic New York Heart Association (NYHA) 
Functional Class III/IV heart disease [severe CAD; 
left ventricular dysfunction (ejection fraction < 
30%); severe valvular disease] be excluded from 
kidney transplantation unless there are mitigating 
factors that give the patient an estimated survival 
which is acceptable according to national stand-
ards (2D).
 13.7.1: Patients with severe heart failure (NYHA 
III/IV) who are otherwise suitable for kid-
ney transplantation should be assessed by a 
cardiologist and considered for combined/
simultaneous heart and kidney transplan-
tation (Not Graded).
 13.8: Perform cardiac imaging in patients with systemic 
amyloidosis. Exclude such patients from kidney 
transplantation if significant cardiac amyloid is 
confirmed (Not Graded). (see Rec 9.13.3.1)
 13.9: We suggest that candidates who have a myocardial 
infarction be assessed by a cardiologist to deter-
mine whether further testing is warranted and 
when they can safely proceed with kidney trans-
plantation (2B).
 13.10: We suggest that transplantation be delayed an 
appropriate amount of time after placement of a 
coronary stent as recommended by the patient’s 
cardiologist (2B).
 13.11: We suggest that maintenance aspirin, β-blockers, 
and statins be continued while on the waiting list 
and perioperatively, according to local cardiac 
guidelines (2A).
Definitions
 • Coronary angiogram: Imaging modality of coronary 
arteries by injection of contrast medium usually by 
selective catheterization of coronary arteries.
 • Coronary artery disease (CAD): CAD is a narrowing or 
blockage of the arteries supplying the heart caused by 
atherosclerosis.
 • Heart failure: The pathophysiological state in which an 
abnormality of cardiac function is responsible for the 
failure of the heart to pump blood at a rate sufficient for 
the requirements of the body.
 • Metabolic equivalents (METs): The ratio of the work 
metabolic rate to the resting metabolic rate. One MET 
is defined as 1 kcal/kg/hour and is roughly equivalent to 
the energy cost of sitting quietly.
 • Myocardial infarction (MI): Myocardial necrosis in 
a clinical setting consistent with acute myocardial 
ischemia.
 • Perioperative: Around the time of surgery
 • Pulmonary hypertension: A mean pulmonary arterial 
pressure ≥ 25 mm Hg at rest usually confirmed by right 
heart catheterization.
 • Valvular heart disease: Any disease process involving 
one or more of the four valves of the heart (the aortic 
and mitral valves on the left and the pulmonary and tri-
cuspid valves on the right)
BACKGROUND
Cardiac disease is the most common cause of death 
in dialysis patients and the incidence of cardiac events 
increases with worsening CKD. Patients with ESKD being 
assessed for kidney transplantation have an increased risk 
of CAD, impaired left ventricular function, pulmonary 
hypertension and valvular heart disease compared to the 
general population. These risks are further increased in 
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patients with older age, DM, and previous vascular events. 
Risks are also elevated in smokers and those with a longer 
duration of dialysis. Additionally, patients with cardiac 
disease have a higher risk of death and cardiac events in 
the peri-transplant and post-transplant periods. Kidney 
transplantation is generally classified as intermediate risk 
surgery, however many patients have comorbidities that 
increase the risk for cardiac events. For these reasons, 
assessment for cardiac disease is important in the evalua-
tion of candidates.
RATIONALE
 • There is evidence that patients with ESKD have a higher 
risk of cardiac disease than the general population.
 • There is evidence that abnormal echocardiography find-
ings and positive non-invasive stress testing are predic-
tive significant CAD, cardiac events and death in patients 
assessed for kidney transplantation. However, evidence 
that screening for CAD results in improved survival or a 
reduction in CAD events is lacking.
 • There is no evidence that revascularization of coro-
nary artery stenoses exclusively to reduce perioperative 
events is beneficial.
 • There is evidence that the risk of death is highest in the 
first month after a MI.
 • There is evidence that dual antiplatelet therapy should 
be maintained for at least one month after insertion of a 
bare metal stent.
 • There is evidence that dual antiplatelet therapy should 
be maintained for at least six months after insertion of a 
drug eluting stent.
 • There is evidence from the general population that 
patients benefit from continuing cardioprotective medi-
cation in the perioperative period.
 • There is evidence that echocardiography does not accu-
rately measure right heart pressures in patients with 
severe pulmonary hypertension.
 • There is evidence that patients with an ejection fraction 
of less than 30% are at increased risk of death after kid-
ney transplantation.
Patients with CKD G5 and those on dialysis (G5D) have 
a significantly higher incidence of CAD than those of the 
general population.404 The diagnosis of CAD is challeng-
ing as many patients are asymptomatic with no clinical 
evidence of cardiac ischemia. There are a number of guide-
lines and consensus statements in the literature regarding 
cardiac assessment for patients prior to both general and 
kidney transplant surgery.28,89,405–407
The goal of a perioperative assessment is to establish 
whether there is active cardiac disease present. Active 
conditions include unstable coronary syndromes, signifi-
cant heart failure, arrhythmias and valvular heart disease. 
Hence, a thorough history and full physical examina-
tion should be undertaken in all patients assessed for 
kidney transplantation. The updated American College 
of Cardiology/American Heart Association (ACC/AHA) 
guidelines on perioperative cardiovascular evaluation 
and care for non-cardiac surgery suggests consideration 
of a 12-lead electrocardiogram (ECG) in asymptomatic 
patients without known CAD except for those undergoing 
low risk surgery.405 Statements from the AHA/ACC scien-
tific statement on cardiac evaluation for kidney and liver 
transplantation recommend a 12-lead ECG in potential 
kidney transplant candidates with known CAD, peripheral 
vascular disease, or any cardiovascular symptoms and sug-
gest that a 12-lead ECG is reasonable in candidates with-
out known CVD.406
Due to the high risk of CAD in patients with ESKD, 
non-invasive stress testing of asymptomatic patients has 
become commonplace in patients assessed for kidney 
transplantation with the aim of diagnosing occult CAD 
and thereby reducing peri-transplant cardiac events and 
mortality. While multiple studies have demonstrated rea-
sonable sensitivity and specificity for the detection of sig-
nificant CAD with non-invasive stress testing in addition 
to reasonable positive predictive value for death and major 
adverse cardiac events, there are no studies demonstrat-
ing a survival benefit in patients assessed for kidney trans-
plantation undergoing stress testing for asymptomatic 
CAD.408,409 Patients with a positive stress test are how-
ever less likely to be listed for kidney transplantation.410 
In the diabetic population, the Detection of Ischemia in 
Asymptomatic Diabetes (DIAD) trial did not show a ben-
efit in survival or cardiac events in patients randomized to 
non-invasive screening versus medical management, with 7 
nonfatal MIs and 8 cardiac deaths (2.7%) in the screened 
group and 10 nonfatal MIs and 7 cardiac deaths (3.0%) 
among the not screened group (hazard ratio [HR] 0.88, 
95% CI: 0.44–1.88; P = 0.73).411
In the general population, patients with excellent func-
tional capacity (> 10 METs) have a low risk of cardiac 
events and recommendations from the ACC/AHA state 
that it is reasonable to forgo exercise testing in this popu-
lation but suggests that cardiac stress testing be consid-
ered in patients with poor (< 4 METs; eg, unable to climb 
one flight of stairs) or unknown functional capacity.405 
Similarly in the European Society of Cardiology (ESC)/ 
European Society of Anaesthesiology guidelines on non-
cardiac surgery, cardiovascular management and assess-
ment recommend stress testing in patients who have poor 
functional capacity (< 4 METs) and greater than 2 risk 
factors for CAD.407
As patients assessed for kidney transplant have at least 
one clinical risk factor for CAD (kidney failure) and there 
is a high incidence of additional risk factors in this popu-
lation, the AHA/ACC scientific statement recommends 
that non-invasive stress testing be considered for kidney 
transplant candidates with three or more CAD risk factors 
regardless of functional status.406,412 Relevant risk factors 
include DM, prior CVD, a duration of dialysis of > 1 year, 
older age, smoking, hypertension and dyslipidemia.
There is little evidence to support periodically screen-
ing asymptomatic candidates while on the waiting list 
although this is common practice. This practice is currently 
the subject of a RCT (CARSK [Canadian Australasian 
Randomized Trial of Screening Kidney Transplant 
Candidates for Coronary Artery Disease]).413
Coronary revascularization exclusively to reduce peri-
operative cardiac events is not recommended in the gen-
eral population prior to surgery. The Coronary Artery 
Revascularization Prophylaxis (CARP) trial randomly 
assigned over 500 patients with stable CAD requiring elec-
tive vascular surgery to either medical therapy alone or 
medical therapy plus revascularization and found no differ-
ence in mortality between the two groups.414 Similar find-
ings were found in the Dutch Echocardiographic Cardiac 
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Risk Evaluation Applying Stress Echo (DECREASE) V 
trial where 101 patients with significant stress-induced 
ischemia on dobutamine stress echocardiography were 
randomized to medical therapy or revascularization prior 
to elective vascular surgery.415 In guidelines for the general 
population it is not recommended that coronary revas-
cularization be undertaken prior to non-cardiac surgery 
exclusively to reduce perioperative events in low and inter-
mediate risk surgery.405,407
In patients in whom revascularization is recommended 
according to existing clinical practice guidelines, this 
should occur prior to transplantation.406 Risks associated 
with major cardiac surgery are increased in the people 
with ESKD; however one large, multicenter, retrospec-
tive analysis has documented declining mortality rates 
over successive eras, reporting a 30-day mortality rate of 
7% between 2000 and 2003.416 Only one RCT has evalu-
ated the outcome of revascularization in patients assessed 
for kidney transplantation.417 Twenty-six patients with 
insulin-dependent DM and clinically significant CAD 
were randomized to medical therapy or revasculariza-
tion prior to kidney transplantation. The outcome for 
those managed medically was markedly inferior to that 
of those who were revascularized. Only 2 of 13 revas-
cularized patients reached a cardiovascular endpoint in 
8.4 months of follow-up compared to 10 of 13 who were 
managed medically. This trial, however, was limited by 
the use of short-acting calcium channel blockers in the 
medically managed group, suboptimal use of aspirin, 
small sample size, and short follow-up (Summary Table 
and Evidence Profile: CABG and cardiac revascularization 
pre-transplantation).
There have been a number of publications including 
systematic reviews examining the role of perioperative 
medical therapy. Continuation of β-blockade has been 
shown to be beneficial in multiple observational studies 
in the general population418–420 and continuation has been 
recommended by the ACC/AHA and ESC.405–407 Similarly, 
these guidelines recommend continuation of statins in the 
perioperative period. The KDIGO guideline for lipid man-
agement in CKD recommends statin treatment in kidney 
transplant recipients to reduce cardiac death and non-fatal 
MI and therefore maintaining statin use in those about to 
be transplanted is reasonable.421 There is an increased risk 
of rhabdomyolysis with the use of calcineurin inhibitors— 
in particular cyclosporine— and hence, surveillance for this 
rare but important side effect is warranted.422 There are no 
RCTs evaluating the efficacy of aspirin to prevent CVD in 
dialysis and CKD patients. However, observational stud-
ies suggest that aspirin is associated with a reduction in 
mortality in patients with a previous MI and hence main-
taining aspirin in patients with known vascular disease is 
reasonable.423,424 There are similar recommendations from 
the ACC/AHA regarding angiotensin-converting enzyme 
inhibitors.405
In patients prescribed with anticoagulant therapy, the 
risk of bleeding needs to be weighed against the risk of 
thrombosis. Vitamin K antagonists such as warfarin are 
commonly used in patients with atrial fibrillation or 
prosthetic heart valves. In patients with atrial fibrilla-
tion without mechanical heart valves requiring interrup-
tion of anticoagulation for procedures, guidelines from 
the AHA/ACC state that decisions on bridging therapy 
should balance the risks of stroke and bleeding.425 In 
patients with prosthetic heart valves, bridging antico-
agulation with either intravenous unfractionated heparin 
or low molecular weight heparin is recommended in the 
perioperative period in patients with a mechanical aor-
tic valve replacement and any thromboembolic risk fac-
tor, older generation mechanical aortic valve replacement 
or mechanic mitral valve replacement.426 The use of oral 
direct thrombin inhibitors or anti-Xa agents in patients 
with mechanical valves is not recommended, due to the 
role of kidney function in drug clearance and the difficul-
ties involved in reversing anticoagulation in the case of 
excess bleeding at the time of transplantation.
There is an increased risk of mortality in patients hav-
ing surgery after a recent MI. The ACC/AHA task force 
recommends waiting for 4-6 weeks after a MI prior to 
undertaking elective surgery.427 A study using discharge 
data showed that the post-operative MI rate decreased 
substantially as the length of time from MI to operation 
increased from 32.8% at less than 30 days after MI to 
5.9% at 90-180 days after MI. Similarly 30-day post-oper-
ative mortality was highest in the first month after MI.427 
Both the ESC and AHA/ACC guidelines recommend that 
in the setting of an acute coronary syndrome, guidelines for 
treatment for ST-segment elevation MI or non-ST- segment 
elevation MI should be followed. In those patients with a 
MI who have been treated with revascularization and dual 
antiplatelet therapy, guidelines for duration of antiplatelet 
therapy should be followed.405,407
Coronary artery revascularization using percutaneous 
angioplasty and coronary artery stenting after both MI and 
in patients with stable CAD generally requires the use of 
dual antiplatelet therapy. Dual antiplatelet therapy is asso-
ciated with an increased risk of bleeding which is likely 
to be increased in the CKD population.428 Additionally 
there is an increased risk of cardiac events in the first six 
months after coronary artery stenting.429 The ACC/AHA 
recommends delaying non-cardiac surgery for a duration 
of at least 14 days after balloon angioplasty and at least 
30 days after insertion of a bare metal stent.405 Similarly 
they recommend delaying elective surgery for at least a 
year after insertion of a drug eluting stent although more 
recent data has suggested that surgery after 6 months may 
be possible with no increase in risk.407,430,431 Guidelines 
have recommended delaying elective non-cardiac sur-
gery until completion of a full course of dual antiplatelet 
therapy to reduce the risk of perioperative bleeding and 
requirement for transfusion.405 In patients who have had 
coronary artery stenting, both the ESC and ACC/AHA 
guidelines recommend continuation of aspirin at a dose of 
75-100 mg daily.
Valvular heart disease is common in the setting of 
ESKD with an incidence in dialysis patients that is five 
times greater than that of the general population.432 
Additionally, survival after valve replacement surgery 
is significantly lower than that of the general popula-
tion with a 2-year mortality of 39.5-60% as previously 
reported.433 Similarly the incidence of pulmonary hyper-
tension increases with worsening CKD with an inci-
dence of 32.8% reported in patients with CKD G5 in the 
Chronic Renal Insufficiency Cohort (CRIC) study partici-
pants.434 Pulmonary hypertension as defined by a pulmo-
nary artery systolic pressure (PASP) > 35 mm Hg and or 
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tricuspid regurgitant velocity > 2.5 m/s had an adjusted 
38% increased risk of all-cause mortality and 23% risk 
for cardiac events with a significantly higher risk in 
patients with a PASP > 55 mm Hg. In patients assessed 
for kidney transplantation, pulmonary hypertension has 
been shown to be associated with an increased risk of 
cardiac events and death.435 As volume status may impact 
on right heart pressure estimates, the National Kidney 
Foundation’s Kidney Disease Outcomes Quality Initiative 
(KDOQI) recommends that echocardiograms should 
be performed once “dry weight” has been achieved.436 
Echocardiographic estimates of PASP may be inaccurate 
and hence, the 2012 AHA/ACC scientific statement on 
evaluation of cardiac disease in kidney and liver trans-
plant candidates recommends consideration of right 
heart catheterization in candidates with PASP ≥ 50 mm 
Hg.437 Severe pulmonary hypertension is defined as PASP 
> 60 mm Hg. There are a number of therapeutic and man-
agement strategies that may be beneficial in patients with 
severe pulmonary hypertension although these have not 
been rigorously tested in the ESKD population. Therefore, 
patients with moderate (PASP 45 – 59 mm Hg) or severe 
pulmonary hypertension who are at a satisfactory dry 
weight should be referred to a cardiologist for assessment 
and management. Despite the association of pulmonary 
hypertension with increased mortality and morbidity, 
there is some evidence that regression of elevated pul-
monary pressure may occur after transplantation. Thus, 
assessment of this risk should be integrated with other 
known risk factors when deciding if an individual will 
benefit from kidney transplantation.437
In the general population, the European guidelines rec-
ommend that patients with established or suspected heart 
failure scheduled for high or intermediate risk surgery 
undergo evaluation of left ventricular function with echo-
cardiography while the ACC/AHA guidelines suggest it is 
reasonable for patients with dyspnea of unknown origin 
or heart failure to undergo echocardiography.405,407 The 
KDOQI guidelines for CVD in dialysis patients recommend 
a resting echocardiogram in all patients at the initiation 
of dialysis once the patient has achieved a dry weight.436 
Impaired left ventricular function has been shown to be 
a strong predictor of mortality in both the general popu-
lation and kidney transplant candidates (Summary Table 
and Evidence Profile: Echocardiography).438,439 In a large 
series of hemodialysis patients, the risk of cardiovascular 
death in patients with a left ventricular ejection fraction 
(LVEF) of < 30% was more than nine times that of those 
with a LVEF of ≥ 60%.440 Due to the high risk of mortality 
with severe impairment of left ventricular function, dialy-
sis treatment to improve fluid overload and consideration 
of carvedilol which has been shown to reduce mortality 
in the general population and in a small cohort of dialysis 
patients, may be beneficial.441 Patients with severe heart 
failure (New York Heart Association [NYHA] Functional 
Class III/IV) or with a LVEF persistently < 30% despite 
adequate fluid removal on dialysis who are otherwise 
suitable for kidney transplantation should be referred to 
a heart transplant service for assessment for combined 
heart-kidney transplantation.
There are a number of cardiology guidelines recom-
mending optimal investigation and treatment of valvular 
heart disease, and patients with ESKD should be evaluated 
according to up-to-date guidelines unless evidence emerges 
to the contrary.426,442
Systemic amyloidosis is a rare multisystem disease that 
can result in ESKD. Registry data have shown that patients 
with amyloid have inferior survival both on dialysis and 
after kidney transplantation. However, in carefully selected 
cases (i.e., those without significant amyloid heart dis-
ease), successful kidney transplantation has been under-
taken.274,443,444 Cardiac involvement is a leading cause of 
mortality and morbidity and can occur in amyloidosis of all 
etiologies. In particular cardiac involvement is most com-
mon in primary light chain AL amyloid.445 Cardiac amyloid 
is a restrictive cardiomyopathy which causes progressive 
diastolic and later biventricular dysfunction. Additionally, 
myocardial ischemia can result from amyloid deposits in the 
microvasculature. There is no consistent ECG finding in car-
diac amyloid although low QRS voltages occur in up to 50% 
of patients with cardiac AL amyloidosis. Recommendations 
from amyloid centers are that all patients with amyloidosis 
undergo echocardiography. Findings of advanced disease 
have prognostic significance and these patients are unlikely 
to be suitable for kidney transplantation. Assessment and 
decisions about more advanced imaging should be under-
taken by a cardiologist with expertise in amyloidosis.
What prior guidelines recommend
Our Work Group is in general agreement with 
multiple guidelines outlining recommendations for 
assessment and management of cardiac disease in candi-
dates.23,27–29,143,405,406 Specifically, the Work Group agrees 
with guidelines which recommend that candidates be 
assessed for cardiac disease and that patients with sig-
nificant risk of CAD be assessed with non-invasive test-
ing prior to acceptance for transplantation. The Work 
Group also agrees with guidelines suggesting that non-
invasive testing is not necessary in asymptomatic patients 
at low risk of CAD. Due to the lack of evidence, we differ 
from previous guidelines27,29 which recommend periodic 
non-invasive screening for occult CAD after admission 
to a waitlist. There is no evidence that angiography is 
required in asymptomatic patients who have a negative 
non-invasive stress test. We are also in general concord-
ance with most guidelines that recommend assessing trans-
plant candidates for left ventricular dysfunction, valvular 
heart disease and pulmonary hypertension, initially by 
echocardiography.27,29,405,406
The Work Group agrees with most guidelines that 
recommend continuing maintenance cardioprotective 
medications while waiting for kidney transplantation. In 
terms of revascularization, the Work Group agrees with 
the AHA/ACC Scientific Statement on cardiac disease 
evaluation and management among kidney and liver can-
didates,406 that routine prophylactic coronary revasculari-
zation is not recommended in patients with stable CAD 
who have no symptoms and have no survival indication 
for revascularization.
Our recommendations on timing of transplantation 
after MI and coronary artery stenting differ slightly from 
other guidelines29,406 but overall the Work Group is in 
general agreement with guidance provided by the recent 
ACC/AHA Guideline on Perioperative Cardiovascular 
Evaluation and Management of Patients Undergoing 
Noncardiac Surgery.405
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RESEARCH RECOMMENDATIONS
 • RCTs should be conducted to examine the costs and ben-
efits of non-invasive cardiac testing for CAD in patients 
being assessed for kidney transplantation, and similarly 
for periodic screening of patients already listed for trans-
plantation. The results of the CARSK study are awaited.413
 • RCTs should be conducted to compare revascularization 
versus optimal medical management prior to kidney 
transplantation in patients with severe but asympto-
matic CAD. The results of the randomized controlled 
trial ISCHEMIA-CKD are awaited.446
 • Further research on the development of valid prediction 
scores for survival after kidney transplantation for car-
diac disease, including combinations of cardiac comor-
bidities, should be encouraged.
 • Studies should examine the efficacy of treatment options 
for pulmonary hypertension in patients with ESKD.
RELEVANT SUPPLEMENTAL MATERIAL
Summary table: CABG
Summary table: CABG (quality assessment)
 Evidence profile: Cardiac revascularization 
pre-transplantation
Summary table: Echocardiography
Summary table: Echocardiography (quality assessment)
Evidence profile: Echocardiography pre-transplantation
SECTION 14: PERIPHERAL ARTERIAL DISEASE (PAD)
 14.1: Evaluate all candidates for presence and severity of 
peripheral arterial disease (PAD) with history and 
physical examination (Not Graded).
 14.2: We suggest that candidates without clinically 
apparent PAD, but who are at high risk for PAD, 
undergo non-invasive vascular testing (2D).
 14.3: Candidates with clinically apparent PAD should 
undergo imaging and management of their PAD 
in consultation with a vascular surgeon prior to 
transplantation (Not Graded).
 14.4: We suggest that candidates with clinically appar-
ent PAD, abnormal non-invasive testing, or prior 
vascular procedures, undergo non-contrast CT 
imaging of the abdomen/pelvis to evaluate arterial 
calcification and improve operative planning (2D).
 14.5: Exclude candidates with non-healing extremity 
wounds with active infection from transplantation 
until the infection is resolved (Not Graded).
 14.6: We suggest not excluding patients with prior aorto-
iliac procedures including iliac artery stent place-
ment from kidney transplantation if there is sufficient 
native artery available for vascular anastomosis (2D).
 14.7: We suggest not excluding patients with severe 
aorto-iliac disease or distal vascular disease from 
kidney transplantation; however, the risk of pro-
gression after transplantation should be a key 
consideration and the patient should have an esti-
mated survival which is acceptable according to 
national standards (2D).
RATIONALE
Prevalence of PAD in transplant candidates
Peripheral arterial disease (PAD) is highly prevalent in 
the ESKD population due to high rates of hypertension, 
DM, tobacco abuse, and altered calcium and phosphorus 
balance. Population-based estimates of dialysis-dependent 
patients demonstrate that 24% of patients with CKD have 
evidence of PAD using non-invasive studies.447 Among 
dialysis patients, 24% have clinical evidence of PAD (eg, 
claudication, rest pain, or tissue loss), 35% have evidence 
of an abnormal ankle-brachial index, and nearly 46% 
have health care claims related to peripheral vascular dis-
ease. Overall survival among ESKD patients who develop 
critical limb ischemia is less than 23% at five years.
The incidence of PAD among transplant candidates 
is lower as patients with advanced disease are excluded. 
While reporting of PAD to registries may be incomplete, 
one registry analysis reported that only 7% of kidney 
transplant candidates in UNOS (listed 1994-2008) were 
listed as having PAD. PAD was a risk factor for waitlist 
mortality (HR 1.47; P < 0.001) and subsequent allograft 
loss (HR 2.01; P < 0.001).448 Furthermore, the degree of 
iliac artery calcification increases with length of dialy-
sis prior to evaluation and listing.449 However, when 
compared to remaining on dialysis, kidney transplant in 
patients with PAD was associated with 50% reduction in 
mortality at five years (68.1% vs. 34.5%, P < 0.0001). For 
this reason, the Work Group believes that PAD is not an 
absolute contraindication to transplantation. Candidates 
with evidence PAD should be counseled regarding the ces-
sation of tobacco as this is a major risk factor for progres-
sion of disease.
Evaluation of PAD
Previous KDIGO guidelines have emphasized the need 
for appropriate assessment of PAD among patients with 
CKD.3 Characterization of PAD in transplant candidates 
relies on history, physical examination and imaging studies. 
The Work Group believes that all patients with risk fac-
tors for PAD (eg, DM, tobacco use, history of CAD and 
long-term dialysis dependence) or clinical evidence of limb 
ischemia (eg, claudication, rest pain, or prior amputations) 
should be screened for PAD. In addition, a complete history 
of all prior open and endovascular interventions should be 
obtained prior to the determination of candidacy.
Assessment of the severity of PAD can be accomplished 
through lower extremity segmental flow and pressure 
studies and non-invasive duplex evaluation.450 These tests 
have been demonstrated to be reliable and correlate with 
post-transplant outcomes.451 In patients with established 
PAD, arteriography (with CO2 or iodinated contrast dye) 
or CT scan without contrast can provide important infor-
mation on the degree of proximal iliac artery and aortic 
calcification which assists with preoperative planning.449 
Andres et al., in a prospective evaluation of 114 helical 
CT scans of pre-transplant candidates with risk factors for 
iliac stenosis, reported a 29% rate of iliac artery calcifica-
tion sufficient to preclude transplantation.452 Infrainguinal 
arterial disease is best assessed using angiography.
Severe aortoiliac disease is a relative 
contraindication to kidney transplant
Advanced aortoiliac disease is a relative contraindication 
to kidney transplantation.453 High-grade, calcific stenosis 
precludes kidney transplant in the ipsilateral iliac fossa, if 
there is an insufficient length of soft artery to allow safe 
clamp placement and anastomosis. Selected patients can 
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be considered for placement of an interposition graft with 
donor iliac artery (when available) or prosthetic with imme-
diate or staged transplantation.454–456 Small clinical series 
report successful outcomes from both approaches with a low 
rate of vascular graft infection or allograft loss. Patients with 
common iliac artery disease or aortic/iliac aneurysms can be 
considered for pre-transplant endovascular repair provided 
the external iliac arteries are not overly diseased and there is 
room for a vascular clamp below the level of the stent.
Infrainguinal vascular disease in transplant 
candidates
PAD below the inguinal ligament is common in patients 
with advanced CKD and ESKD who are candidates for 
kidney transplant.457 The manifestations of distal PAD 
include claudication, rest pain, tissue loss, infection, and 
amputation. Successful transplant has the potential to sta-
bilize distal disease and reduce arterial stiffness.458 There 
is no evidence that kidney transplant to the ipsilateral iliac 
artery worsens steal syndrome or increases the risk of tissue 
loss.459 However, pre-transplant correction of PAD should 
be considered to reduce potential post-transplant exposure 
to iodinated contrast dye and other complications.
Aortic aneurysmal disease
Patients being evaluated for kidney transplant should 
be evaluated for abdominal aortic aneurysm if they have 
established risk factors (eg, males, advanced age, tobacco 
abuse, chronic obstructive pulmonary disease, PAD, prior 
MI, prior transient ischemic attack [TIA]). Endovascular 
repair of abdominal aortic aneurysm does not preclude 
transplant provided the iliac limbs are not extended into 
the external iliac arteries bilaterally.
What prior guidelines recommend
Prior guidelines point to peripheral vascular disease as 
a marker for general cardiovascular morbidity as well as a 
risk factor for technical complications. The AST guidelines28 
suggest that peripheral vascular occlusive disease alone is 
not a contraindication, though patients should be carefully 
screened for associated CVD and cerebrovascular disease. 
No specific imaging modality was recommended, though 
routine angiography was unlikely to be beneficial. The pres-
ence of large unrepaired aortic aneurysms, advanced aortoil-
iac disease, active atheroembolic disease, or gangrene should 
be considered as absolute contraindications until treated and 
resolved. Patients with advanced aortoiliac occlusive disease 
should not be considered for transplant as the risk of graft 
loss is excessive in patients with inadequate arterial inflow. 
The CST29 similarly classified peripheral vascular occlusive 
disease as a risk factor for poor outcomes though not as an 
absolute contraindication unless symptomatic. Patients with 
symptomatic, recurrent peripheral vascular occlusive disease 
experienced markedly lower post-transplant survival (5-year 
survival 81% vs. 10-year survival 26%) and may not benefit 
from transplantation.460 The use of arterial grafts for arterial 
inflow should be seen as a last resort as higher complication 
rates have been reported. The ERA-EDTA guidelines88 state 
only the patient should be screened for peripheral vascular 
occlusive disease and symptomatic or clinical significant dis-
ease should be treated as soon as possible and preferably 
prior to transplantation as these conditions are associated 
with poor long-term patient survival.
RESEARCH RECOMMENDATIONS
 • RCTs should be conducted to examine the costs and 
benefits of different non-invasive testing (eg, Doppler 
ultrasound, non-contrast CT scan) for PAD in patients 
being assessed for kidney transplantation.
 • Similar studies could be conducted on patients already 
listed for transplantation to determine the utility and 
frequency of periodic screening for PAD.
SECTION 15: NEUROLOGIC DISEASE
 15.1: We suggest waiting at least 6 months after a stroke 
or 3 months after a transient ischemic attack (TIA) 
before kidney transplantation (2D).
 15.2: We recommend not screening asymptomatic can-
didates for carotid artery disease (1D).
 15.3: We suggest screening candidates with autosomal 
dominant polycystic kidney (ADPKD) disease for 
intracranial aneurysms only if they are at high risk 
due to prior history of or a family history of suba-
rachnoid hemorrhage (2D).
 15.4: Patients with progressive central neurodegen-
erative disease should not undergo kidney trans-
plantation if survival and quality of life are not 
expected to be substantially improved by trans-
plantation (Not Graded).
 15.5: Assess mental status in candidates with known or 
suspected cognitive impairment (Not Graded).
 15.5.1: We recommend not excluding candidates 
from kidney transplantation because of 
non-progressive intellectual, developmen-
tal, or cognitive disability (1D).
 15.6: Patients with symptomatic peripheral neuropathy 
should be assessed by a neurologist (Not Graded).
 15.6.1: We suggest people with progressive periph-
eral neuropathy attributed to uremia be 
considered for urgent kidney transplanta-
tion, if available (2D).
 15.6.2: We recommend not excluding candidates 
from kidney transplantation because of 
peripheral neuropathy (1D).
Definitions
 • Transient ischemic attack (TIA): Episode of temporary 
and focal cerebral dysfunction of vascular origin, rapid 
in onset which commonly last 2-15 minutes but occa-
sionally up to 24 hours with no permanent neurologic 
deficit.461
 • Carotid artery disease: Stenosis of carotid arteries, gen-
erally caused by atherosclerosis and only rarely caused 
by radiation therapy, vasculitis, dissection, or fibromus-
cular dysplasia.
 • Central neurodegenerative disease: Neurologic diseases 
that cause diminished quality of life and survival despite 
treatment (eg, Alzheimer’s disease and other progressive 
dementias, Parkinson’s disease, Huntington’s disease, 
and motor neuron diseases).
RATIONALE
Waiting period
There are no data to guide decisions on when it is 
safe for CKD patients who have had a stroke or TIA to 
undergo transplantation. Observational data from the gen-
eral population indicate that the risk of poorer outcomes 
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after elective non-cardiac surgery is increased if surgery 
is performed within 12 months of a stroke or TIA.462,463 
However, since the risk of death is substantially higher 
on dialysis compared to transplant, waiting too long may 
increase the patients overall risk of death. The Work Group 
agreed that waiting for at least 6 months after a stroke or 
3 months after a TIA seemed reasonable, based on expert 
opinion. This suggestion assumes there is not a quality-
of-life-limiting neurologic deficit from the stroke, such as 
vascular dementia, dense hemiplegia, etc.
Screening in patients with a history of stroke or 
TIA
It is good medical practice to screen for treatable causes 
of stroke or TIA when they occur. This includes echocar-
diography to determine if there is valvular heart disease 
that might be the source of emboli; ECG to rule out atrial 
fibrillation; and carotid artery imaging to rule out a treat-
able cause of stroke or TIA. Therefore, the Work Group 
concluded that these tests should be done at some time 
before transplantation based on expert opinion.
Screening for carotid stenosis
A systematic review of evidence from the general popula-
tion found no trials comparing screening versus no screen-
ing, or carotid stenting versus medical therapy.464 The 
specificity of ultrasonography for detecting carotid artery 
stenosis was found to be low, so that many false positives 
could be expected. A study of patients undergoing kidney 
transplantation found no association between pre-trans-
plant carotid stenosis found on duplex ultrasonography 
and post-transplantation risk of stroke or TIA (Summary 
Table and Evidence Profile: Carotid screening).465 For 
carotid endarterectomy versus medical management, the 
absolute reduction of non-perioperative strokes was 5.5% 
(95% CI: 3.9-7.0%) in 3 trials with 5223 participants with 
approximately 5 years of follow-up. However, the 30-day 
rates of stroke or death after carotid endarterectomy in 
trials and cohort studies were 2.4% (95% CI: 1.7-3.1%) 
in 6 trials with 3435 participants, and 3.3% (95% CI: 2.7-
3.9%) in 7 studies with 17,474 participants. Other harms 
of interventions included MI, nerve injury, and hematoma. 
The authors of the systematic review concluded that the 
evidence did not indicate an overall benefit of carotid 
endarterectomy, stenting, or intensification of medical 
therapy.464 Based on this evidence, the US Preventative 
Services Task Force recommended against screening for 
asymptomatic carotid stenosis.466
There have been no trials investigating the potential ben-
efits and harms of screening and intervention for asymp-
tomatic extracranial disease in CKD. Similarly, there have 
been no trials comparing intervention with no interven-
tion or medical management for carotid artery stenosis in 
patients with CKD. However, there is no reason to believe 
that screening in CKD would be more specific than screen-
ing in the general population, or that the prevalence of 
carotid stenosis would be greater in advanced CKD than in 
the general population. In a recent series of 882 transplant 
candidates, only 1.5% had evidence of significant stenosis 
on screening carotid ultrasound.467 Therefore, given these 
factors, it is unlikely that the benefits would outweigh the 
harms of screening for asymptomatic carotid artery steno-
sis in transplant candidates.
Screening for intracranial aneurysms in ADPKD
Intracranial aneurysms (ICAs) occur in 9-12% of 
patients with ADPKD468,469 compared with 2-3% in the 
general population.470 From studies in the general popu-
lation, ICAs less than 7 mm in diameter are more often 
identified with screening but are lower risk for rupture 
compared to larger ICAs. Patients with ADPKD and a fam-
ily history of ICA rupture may be at higher risk of rupture. 
However, surgical repair of asymptomatic ICA is associ-
ated with a high incidence of morbidity and mortality.471
A 2014 KDIGO Controversies Conference did not rec-
ommend routine screening for ICA.472 However, screening 
could be considered in patients with a family history of 
ICAs or subarachnoid hemorrhage, previous ICA rupture, 
high-risk professions (eg, airline pilots), and increased 
patient anxiety473 (Summary Table and Evidence Profile: 
ADPKD-related cerebral aneurysm). The Conference par-
ticipants concluded that time-of-flight magnetic resonance 
imaging without gadolinium enhancement is the method 
of choice if screening is undertaken. Individuals with ICAs 
should be reevaluated every 6-24 months.468,474,475 Patients 
with a family history of ICA but no ICA on screening 
should be rescreened at 5 to 10-year intervals.474
Peripheral neuropathy is common among people with 
ESKD, particularly when ESKD has been caused by a mul-
tisystem condition known to impact nerves and kidney, 
such as diabetes, vasculitis or amyloidosis. The etiology of 
neuropathy may be clinically evident in some cases, but 
not so in others. In rare instances of painful, progressive 
sensory-motor peripheral neuropathy, uremia itself may be 
the cause. To better define the cause, type, extent and prog-
nosis of peripheral neuropathy, consultation by a neurolo-
gist is recommended. Although the diagnosis of peripheral 
neuropathy is unlikely to limit suitability for kidney trans-
plantation, information on cause, prognosis, symptom 
management and suggestions for perioperative manage-
ment may be of use to the patient and transplant team. 
For cases attributed to uremia, which progress despite 
aggressive dialysis, successful kidney transplantation may 
halt progression and reverse both symptoms and nerve 
conduction defects in some cases.476 We recommend con-
sidering priority access to transplantation for such cases, 
if available.
What prior guidelines recommend
The US Preventative Services Task Force and several 
other guideline organizations recommend against screen-
ing for asymptomatic carotid artery stenosis in the gen-
eral population.466 These guidelines are consistent with 
our recommendation against screening in asymptomatic 
transplant candidates. KHA-CARI ADPKD guidelines 
are consistent with our recommendation of screening for 
ICA only in transplant candidates at increased risk.473 The 
CST transplant eligibility guidelines make no distinction 
between stroke and TIA; a delay of at least 6 months is 
suggested for each condition.29
RESEARCH RECOMMENDATIONS
 • Further studies should examine the outcomes of patients 
transplanted with known cerebrovascular disease.
 • RCTs should be conducted to examine the utility of 
different cognitive screening tests (eg, Mini-Mental 
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State Examination, Montreal Cognitive Assessment) in 
patients being evaluated for transplantation.
RELEVANT SUPPLEMENTAL MATERIAL
Summary table: Carotid screening
Summary table: Carotid screening (quality assessment)
Evidence profile: Carotid artery testing
Summary table: ADPKD-related cerebral aneurysm
 Summary table: ADPKD-related cerebral aneurysm 
(quality assessment)
 Evidence profile: Intracranial imaging in patients with 
ADPKD
SECTION 16: GASTROINTESTINAL AND LIVER 
DISEASE
 16.1: Evaluate all candidates for the presence of gas-
trointestinal disease, including liver disease, with 
a targeted history and physical examination (Not 
Graded).
 16.2 Peptic ulcer disease
 16.2.1: We recommend that candidates with symp-
toms suggestive of active peptic ulcer dis-
ease undergo esophagogastroscopy and H. 
pylori testing prior to kidney transplanta-
tion (1C).
 16.2.2: Delay kidney transplantation in candidates 
with endoscopically-proven peptic ulcer 
disease until symptoms have resolved (Not 
Graded).
 16.2.3: We recommend not screening candidates 
with a history of peptic ulcer disease with 
esophagogastroscopy (1C).
 16.2.4: We recommend not excluding candidates 
with a history of peptic ulcer disease from 
kidney transplantation (1D).
 16.3 Diverticulitis
 16.3.1: Delay kidney transplantation in candidates 
with active diverticulitis until symptoms 
have resolved (Not Graded).
 16.3.2: We recommend not screening asympto-
matic candidates for diverticulosis (1C).
 16.3.3: We recommend not performing prophylac-
tic colectomy in patients with a history of 
diverticulitis or asymptomatic diverticulo-
sis (1C).
 16.3.4: We recommend not excluding candidates 
with a history of diverticulitis from kidney 
transplantation (1C).
 16.4 Pancreatitis
 16.4.1: Delay kidney transplantation in candidates 
with acute pancreatitis a minimum of three 
months after symptoms have resolved (Not 
Graded).
 16.4.2: We suggest not excluding candidates with 
a history of acute or chronic pancreatitis 
from kidney transplantation (2C).
 16.5 Cholelithiasis
 16.5.1: Delay kidney transplantation in candidates 
with symptomatic gallstone or gallbladder 
disease until symptoms have resolved (Not 
Graded).
 16.5.2: We recommend that candidates with a his-
tory of cholecystitis undergo cholecystec-
tomy before kidney transplantation (1C).
 16.5.3: We recommend not screening asympto-
matic candidates for cholelithiasis (1C).
 16.5.4: We recommend not performing prophy-
lactic cholecystectomy in candidates with 
asymptomatic cholelithiasis (1C).
 16.5.5: We recommend not excluding candidates 
with asymptomatic cholelithiasis from kid-
ney transplantation (1A).
 16.6 Inflammatory bowel disease
 16.6.1: Delay kidney transplantation in candidates 
with active symptomatic inflammatory 
bowel disease (Not Graded).
 16.6.1.1: Determine timing of transplanta-
tion for such patients in consul-
tation with a gastroenterologist 
(Not Graded).
 16.6.2: We recommend screening for bowel cancer 
in candidates with inflammatory bowel dis-
ease as per local guidelines (1C). (Same as 
Rec 11.1.5)
 16.6.3: We recommend not excluding candidates 
with a history of inflammatory bowel dis-
ease from kidney transplantation (1D).
 16.7 Liver disease
 16.7.1: Screen kidney transplant candidates for 
liver disease with a total bilirubin, alanine 
aminotransferase, international normalized 
ratio, and albumin (Not Graded).
 16.7.2: Delay kidney transplantation until acute 
hepatitis, of any cause, has resolved and a 
long-term strategy for managing liver dis-
ease has been implemented (Not Graded).
 16.7.3: We recommend that candidates with cir-
rhosis or suspected cirrhosis be referred 
to a specialist with expertise in combined 
liver-kidney transplantation for evaluation 
(1B).
 16.7.3.1: We recommend that patients 
undergo isolated kidney trans-
plantation if deemed to have com-
pensated cirrhosis after specialist 
evaluation (1B).
 For liver disease associated with HBV or HCV 
infection, see Sections 10.5.2 nd 10.5.3
 16.7.4: We recommend screening for hepatocellu-
lar carcinoma in candidates with cirrhosis 
prior to transplantation using techniques 
(eg, ultrasound, alpha-fetoprotein) and fre-
quency as per local guidelines (1C). (Same 
as Rec 11.1.4)
RATIONALE
Purpose of the evaluation
 • To provide an accurate assessment of the risk factors for 
perioperative morbidity and post-transplant complica-
tions related to gastrointestinal organs
 • To determine the severity of the comorbid gastrointesti-
nal conditions as a contraindication to transplantation
Peptic ulcer disease is the most common post-transplant 
gastrointestinal complication.477,478 One study conducted 
in the 1990s reported a 3.7% incidence of post-trans-
plant peptic ulcer disease, including 1.3% with serious 
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complications (1.0% bleeding and 0.3% perforation).477 
Peptic ulcer disease was present in 16.9% of patients in 
a post-transplant esophagogastroduodenoscopy (EGD) 
study, which was 1.7-fold higher than that of the general 
gastroenterology patients.477,478 Although the incidence 
and severity of peptic ulcer disease after kidney transplan-
tation has been reduced,479,480 treatment of active peptic 
ulcer disease and eradication of H. pylori infection prior to 
transplantation is recommended. These recommendations 
are based on the relatively higher incidence of early post-
transplant peptic ulcer disease, which is often serious and 
requiring surgical treatment.28,89,481
There is little evidence to support pre-transplant H. pylori 
screening for all transplant candidates. Observational stud-
ies have reported a 20% to 60% prevalence of H. pylori 
in kidney transplant candidates, which is similar to rates 
found in the general population.478 Eradication of H. pylori 
has been shown to significantly reduce the incidence of 
post-transplant peptic ulcer disease and mucosa-associated 
lymphoid tissue (MALT) lymphoma.481,482 However, the 
association of pre-transplant H. pylori with the occurrence 
of peptic ulcer disease within the first year post-transplant 
has not been proven.478,483
Post-transplant immunosuppression leads to an 
increased risk of colonic perforation and may mask typical 
signs and symptoms of diverticulitis.484 As such, evalua-
tion for diverticulosis and consideration of pre-transplant 
partial colectomy have been previously recommended.89 
However, a recent systematic review found that the inci-
dence of post-transplant diverticulitis (0.8%) and compli-
cated diverticulitis (1%) were both relatively low.485 These 
incidence rates do not support routine screening for diver-
ticulosis and pre-transplant colectomy in kidney trans-
plant candidates. Moreover, there is a lack of evidence for 
prophylactic colectomy and elective resection is not totally 
benign with a reported mortality rate of 1.9% and a major 
complication rate of 25%.486
Post-transplant acute pancreatitis is relatively uncom-
mon (1 to 2%) but is associated with an increased risk 
for both local complications and death.487 There is no evi-
dence to support the routine pre-transplant evaluation of 
the pancreas in asymptomatic patients. However, patients 
with a history of pancreatitis should be evaluated for tra-
ditional risk factors (eg, gallstones, hyperlipidemia) and, 
if present, manage these prior to transplantation. There 
are limited data on when to proceed with transplanta-
tion after an episode of acute pancreatitis but 3 months 
seems reasonable to prevent an early recurrence. In the 
case of chronic pancreatitis, patients should be stable and 
exocrine insufficiency symptoms should be managed with 
pancreatic enzyme replacement therapy.
Cholecystectomy for transplant candidates with asymp-
tomatic cholelithiasis is a controversial issue. The inci-
dence of post-transplant emergency cholecystectomy (1%) 
and mortality (1%) are low. Observational studies have 
not definitively shown benefit of elective, pre-transplant 
cholecystectomy on post-transplant morbidity or mor-
tality.488–491 Prophylactic cholecystectomy for selective 
high-risk patients (eg, older, obese, previous gallstone pan-
creatitis) could be considered, although supportive data 
are lacking.492,493
Approximately 30% of patients with inflammatory 
bowel disease will develop an acute exacerbation following 
transplantation.494 In a liver transplant study, active inflam-
matory bowel disease at the time of transplant was a risk 
factor for a post-transplant flare of disease activity.495 The 
use of tacrolimus might be a risk factor for inflammatory 
bowel disease relapse, although the causal relationship is 
unclear.496–498 Anti-tumor necrosis factor therapy is now 
an option for transplant patients with inflammatory bowel 
disease who previously were treated with escalating doses 
of steroid.499 Inflammatory bowel disease is a major risk 
factor for the development of colorectal cancer.500 As such, 
virtually all major societies and guidelines recommend 
screening for bowel cancer in patients with inflammatory 
bowel disease.501–503 Given the added risk of cancer with 
immunosuppression, it seems appropriate to also screen 
kidney transplant candidates with inflammatory bowel 
disease for colorectal malignancies.
The decision to proceed with isolated kidney transplan-
tation or combined liver-kidney transplantation in the 
setting of liver disease and CKD is complex and practice 
is highly variable worldwide. Discussion of the merits of 
combined organ transplantation is beyond the scope of the 
guideline. We have, however, recommended the involve-
ment of specialists with expertise in combined liver-kidney 
transplantation for evaluation of patients with known or 
suspected cirrhosis. This recommendation follows stand-
ard clinical practice in most regions of the world. Although 
there are exceptions, most transplant candidates with-
out decompensated cirrhosis or severe portal hyperten-
sion can safely and successfully undergo isolated kidney 
transplantation.504
What prior guidelines recommend
Both the AST and the CST evaluation guidelines suggest 
that patients with a prior history of peptic ulcer disease 
be considered for screening with EGD.28,29 We have rec-
ommended against this practice as there is no evidence to 
support EGD in the absence of symptoms.
The AST evaluation guidelines suggest that diabetic 
patients be screened for cholelithiasis and offered a pre-
transplant cholecystectomy if gallstones are found.28 We 
have recommended against routine screening and prophy-
lactic cholecystectomy for all patients except those with a 
history of cholecystitis. This recommendation is based on 
the relatively low incidence of post-transplant acute chol-
ecystitis and the lack of measurable impact of prophylactic 
cholecystectomy on clinical outcomes.
The CST guidelines suggest that patients with a history 
of diverticulitis be evaluated and considered for partial 
colectomy before transplant.29 We have advised against 
this practice. Similar to cholecystectomy, there is little sup-
porting evidence that prophylactic colectomy alters the 
post-transplant course in patients with diverticulitis or 
diverticulosis.
The CST guidelines recommend a 6-month remission 
period following acute pancreatitis and a 12-month remis-
sion for those with chronic pancreatitis before proceeding 
with transplantation.29 These recommendations were based 
on expert opinion at the time of publication in 2005. Given 
improvements in overall medical care for pancreatitis and 
the known benefits of kidney transplantation, we have sug-
gested only a 3-month wait following acute pancreatitis. 
Similar to the CST guideline, this recommendation is based 
on expert opinion with little supporting evidence.
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Similar to our recommendations, the UK Renal 
Association guideline23 suggests that there is no evidence 
to support routine screening for diverticular disease, pep-
tic ulceration or gallbladder stones in asymptomatic trans-
plant candidates but makes no mention of liver disease. 
The KHA-CARI evaluation guideline and the ERA-EDTA 
evaluation guideline do not specifically address issues 
related to the gastrointestinal system or liver disease with 
the exception of viral hepatitis.27,77
RESEARCH RECOMMENDATION
 • Future studies should determine the incidence of post-
transplant diverticulitis among those with at least one 
episode of diverticulitis prior to transplantation.
SECTION 17: HEMATOLOGIC DISORDERS
 17.1: We recommend not routinely screening for throm-
bophilia in candidates (1C).
 17.1.1: We suggest screening for thrombophilia 
only in candidates who have experienced 
a venous thromboembolic event, recurrent 
arteriovenous access thromboses, non-ath-
erosclerotic arterial thrombosis, or family 
history of venous thromboembolism to 
identify candidates at higher risk of graft 
thrombosis (2C).
 17.2: We suggest testing for antiphospholipid antibod-
ies (APLAs) in patients with systemic lupus erythe-
matosus or features of antiphospholipid syndrome 
(APS) (2C).
 17.3: Candidates should not be excluded from consid-
eration for kidney transplantation because of their 
need for anticoagulation, antiplatelet therapy or a 
history of HIT (Not Graded). [same as Rec 7.4]
 17.3.1: Single antiplatelet agents (eg, aspirin, clopi-
dogrel, ticagrelor) can be continued while 
waiting for deceased donor transplant (Not 
Graded). [same as Rec 7.4.1]
 17.3.2: Delay transplantation for the mandated 
period of treatment with dual antiplatelet 
therapy (eg, aspirin plus clopidogrel) when 
the risk of stopping medication (eg, stent 
thrombosis) or operating while on treat-
ment (eg, surgical bleeding) exceeds the 
anticipated benefit of transplantation (Not 
Graded). [same as Rec 7.4.2]
 17.3.2.1: Antiplatelet agents (except aspi-
rin) should be stopped 5 days 
prior to living donor transplan-
tation (unless cessation is con-
traindicated) and during the 
perioperative period for deceased 
donor transplantation (Not 
Graded). [same as Rec. 7.4.2.1]
 17.3.3: Do not transplant patients on direct-acting 
oral anticoagulants (DOACs; eg, apixaban, 
rivaroxaban) except when there is specific 
expertise using DOACs perioperatively 
and access to DOAC reversal agents (Not 
Graded). [same as Rec 7.4.3]
 17.3.3.1: Switch to an alternative anti-
coagulant (eg, warfarin) prior 
to waitlisting or living donor 
transplantation if recommended 
by a thrombosis expert/hema-
tologist or if there is no expertise 
using DOACs perioperatively or 
access to DOAC reversal agents 
(Not Graded). [same as Rec. 
7.4.3.1]
 17.3.4: Use non-heparin based agents for periop-
erative anticoagulation in candidates with 
a history of HIT (Not Graded). [same as 
Rec. 7.4.4]
 17.4: Evaluate transplant suitability of patients with 
significant cytopenias based on cause and severity 
(Not Graded).
 17.5: We recommend that candidates with sickle cell dis-
ease or thalassemia not be excluded from kidney 
transplantation [see sections on recurrent disease: 
Section 9.19: sickle cell disease] (1C).
17.6  Monoclonal gammopathy of undetermined signifi-
cance (MGUS)
 17.6.1: We suggest not excluding candidates with 
MGUS from kidney transplantation; 
however, a higher risk of post-transplant 
lymphoproliferative disease and other 
hematological malignancies should be con-
sidered and discussed with candidates (2D).
 17.6.2: We suggest not excluding candidates with 
smouldering multiple myeloma from kid-
ney transplantation; however, a significant 
risk of transformation into multiple mye-
loma should be considered and discussed 
with candidates (2D).
 17.6.3: We recommend careful evaluation of candi-
dates with MGUS for other types of plasma 
cell disorders prior to kidney transplanta-
tion (1D).
 17.7 Acute leukemia and high-grade lymphoma, includ-
ing post-transplant lymphoproliferative disease 
(Same as Section 11.3.1)
 17.7.1: Avoid transplanting patients with leuke-
mia or lymphoma until they have received 
curative therapy, achieved remission 
and remained cancer free for a period to 
be determined in consultation with the 
patient, a hematologist/oncologist and the 
transplant program (Not Graded).
 17.8 Myelodysplasias, chronic leukemia and chronic/
low-grade lymphoma (Same as Section 13.3.2)
 17.8.1: Decisions about kidney transplantation 
in patients with myelodysplasia should be 
made in collaboration with a hematologist 
(Not Graded).
 17.8.2: Advise consultation with a hematologist 
with transplant experience in determining 
transplant candidacy since many lesions 
may be deemed to be at high risk of accel-
erated progression or transformation post-
transplant (Not Graded).
 17.9: Decisions about kidney transplantation in patients 
with a prior history of hematological malignancy 
who are now in remission should be made in col-
laboration with a hematologist (Not Graded). 
(Same as Rec 11.3.3)
RATIONALE
Arterial or venous thrombosis represents an important 
cause of early graft loss, leading to loss of approximately 
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2% of grafts.505 There are inherited and acquired risk 
factors that predispose to thrombosis. Inherited factors 
include Factor V Leiden (FVL), prothrombin variants and 
deficiencies in antithrombin III and Protein C or S with 
acquired defects including APS and hyperhomocysteine-
mia. FVL is most common and can be found in 5-8% 
of European populations, 20% of patients who have a 
thrombotic episode and up to 50% of patients with recur-
rent thromboses, and FVL is associated with a 4-fold 
increased risk of graft vein thrombosis.506,507 Although 
other inherited deficiencies are reported to increase 
thrombotic risk, data definitively linking them to graft 
thrombosis is lacking.
Low-titer APLAs are found commonly in healthy popu-
lations and more commonly in ESKD populations. They 
are found in 10-26% of patients with a clinical thrombosis 
and in up to 50% of patients with systemic lupus erythe-
matosus. The outcome of transplantation in patients with 
APS (as opposed to APLAs without clinical manifestations) 
is poor with 100% graft loss reported in one study without 
anticoagulation.508 However, in patients without clinical 
manifestations, APLAs did not predict graft thrombosis. 
Other acquired risk factors for thrombosis are common 
in the ESKD population, for example hyperhomocysteine-
mia, acquired protein C and S deficiency, but their impact 
on graft thrombosis is unknown.
Screening all candidates for thrombophilia is likely to 
have a high false-positive rate and may lead to unneces-
sary use of perioperative anticoagulation and higher risk 
of bleeding. There is insufficient evidence for untargeted 
screening and it is therefore not recommended (Summary 
Table and Evidence Profile: Thrombophilia testing). 
Screening patients with a history of venous, arterial or dial-
ysis access thrombosis, particularly if recurrent, features of 
APS or a family history of recurrent thrombosis is more 
likely to identify clinically significant thrombophilia and is 
the approach suggested. Screening should include coagula-
tion tests (activated partial thromboplastin time and pro-
thrombin time), FVL, prothrombin variants, Protein C and 
S, antithrombin III and APLAs/anticardiolipin. This will 
allow use of anticoagulation in candidates most at risk of 
graft thrombosis. This strategy is anecdotal however, with 
current evidence being sparse and inconsistent.509–511
CAD is common in kidney transplant candidates and 
may have been treated with drug-eluting stents. Dual anti-
platelet therapy is frequently used in this situation, com-
bining aspirin with a P2Y12 inhibitor such as clopidogrel, 
ticagrelor and prasugrel.512 There is a risk of in-stent 
thrombosis if antiplatelet therapy is discontinued before 
full stent endothelialization. Continuing dual therapy will 
increase the risk of perioperative bleeding. There are dif-
ferent considerations for a living donor, when the date of 
transplant is known, and a deceased donor transplant, 
which would require the candidate to be off dual anti-
platelet therapy for longer periods. Newer P2Y12 inhibi-
tors with shorter duration of action may provide greater 
flexibility. The complex balance of risk and benefit to the 
transplant candidate requires careful consideration by 
a multidisciplinary team involving transplant surgeons, 
hematologists and cardiologists.405
The ESC recommends avoiding elective surgery in patients 
on dual antiplatelet therapy for the mandated period of 
treatment, usually 6 months for stable CAD or 12 months 
for acute coronary syndrome.513 When surgery is being con-
sidered in transplant candidates on aspirin and clopidogrel, 
standard advice is to withdraw clopidogrel more than 
5 days prior to surgery. Testing platelet function may allow 
a shorter period of withdrawal.513 Withdrawal of ticagre-
lor for 5 days and prasugrel for 7 days is recommended.513 
Aspirin should be continued through the procedure.
Oral anticoagulation with the vitamin K antagonist 
warfarin is not a contraindication to transplantation as 
the effect can be reversed. Direct thrombin inhibitors are 
difficult to reverse, not licensed for use in CKD G4 or G5 
in many jurisdictions and we suggest they should generally 
be avoided in candidates awaiting transplantation.
Significant cytopenias require investigation and the 
impact on kidney transplantation depends on the cause 
and severity. Myelodysplastic syndromes have the poten-
tial to progress to hematological malignancy. The risk of 
this transformation should be considered prior to kid-
ney transplantation in consultation with a hematologist. 
Specific considerations are required when transplanting 
patients with sickle cell disease.294 Patients with forms 
of thalassemia who develop ESKD can be considered for 
transplantation.
MGUS is a pre-cancerous state preceding multiple mye-
loma. The prevalence in kidney transplant candidates var-
ies between 1-5%. It is characterized by the presence of < 
3 g/dl monoclonal protein in the serum and bone marrow 
involvement by less than 10% of plasma cells.514 Systemic 
involvement such as lytic bone lesions, anemia, hypercal-
cemia and kidney dysfunction is not present in MGUS.514 
The risk of disease progression to multiple myeloma has 
been reported to be approximately 1-1.5% annually. The 
main risk factors for progression to multiple myeloma 
include a non-IgG isotype, an M protein concentration of 
more than 15 g/l and an abnormal serum free-light-chain 
ratio.
Smouldering multiple myeloma (also termed smoul-
dering myeloma) follows the next stage of MGUS in the 
spectrum of plasma cell dyscrasias. While it is considered 
a pre-malignant condition, the risk of progressing to mul-
tiple myeloma is higher than candidates with MGUS, and 
ranges between 8-10% within the first 5 years of diagno-
sis, but tapers to approximately 3% annually thereafter. 
The standard care for patients with smouldering multiple 
myeloma is regular monitoring without treatment, until 
progression to multiple myeloma. However, the manage-
ment for candidates with smouldering multiple myeloma 
and renal lesions is less well-defined. Guidelines from the 
International Myeloma Working Group suggest candidates 
with smouldering multiple myeloma and renal lesions 
should not be regarded as having myeloma defining events 
and do not warrant immediate myeloma treatment.515 
Currently, there is no consensus regarding the definitive 
treatment strategies for these patients. However, it would 
not be unreasonable to adopt similar treatment strategies 
as for candidates with monoclonal gammopathy of renal 
significance prior to kidney transplantation to prevent dis-
ease recurrence in the allograft and malignant transforma-
tion into multiple myeloma.516
The risk of transformation from these pre-malignant 
conditions into multiple myeloma after kidney trans-
plantation is uncertain. The current evidence is limited to 
observational data, with short follow-up time, small events 
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rates, and single center studies of retrospective designs. 
There is no conclusive evidence to suggest an increased 
risk of disease progression to multiple myeloma com-
pared to those without MGUS.517 However, some have 
suggested an increased risk of monoclonal B cell lympho-
cytosis and post-transplant lymphoproliferative disease 
among those who have MGUS prior to transplantation.518 
Observational data also suggested no differences in the 
overall risk of graft and patient survival and other com-
plications such as infection between potential candidates 
with and without MGUS, but the certainty of the evidence 
of low518 (Summary Tables: MGUS; Study Limitations).
It is in the Work Group’s opinion that patients with 
acute leukemia and high-grade lymphomas should 
avoid transplantation until the potential candidate has 
received potentially curative therapy, achieved remission, 
and remained cancer free for a period to be determined 
in consultation with the patient, treating hematologist/
oncologist and the transplant program. For patients with 
myelodysplasias, chronic leukemia and chronic/low-grade 
lymphomas, the Work Group advises consultation with a 
hematologist with transplant experience in determining 
transplant candidacy since many lesions may be deemed to 
be at high risk for accelerated progression or transforma-
tion post-transplant.
What prior guidelines recommend
The CST guideline also considers thrombophilia and rec-
ommends that this is not a contraindication to transplan-
tation.29 There is also agreement that routine screening for 
thrombophilia, in the absence of a history of thrombotic 
events, is not required. Previously published guidelines 
have not considered patients on either dual antiplatelet 
or direct acting oral anticoagulant therapy, reflecting the 
more recent introduction of some of these agents. Similar 
to the CST guideline, we recommend evaluation of patients 
for the cause of cytopenia. We are in agreement with the 
AST guideline28 with regards to sickle cell disease and with 
KHA-CARI27 with regard to MGUS. Thalassemia is not 
considered in the other guidelines.
For patients with high grade lymphoma, leukemia and 
post-transplant lymphoproliferative disease, the KDIGO 
guideline states that transplantation be avoided until the 
patient has been cancer free for a period of determined 
duration following discussion with the patient and the 
hematology/oncology team. In contrast, other guidelines 
have suggested a definitive period (2 years for CST,29 KHA-
CARI27 and AST guidelines28 and 1-3 years for European 
Renal Best Practice143). The difference in guidance reflects 
the changes in treatment and prognosis in this patient 
group and emphasizes the need for a multidisciplinary 
approach. Most of other chronic hematologic disorders 
are not generally considered in other published guidelines.
RESEARCH RECOMMENDATIONS
 • Future research should identify the best strategy for 
anticoagulation in the peri-operative period to minimize 
bleeding or thrombotic events in patients who are iden-
tified at an increased risk of graft thrombosis.
 • The increasing use of DOACs in patients with 
advanced kidney disease has significant implications for 
transplantation. Future research should address whether 
the use of DOAC reversal, when available, prior to 
transplantation is a safe strategy to permit DOAC use in 
ESKD patients on the transplant waiting list.
 • The length of time required after the successful treat-
ment of a hematological malignancy and kidney trans-
plantation is not known for many cancer types. More 
research is required to understand how newer cancer 
treatment strategies will affect the time a patient should 
wait, balancing risk of earlier transplantation with the 
increased morbidity and mortality associated with dial-
ysis treatment.
RELEVANT SUPPLEMENTAL MATERIAL
Summary table: Thrombophilia
Summary table: Thrombophilia (quality assessment)
Evidence profile: Thrombophilia testing
Summary table: MGUS
Summary table: Study Limitations (MGUS and non-MGUS)
SECTION 18: BONE AND MINERAL METABOLISM
 18.1: Measure serum parathyroid hormone (PTH) at the 
time of transplant evaluation (Not Graded).
 18.2: We suggest not transplanting patients with severe 
hyperparathyroidism until they are adequately 
treated (medically or surgically) as per KDIGO 
Chronic Kidney Disease-Mineral and Bone 
Disorder (CKD-MBD) guideline (2D).
 18.3: Bone mineral density (BMD) should not be meas-
ured as part of the transplant evaluation (Not 
Graded).
BACKGROUND
Most patients with advanced CKD have disorders of 
bone and mineral metabolism to some extent. Studies 
showed that up to 30% of bone mineral density (BMD) 
is lost within the first six months after kidney transplan-
tation.519,520 Recent studies have shown that despite this 
persistent decrease in BMD, trabecular microarchitec-
ture remains normal in long-term transplant recipients 
suggesting that there is bone recovery occurring late 
post-transplantation.521
No intervention has been proven to prevent fractures 
after transplantation. Thus, prevention of bone loss is of 
key importance in this population. The overriding risk 
for fractures can be appreciated from large registry data. 
Recent data from Canada suggest that kidney transplant 
recipients have a 10-year cumulative incidence of hip frac-
ture of approximately 2%, which is lower than previously 
reported.522 The same group, however, previously reported 
in a systematic review that the 5-year cumulative incidence 
for fracture varied from 0.9% to 27%.523 American regis-
try data showed that the median 5-year fracture rate was 
23%.524 The variability in reported fracture rate suggests 
that individual parameters such as age, gender, dialysis vin-
tage and immunosuppressive regimen, have a substantial 
impact on fracture occurrence. Preventive measures of bone 
disease and fractures after kidney transplantation include 
interventions such as vitamin D, bisphosphonates, deno-
sumab and calcitonin. However, the preferred intervention 
and timing of intervention have yet to be determined.525
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RATIONALE
 • Kidney transplantation causes considerable bone loss 
within the first months after transplantation.
 • Most patients evaluated for transplantation already 
have a reduced BMD.
 • Risk factors for bone loss and fracture included age, 
sex, frailty, previous fractures, hyperparathyroidism and 
cumulative steroid exposure.
 • Post-transplant interventions for prevention of bone 
loss/fracture include vitamin D, bisphosphonates, deno-
sumab and calcitonin which should be used according 
to individual risk.
 • Pre-transplant measurement of BMD does not help in 
decision-making regarding the use of post-transplant 
preventative therapies.
 • Severe hyperparathyroidism needs to be treated before 
transplantation.
Access to transplantation
All patients with progressive CKD suffer from some degree 
of mineral and bone disorder (CKD-MBD). Treatment of 
the original kidney disease with steroids, dialysis vintage as 
well as previous transplants are key risk factors for CKD-
MBD. After transplantation, the complexity of bone disease 
increases further due to immunosuppression.526 Bone disor-
ders in transplant candidates are complex and span the whole 
spectrum from high-turnover to adynamic bone disease.
In general, serum biomarkers of bone turnover in 
patients with advanced CKD or on dialysis have low diag-
nostic accuracy when compared to the gold standard of 
bone histology on biopsy.527 Nevertheless, intact parathy-
roid hormone (PTH) is determined at routine intervals in 
most CKD patients because values in the extremes, when 
used in combination with alkaline phosphatase, poten-
tially help to guide treatment decisions before transplanta-
tion. As per recent KDIGO CKD-MBD update,528 patients 
requiring PTH-lowering therapy should first receive medi-
cal therapy in the form of calcimimetics, calcitriol, or vita-
min D analogs. Patients who fail to respond to medical 
therapy should undergo parathyroidectomy before trans-
plantation. Several reports have shown worsening kidney 
function if parathyroidectomy is performed after trans-
plantation,529,530 however, this finding has not been uni-
versal.531 Patients with adynamic bone disease represent 
an even more challenging population because no inter-
vention has been shown to be effective. Small studies on 
the use of recombinant PTH for this indication, either on 
dialysis or after transplantation, were inconclusive.532,533
What prior guidelines recommend
Prior 2013 guidelines from KHA-CARI do not specifi-
cally address the topic of bone and mineral metabolism as 
a part of recipient assessment prior to transplantation.27
The AST evaluation guideline suggests measuring serum 
calcium, phosphorus, and PTH as part of the pre-trans-
plant evaluation. They also recommend pretransplant par-
athyroidectomy for patients with symptomatic secondary 
hyperparathyroidism.28 The 2009 KDIGO guideline on 
the management of the kidney transplant recipient does 
not make any recommendations regarding bone and min-
eral metabolism in the transplant candidate.30 Similarly, 
the recent 2017 KDIGO Clinical Practice Guideline update 
for the diagnosis, evaluation, prevention, and treatment of 
CKD-MBD do not have a specific bone disease recommen-
dations for transplant candidates.528
The 2005 CST consensus guideline on eligibility for kid-
ney transplantation suggests that calcium, phosphorus and 
PTH levels should be measured as part of the pre-transplant 
evaluation (Grade A) and that parathyroidectomy should 
be considered for those who have failed medical manage-
ment or have severe, persistent complications of hyperpar-
athyroidism (Grade B).29 The ERA-EDTA recommended in 
2013 that a deceased donor allograft should not be refused 
only because of uncontrolled hyperparathyroidism in the 
recipient (Level 1D).77 The UK Renal Association and the 
British Transplant Society have no specific directions on 
bone and mineral disease in their 2011 guidelines about the 
assessment of the potential kidney transplant recipient.23
RESEARCH RECOMMENDATIONS
 • An adequately powered RCT should be conducted to 
examine the effect of teriparatide (recombinant PTH) 
on BMD and fracture risk in transplant candidates with 
adynamic bone disease.
 • A large, multicenter cohort study should be conducted 
to examine the association between pre-transplant PTH 
level and clinically important post-transplant outcomes.
SECTION 19: IMMUNOLOGICAL ASSESSMENT
 19.1: Communicate all sensitizing events (eg, blood 
product transfusion, including platelets, pregnancy 
or miscarriage) or clinical events that can impact 
panel reactive antibody (PRA) (eg, vaccination, 
withdrawal of immunosuppression, transplant 
nephrectomy, significant infection) to the human 
leukocyte antigen (HLA) laboratory (Not Graded).
 19.2: Perform HLA antibody testing at transplant evalu-
ation, at regular intervals prior to transplantation 
and after a sensitizing event or a clinical event that 
can impact PRA (Not Graded).
 19.3: We recommend that HLA antibody testing be per-
formed using solid phase assays (1B).
 19.4: We recommend HLA typing of candidates at eval-
uation using molecular methods, optimally at all 
loci (1D).
 19.5: We suggest not routinely testing candidates for 
non-HLA antibodies (2C).
 19.6: We suggest not routinely testing candidates for 
complement-binding HLA antibodies (2C).
 19.7: We suggest informing candidates about their 
access to transplantation based on blood type and 
histocompatibility testing results (2C).
 19.7.1: We recommend offering candidates with 
immunologically-reduced access to transplant 
access to a larger deceased donor pool, kidney 
exchange programs, and/or desensitization 
(1C).
 19.7.2: We suggest that antibody avoidance (eg, 
kidney exchange programs or deceased 
donor acceptable mismatch allocation) be 
considered before desensitization (2C).
BACKGROUND
Sensitizing events including pregnancy, blood transfu-
sion and prior transplant can lead to the formation of 
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HLA antibodies in transplant candidates. These antibod-
ies, depending on donor HLA typing and donor poten-
tial, may significantly limit a candidate’s access to donors. 
The goal of HLA testing during candidate evaluation and 
while waitlisted is to estimate the risk of reduced access to 
potential donors based upon HLA antibodies/HLA typing. 
In addition, up-to-date testing will ensure the ready avail-
ability of the necessary recipient information required to 
facilitate allocation, perform transplant decision making 
and donor-recipient immunologic risk assessment at the 
time of transplant. This section contains clinical recom-
mendations for histocompatibility testing, basic technical 
interpretation and actions as they relate to immunologic 
risk assessment of the potential transplant recipient during 
workup and while waitlisted. The spectrum of potential 
use of the testing results in allocation and transplant deci-
sion making, as well as HLA testing for potential kidney 
donors, are beyond the scope of this guideline. HLA testing 
of living and deceased donors, testing to guide allocation 
or the interpretation of the testing for specific donor-recip-
ient transplant decision making or risk assessment are out-
side of the scope of this guideline.
Definitions
 • HLA antibody: Any antibody to any HLA antigen or 
allelic variant of an antigen
 • PRA: Panel reactive antibody, the presence of any detect-
able HLA antibody
 • cPRA: Calculated PRA, an estimate of the percentage of 
donors in a population to whom a transplant candidate 
has at least one HLA antibody specificity directed
RATIONALE
Sensitizing events (blood product transfusions includ-
ing platelets, pregnancy/miscarriage, and prior transplant) 
as well as clinical events that can impact PRA (including 
vaccination, significant infection, withdrawal of immuno-
suppression/non adherence and nephrectomy) should be 
communicated to the HLA laboratory in a timely fash-
ion.534–543 A sensitization history is essential for HLA 
laboratory staff to interpret testing results where antibody 
levels can be dynamic over time and not always captured 
with PRA testing while on the waitlist. Documenting and 
reporting a reliable clinical history is an ungraded recom-
mendation as there are no specific studies addressing the 
impact of this practice; however it is low cost, of high ben-
efit, and universally accepted as necessary for good clini-
cal practice. Equally importantly, patients with a history 
of a sensitizing event, even without circulating HLA anti-
bodies detected, should be considered as having potential 
for memory responses after transplant.544–546 As such, the 
immunologic history is also critical for perioperative man-
agement of patients.
A precise recommendation for the optimal frequency of 
HLA antibody testing cannot be made. Laboratories often 
use their own data to determine the stability of patient 
results over time to then inform the recommended test-
ing frequency in their unique populations and best iden-
tify humoral alloreactivity and potential for memory 
responses. Protocols widely in use vary in testing frequency 
from 4 to 24 weeks to have greater reassurance that test 
results used in allocation (eg, virtual crossmatching, donor-
specific antibody [DSA] assessment) are representative of 
the patient`s immunologic state at the time of transplant. 
The Work Group acknowledges that both fiscal and clini-
cal considerations (eg, history reliably negative for sensi-
tizing events, whether HLA antibody specificity is used to 
guide allocation) may reduce the frequency of testing with-
out clinical impact in certain settings. This recommenda-
tion for testing frequency is made with the intent that the 
clinical team liaise with their respective laboratories about 
the testing frequency that can be supported at their site, 
which would provide adequate immunologic risk assess-
ment for a given patient. Indeed, testing frequency may 
also vary between patients at a given center depending on 
the relevant clinical circumstances. Additional testing after 
interval sensitizing events is recommended in all patients 
to accurately document de novo as well as memory 
responses which may in some cases be transient and not 
readily detectable at the time of the next routinely schedule 
clinical test. De novo HLA IgG antibodies may take up 
to 6 weeks to form, whereas memory responses can occur 
within 7-14 days. The timing of testing after a sensitizing 
event may be sooner than six weeks depending on clinical 
need. Where financial considerations may prevent regular 
testing, we encourage a baseline test and repeat testing 2 
to 6 weeks after sensitizing events. Where live donors and 
recipients are reliably shown to be HLA identical at all 
loci, testing may also be reduced without impacting clini-
cal risk assessment.
There are two basic assays for detecting HLA antibod-
ies: cytotoxic and solid phase. In the former, serum from 
the recipient is mixed with a panel of cells derived from a 
population that is immunogenetically comparable to the 
donor population of interest. The proportion of different 
cells lysed in the presence of complement estimates the per-
centage of donors in the population to whom the recipient 
would be expected to have cytotoxic DSA. These assays 
are both insensitive547–549 (i.e., can miss clinically relevant 
low level antibody including antibodies to HLA-C550 and 
DP551–554 antigens) and non-specific, with frequent false 
positive results due to irrelevant IgM or non-HLA anti-
bodies.555,556 Conversely, solid phase assays are engineered 
to specifically detect HLA antibodies and are significantly 
more sensitive ensuring lower level and other clinically 
relevant antibodies are not missed.547–554,556–562 Although 
far more specific than cytotoxic assays, recent data sug-
gest that some non-specificity may occur with solid phase 
assays as well.563,564 Furthermore, where resources per-
mit the use of single antigen bead assays, full delineation 
of antibody specificities should be performed. This will 
permit the calculation of a cPRA and a list of antibody 
specificities can be compiled for comparison to all future 
potential donors.565,566
Notwithstanding regulatory requirements of any par-
ticular jurisdiction, complete HLA typing by molecular 
methods is optimal for interpreting HLA antibody results 
and describing donor-recipient mismatch with chronic 
rejection, de novo DSA and graft loss. At a minimum, typ-
ing should be completed at loci required to interpret any 
detectable HLA antibodies (i.e., corresponding to the loci 
of the detected antibody). Optimally, HLA typing should 
be completed at all loci (HLA-A, B, C; DRB1, 3, 4, 5; 
DQA1, DQB1; DPA1, DPB1).
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Serologic (cell-based complement dependent) methods 
of HLA typing do not provide sufficient resolution to adju-
dicate allele-specific HLA antibodies as DSA, nor to reli-
ably and routinely identify antigens from HLA-C, DQA, 
DPA1 and DPB1. There are increasing data that antibod-
ies to these loci may also be deleterious after transplant, 
requiring that they be fully characterized in recipients; this 
will provide a robust antibody analysis as well as quantify 
mismatches with future donors.550–554,567,568 Although no 
direct comparisons have been made with serologic test-
ing, studies using molecular methods for HLA typing have 
identified more meaningful metrics associated with trans-
plant outcomes of interest including the ability to more 
specifically identify donor and recipient differences with 
the greatest immunologic relevance.569–575
Histocompatibility-based quantification of access to 
transplant lies at the complex intersection of breadth of 
sensitization (cPRA or PRA) to the local donor pool;576 
the absolute (not relative) number of ABO compatible 
deceased donors available; the allocation prioritization 
given to sensitized candidates; the HLA phenotypes and 
frequencies in the accessible donor population; the poten-
tial for living donors; and the access to specialty programs 
(eg, acceptable mismatch programs,577,578 prioritization 
for highly sensitized patients, kidney paired donation, 
desensitization). It is imperative to utilize a region’s own 
data to determine what level of cPRA (or equivalent) anti-
body metric is associated with reduced HLA-based access 
to transplantation.565,579,580 No specific PRA, cPRA or 
other equivalent local metric (such as calculated reaction 
frequency utilized in the UK) threshold should be defined 
as “highly sensitized” across different populations. HLA-
based access to transplant is indeed a continuum of risk 
and the cPRA level above which access is considered 
reduced must be considered not only in the context of 
the metric, but also wait times and waitlist mortality for 
a given degree of sensitization in the local region.581 We 
specifically note that cPRA (or equivalent) itself is not a 
measure of rejection risk. In regions where a DSA positive 
donor may be allocated, the cPRA is representative of an 
increased risk of having DSA whereas it is the presence of 
DSA that confers the immunologic risk.578,582,583 We also 
note the importance of race in HLA phenotype determina-
tion and allele frequency,584–587 and the resultant impor-
tance of cPRA (or equivalent metric) being determined in 
a population with comparable racial/HLA distribution to 
the recipient’s local donor population. Finally, we acknowl-
edge the importance of the loci included in the cPRA cal-
culator in determining the calculated value. It is imperative 
to include all loci where DSA at those loci would influence 
transplant decision-making as this will provide the best 
estimate of transplant access.566
Despite associations reported between non-HLA 
antibodies (eg, anti-angiotensin II type 1 receptor anti-
body,588–590 major histocompatibility complex class I chain-
related gene A (MICA) antibody,590–593 anti-endothelial 
antibodies594–596 and others), with rejection and or graft 
loss, the role of these antibodies independent of HLA anti-
bodies in identifying humoral risk pre-transplant remains 
controversial. We note that these antibodies may augment 
the effect of HLA DSA in some,589,597 but not all, patients. 
In patients where history or clinical status indicates that 
these antibodies may have clinical relevance, testing should 
be performed on a case-by-case basis. However, routine 
pre-transplant measurement of non-HLA antibodies can-
not be recommended.
Complement binding single antigen bead assays test 
for the presence of high titer anti-HLA IgG1 and IgG3 
antibodies capable of binding C1q or C3 in vitro, and 
are not a unique property of the antibody itself.598–600 
Complement-based assays do not accurately quantify anti-
body titer. Serum dilution can abrogate a positive assay 
and serum concentration can change a previously negative 
assay to positive.598 Additionally, the assay cannot account 
for variation in target antigen expression on endothe-
lium which may also impact complement activation in 
vivo. For all antibodies of unique specificity detected in a 
serum, the occurrence of isolated weak/non-complement-
binding HLA DSA is rare, estimated to be in the range 
of 1-5%.601–604 Readily available single antigen bead 
metrics (eg, mean fluorescent intensity after serum dilu-
tion) may also estimate complement binding capacity in 
many cases. Conflicting data exist as to the relationship 
between complement binding assay results and transplant 
outcomes.605–607 In the largest study to date608 pre-trans-
plant DSA conferred higher odds of graft loss compared to 
pre-transplant C1q assay positivity.598–609 For the reasons 
noted above, routine testing in all patients for complement 
binding HLA antibodies cannot be recommended with the 
current level of data, but may have a role in specific patient 
testing algorithms.
For transplant candidates in whom histocompatibility 
testing indicates a general reduction in transplant access 
(high cPRA or equivalent) or a specific barrier to a living 
donor (known DSA), offering increased access to a larger 
donor pool (eg, national or regional deceased donor shar-
ing or living kidney paired donation) is recommended to 
increase the chance of finding a DSA-negative donor. Indeed, 
such HLA antibody avoidance is associated with improved 
graft survival (comparable to unsensitized recipients) in 
comparison to transplantation with DSA present.610–622 
However, in those with very high cPRA or fewer absolute 
donors available in their jurisdiction, desensitization should 
be explored as an option to achieve transplantation.623–629 
Compared to remaining on dialysis, desensitization has 
been associated with improved patient survival in the US 
but not in studies from the UK; the role of desensitization 
must be considered in any region in the context of the com-
peting risks of additional time on dialysis to wait for a DSA-
negative organ.622,630 No specific desensitization protocol 
can be recommended based upon the available data; fac-
tors in success, regardless of protocol, are the ability of the 
patient to tolerate immunosuppression, antibody titer, and 
center experience. Desensitization with anti-B cell agents 
(eg, rituximab), proteasome inhibitors (eg, bortezomib), 
alone or in combination with other protocols, may increase 
transplant opportunities in the short term but, depending on 
antibody strength, can be associated with shortened long-
term survival.612,623,628,631,632 Therefore, antibody avoidance 
is still the preferred strategy where patient characteristics 
and available resources permit.
The KDIGO recommendations presented here are not 
intended to supplant or replace any local accreditation 
standards. The American Society for Histocompatibility 
and Immunogenetics (ASHI) Accreditation Standards 
should be consulted for those labs under its jurisdiction
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(http://www.ashi-hla.org/resource/resmgr/docs/
Standards/152017_CMS_Approved_2016_ASH.pdf).
The corresponding standards from European Federation 
of Immunogenetics may be found at:
h t t p s : / / e f i - w e b . o r g / f i l e a d m i n / u s e r _ u p l o a d /
Standardv6.3.pdf
For additional technical recommendations not 
included in this document, the reader is referred to the 
relevant sections of ASHI-AST STAR Guideline and The 
Transplantation Society 2013 Consensus Guideline for 
antibody testing and clinical management.633,634
What prior guidelines recommend
The most recent comparable guideline for HLA antibody 
testing are Consensus Guidelines on the Testing and Clinical 
Management Issues Associated with HLA and Non-HLA 
Antibodies in Transplantation.634 In comparison, the cur-
rent guidance provides specific recommendations as to the 
nature, frequency and implementation of testing specifi-
cally during workup and on the waitlist, and gives updated 
context for complement binding assay application. The for-
mer guidance recommended best practices, with the current 
guideline providing alternatives to best practices in certain 
circumstances, while being mindful of international differ-
ences in patient populations and resources.
RESEARCH RECOMMENDATIONS
 • Future research should determine the optimal frequency 
of testing on the waitlist in patients with different risks 
of sensitization.
 • Future research should determine at what resolution of 
typing is optimal in solid organ transplantation to best 
quantify donor and recipient mismatch and associated 
outcomes.
 • Future research should determine in which groups of 
waitlisted patients are non-HLA antibody tests of the 
greatest incremental benefit in predicting transplant 
outcomes.
ACKNOWLEDGMENTS
A special debt of gratitude is owed to the KDIGO 
Co-Chairs, Michel Jadoul and Wolfgang C. Winkelmayer, 
immediate past Co-Chair David Wheeler, and the KDIGO 
Executive Committee for their invaluable guidance 
throughout the development of this guideline. In particu-
lar, KDIGO thanks the ERT members for their substantial 
contribution to the rigorous assessment of the available 
evidence. KDIGO is also especially grateful to the Work 
Group members for their expertise throughout the entire 
process of literature review, meeting participation, the 
critical writing and editing of the statements and ration-
ale, which made the publication of this guideline possible. 
The generous gift of their time and dedication is greatly 
appreciated.
Finally, and on behalf of the Work Group, KDIGO 
gratefully acknowledges the careful assessment of the draft 
guideline by external reviewers. The Work Group consid-
ered all of the valuable comments made and, where appro-
priate, suggested changes were incorporated into the final 
publication. The following individuals provided feedback 
during the public review of the draft guideline:
Patricia Ferreira Abreu, Ahmed Alashker, Ala Ali, 
Bülent Altun, Cynthia Armistead, Mariano Arriola, Suheir 
Assady, Rasha Ata, Eric Au, Emir Avdić, Vinod Baburajan, 
Clive Banda, Willa Bandler, Peter Bárány, Rashad S. 
Barsoum, Rommel Bataclan, Kim Baunach, Irene Bellini, 
Ali Benziane, Carmen Bernis, Rahul Bhardwaj, Rajendra 
Bhimma, Allison Blagg, Danette Borg, Mohammad 
Bourini, Edwina A. Brown, Markus Burgmer, Kevin 
Burns, Scott Campbell, Antonio Cardoso, Valerie Cass, 
Pasqualina Cecere, John Chan, Rafia Chaudhry, Hicham 
I. Cheikh Hassan, Mary Chittenden, Rolando Claure-
Del Granado, Philip Clayton, Abraham Cohen-Bucay, 
Beatrice Concepcion, Giuseppe Conte, Cindy Cornell, 
Nick Cross, Helen Currier, Jan Davis, Pat Dennis, Arley 
Diaz, Fritz Diekmann, Ian Dittmer, Sine Donnellan, 
Mohammed Edrees, Edmar Elcarte, Magdy El-Sharkawy, 
Grant England, Riadh Fadhil, Stuart Flechner, Leeann 
Fox, Ross Francis, Eleni Frangou, Hideki Fujii, Daniel 
Gale, Alvaro Garcia, Valter Garcia, Michael J. Germain, 
Osama Gheith, Cara Giglia, Carlo Gochuico, Abdellatif 
Goda, Nelson Goes, Lisa Goodwin, Barbara Greco, 
Carmel Gregan-Ford, Siân Griffin, Paul C. Grimm, 
Shirley Grube, Mehmet Haberal, Karine Hadaya, Paul 
Harden, Jeff Harder, Kristen Hardy, Meera Harhay, Tess 
Harris, Niwrutti Hase, Clarissa Havel, Rebecca Hays, 
Domingo Hernández, Rachel Hilton, Katie Hodgson, 
Melanie P. Hoenig, Lai Seong Hooi, Dane Howard, Lee-
Anne Hyer, Christin Iroegbu, Nicole Isbel, Deeb Jabr, 
Tia Jackson, Elizabeth Jones, Kelly Jones, Nada Kanaan, 
John Kanellis, Dixon Kaufman, John Knorr, Hüseyin 
Koçak, Louis P. Kohl, Monica Kriete, Girish Kumthekar, 
Kelly Lambert, Darren Lee, Edgar V. Lerma, Wai Lim, 
Eduardo Lorca, Fiona Mackie, Magdy Maksy, Francesca 
Mallamaci, Nizam Mamode, Sreedhar A. Mandayam, 
Francesco Marchini, Stephen Marks, Roberto Ramirez 
Marmolejo, Gerson Marques, Carlos E. Marroquin, 
Loeffler Martha, Lauren Maston, Sebastian Maus, Neve 
Mazique-Bianco, Mignon McCulloch, Tom McDowell, 
Stella McGinn, Diane McRae, Martha Minteer, Eugen 
Mota, Robert Najem, Abdou Niang, Maurizio Nordio, 
Annel Ortiz, Alvaro Pacheco-Silva, Manzoor Parry, Katie 
Peoples, Mary Peterson, Stephen Pollard, Pradeep Kumar 
Rai, Natalie Reeves, Dayna Reidenouer, Cibele Isaac 
Saad Rodrigues, Juan Carlos Ruiz San Millán, Vicente 
Sanchez Polo, Ruth Sapir-Pichhadze, Dori Schatell, 
Morgan Scherer, Andrea Schlechty, Deepak Sharma, 
Gautam R. Shroff, Habib Skhiri, Maria Fernanda Slon 
Roblero, Bill Smith, Rachel Stephenson, Sudhir Thaduri, 
Maria Tomkins, Luis Trindade, Lara Tushla, Nicole van 
de Kar, Anna Vila Santandreu, Amanda Vinson, Theodôr 
Vogels, Talia Weinstein, David White, Simon Winther, 
Beth Witten, Rosnawati Yahya, Tracey Ying, Arunas 
Zelvys, Carmine Zoccali.
Participation in the review does not necessarily con-
stitute endorsement of the content of this report by the 
above individuals, or the organization or institution they 
represent.
Steven J. Chadban, BMed (hons), PhD, FAAHMS, FRACP
Gregory A. Knoll, MD, MSc, FRCPC
Work Group Co-Chairs
S84 Transplantation  ■  April 2020  ■ Volume 104  ■  Number 4S www.transplantjournal.com
REFERENCES
 1. The Declaration of Istanbul on organ trafficking and transplant tour-
ism. Kidney Int. 2008; 74: 854–859.
 2. Tonelli M, Wiebe N, Knoll G, et al. Systematic review: kidney trans-
plantation compared with dialysis in clinically relevant outcomes. Am 
J Transplant. 2011; 11: 2093–2109.
 3. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work 
Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and 
Management of Chronic Kidney Disease. Kidney Int Suppl. 2013; 3: 
1–150.
 4. IOM (Institute of Medicine). 2011. Finding What Works in Health Care: 
Standards for Systematic Reviews. Washington, DC: The National 
Academies Press.
 5. IOM (Institute of Medicine). 2011. Clinical Practice Guidelines We Can 
Trust. Washington, DC: The National Academies Press.
 6. Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane 
Collaboration’s tool for assessing risk of bias in randomised trials. 
BMJ. 2011; 343: d5928.
 7. Wells GAS, B.;O’Connell, D.;Peterson, J.; et al. The Newcastle-
Ottawa Scale (NOS) for assessing the quality of nonrandomised 
studies in meta-analyses. http://www.ohri.ca/programs/clinical_epi-
demiology/oxford.asp Accessed February 28, 2020.
 8. Atkins D, Best D, Briss PA, et al. Grading quality of evidence and 
strength of recommendations. BMJ. 2004; 328: 1490.
 9. Guyatt GH, Oxman AD, Kunz R, et al. Going from evidence to recom-
mendations. BMJ. 2008; 336: 1049–1051.
 10. Uhlig K, Macleod A, Craig J, et al. Grading evidence and recommen-
dations for clinical practice guidelines in nephrology. A position state-
ment from Kidney Disease: Improving Global Outcomes (KDIGO). 
Kidney Int. 2006; 70: 2058–2065.
 11. Shiffman RN, Shekelle P, Overhage JM, et al. Standardized report-
ing of clinical practice guidelines: a proposal from the Conference on 
Guideline Standardization. Ann Intern Med. 2003; 139: 493–498.
 12. Haller M, Gutjahr G, Kramar R, et al. Cost-effectiveness analysis of 
renal replacement therapy in Austria. Nephrol Dial Transplant. 2011; 
26: 2988–2995.
 13. Klarenbach SW, Tonelli M, Chui B, et al. Economic evaluation of dialy-
sis therapies. Nat Rev Nephrol. 2014; 10: 644–652.
 14. Laupacis A, Keown P, Pus N, et al. A study of the quality of life and 
cost-utility of renal transplantation. Kidney Int. 1996; 50: 235–242.
 15. Wong G, Howard K, Chapman JR, et al. Comparative survival and 
economic benefits of deceased donor kidney transplantation and 
dialysis in people with varying ages and co-morbidities. PLoS One. 
2012; 7: e29591.
 16. Bayat S, Macher MA, Couchoud C, et al. Individual and regional fac-
tors of access to the renal transplant waiting list in france in a cohort 
of dialyzed patients. Am J Transplant. 2015; 15: 1050–1060.
 17. Plantinga LC, Pastan SO, Wilk AS, et al. Referral for Kidney 
Transplantation and Indicators of Quality of Dialysis Care: A Cross-
sectional Study. Am J Kidney Dis. 2017; 69: 257–265.
 18. Israni AK, Salkowski N, Gustafson S, et al. New national allocation 
policy for deceased donor kidneys in the United States and possible 
effect on patient outcomes. J Am Soc Nephrol. 2014; 25: 1842–1848.
 19. Smith JM, Schnitzler MA, Gustafson SK, et al. Cost Implications of 
New National Allocation Policy for Deceased Donor Kidneys in the 
United States. Transplantation. 2016; 100: 879–885.
 20. The Transplantation Society of Australia and New Zealand, Clinical 
Guidelines for Organ Transplantation from Deceased Donors. 97pp 
(2017). http://www.donatelife.gov.au/sites/default/files/TSANZ%20
Clinical%20Guidelines%20for%20Organ%20Transplantation%20
from%20Deceased%20Donors_Version%201.0_April%202016.pdf 
(Accessed February 28, 2020).
 21. BC Transplant. Clinical Guidelines for Kidney. 66pp. (2017). http://
www.transplant.bc.ca/Documents/Health%20Professionals/
Clinical%20guidelines/Clinical%20Guidelines%20for%20Kidney%20
Transplantation.pdf (Accessed February 28, 2020).
 22. Trillium Gift of Life Network. Ontario’s Referral and Listing Criteria 
for Adult Kidney Transplantation. 8pp. (2015). https://www.giftoflife.
on.ca/resources/pdf/transplant/ON_Adult_Kidney_Tx_Referral_and_
Listing_Criteria_3.0_Updated.pdf (Accessed February 28, 2020).
 23. Dudley C, Harden P. Renal Association Clinical Practice Guideline on 
the assessment of the potential kidney transplant recipient. Nephron 
Clin Pract. 2011; 118 Suppl 1: c209–224.
 24. van Walraven C, Austin PC, Knoll G. Predicting potential survival ben-
efit of renal transplantation in patients with chronic kidney disease. 
CMAJ. 2010; 182: 666–672.
 25. Molnar MZ, Nguyen DV, Chen Y, et al. Predictive Score for 
Posttransplantation Outcomes. Transplantation. 2017; 101: 
1353–1364.
 26. Patzer RE, Basu M, Larsen CP, et al. iChoose Kidney: A Clinical 
Decision Aid for Kidney Transplantation Versus Dialysis Treatment. 
Transplantation. 2016; 100: 630–639.
 27. Campbell S, Pilmore H, Gracey D, et al. KHA-CARI guideline: recipi-
ent assessment for transplantation. Nephrology (Carlton). 2013; 18: 
455–462.
 28. Kasiske BL, Cangro CB, Hariharan S, et al. The evaluation of 
renal transplantation candidates: clinical practice guidelines. Am J 
Transplant. 2001; 1 Suppl 2: 3–95.
 29. Knoll G, Cockfield S, Blydt-Hansen T, et al. Canadian Society of 
Transplantation: consensus guidelines on eligibility for kidney trans-
plantation. CMAJ. 2005; 173: S1–25.
 30. KDIGO clinical practice guideline for the care of kidney transplant 
recipients. Am J Transplant. 2009; 9 Suppl 3: S1–155.
 31. Heemann U, Abramowicz D, Spasovski G, et al. Endorsement of the 
Kidney Disease Improving Global Outcomes (KDIGO) guidelines on 
kidney transplantation: a European Renal Best Practice (ERBP) posi-
tion statement. Nephrol Dial Transplant. 2011; 26: 2099–2106.
 32. Rao PS, Schaubel DE, Guidinger MK, et al. A comprehensive risk 
quantification score for deceased donor kidneys: the kidney donor 
risk index. Transplantation. 2009; 88: 231–236.
 33. Hart A, Smith JM, Skeans MA, et al. Kidney. Am J Transplant. 2016; 
16 Suppl 2: 11–46.
 34. Stevens KK, Woo YM, Clancy M, et al. Deceased donor transplanta-
tion in the elderly--are we creating false hope? Nephrol Dial Transplant. 
2011; 26: 2382–2386.
 35. Ponticelli C, Podesta MA, Graziani G. Renal transplantation in elderly 
patients. How to select the candidates to the waiting list? Transplant 
Rev. 2014; 28: 188–192.
 36. Garonzik-Wang JM, Govindan P, Grinnan JW, et al. Frailty and delayed 
graft function in kidney transplant recipients. Arch Surg. 2012; 147: 
190–193.
 37. Karim A, Farrugia D, Cheshire J, et al. Recipient age and risk for mor-
tality after kidney transplantation in England. Transplantation. 2014; 
97: 832–838.
 38. McAdams-Demarco MA, Grams ME, Hall EC, et al. Early hospital 
readmission after kidney transplantation: patient and center-level 
associations. Am J Transplant. 2012; 12: 3283–3288.
 39. McAdams-DeMarco MA, Ying H, Olorundare I, et al. Individual 
Frailty Components and Mortality in Kidney Transplant Recipients. 
Transplantation. 2017; 101: 2126–2132.
 40. McAdams-DeMarco MA, James N, Salter ML, et al. Trends in kid-
ney transplant outcomes in older adults. J Am Geriatr Soc. 2014; 62: 
2235–2242.
 41. Gill JS, Schaeffner E, Chadban S, et al. Quantification of the early risk 
of death in elderly kidney transplant recipients. Am J Transplant. 2013; 
13: 427–432.
 42. Lloveras J, Arcos E, Comas J, et al. A paired survival analysis com-
paring hemodialysis and kidney transplantation from deceased elderly 
donors older than 65 years. Transplantation. 2015; 99: 991–996.
 43. Macrae J, Friedman AL, Friedman EA, et al. Live and deceased donor 
kidney transplantation in patients aged 75 years and older in the 
United States. Int Urol Nephrol. 2005; 37: 641–648.
 44. Massie AB, Luo X, Chow EK, et al. Survival benefit of primary deceased 
donor transplantation with high-KDPI kidneys. Am J Transplant. 2014; 
14: 2310–2316.
 45. Merion RM, Ashby VB, Wolfe RA, et al. Deceased-donor character-
istics and the survival benefit of kidney transplantation. JAMA. 2005; 
294: 2726–2733.
 46. Ojo AO, Hanson JA, Meier-Kriesche H, et al. Survival in recipients 
of marginal cadaveric donor kidneys compared with other recipients 
and wait-listed transplant candidates. J Am Soc Nephrol. 2001; 12: 
589–597.
 47. Perez-Saez MJ, Arcos E, Comas J, et al. Survival Benefit From 
Kidney Transplantation Using Kidneys From Deceased Donors Aged 
≥ 75 Years: A Time-Dependent Analysis. Am J Transplant. 2016; 16: 
2724–2733.
 48. Rao PS, Merion RM, Ashby VB, et al. Renal transplantation in elderly 
patients older than 70 years of age: results from the Scientific Registry 
of Transplant Recipients. Transplantation. 2007; 83: 1069–1074.
 49. Savoye E, Tamarelle D, Chalem Y, et al. Survival benefits of kidney 
transplantation with expanded criteria deceased donors in patients 
aged 60 years and over. Transplantation. 2007; 84: 1618–1624.
© 2020 Wolters Kluwer  S85
 50. Schold JD, Howard RJ, Scicchitano MJ, et al. The expanded criteria 
donor policy: an evaluation of program objectives and indirect ramifi-
cations. Am J Transplant. 2006; 6: 1689–1695.
 51. Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all 
patients on dialysis, patients on dialysis awaiting transplantation, and 
recipients of a first cadaveric transplant. N Engl J Med. 1999; 341: 
1725–1730.
 52. Kauffman HM, McBride MA, Cors CS, et al. Early mortality rates in 
older kidney recipients with comorbid risk factors. Transplantation. 
2007; 83: 404–410.
 53. Al-Shraideh Y, Farooq U, Farney AC, et al. Influence of recipient age 
on deceased donor kidney transplant outcomes in the expanded cri-
teria donor era. Clin Transplant. 2014; 28: 1372–1382.
 54. Cacho DT, Cusi LI, Pique AA, et al. Elderly donor kidney trans-
plant: factors involved in graft survival. Transplant Proc. 2005; 37: 
3690–3692.
 55. Cohen B, Smits JM, Haase B, et al. Expanding the donor pool to 
increase renal transplantation. Nephrol Dial Transplant. 2005; 20: 
34–41.
 56. Fabrizii V, Winkelmayer WC, Klauser R, et al. Patient and graft sur-
vival in older kidney transplant recipients: does age matter? J Am Soc 
Nephrol. 2004; 15: 1052–1060.
 57. Foley DP, Patton PR, Meier-Kriesche HU, et al. Long-term outcomes 
of kidney transplantation in recipients 60 years of age and older at the 
University of Florida. Clin Transplant. 2005: 101–109.
 58. Foss A, Tuvin D, Leivestad T, et al. Should kidneys from older cadav-
eric donors be age-matched to the recipient? Transplant Proc. 2005; 
37: 3280–3282.
 59. Frei U, Noeldeke J, Machold-Fabrizii V, et al. Prospective age-match-
ing in elderly kidney transplant recipients--a 5-year analysis of the 
Eurotransplant Senior Program. Am J Transplant. 2008; 8: 50–57.
 60. Heldal K, Hartmann A, Leivestad T, et al. Clinical outcomes in elderly 
kidney transplant recipients are related to acute rejection episodes rather 
than pretransplant comorbidity. Transplantation. 2009; 87: 1045–1051.
 61. Huang E, Poommipanit N, Sampaio MS, et al. Intermediate-term out-
comes associated with kidney transplantation in recipients 80 years 
and older: an analysis of the OPTN/UNOS database. Transplantation. 
2010; 90: 974–979.
 62. Humar A, Denny R, Matas AJ, et al. Graft and quality of life outcomes 
in older recipients of a kidney transplant. Exp Clin Transplant. 2003; 1: 
69–72.
 63. Ma MK, Lim WH, Craig JC, et al. Mortality among Younger and Older 
Recipients of Kidney Transplants from Expanded Criteria Donors 
Compared with Standard Criteria Donors. Clin J Am Soc Nephrol. 
2016; 11: 128–136.
 64. Meier-Kriesche HU, Schold JD, Gaston RS, et al. Kidneys from 
deceased donors: maximizing the value of a scarce resource. Am J 
Transplant. 2005; 5: 1725–1730.
 65. Mezrich JD, Pirsch JD, Fernandez LA, et al. Differential outcomes of 
expanded-criteria donor renal allografts according to recipient age. 
Clin J Am Soc Nephrol. 2012; 7: 1163–1171.
 66. Molnar MZ, Streja E, Kovesdy CP, et al. Age and the associations of 
living donor and expanded criteria donor kidneys with kidney trans-
plant outcomes. Am J Kidney Dis. 2012; 59: 841–848.
 67. Nyberg SL, Matas AJ, Kremers WK, et al. Improved scoring sys-
tem to assess adult donors for cadaver renal transplantation. Am J 
Transplant. 2003; 3: 715–721.
 68. Rose C, Schaeffner E, Frei U, et al. A Lifetime of Allograft Function with 
Kidneys from Older Donors. J Am Soc Nephrol. 2015; 26: 2483–2493.
 69. Shah T, Bunnapradist S, Hutchinson I, et al. The evolving notion 
of “senior” kidney transplant recipients. Clin Transplant. 2008; 22: 
794–802.
 70. Smits JM, Persijn GG, van Houwelingen HC, et al. Evaluation of the 
Eurotransplant Senior Program. The results of the first year. Am J 
Transplant. 2002; 2: 664–670.
 71. Sola R, Guirado L, Lopez-Navidad A, et al. Is it appropriate to implant 
kidneys from elderly donors in young recipients? Transplantation. 
2010; 90: 286–291.
 72. Tullius SG, Tran H, Guleria I, et al. The combination of donor and 
recipient age is critical in determining host immunoresponsiveness 
and renal transplant outcome. Ann Surg. 2010; 252: 662–674.
 73. Swanson SJ, Hypolite IO, Agodoa LY, et al. Effect of donor factors 
on early graft survival in adult cadaveric renal transplantation. Am J 
Transplant. 2002; 2: 68–75.
 74. Rao PS, Ojo A. The alphabet soup of kidney transplantation: SCD, 
DCD, ECD--fundamentals for the practicing nephrologist. Clin J Am 
Soc Nephrol. 2009; 4: 1827–1831.
 75. Haller MC, Kainz A, Baer H, et al. Dialysis Vintage and Outcomes after 
Kidney Transplantation: A Retrospective Cohort Study. Clin J Am Soc 
Nephrol. 2017; 12: 122–130.
 76. Miles CD, Schaubel DE, Jia X, et al. Mortality experience in recipi-
ents undergoing repeat transplantation with expanded criteria donor 
and non-ECD deceased-donor kidneys. Am J Transplant. 2007; 7: 
1140–1147.
 77. European Renal Best Practice Transplantation Guideline Development 
G. ERBP Guideline on the Management and Evaluation of the Kidney 
Donor and Recipient. Nephrol Dial Transplant. 2013; 28 Suppl 2: ii1–71.
 78. Gerson AC, Butler R, Moxey-Mims M, et al. Neurocognitive outcomes 
in children with chronic kidney disease: Current findings and con-
temporary endeavors. Ment Retard Dev Disabil Res Rev. 2006; 12: 
208–215.
 79. Reed-Knight B, Lee JL, Cousins LA, et al. Intellectual and academic 
performance in children undergoing solid organ pretransplant evalua-
tion. Pediatr Transplant. 2015; 19: 229–234.
 80. Haavisto A, Korkman M, Holmberg C, et al. Neuropsychological pro-
file of children with kidney transplants. Nephrol Dial Transplant. 2012; 
27: 2594–2601.
 81. Icard P, Hooper SR, Gipson DS, et al. Cognitive improvement in 
children with CKD after transplant. Pediatr Transplant. 2010; 14: 
887–890.
 82. Gulleroglu K, Baskin E, Bayrakci US, et al. Neurocognitive functions 
in pediatric renal transplant patients. Transplant Proc. 2013; 45: 
3511–3513.
 83. Mendley SR, Zelko FA. Improvement in specific aspects of neurocog-
nitive performance in children after renal transplantation. Kidney Int. 
1999; 56: 318–323.
 84. Johnson RJ, Warady BA. Long-term neurocognitive outcomes of 
patients with end-stage renal disease during infancy. Pediatr Nephrol. 
2013; 28: 1283–1291.
 85. Olbrisch ME, Benedict SM, Ashe K, et al. Psychological assessment 
and care of organ transplant patients. J Consult Clin Psychol. 2002; 
70: 771–783.
 86. Levenson JL, Olbrisch ME. Psychosocial evaluation of organ trans-
plant candidates. A comparative survey of process, criteria, and out-
comes in heart, liver, and kidney transplantation. Psychosomatics. 
1993; 34: 314–323.
 87. Dew MA, Switzer GE, DiMartini AF, et al. Psychosocial assessments 
and outcomes in organ transplantation. Prog Transplant. 2000; 10: 
239–259.
 88. EBPG (European Expert Group on Renal Transplantation); European 
Renal Association (ERA-EDTA); European Society for Organ 
Transplantation (ESOT). European Best Practice Guidelines for Renal 
Transplantation (part 1). Nephrol Dial Transplant. 2000; 15 Suppl 7: 1–85.
 89. Knoll G, Cockfield S, Blydt-Hansen T, et al. Canadian Society of 
Transplantation consensus guidelines on eligibility for kidney trans-
plantation. CMAJ. 2005; 173: 1181–1184.
 90. The Transplantation Society of Australia and New Zealand. Organ 
transplantation from deceased donors: Consensus statement on eli-
gibility criteria and allocation protocols. Australian Government Organ 
and Tissue Authority, June 2011.
 91. Batabyal P, Chapman JR, Wong G, et al. Clinical practice guidelines 
on wait-listing for kidney transplantation: consistent and equitable? 
Transplantation. 2012; 94: 703–713.
 92. Segall L, Nistor I, Pascual J, et al. Criteria for and Appropriateness 
of Renal Transplantation in Elderly Patients With End-Stage Renal 
Disease: A Literature Review and Position Statement on Behalf of 
the European Renal Association-European Dialysis and Transplant 
Association Descartes Working Group and European Renal Best 
Practice. Transplantation. 2016; 100: e55–65.
 93. Dobbels F, De Geest S, Cleemput I, et al. Psychosocial and behavio-
ral selection criteria for solid organ transplantation. Prog Transplant. 
2001; 11: 121–130.
 94. Faeder S, Moschenross D, Rosenberger E, et al. Psychiatric aspects 
of organ transplantation and donation. Curr Opin Psychiatry. 2015; 
28: 357–364.
 95. Kuntz K, Weinland SR, Butt Z. Psychosocial Challenges in Solid 
Organ Transplantation. J Clin Psychol Med Settings. 2015; 22: 
122–135.
 96. Maldonado JR, Dubois HC, David EE, et al. The Stanford Integrated 
Psychosocial Assessment for Transplantation (SIPAT): a new tool 
for the psychosocial evaluation of pre-transplant candidates. 
Psychosomatics. 2012; 53: 123–132.
 97. Maldonado JR, Sher Y, Lolak S, et al. The Stanford Integrated 
Psychosocial Assessment for Transplantation: A Prospective Study 
S86 Transplantation  ■  April 2020  ■ Volume 104  ■  Number 4S www.transplantjournal.com
of Medical and Psychosocial Outcomes. Psychosom Med. 2015; 
77: 1018–1030.
 98. Pai AL, Tackett A, Ittenbach RF, et al. Psychosocial Assessment Tool 
2.0_General: validity of a psychosocial risk screener in a pediatric 
kidney transplant sample. Pediatr Transplant. 2012; 16: 92–98.
 99. Olbrisch, ME, Levenson, JL, Hamer, R. The PACT: A rating scale for 
the study of clinical decision-making in psychosocial screening of 
organ transplant candidates. Clin Transplant. 1989; 6: 164–169.
 100. Mori DL, Gallagher P, Milne J. The Structured Interview for Renal 
Transplantation--SIRT. Psychosomatics. 2000; 41: 393–406.
 101. Twillman RK, Manetto C, Wellisch DK, et al. The Transplant 
Evaluation Rating Scale. A revision of the psychosocial levels system 
for evaluating organ transplant candidates. Psychosomatics. 1993; 
34: 144–153.
 102. Greene GM. Description of a psychosocial assessment instru-
ment and risk criteria to support social work recommendations for 
kidney transplant candidates. Soc Work Health Care. 2013; 52: 
370–396.
 103. Michaud L, Ludwig G, Berney S, et al. Immunosuppressive therapy 
after solid-organ transplantation: does the INTERMED identify patients 
at risk of poor adherence? Pharm Pract (Granada). 2016; 14: 822.
 104. Chilcot J, Spencer BW, Maple H, et al. Depression and kidney trans-
plantation. Transplantation. 2014; 97: 717–721.
 105. Muller HH, Englbrecht M, Wiesener MS, et al. Depression, Anxiety, 
Resilience and Coping Pre and Post Kidney Transplantation - Initial 
Findings from the Psychiatric Impairments in Kidney Transplantation 
(PI-KT)-Study. PLoS One. 2015; 10: e0140706.
 106. Corruble E, Barry C, Varescon I, et al. Report of depressive symp-
toms on waiting list and mortality after liver and kidney transplanta-
tion: a prospective cohort study. BMC Psychiatry. 2011; 11: 182.
 107. Kuntz KK, Bonfiglio DB. Psychological distress in patients presenting 
for initial renal transplant evaluation. J Clin Psychol Med Settings. 
2011; 18: 307–311.
 108. Mucsi I, Bansal A, Jeannette M, et al. Mental Health and Behavioral 
Barriers in Access to Kidney Transplantation: A Canadian Cohort 
Study. Transplantation. 2017; 101: 1182–1190.
 109. Dew MA, Rosenberger EM, Myaskovsky L, et al. Depression 
and Anxiety as Risk Factors for Morbidity and Mortality After 
Organ Transplantation: A Systematic Review and Meta-Analysis. 
Transplantation. 2015; 100: 988–1003.
 110. Bunzel B, Laederach-Hofmann K. Solid organ transplantation: are 
there predictors for posttransplant noncompliance? A literature over-
view. Transplantation. 2000; 70: 711–716.
 111. Corbett C, Armstrong MJ, Parker R, et al. Mental health disorders 
and solid-organ transplant recipients. Transplantation. 2013; 96: 
593–600.
 112. Calia R, Lai C, Aceto P, et al. Preoperative psychological factors 
predicting graft rejection in patients undergoing kidney transplant: a 
pilot study. Transplant Proc. 2011; 43: 1006–1009.
 113. Dobbels F, Skeans MA, Snyder JJ, et al. Depressive disorder in renal 
transplantation: an analysis of Medicare claims. Am J Kidney Dis. 
2008; 51: 819–828.
 114. Rosenberger EM, Dew MA, Crone C, et al. Psychiatric disorders as 
risk factors for adverse medical outcomes after solid organ trans-
plantation. Curr Opin Organ Transplant. 2012; 17: 188–192.
 115. Parker R, Armstrong MJ, Corbett C, et al. Alcohol and substance 
abuse in solid-organ transplant recipients. Transplantation. 2013; 
96: 1015–1024.
 116. Lentine KL, Lam NN, Xiao H, et al. Associations of pre-transplant 
prescription narcotic use with clinical complications after kidney 
transplantation. Am J Nephrol. 2015; 41: 165–176.
 117. Lentine KL, Yuan H, Tuttle-Newhall JE, et al. Quantifying prog-
nostic impact of prescription opioid use before kidney transplan-
tation through linked registry and pharmaceutical claims data. 
Transplantation. 2015; 99: 187–196.
 118. Garg J, Karim M, Tang H, et al. Social adaptability index predicts 
kidney transplant outcome: a single-center retrospective analysis. 
Nephrol Dial Transplant. 2012; 27: 1239–1245.
 119. Dew MA, DiMartini AF, Steel J, et al. Meta-analysis of risk for relapse 
to substance use after transplantation of the liver or other solid 
organs. Liver Transpl. 2008; 14: 159–172.
 120. The Diagnostic and Statistical Manual of Mental Disorders, 5th ed. 
(DSM-5). American Psychiatric Association, 2013.
 121. Dobbels F, Vanhaecke J, Dupont L, et al. Pretransplant predictors of 
posttransplant adherence and clinical outcome: an evidence base 
for pretransplant psychosocial screening. Transplantation. 2009; 87: 
1497–1504.
 122. Fine RN, Becker Y, De Geest S, et al. Nonadherence consensus 
conference summary report. Am J Transplant. 2009; 9: 35–41.
 123. Pinsky BW, Takemoto SK, Lentine KL, et al. Transplant outcomes 
and economic costs associated with patient noncompliance to 
immunosuppression. Am J Transplant. 2009; 9: 2597–2606.
 124. Dobbels F, Hames A, Aujoulat I, et al. Should we retransplant a 
patient who is non-adherent? A literature review and critical reflec-
tion. Pediatr Transplant. 2012; 16: 4–11.
 125. De Geest S, Burkhalter H, Bogert L, et al. Describing the evolution 
of medication nonadherence from pretransplant until 3 years post-
transplant and determining pretransplant medication nonadherence 
as risk factor for post-transplant nonadherence to immunosup-
pressives: the Swiss Transplant Cohort Study. Transpl Int 2014; 27: 
657–666.
 126. Howard K, Jan S, Rose J, et al. Community Preferences for the 
Allocation & Donation of Organs--the PAraDOx Study. BMC Public 
Health. 2011; 11: 386.
 127. Tong A, Jan S, Wong G, et al. Rationing scarce organs for transplan-
tation: healthcare provider perspectives on wait-listing and organ 
allocation. Clin Transplant. 2013; 27: 60–71.
 128. Tong A, Jan S, Wong G, et al. Patient preferences for the allocation 
of deceased donor kidneys for transplantation: a mixed methods 
study. BMC Nephrol. 2012; 13: 18.
 129. Brar A, Babakhani A, Salifu MO, et al. Evaluation of non-adherence 
in patients undergoing dialysis and kidney transplantation: United 
States transplantation practice patterns survey. Transplant Proc. 
2014; 46: 1340–1346.
 130. Wiebe C, Nevins TE, Robiner WN, et al. The Synergistic Effect 
of Class II HLA Epitope-Mismatch and Nonadherence on 
Acute Rejection and Graft Survival. Am J Transplant. 2015; 15: 
2197–2202.
 131. Dunn TB, Browne BJ, Gillingham KJ, et al. Selective retransplant 
after graft loss to nonadherence: success with a second chance. Am 
J Transplant. 2009; 9: 1337–1346.
 132. Casey BJ, Jones RM, Hare TA. The adolescent brain. Ann N Y Acad 
Sci. 2008; 1124: 111–126.
 133. Reyna VF, Farley F. Risk and Rationality in Adolescent Decision 
Making: Implications for Theory, Practice, and Public Policy. Psychol 
Sci Public Interest. 2006; 7: 1–44.
 134. Sowell ER, Thompson PM, Holmes CJ, et al. In vivo evidence for 
post-adolescent brain maturation in frontal and striatal regions. Nat 
Neurosci. 1999; 2: 859–861.
 135. Foster BJ, Dahhou M, Zhang X, et al. Association between age 
and graft failure rates in young kidney transplant recipients. 
Transplantation. 2011; 92: 1237–1243.
 136. Thomsen T, Villebro N, Moller AM. Interventions for preoperative 
smoking cessation. Cochrane Database Syst Rev. 2014: CD002294.
 137. Duerinckx N, Burkhalter H, Engberg SJ, et al. Correlates and 
Outcomes of Posttransplant Smoking in Solid Organ Transplant 
Recipients: A Systematic Literature Review and Meta-Analysis. 
Transplantation. 2016; 100: 2252–2263.
 138. Nourbala MH, Nemati E, Rostami Z, et al. Impact of cigarette smok-
ing on kidney transplant recipients: a systematic review. Iran J 
Kidney Dis. 2011; 5: 141–148.
 139. Corbett C, Armstrong MJ, Neuberger J. Tobacco smoking and solid 
organ transplantation. Transplantation. 2012; 94: 979–987.
 140. Suls JM, Luger TM, Curry SJ, et al. Efficacy of smoking-cessation 
interventions for young adults: a meta-analysis. Am J Prev Med. 
2012; 42: 655–662.
 141. Suissa K, Lariviere J, Eisenberg MJ, et al. Efficacy and Safety of 
Smoking Cessation Interventions in Patients With Cardiovascular 
Disease: A Network Meta-Analysis of Randomized Controlled Trials. 
Circ Cardiovasc Qual Outcomes. 2017; 10.
 142. National Lung Screening Trial Research T, Aberle DR, Adams AM, et 
al. Reduced lung-cancer mortality with low-dose computed tomo-
graphic screening. N Engl J Med. 2011; 365: 395–409.
 143. Abramowicz D, Cochat P, Claas FH, et al. European Renal Best 
Practice Guideline on kidney donor and recipient evaluation and 
perioperative care. Nephrol Dial Transplant. 2015; 30: 1790–1797.
 144. Mitnitski AB, Mogilner AJ, Rockwood K. Accumulation of deficits 
as a proxy measure of aging. Scientific World Journal. 2001; 1: 
323–336.
 145. Drost D, Kalf A, Vogtlander N, et al. High prevalence of frailty in end-
stage renal disease. Int Urol Nephrol. 2016; 48: 1357–1362.
 146. NIH National Institute of Diabetes and Digestive and Kidney Diseases. 
Overweight & Obesity Statistics. (2017). https://www.niddk.nih.gov/
© 2020 Wolters Kluwer  S87
health-information/health-statistics/Pages/overweight-obesity-sta-
tistics.aspx (Accessed February 28, 2020).
 147. Schold JD, Srinivas TR, Guerra G, et al. A “weight-listing” paradox 
for candidates of renal transplantation? Am J Transplant. 2007; 7: 
550–559.
 148. Molnar MZ, Streja E, Kovesdy CP, et al. Associations of body mass 
index and weight loss with mortality in transplant-waitlisted mainte-
nance hemodialysis patients. Am J Transplant. 2011; 11: 725–736.
 149. Gill JS, Lan J, Dong J, et al. The survival benefit of kidney transplan-
tation in obese patients. Am J Transplant. 2013; 13: 2083–2090.
 150. Krishnan N, Higgins R, Short A, et al. Kidney Transplantation 
Significantly Improves Patient and Graft Survival Irrespective of BMI: 
A Cohort Study. Am J Transplant. 2015; 15: 2378–2386.
 151. Oberholzer J, Giulianotti P, Danielson KK, et al. Minimally invasive 
robotic kidney transplantation for obese patients previously denied 
access to transplantation. Am J Transplant. 2013; 13: 721–728.
 152. Troppmann C, Santhanakrishnan C, Kuo JH, et al. Impact of pan-
niculectomy on transplant candidacy of obese patients with chronic 
kidney disease declined for kidney transplantation because of a 
high-risk abdominal panniculus: A pilot study. Surgery. 2016; 159: 
1612–1622.
 153. McAdams-DeMarco MA, Law A, Salter ML, et al. Frailty as a novel 
predictor of mortality and hospitalization in individuals of all ages 
undergoing hemodialysis. J Am Geriatr Soc. 2013; 61: 896–901.
 154. McAdams-DeMarco MA, Law A, King E, et al. Frailty and mortality in 
kidney transplant recipients. Am J Transplant. 2015; 15: 149–154.
 155. Broggi E, Bruyere F, Gaudez F, et al. Risk factors of severe incisional 
hernia after renal transplantation: a retrospective multicentric case-
control study on 225 patients. World J Urol. 2017; 35: 1111–1117.
 156. Ooms LS, Verhelst J, Jeekel J, et al. Incidence, risk factors, 
and treatment of incisional hernia after kidney transplantation: 
An analysis of 1,564 consecutive patients. Surgery. 2016; 159: 
1407–1411.
 157. Smith CT, Katz MG, Foley D, et al. Incidence and risk factors of inci-
sional hernia formation following abdominal organ transplantation. 
Surg Endosc. 2015; 29: 398–404.
 158. Harrison B, Sanniec K, Janis JE. Collagenopathies-Implications 
for Abdominal Wall Reconstruction: A Systematic Review. Plast 
Reconstr Surg Glob Open. 2016; 4: e1036.
 159. Zimmerman D, Sood MM, Rigatto C, et al. Systematic review and 
meta-analysis of incidence, prevalence and outcomes of atrial fibril-
lation in patients on dialysis. Nephrol Dial Transplant. 2012; 27: 
3816–3822.
 160. Garg L, Chen C, Haines DE. Atrial fibrillation and chronic kidney 
disease requiring hemodialysis - Does warfarin therapy improve the 
risks of this lethal combination? Int J Cardiol. 2016; 222: 47–50.
 161. Marzouk K, Lawen J, Kiberd BA. Blood transfusion in deceased 
donor kidney transplantation. Transplant Res. 2013; 2: 4.
 162. Peacock WF, Rafique Z, Singer AJ. Direct-Acting Oral Anticoagulants: 
Practical Considerations for Emergency Medicine Physicians. Emerg 
Med Int. 2016; 1781684.
 163. Izquierdo L, Peri L, Piqueras M, et al. Third and fourth kidney 
transplant: still a reasonable option. Transplant Proc. 2010; 42: 
2498–2502.
 164. Parekh VB, Niyyar VD, Vachharajani TJ. Lower Extremity Permanent 
Dialysis Vascular Access. Clin J Am Soc Nephrol. 2016; 11: 
1693–1702.
 165. Veroux M, Zerbo D, Basile G, et al. Simultaneous Native Nephrectomy 
and Kidney Transplantation in Patients With Autosomal Dominant 
Polycystic Kidney Disease. PLoS One. 2016; 11: e0155481.
 166. Chebib FT, Prieto M, Jung Y, et al. Native Nephrectomy in Renal 
Transplant Recipients with Autosomal Dominant Polycystic Kidney 
Disease. Transplant Direct. 2015; 1: e43.
 167. Ahmad SB, Inouye B, Phelan MS, et al. Live Donor Renal Transplant 
With Simultaneous Bilateral Nephrectomy for Autosomal Dominant 
Polycystic Kidney Disease Is Feasible and Satisfactory at Long-term 
Follow-up. Transplantation. 2016; 100: 407–415.
 168. Salvatierra O, Jr., Singh T, Shifrin R, et al. Successful transplanta-
tion of adult-sized kidneys into infants requires maintenance of high 
aortic blood flow. Transplantation. 1998; 66: 819–823.
 169. Ghane Sharbaf F, Bitzan M, Szymanski KM, et al. Native nephrec-
tomy prior to pediatric kidney transplantation: biological and clinical 
aspects. Pediatr Nephrol. 2012; 27: 1179–1188.
 170. Kravarusic D, Sigalet DL, Hamiwka LA, et al. Persistent post-
transplant polyuria managed by bilateral native-kidney laparoscopic 
nephrectomy. Pediatr Nephrol. 2006; 21: 880–882.
 171. Lau SO, Tkachuck JY, Hasegawa DK, et al. Plasminogen and 
antithrombin III deficiencies in the childhood nephrotic syndrome 
associated with plasminogenuria and antithrombinuria. J Pediatr. 
1980; 96: 390–392.
 172. Cochat P, Offner G. European Best Practice Guidelines for Renal 
Transplantation (Part 2). IV.11 Paediatrics (specific problems). 
Nephrol Dial Transplant. 2002; 17: 55–58.
 173. Chadban SJ, Staplin ND. Is it time to increase access to transplan-
tation for those with diabetic end-stage kidney disease? Kidney Int. 
2014; 86: 464–466.
 174. Keddis MT, El Ters M, Rodrigo E, et al. Enhanced posttransplant 
management of patients with diabetes improves patient outcomes. 
Kidney Int. 2014; 86: 610–618.
 175. Boucek P, Saudek F, Pokorna E, et al. Kidney transplantation in type 
2 diabetic patients: a comparison with matched non-diabetic sub-
jects. Nephrol Dial Transplant. 2002; 17: 1678–1683.
 176. Lim WH, Wong G, Pilmore HL, et al. Long-term outcomes of kidney 
transplantation in people with type 2 diabetes: a population cohort 
study. Lancet Diabetes Endocrinol. 2017; 5: 26–33.
 177. Yates CJ, Fourlanos S, Hjelmesaeth J, et al. New-onset diabe-
tes after kidney transplantation-changes and challenges. Am J 
Transplant. 2012; 12: 820–828.
 178. Cole EH, Johnston O, Rose CL, et al. Impact of acute rejection and 
new-onset diabetes on long-term transplant graft and patient sur-
vival. Clin J Am Soc Nephrol. 2008; 3: 814–821.
 179. Hjelmesaeth J, Hartmann A, Kofstad J, et al. Glucose intolerance 
after renal transplantation depends upon prednisolone dose and 
recipient age. Transplantation. 1997; 64: 979–983.
 180. Vincenti F, Friman S, Scheuermann E, et al. Results of an interna-
tional, randomized trial comparing glucose metabolism disorders 
and outcome with cyclosporine versus tacrolimus. Am J Transplant. 
2007; 7: 1506–1514.
 181. Hecking M, Haidinger M, Doller D, et al. Early basal insulin therapy 
decreases new-onset diabetes after renal transplantation. J Am Soc 
Nephrol. 2012; 23: 739–749.
 182. Caillard S, Eprinchard L, Perrin P, et al. Incidence and risk factors of 
glucose metabolism disorders in kidney transplant recipients: role of 
systematic screening by oral glucose tolerance test. Transplantation. 
2011; 91: 757–764.
 183. Mathew JT, Rao M, Job V, et al. Post-transplant hyperglycaemia: a 
study of risk factors. Nephrol Dial Transplant. 2003; 18: 164–171.
 184. Tokodai K, Amada N, Haga I, et al. The 5-time point oral glucose tol-
erance test as a predictor of new-onset diabetes after kidney trans-
plantation. Diabetes Res Clin Pract. 2014; 103: 298–303.
 185. Ramesh Prasad GV, Huang M, Bandukwala F, et al. Pre-
transplantation glucose testing for predicting new-onset diabe-
tes mellitus after renal transplantation. Clin Nephrol. 2009; 71: 
140–146.
 186. Armstrong KA, Prins JB, Beller EM, et al. Should an oral glucose tol-
erance test be performed routinely in all renal transplant recipients? 
Clin J Am Soc Nephrol. 2006; 1: 100–108.
 187. Valderhaug TG, Jenssen T, Hartmann A, et al. Fasting plasma glu-
cose and glycosylated hemoglobin in the screening for diabetes mel-
litus after renal transplantation. Transplantation. 2009; 88: 429–434.
 188. Sharif A, Baboolal K. Diagnostic application of the A(1c) assay in 
renal disease. J Am Soc Nephrol. 2010; 21: 383–385.
 189. Eide IA, Halden TA, Hartmann A, et al. Limitations of hemoglobin A1c 
for the diagnosis of posttransplant diabetes mellitus. Transplantation. 
2015; 99: 629–635.
 190. Briganti EM, Russ GR, McNeil JJ, et al. Risk of renal allograft 
loss from recurrent glomerulonephritis. N Engl J Med. 2002; 347: 
103–109.
 191. Allen PJ, Chadban SJ, Craig JC, et al. Recurrent glomerulonephri-
tis after kidney transplantation: risk factors and allograft outcomes. 
Kidney Int. 2017; 92: 461–469.
 192. Lim WH, Wong G, McDonald SP, et al. Long-term outcomes of kid-
ney transplant recipients with end-stage kidney disease attributed 
to presumed/advanced glomerulonephritis or unknown cause. Sci 
Rep. 2018; 8: 9021.
 193. Cosio FG, Cattran DC. Recent advances in our understanding of 
recurrent primary glomerulonephritis after kidney transplantation. 
Kidney Int. 2017; 91: 304–314.
 194. Dantal J, Baatard R, Hourmant M, et al. Recurrent nephrotic syn-
drome following renal transplantation in patients with focal glo-
merulosclerosis. A one-center study of plasma exchange effects. 
Transplantation. 1991; 52: 827–831.
S88 Transplantation  ■  April 2020  ■ Volume 104  ■  Number 4S www.transplantjournal.com
 195. Ingulli E, Tejani A. Incidence, treatment, and outcome of recurrent 
focal segmental glomerulosclerosis posttransplantation in 42 allo-
grafts in children--a single-center experience. Transplantation. 1991; 
51: 401–405.
 196. Hickson LJ, Gera M, Amer H, et al. Kidney transplantation for pri-
mary focal segmental glomerulosclerosis: outcomes and response 
to therapy for recurrence. Transplantation. 2009; 87: 1232–1239.
 197. Francis A, Trnka P, McTaggart SJ. Long-Term Outcome of 
Kidney Transplantation in Recipients with Focal Segmental 
Glomerulosclerosis. Clin J Am Soc Nephrol. 2016; 11: 2041–2046.
 198. Franco Palacios CR, Lieske JC, Wadei HM, et al. Urine but not serum 
soluble urokinase receptor (suPAR) may identify cases of recurrent 
FSGS in kidney transplant candidates. Transplantation. 2013; 96: 
394–399.
 199. Spinale JM, Mariani LH, Kapoor S, et al. A reassessment of soluble 
urokinase-type plasminogen activator receptor in glomerular dis-
ease. Kidney Int. 2015; 87: 564–574.
 200. Cibrik DM, Kaplan B, Campbell DA, et al. Renal allograft survival in 
transplant recipients with focal segmental glomerulosclerosis. Am J 
Transplant. 2003; 3: 64–67.
 201. Vincenti F, Ghiggeri GM. New insights into the pathogenesis and 
the therapy of recurrent focal glomerulosclerosis. Am J Transplant. 
2005; 5: 1179–1185.
 202. Ruf RG, Lichtenberger A, Karle SM, et al. Patients with mutations in 
NPHS2 (podocin) do not respond to standard steroid treatment of 
nephrotic syndrome. J Am Soc Nephrol. 2004; 15: 722–732.
 203. Bertelli R, Ginevri F, Caridi G, et al. Recurrence of focal segmental 
glomerulosclerosis after renal transplantation in patients with muta-
tions of podocin. Am J Kidney Dis. 2003; 41: 1314–1321.
 204. Gohh RY, Yango AF, Morrissey PE, et al. Preemptive plasmapheresis 
and recurrence of FSGS in high-risk renal transplant recipients. Am J 
Transplant. 2005; 5: 2907–2912.
 205. Yabu JM, Ho B, Scandling JD, et al. Rituximab failed to improve 
nephrotic syndrome in renal transplant patients with recurrent focal 
segmental glomerulosclerosis. Am J Transplant. 2008; 8: 222–227.
 206. Dabade TS, Grande JP, Norby SM, et al. Recurrent idiopathic mem-
branous nephropathy after kidney transplantation: a surveillance 
biopsy study. Am J Transplant. 2008; 8: 1318–1322.
 207. Grupper A, Cornell LD, Fervenza FC, et al. Recurrent Membranous 
Nephropathy After Kidney Transplantation: Treatment and Long-
Term Implications. Transplantation. 2016; 100: 2710–2716.
 208. El-Zoghby ZM, Grande JP, Fraile MG, et al. Recurrent idiopathic 
membranous nephropathy: early diagnosis by protocol biopsies and 
treatment with anti-CD20 monoclonal antibodies. Am J Transplant. 
2009; 9: 2800–2807.
 209. Cosyns JP, Couchoud C, Pouteil-Noble C, et al. Recurrence of 
membranous nephropathy after renal transplantation: probability, 
outcome and risk factors. Clin Nephrol. 1998; 50: 144–153.
 210. Kattah A, Ayalon R, Beck LH, Jr., et al. Anti-phospholipase A(2) 
receptor antibodies in recurrent membranous nephropathy. Am J 
Transplant. 2015; 15: 1349–1359.
 211. Quintana LF, Blasco M, Seras M, et al. Antiphospholipase A2 
Receptor Antibody Levels Predict the Risk of Posttransplantation 
Recurrence of Membranous Nephropathy. Transplantation. 2015; 
99: 1709–1714.
 212. Ruggenenti P, Chiurchiu C, Brusegan V, et al. Rituximab in idiopathic 
membranous nephropathy: a one-year prospective study. J Am Soc 
Nephrol. 2003; 14: 1851–1857.
 213. Ponticelli C, Traversi L, Banfi G. Renal transplantation in patients 
with IgA mesangial glomerulonephritis. Pediatr Transplant. 2004; 8: 
334–338.
 214. Ortiz F, Gelpi R, Koskinen P, et al. IgA nephropathy recurs early in the 
graft when assessed by protocol biopsy. Nephrol Dial Transplant. 
2012; 27: 2553–2558.
 215. Andresdottir MB, Hoitsma AJ, Assmann KJ, et al. Favorable out-
come of renal transplantation in patients with IgA nephropathy. Clin 
Nephrol. 2001; 56: 279–288.
 216. Moroni G, Longhi S, Quaglini S, et al. The long-term outcome of renal 
transplantation of IgA nephropathy and the impact of recurrence on 
graft survival. Nephrol Dial Transplant. 2013; 28: 1305–1314.
 217. Soler MJ, Mir M, Rodriguez E, et al. Recurrence of IgA nephropathy 
and Henoch-Schonlein purpura after kidney transplantation: risk fac-
tors and graft survival. Transplant Proc. 2005; 37: 3705–3709.
 218. Kanaan N, Mourad G, Thervet E, et al. Recurrence and graft 
loss after kidney transplantation for Henoch-Schonlein purpura 
nephritis: a multicenter analysis. Clin J Am Soc Nephrol. 2011; 6: 
1768–1772.
 219. Samuel JP, Bell CS, Molony DA, et al. Long-term outcome of renal 
transplantation patients with Henoch-Schonlein purpura. Clin J Am 
Soc Nephrol. 2011; 6: 2034–2040.
 220. Lorenz EC, Sethi S, Leung N, et al. Recurrent membranoproliferative 
glomerulonephritis after kidney transplantation. Kidney Int. 2010; 77: 
721–728.
 221. Angelo JR, Bell CS, Braun MC. Allograft failure in kidney transplant 
recipients with membranoproliferative glomerulonephritis. Am J 
Kidney Dis. 2011; 57: 291–299.
 222. Nasr SH, Sethi S, Cornell LD, et al. Proliferative glomerulonephritis 
with monoclonal IgG deposits recurs in the allograft. Clin J Am Soc 
Nephrol. 2011; 6: 122–132.
 223. Medjeral-Thomas NR, O’Shaughnessy MM, O’Regan JA, et al. C3 
glomerulopathy: clinicopathologic features and predictors of out-
come. Clin J Am Soc Nephrol. 2014; 9: 46–53.
 224. Zand L, Lorenz EC, Cosio FG, et al. Clinical findings, pathology, and 
outcomes of C3GN after kidney transplantation. J Am Soc Nephrol. 
2014; 25: 1110–1117.
 225. Servais A, Noel LH, Roumenina LT, et al. Acquired and genetic com-
plement abnormalities play a critical role in dense deposit disease 
and other C3 glomerulopathies. Kidney Int. 2012; 82: 454–464.
 226. Braun MC, Stablein DM, Hamiwka LA, et al. Recurrence of mem-
branoproliferative glomerulonephritis type II in renal allografts: The 
North American Pediatric Renal Transplant Cooperative Study expe-
rience. J Am Soc Nephrol. 2005; 16: 2225–2233.
 227. Lu DF, Moon M, Lanning LD, et al. Clinical features and outcomes of 
98 children and adults with dense deposit disease. Pediatr Nephrol. 
2012; 27: 773–781.
 228. Berthoux FC, Ducret F, Colon S, et al. Renal transplantation in 
mesangioproliferative glomerulonephritis (MPGN): relationship 
between the high frquency of recurrent glomerulonephritis and 
hypocomplementemia. Kidney Int Suppl. 1975: 323–327.
 229. Leibowitch J, Halbwachs L, Wattel S, et al. Recurrence of dense 
deposits in transplanted kidney: II. Serum complement and nephritic 
factor profiles. Kidney Int. 1979; 15: 396–403.
 230. Goral S, Ynares C, Shappell SB, et al. Recurrent lupus nephritis in 
renal transplant recipients revisited: it is not rare. Transplantation. 
2003; 75: 651–656.
 231. Nyberg G, Blohme I, Persson H, et al. Recurrence of SLE in trans-
planted kidneys: a follow-up transplant biopsy study. Nephrol Dial 
Transplant.1992; 7: 1116–1123.
 232. Mojcik CF, Klippel JH. End-stage renal disease and systemic lupus 
erythematosus. Am J Med. 1996; 101: 100–107.
 233. Burgos PI, Perkins EL, Pons-Estel GJ, et al. Risk factors and impact 
of recurrent lupus nephritis in patients with systemic lupus erythema-
tosus undergoing renal transplantation: data from a single US institu-
tion. Arthritis Rheum. 2009; 60: 2757–2766.
 234. Contreras G, Mattiazzi A, Guerra G, et al. Recurrence of lupus 
nephritis after kidney transplantation. J Am Soc Nephrol. 2010; 21: 
1200–1207.
 235. Norby GE, Strom EH, Midtvedt K, et al. Recurrent lupus nephritis 
after kidney transplantation: a surveillance biopsy study. Ann Rheum 
Dis. 2010; 69: 1484–1487.
 236. Stone JH, Amend WJ, Criswell LA. Outcome of renal transplantation 
in systemic lupus erythematosus. Semin Arthritis Rheum. 1997; 27: 
17–26.
 237. Bunnapradist S, Chung P, Peng A, et al. Outcomes of renal 
transplantation for recipients with lupus nephritis: analysis of 
the Organ Procurement and Transplantation Network database. 
Transplantation. 2006; 82: 612–618.
 238. Grimbert P, Frappier J, Bedrossian J, et al. Long-term outcome of 
kidney transplantation in patients with systemic lupus erythemato-
sus: a multicenter study. Groupe Cooperatif de Transplantation d’ile 
de France. Transplantation. 1998; 66: 1000–1003.
 239. Mejia G, Zimmerman SW, Glass NR, et al. Renal transplantation in 
patients with systemic lupus erythematosus. Arch Intern Med. 1983; 
143: 2089–2092.
 240. Goss JA, Cole BR, Jendrisak MD, et al. Renal transplantation for 
systemic lupus erythematosus and recurrent lupus nephritis. A sin-
gle-center experience and a review of the literature. Transplantation. 
1991; 52: 805–810.
 241. Roth D, Milgrom M, Esquenazi V, et al. Renal transplantation in sys-
temic lupus erythematosus: one center’s experience. Am J Nephrol. 
1987; 7: 367–374.
 242. Canaud G, Bienaime F, Noel LH, et al. Severe vascular lesions and 
poor functional outcome in kidney transplant recipients with lupus 
anticoagulant antibodies. Am J Transplant. 2010; 10: 2051–2060.
© 2020 Wolters Kluwer  S89
 243. Ducloux D, Pellet E, Fournier V, et al. Prevalence and clinical signifi-
cance of antiphospholipid antibodies in renal transplant recipients. 
Transplantation. 1999; 67: 90–93.
 244. Gauthier M, Canoui-Poitrine F, Guery E, et al. Anticardiolipin anti-
bodies and 12-month graft function in kidney transplant recipi-
ents: a prognosis cohort survey. Nephrol Dial Transplant. 2018; 33: 
709–716.
 245. Moroni G, Torri A, Gallelli B, et al. The long-term prognosis of renal 
transplant in patients with systemic vasculitis. Am J Transplant. 
2007; 7: 2133–2139.
 246. Nachman PH, Segelmark M, Westman K, et al. Recurrent ANCA-
associated small vessel vasculitis after transplantation: A pooled 
analysis. Kidney Int.1999; 56: 1544–1550.
 247. Gera M, Griffin MD, Specks U, et al. Recurrence of ANCA-associated 
vasculitis following renal transplantation in the modern era of immu-
nosupression. Kidney Int. 2007; 71: 1296–1301.
 248. Geetha D, Eirin A, True K, et al. Renal transplantation in antineutro-
phil cytoplasmic antibody-associated vasculitis: a multicenter experi-
ence. Transplantation. 2011; 91: 1370–1375.
 249. Little MA, Hassan B, Jacques S, et al. Renal transplantation in sys-
temic vasculitis: when is it safe? Nephrol Dial Transplant. 2009; 24: 
3219–3225.
 250. Lobbedez T, Comoz F, Renaudineau E, et al. Recurrence of ANCA-
positive glomerulonephritis immediately after renal transplantation. 
Am J Kidney Dis. 2003; 42: E2–6.
 251. Deegens JK, Artz MA, Hoitsma AJ, et al. Outcome of renal trans-
plantation in patients with pauci-immune small vessel vasculitis or 
anti-GBM disease. Clin Nephrol. 2003; 59: 1–9.
 252. Netzer KO, Merkel F, Weber M. Goodpasture syndrome and end-
stage renal failure--to transplant or not to transplant? Nephrol Dial 
Transplant. 1998; 13: 1346–1348.
 253. Ferraris JR, Ramirez JA, Ruiz S, et al. Shiga toxin-associated hemo-
lytic uremic syndrome: absence of recurrence after renal transplanta-
tion. Pediatr Nephrol. 2002; 17: 809–814.
 254. Alberti M, Valoti E, Piras R, et al. Two patients with history of STEC-
HUS, posttransplant recurrence and complement gene mutations. 
Am J Transplant. 2013; 13: 2201–2206.
 255. Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J 
Med. 2009; 361: 1676–1687.
 256. Bresin E, Daina E, Noris M, et al. Outcome of renal transplantation 
in patients with non-Shiga toxin-associated hemolytic uremic syn-
drome: prognostic significance of genetic background. Clin J Am 
Soc Nephrol. 2006; 1: 88–99.
 257. Noris M, Remuzzi G. Thrombotic microangiopathy after kidney 
transplantation. Am J Transplant. 2010; 10: 1517–1523.
 258. Le Quintrec M, Zuber J, Moulin B, et al. Complement genes strongly 
predict recurrence and graft outcome in adult renal transplant recipi-
ents with atypical hemolytic and uremic syndrome. Am J Transplant. 
2013; 13: 663–675.
 259. Zuber J, Fakhouri F, Roumenina LT, et al. Use of eculizumab for 
atypical haemolytic uraemic syndrome and C3 glomerulopathies. 
Nat Rev Nephrol. 2012; 8: 643–657.
 260. Saland JM, Ruggenenti P, Remuzzi G, et al. Liver-kidney transplanta-
tion to cure atypical hemolytic uremic syndrome. J Am Soc Nephrol. 
2009; 20: 940–949.
 261. Gibney EM, Parikh CR, Jani A, et al. Kidney transplantation for sys-
temic sclerosis improves survival and may modulate disease activity. 
Am J Transplant. 2004; 4: 2027–2031.
 262. Bleyer AJ, Donaldson LA, McIntosh M, et al. Relationship between 
underlying renal disease and renal transplantation outcome. Am J 
Kidney Dis. 2001; 37: 1152–1161.
 263. Bertrand D, Dehay J, Ott J, et al. Kidney transplantation in patients 
with systemic sclerosis: a nationwide multicentre study. Transpl Int. 
2017; 30: 256–265.
 264. Bansal T, Garg A, Snowden JA, et al. Defining the role of renal 
transplantation in the modern management of multiple myeloma 
and other plasma cell dyscrasias. Nephron Clin Pract. 2012; 120: 
c228–235.
 265. Eleutherakis-Papaiakovou V, Bamias A, Gika D, et al. Renal failure 
in multiple myeloma: incidence, correlations, and prognostic signifi-
cance. Leuk Lymphoma. 2007; 48: 337–341.
 266. Walker F, Bear RA. Renal transplantation in light-chain multiple mye-
loma. Am J Nephrol. 1983; 3: 34–37.
 267. van Bommel EF. Multiple myeloma treatment in dialysis-dependent 
patients: to transplant or not to transplant? Nephrol Dial Transplant. 
1996; 11: 1486–1487.
 268. Tsakiris DJ, Stel VS, Finne P, et al. Incidence and outcome of patients 
starting renal replacement therapy for end-stage renal disease due 
to multiple myeloma or light-chain deposit disease: an ERA-EDTA 
Registry study. Nephrol Dial Transplant. 2010; 25: 1200–1206.
 269. Spitzer TR, Sykes M, Tolkoff-Rubin N, et al. Long-term follow-up 
of recipients of combined human leukocyte antigen-matched bone 
marrow and kidney transplantation for multiple myeloma with end-
stage renal disease. Transplantation. 2011; 91: 672–676.
 270. Huskey JL, Heilman RL, Khamash H, et al. Kidney Transplant in the 
Era of Modern Therapy for Multiple Myeloma. Transplantation. 2018; 
102: 1994–2001.
 271. Leung N, Lager DJ, Gertz MA, et al. Long-term outcome of renal 
transplantation in light-chain deposition disease. Am J Kidney Dis. 
2004; 43: 147–153.
 272. Oe Y, Soma J, Sato H, et al. Heavy chain deposition disease: an 
overview. Clin Exp Nephrol. 2013; 17: 771–778.
 273. Joly F, Cohen C, Javaugue V, et al. Randall-type monoclonal immu-
noglobulin deposition disease: novel insights from a nationwide 
cohort study. Blood. 2019; 133: 576–587.
 274. Angel-Korman A, Stern L, Sarosiek S, et al. Long-term outcome 
of kidney transplantation in AL amyloidosis. Kidney Int. 2019; 95: 
405–411.
 275. Sherif AM, Refaie AF, Sobh MA, et al. Long-term outcome of live 
donor kidney transplantation for renal amyloidosis. Am J Kidney Dis. 
2003; 42: 370–375.
 276. Heering P, Hetzel R, Grabensee B, et al. Renal transplantation in sec-
ondary systemic amyloidosis. Clin Transplant. 1998; 12: 159–164.
 277. Kofman T, Grimbert P, Canoui-Poitrine F, et al. Renal transplantation 
in patients with AA amyloidosis nephropathy: results from a French 
multicenter study. Am J Transplant. 2011; 11: 2423–2431.
 278. Calls Ginesta J, Torras A, Ricart MJ, et al. Fibrillary glomerulonephri-
tis and pulmonary hemorrhage in a patient with renal transplantation. 
Clin Nephrol. 1995; 43: 180–183.
 279. Samaniego M, Nadasdy GM, Laszik Z, et al. Outcome of renal transplan-
tation in fibrillary glomerulonephritis. Clin Nephrol. 2001; 55: 159–166.
 280. Czarnecki PG, Lager DJ, Leung N, et al. Long-term outcome of 
kidney transplantation in patients with fibrillary glomerulonephritis or 
monoclonal gammopathy with fibrillary deposits. Kidney Int. 2009; 
75: 420–427.
 281. Mallett A, Tang W, Hart G, et al. End-Stage Kidney Disease Due 
to Fibrillary Glomerulonephritis and Immunotactoid Glomerulopathy 
- Outcomes in 66 Consecutive ANZDATA Registry Cases. Am J 
Nephrol. 2015; 42: 177–184.
 282. Broyer M, Brunner FP, Brynger H, et al. Kidney transplantation in pri-
mary oxalosis: data from the EDTA Registry. Nephrol Dial Transplant. 
1990; 5: 332–336.
 283. Bergstralh EJ, Monico CG, Lieske JC, et al. Transplantation out-
comes in primary hyperoxaluria. Am J Transplant. 2010; 10: 
2493–2501.
 284. Harambat J, van Stralen KJ, Espinosa L, et al. Characteristics and 
outcomes of children with primary oxalosis requiring renal replace-
ment therapy. Clin J Am Soc Nephrol. 2012; 7: 458–465.
 285. Ruder H, Otto G, Schutgens RB, et al. Excessive urinary oxalate 
excretion after combined renal and hepatic transplantation for cor-
rection of hyperoxaluria type 1. Eur J Pediatr. 1990; 150: 56–58.
 286. Malla I, Lysy PA, Godefroid N, et al. Two-step transplantation for 
primary hyperoxaluria: cadaveric liver followed by living donor related 
kidney transplantation. Pediatr Transplant. 2009; 13: 782–784.
 287. Liebow A, Li X, Racie T, et al. An Investigational RNAi Therapeutic 
Targeting Glycolate Oxidase Reduces Oxalate Production in Models 
of Primary Hyperoxaluria. J Am Soc Nephrol. 2017; 28: 494–503.
 288. Milliner DS. siRNA Therapeutics for Primary Hyperoxaluria: A 
Beginning. Mol Ther. 2016; 24: 666–667.
 289. Langman CB, Barshop BA, Deschenes G, et al. Controversies 
and research agenda in nephropathic cystinosis: conclusions 
from a “Kidney Disease: Improving Global Outcomes” (KDIGO) 
Controversies Conference. Kidney Int. 2016; 89: 1192–1203.
 290. Shah T, Gill J, Malhotra N, et al. Kidney transplant outcomes in 
patients with Fabry disease. Transplantation. 2009; 87: 280–285.
 291. Cybulla M, Kurschat C, West M, et al. Kidney transplantation and 
enzyme replacement therapy in patients with Fabry disease. J 
Nephrol. 2013; 26: 645–651.
 292. Mignani R, Feriozzi S, Schaefer RM, et al. Dialysis and transplanta-
tion in Fabry disease: indications for enzyme replacement therapy. 
Clin J Am Soc Nephrol. 2010; 5: 379–385.
S90 Transplantation  ■  April 2020  ■ Volume 104  ■  Number 4S www.transplantjournal.com
 293. Miner DJ, Jorkasky DK, Perloff LJ, et al. Recurrent sickle cell 
nephropathy in a transplanted kidney. Am J Kidney Dis. 1987; 10: 
306–313.
 294. Okafor UH, Aneke E. Outcome and challenges of kidney transplant 
in patients with sickle cell disease. J Transplant. 2013; 614610.
 295. Ojo AO, Govaerts TC, Schmouder RL, et al. Renal transplantation 
in end-stage sickle cell nephropathy. Transplantation. 1999; 67: 
291–295.
 296. Mann DM, Fyfe B, Osband AJ, et al. Sarcoidosis within a renal allo-
graft: a case report and review of the literature. Transplant Proc. 
2013; 45: 838–841.
 297. Aouizerate J, Matignon M, Kamar N, et al. Renal transplantation in 
patients with sarcoidosis: a French multicenter study. Clin J Am Soc 
Nephrol. 2010; 5: 2101–2108.
 298. Kelly YP, Patil A, Wallis L, et al. Outcomes of kidney transplantation 
in Alport syndrome compared with other forms of renal disease. Ren 
Fail. 2017; 39: 290–293.
 299. Taylor CM, Machin S, Wigmore SJ, et al. Clinical practice guidelines 
for the management of atypical haemolytic uraemic syndrome in the 
United Kingdom. Br J Haematol. 2010; 148: 37–47.
 300. Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the 
diagnosis and management of intravascular catheter-related infec-
tion: 2009 Update by the Infectious Diseases Society of America. 
Clin Infect Dis. 2009; 49: 1–45.
 301. Rozanski J, Kozlowska I, Myslak M, et al. Pretransplant nephrec-
tomy in patients with autosomal dominant polycystic kidney disease. 
Transplant Proc. 2005; 37: 666–668.
 302. Kanaan N, Devuyst O, Pirson Y. Renal transplantation in autosomal 
dominant polycystic kidney disease. Nat Rev Nephrol. 2014; 10: 
455–465.
 303. Darby CR, Cranston D, Raine AE, et al. Bilateral nephrectomy before 
transplantation: indications, surgical approach, morbidity and mor-
tality. Br J Surg. 1991; 78: 305–307.
 304. Shoma AM, Eraky I, El-Kappany HA. Pretransplant native nephrec-
tomy in patients with end-stage renal failure: assessment of the role 
of laparoscopy. Urology. 2003; 61: 915–920.
 305. Erturk E, Burzon DT, Orloff M, et al. Outcome of patients with vesi-
coureteral reflux after renal transplantation: the effect of pretrans-
plantation surgery on posttransplant urinary tract infections. Urology. 
1998; 51: 27–30.
 306. Zumla A, Chakaya J, Centis R, et al. Tuberculosis treatment and 
management--an update on treatment regimens, trials, new drugs, 
and adjunct therapies. Lancet Respir Med. 2015; 3: 220–234.
 307. World Health Organization. Treatment of tuberculosis: guide-
lines – 4th ed. 160pp (2010). http://apps.who.int/iris/bitstr
eam/10665/44165/1/9789241547833_eng.pdf?ua=1&ua=1 
(Accessed February 28, 2020).
 308. Weiss P, Chen W, Cook VJ, et al. Treatment outcomes from commu-
nity-based drug resistant tuberculosis treatment programs: a sys-
tematic review and meta-analysis. BMC Infect Dis. 2014; 14: 333.
 309. Simkins J, Abbo LM, Camargo JF, et al. Twelve-Week Rifapentine 
Plus Isoniazid Versus 9-Month Isoniazid for the Treatment of Latent 
Tuberculosis in Renal Transplant Candidates. Transplantation. 2017; 
101: 1468–1472.
 310. Malhotra KK, Dash SC, Dhawan IK, et al. Tuberculosis and renal 
transplantation--observations from an endemic area of tuberculosis. 
Postgrad Med J. 1986; 62: 359–362.
 311. Vachharajani T, Abreo K, Phadke A, et al. Diagnosis and treatment 
of tuberculosis in hemodialysis and renal transplant patients. Am J 
Nephrol. 2000; 20: 273–277.
 312. de Castilla DL, Rakita RM, Spitters CE, et al. Short-course isonia-
zid plus rifapentine directly observed therapy for latent tuberculo-
sis in solid-organ transplant candidates. Transplantation. 2014; 97: 
206–211.
 313. Rogerson TE, Chen S, Kok J, et al. Tests for latent tuberculosis in 
people with ESRD: a systematic review. Am J Kidney Dis. 2013; 61: 
33–43.
 314. Jung JY, Joo DJ, Lee CH, et al. Pre-transplant risk factors for tuber-
culosis after kidney transplant in an intermediate burden area. Int J 
Tuberc Lung Dis. 2012; 16: 248–254.
 315. Getahun H, Matteelli A, Abubakar I, et al. Management of latent 
Mycobacterium tuberculosis infection: WHO guidelines for low 
tuberculosis burden countries. Eur Respir J. 2015; 46: 1563–1576.
 316. Knoll BM, Nog R, Wu Y, et al. Three months of weekly rifapentine 
plus isoniazid for latent tuberculosis treatment in solid organ trans-
plant candidates. Infection. 2017; 45: 335–339.
 317. Singh N, Paterson DL. Mycobacterium tuberculosis infection in 
solid-organ transplant recipients: impact and implications for man-
agement. Clin Infect Dis. 1998; 27: 1266–1277.
 318. Subramanian AK, Morris MI, AST Infectious Diseases Community of 
Practice. Mycobacterium tuberculosis infections in solid organ trans-
plantation. Am J Transplant. 2013; 13 Suppl 4: 68–76.
 319. Nylund KM, Meurman JH, Heikkinen AM, et al. Oral health in patients 
with renal disease: a longitudinal study from predialysis to kidney 
transplantation. Clin Oral Investig. 2018; 22: 339–347.
 320. Nylund K, Meurman JH, Heikkinen AM, et al. Oral health in predialy-
sis patients with emphasis on periodontal disease. Quintessence Int. 
2015; 46: 899–907.
 321. Veisa G, Tasmoc A, Nistor I, et al. The impact of periodontal dis-
ease on physical and psychological domains in long-term hemodi-
alysis patients: a cross-sectional study. Int Urol Nephrol. 2017; 49: 
1261–1266.
 322. Roland ME, Barin B, Huprikar S, et al. Survival in HIV-positive trans-
plant recipients compared with transplant candidates and with HIV-
negative controls. AIDS. 2016; 30: 435–444.
 323. Sawinski D, Forde KA, Eddinger K, et al. Superior outcomes in HIV-
positive kidney transplant patients compared with HCV-infected or 
HIV/HCV-coinfected recipients. Kidney Int. 2015; 88: 341–349.
 324. Abbott KC, Swanson SJ, Agodoa LY, et al. Human immunodefi-
ciency virus infection and kidney transplantation in the era of highly 
active antiretroviral therapy and modern immunosuppression. J Am 
Soc Nephrol. 2004; 15: 1633–1639.
 325. Malat G, Jindal RM, Mehta K, et al. Kidney donor risk index 
(KDRI) fails to predict kidney allograft survival in HIV (+) recipients. 
Transplantation. 2014; 98: 436–442.
 326. Locke JE, Mehta S, Reed RD, et al. A National Study of Outcomes 
among HIV-Infected Kidney Transplant Recipients. J Am Soc 
Nephrol. 2015; 26: 2222–2229.
 327. Stock PG, Barin B, Murphy B, et al. Outcomes of kidney transplanta-
tion in HIV-infected recipients. N Engl J Med. 2010; 363: 2004–2014.
 328. Shelton BA, Mehta S, Sawinski D, et al. Increased Mortality 
and Graft Loss With Kidney Retransplantation Among Human 
Immunodeficiency Virus (HIV)-Infected Recipients. Am J Transplant. 
2017; 17: 173–179.
 329. Kidney Disease: Improving Global Outcomes (KDIGO) Hepatitis 
C Work Group. KDIGO 2018 Clinical Practice Guideline on the 
Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in 
Chronic Kidney Disease. Kidney Int Suppl. 2018;8:91–165.
 330. Levitsky J, Doucette K, AST Infectious Diseases Community 
of Practice. Viral hepatitis in solid organ transplantation. Am J 
Transplant. 2013; 13 Suppl 4: 147–168.
 331. Burdick RA, Bragg-Gresham JL, Woods JD, et al. Patterns of hep-
atitis B prevalence and seroconversion in hemodialysis units from 
three continents: the DOPPS. Kidney Int. 2003; 63: 2222–2229.
 332. Knoll A, Pietrzyk M, Loss M, et al. Solid-organ transplantation in 
HBsAg-negative patients with antibodies to HBV core antigen: low 
risk of HBV reactivation. Transplantation. 2005; 79: 1631–1633.
 333. Chen GD, Gu JL, Qiu J, et al. Outcomes and risk factors for hepatitis 
B virus (HBV) reactivation after kidney transplantation in occult HBV 
carriers. Transpl Infect Dis. 2013; 15: 300–305.
 334. Kotton CN, Kumar D, Caliendo AM, et al. Updated international con-
sensus guidelines on the management of cytomegalovirus in solid-
organ transplantation. Transplantation. 2013; 96: 333–360.
 335. Allen UD, Preiksaitis JK, AST Infectious Diseases Community of 
Practice. Epstein-Barr virus and posttransplant lymphoproliferative 
disorder in solid organ transplantation. Am J Transplant. 2013; 13 
Suppl 4: 107–120.
 336. QuickStats: Age-Adjusted* Trends in the Prevalence of Herpes 
Simplex Virus Type 1 (HSV-1) and Herpes Simplex Virus Type 2 
(HSV-2) Among Adolescents and Adults Aged 14–49 Years - United 
States, 1999–2000 Through 2015–2016. MMWR Morb Mortal Wkly 
Rep. 2018; 67: 203.
 337. Bicalho CS, Oliveira RR, Pierrotti LC, et al. Pre-transplant shedding 
of BK virus in urine is unrelated to post-transplant viruria and viremia 
in kidney transplant recipients. Clin Transplant. 2016; 30: 796–801.
 338. Mitterhofer AP, Tinti F, Pietropaolo V, et al. Role of BK virus infec-
tion in end-stage renal disease patients waiting for kidney transplan-
tation--viral replication dynamics from pre- to post-transplant. Clin 
Transplant. 2014; 28: 299–306.
 339. Ramos E, Vincenti F, Lu WX, et al. Retransplantation in patients with 
graft loss caused by polyoma virus nephropathy. Transplantation. 
2004; 77: 131–133.
© 2020 Wolters Kluwer  S91
 340. Hirsch HH, Ramos E. Retransplantation after polyomavirus-associ-
ated nephropathy: just do it? Am J Transplant. 2006; 6: 7–9.
 341. Montesdeoca Andrade MJ, Correa Diaz EP, Buestan ME. HTLV-1-
associated myelopathy in a solid organ transplant recipient. BMJ 
Case Rep. 2016; 2016: pii: bcr2016215243.
 342. Yoshizumi T, Takada Y, Shirabe K, et al. Impact of human T-cell leu-
kemia virus type 1 on living donor liver transplantation: a multi-center 
study in Japan. J Hepatobiliary Pancreat Sci. 2016; 23: 333–341.
 343. Schar F, Trostdorf U, Giardina F, et al. Strongyloides stercoralis: 
Global Distribution and Risk Factors. PLoS Negl Trop Dis. 2013; 7: 
e2288.
 344. Riarte A, Luna C, Sabatiello R, et al. Chagas’ disease in patients with 
kidney transplants: 7 years of experience 1989–1996. Clin Infect Dis. 
1999; 29: 561–567.
 345. Kocher C, Segerer S, Schleich A, et al. Skin lesions, malaise, and 
heart failure in a renal transplant recipient. Transpl Infect Dis. 2012; 
14: 391–397.
 346. Wheat LJ. Approach to the diagnosis of the endemic mycoses. Clin 
Chest Med. 2009; 30: 379–389.
 347. Imam MH. The accelerated hepatitis B virus vaccination schedule 
among hemodialysis patients, does it work? A randomized con-
trolled trial. J Nephrol. 2017; 30: 803–809.
 348. Jin H, Tan Z, Zhang X, et al. Comparison of Accelerated and 
Standard Hepatitis B Vaccination Schedules in High-Risk Healthy 
Adults: A Meta-Analysis of Randomized Controlled Trials. PLoS One. 
2015; 10: e0133464.
 349. Vandecasteele SJ, Ombelet S, Blumental S, et al. The ABC of pneu-
mococcal infections and vaccination in patients with chronic kidney 
disease. Clin Kidney J. 2015; 8: 318–324.
 350. Lin SY, Liu JH, Wang SM, et al. Association of response to hepatitis 
B vaccination and survival in dialysis patients. BMC Nephrol. 2012; 
13: 97.
 351. Chow KM, Lo SH, Szeto CC, et al. Extra-high-dose hepatitis B 
vaccination does not confer longer serological protection in peri-
toneal dialysis patients: a randomized controlled trial. Nephrol Dial 
Transplant. 2010; 25: 2303–2309.
 352. Potsangbam G, Yadav A, Chandel N, et al. Challenges in containing 
the burden of hepatitis B infection in dialysis and transplant patients 
in India. Nephrology (Carlton). 2011; 16: 383–388.
 353. Tsouchnikas I, Dounousi E, Xanthopoulou K, et al. Loss of hepatitis 
B immunity in hemodialysis patients acquired either naturally or after 
vaccination. Clin Nephrol. 2007; 68: 228–234.
 354. Lal H, Cunningham AL, Godeaux O, et al. Efficacy of an adjuvanted 
herpes zoster subunit vaccine in older adults. N Engl J Med. 2015; 
372: 2087–2096.
 355. Mori K, Kawamura K, Honda M, et al. Responses in children to mea-
sles vaccination associated with perirenal transplantation. Pediatr 
Int. 2009; 51: 617–620.
 356. Kho MM, Zuijderwijk JM, van der Eijk AA, et al. Humoral and cellular 
response after varicella vaccination in VZV IgG seronegative kidney 
transplant candidates. Vaccine. 2017; 35: 71–76.
 357. Tseng HF, Luo Y, Shi J, et al. Effectiveness of Herpes Zoster Vaccine 
in Patients 60 Years and Older With End-stage Renal Disease. Clin 
Infect Dis. 2016; 62: 462–467.
 358. Danziger-Isakov L, Kumar D. Vaccination of solid organ transplant 
candidates and recipients: Guidelines from the American society 
of transplantation infectious diseases community of practice. Clin 
Transplant. 2019: e13563.
 359. Malinis M, Boucher HW. Screening of donor and candidate prior to 
solid organ transplantation-Guidelines from the American Society 
of Transplantation Infectious Diseases Community of Practice. Clin 
Transplant. 2019: e13548.
 360. Subramanian AK, Theodoropoulos NM. Mycobacterium tubercu-
losis infections in solid organ transplantation: Guidelines from the 
infectious diseases community of practice of the American Society 
of Transplantation. Clin Transplant. 2019: e13513.
 361. Hirsch HH, Randhawa PS. BK polyomavirus in solid organ trans-
plantation-Guidelines from the American Society of Transplantation 
Infectious Diseases Community of Practice. Clin Transplant. 2019: 
e13528.
 362. Smith RA, Andrews KS, Brooks D, et al. Cancer screening in the 
United States, 2019: A review of current American Cancer Society 
guidelines and current issues in cancer screening. CA Cancer J Clin. 
2019; 69: 184–210.
 363. Siu AL. Screening for Breast Cancer: U.S. Preventive Services Task 
Force Recommendation Statement. Ann Intern Med. 2016; 164: 
279–296.
 364. Bibbins-Domingo K, Grossman DC, Curry SJ, et al. Screening 
for Colorectal Cancer: US Preventive Services Task Force 
Recommendation Statement. JAMA. 2016; 315: 2564–2575.
 365. Wong G, Hope RL, Howard K, et al. One-Time Fecal Immunochemical 
Screening for Advanced Colorectal Neoplasia in Patients with CKD 
(DETECT Study). J Am Soc Nephrol. 2019; 30: 1061–1072.
 366. Curry SJ, Krist AH, Owens DK, et al. Screening for Cervical Cancer: 
US Preventive Services Task Force Recommendation Statement. 
JAMA. 2018; 320: 674–686.
 367. Moyer VA. Screening for lung cancer: U.S. Preventive Services Task 
Force recommendation statement. Ann Intern Med. 2014; 160: 
330–338.
 368. Grossman DC, Curry SJ, Owens DK, et al. Screening for Prostate 
Cancer: US Preventive Services Task Force Recommendation 
Statement. JAMA. 2018; 319: 1901–1913.
 369. Wong G, Howard K, Webster AC, et al. Screening for renal cancer in 
recipients of kidney transplants. Nephrol Dial Transplant. 2011; 26: 
1729–1739.
 370. Wong G, Staplin N, Emberson J, et al. Chronic kidney disease and 
the risk of cancer: an individual patient data meta-analysis of 32,057 
participants from six prospective studies. BMC Cancer. 2016; 16: 
488.
 371. Shebl FM, Warren JL, Eggers PW, et al. Cancer risk among elderly 
persons with end-stage renal disease: a population-based case-
control study. BMC Nephrol. 2012; 13: 65.
 372. Vajdic CM, McDonald SP, McCredie MR, et al. Cancer inci-
dence before and after kidney transplantation. JAMA. 2006; 296: 
2823–2831.
 373. Atkin W, Wooldrage K, Parkin DM, et al. Long term effects of once-
only flexible sigmoidoscopy screening after 17 years of follow-up: 
the UK Flexible Sigmoidoscopy Screening randomised controlled 
trial. Lancet. 2017; 389: 1299–1311.
 374. Wong G, Hayward JS, McArthur E, et al. Patterns and Predictors of 
Screening for Breast and Cervical Cancer in Women with CKD. Clin 
J Am Soc Nephrol. 2017; 12: 95–104.
 375. Williams NC, Tong A, Howard K, et al. Knowledge, beliefs and atti-
tudes of kidney transplant recipients regarding their risk of cancer. 
Nephrology (Carlton). 2012; 17: 300–306.
 376. James LJ, Wong G, Craig JC, et al. Beliefs and Attitudes to Bowel 
Cancer Screening in Patients with CKD: A Semistructured Interview 
Study. Clin J Am Soc Nephrol. 2017; 12: 568–576.
 377. Kiberd BA, Keough-Ryan T, Clase CM. Screening for prostate, 
breast and colorectal cancer in renal transplant recipients. Am J 
Transplant. 2003; 3: 619–625.
 378. Wong G, Li MW, Howard K, et al. Health benefits and costs of 
screening for colorectal cancer in people on dialysis or who have 
received a kidney transplant. Nephrol Dial Transplant. 2013; 28: 
917–926.
 379. Wong G, Howard K, Webster A, et al. The health and economic 
impact of cervical cancer screening and human papillomavirus vac-
cination in kidney transplant recipients. Transplantation. 2009; 87: 
1078–1091.
 380. Wong G, Chapman JR, Craig JC. Cancer screening in renal trans-
plant recipients: what is the evidence? Clin J Am Soc Nephrol. 2008; 
3 Suppl 2: S87–S100.
 381. Wong G, Howard K, Chapman JR, et al. Cost-effectiveness of breast 
cancer screening in women on dialysis. Am J Kidney Dis. 2008; 52: 
916–929.
 382. Acuna SA, Huang JW, Scott AL, et al. Cancer Screening 
Recommendations for Solid Organ Transplant Recipients: A 
Systematic Review of Clinical Practice Guidelines. Am J Transplant. 
2017; 17: 103–114.
 383. Ishikawa I, Honda R, Yamada Y, et al. Renal cell carcinoma detected 
by screening shows better patient survival than that detected fol-
lowing symptoms in dialysis patients. Ther Apher Dial. 2004; 8: 
468–473.
 384. Sarasin FP, Wong JB, Levey AS, et al. Screening for acquired cystic 
kidney disease: a decision analytic perspective. Kidney Int. 1995; 48: 
207–219.
 385. Singanamala S, Brewster UC. Should screening for acquired cystic 
disease and renal malignancy be undertaken in dialysis patients? 
Semin Dial. 2011; 24: 365–366.
 386. Liakopoulos V, Eleftheriadis T, Mertens PR. Screening for renal cell 
carcinoma in dialysis patients. Kidney Int. 2018; 94: 1238.
 387. Perazella MA, Dreicer R, Rosner MH. The authors reply. Kidney Int. 
2018; 94: 1238–1239.
S92 Transplantation  ■  April 2020  ■ Volume 104  ■  Number 4S www.transplantjournal.com
 388. Viecelli AK, Lim WH, Macaskill P, et al. Cancer-Specific and All-
Cause Mortality in Kidney Transplant Recipients With and Without 
Previous Cancer. Transplantation. 2015; 99: 2586–2592.
 389. Acuna SA, Huang JW, Daly C, et al. Outcomes of Solid Organ 
Transplant Recipients With Preexisting Malignancies in Remission: A 
Systematic Review and Meta-Analysis. Transplantation. 2017; 101: 
471–481.
 390. Dahle DO, Grotmol T, Leivestad T, et al. Association Between 
Pretransplant Cancer and Survival in Kidney Transplant Recipients. 
Transplantation. 2017; 101: 2599–2605.
 391. Chapman JR, Sheil AG, Disney AP. Recurrence of cancer after renal 
transplantation. Transplant Proc. 2001; 33: 1830–1831.
 392. Woodle ES, Gupta M, Buell JF, et al. Prostate cancer prior to solid 
organ transplantation: the Israel Penn International Transplant Tumor 
Registry experience. Transplant Proc. 2005; 37: 958–959.
 393. Mukhtar RA, Piper ML, Freise C, et al. The Novel Application of 
Genomic Profiling Assays to Shorten Inactive Status for Potential 
Kidney Transplant Recipients With Breast Cancer. Am J Transplant. 
2017; 17: 292–295.
 394. Smetana GW. Preoperative pulmonary evaluation. N Engl J Med. 
1999; 340: 937–944.
 395. Fan ST, Lau WY, Yip WC, et al. Prediction of postoperative pulmo-
nary complications in oesophagogastric cancer surgery. Br J Surg. 
1987; 74: 408–410.
 396. Qaseem A, Snow V, Fitterman N, et al. Risk assessment for and 
strategies to reduce perioperative pulmonary complications for 
patients undergoing noncardiothoracic surgery: a guideline from 
the American College of Physicians. Ann Intern Med. 2006; 144: 
575–580.
 397. Rucker L, Frye EB, Staten MA. Usefulness of screening chest roent-
genograms in preoperative patients. JAMA. 1983; 250: 3209–3211.
 398. Archer C, Levy AR, McGregor M. Value of routine preoperative chest 
x-rays: a meta-analysis. Can J Anaesth. 1993; 40: 1022–1027.
 399. Wender R, Fontham ET, Barrera E, Jr., et al. American Cancer 
Society lung cancer screening guidelines. CA Cancer J Clin. 2013; 
63: 107–117.
 400. Kasiske BL, Klinger D. Cigarette smoking in renal transplant recipi-
ents. J Am Soc Nephrol. 2000; 11: 753–759.
 401. Hansen EF, Phanareth K, Laursen LC, et al. Reversible and irrevers-
ible airflow obstruction as predictor of overall mortality in asthma and 
chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 
1999; 159: 1267–1271.
 402. Chailleux E, Fauroux B, Binet F, et al. Predictors of survival in 
patients receiving domiciliary oxygen therapy or mechanical ventila-
tion. A 10-year analysis of ANTADIR Observatory. Chest. 1996; 109: 
741–749.
 403. Bunnapradist S, Danovitch GM. Evaluation of adult kidney transplant 
candidates. Am J Kidney Dis. 2007; 50: 890–898.
 404. Gill JS, Ma I, Landsberg D, et al. Cardiovascular events and investi-
gation in patients who are awaiting cadaveric kidney transplantation. 
J Am Soc Nephrol. 2005; 16: 808–816.
 405. Fleisher LA, Fleischmann KE, Auerbach AD, et al. 2014 ACC/AHA 
guideline on perioperative cardiovascular evaluation and man-
agement of patients undergoing noncardiac surgery: a report of 
the American College of Cardiology/American Heart Association 
Task Force on practice guidelines. J Am Coll Cardiol. 2014; 64: 
e77–137.
 406. Lentine KL, Costa SP, Weir MR, et al. Cardiac disease evaluation 
and management among kidney and liver transplantation candi-
dates: a scientific statement from the American Heart Association 
and the American College of Cardiology Foundation: endorsed by 
the American Society of Transplant Surgeons, American Society of 
Transplantation, and National Kidney Foundation. Circulation. 2012; 
126: 617–663.
 407. Kristensen SD, Knuuti J, Saraste A, et al. 2014 ESC/ESA Guidelines 
on non-cardiac surgery: cardiovascular assessment and manage-
ment: The Joint Task Force on non-cardiac surgery: cardiovascular 
assessment and management of the European Society of Cardiology 
(ESC) and the European Society of Anaesthesiology (ESA). Eur Heart 
J. 2014; 35: 2383–2431.
 408. Wang LW, Fahim MA, Hayen A, et al. Cardiac testing for coronary 
artery disease in potential kidney transplant recipients. Cochrane 
Database Syst Rev. 2011: CD008691.
 409. Wang LW, Masson P, Turner RM, et al. Prognostic value of cardiac 
tests in potential kidney transplant recipients: a systematic review. 
Transplantation. 2015; 99: 731–745.
 410. Patel RK, Mark PB, Johnston N, et al. Prognostic value of cardio-
vascular screening in potential renal transplant recipients: a single-
center prospective observational study. Am J Transplant. 2008; 8: 
1673–1683.
 411. Young LH, Wackers FJ, Chyun DA, et al. Cardiac outcomes after 
screening for asymptomatic coronary artery disease in patients 
with type 2 diabetes: the DIAD study: a randomized controlled trial. 
JAMA. 2009; 301: 1547–1555.
 412. Lee TH, Marcantonio ER, Mangione CM, et al. Derivation and pro-
spective validation of a simple index for prediction of cardiac risk of 
major noncardiac surgery. Circulation. 1999; 100: 1043–1049.
 413. Ying T, Gill J, Webster A, et al. Canadian-Australasian Randomised 
trial of screening kidney transplant candidates for coronary artery 
disease-A trial protocol for the CARSK study. Am Heart J. 2019; 
214: 175–183.
 414. McFalls EO, Ward HB, Moritz TE, et al. Coronary-artery revasculari-
zation before elective major vascular surgery. N Engl J Med. 2004; 
351: 2795–2804.
 415. Poldermans D, Schouten O, Vidakovic R, et al. A clinical randomized 
trial to evaluate the safety of a noninvasive approach in high-risk 
patients undergoing major vascular surgery: the DECREASE-V Pilot 
Study. J Am Coll Cardiol. 2007; 49: 1763–1769.
 416. Bechtel JF, Detter C, Fischlein T, et al. Cardiac surgery in patients on 
dialysis: decreased 30-day mortality, unchanged overall survival. Ann 
Thorac Surg. 2008; 85: 147–153.
 417. Manske CL, Wang Y, Rector T, et al. Coronary revascularisation in 
insulin-dependent diabetic patients with chronic renal failure. Lancet. 
1992; 340: 998–1002.
 418. Lindenauer PK, Pekow P, Wang K, et al. Perioperative beta-blocker 
therapy and mortality after major noncardiac surgery. N Engl J Med. 
2005; 353: 349–361.
 419. Wallace AW, Au S, Cason BA. Association of the pattern of use 
of perioperative beta-blockade and postoperative mortality. 
Anesthesiology. 2010; 113: 794–805.
 420. Andersson C, Merie C, Jorgensen M, et al. Association of beta-
blocker therapy with risks of adverse cardiovascular events and 
deaths in patients with ischemic heart disease undergoing noncar-
diac surgery: a Danish nationwide cohort study. JAMA Intern Med. 
2014; 174: 336–344.
 421. Kidney Disease: Improving Global Outcomes (KDIGO) Lipid Work 
Group. KDIGO Clinical Practice Guideline for Lipid Management in 
Chronic Kidney Disease. Kidney Int Suppl. 2013; 3: 259–305.
 422. Hurst FP, Neff RT, Jindal RM, et al. Incidence, predictors and asso-
ciated outcomes of rhabdomyolysis after kidney transplantation. 
Nephrol Dial Transplant. 2009; 24: 3861–3866.
 423. Berger AK, Duval S, Krumholz HM. Aspirin, beta-blocker, and angi-
otensin-converting enzyme inhibitor therapy in patients with end-
stage renal disease and an acute myocardial infarction. J Am Coll 
Cardiol. 2003; 42: 201–208.
 424. McCullough PA, Sandberg KR, Borzak S, et al. Benefits of aspi-
rin and beta-blockade after myocardial infarction in patients with 
chronic kidney disease. Am Heart J. 2002; 144: 226–232.
 425. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guide-
line for the management of patients with atrial fibrillation: executive 
summary: a report of the American College of Cardiology/American 
Heart Association Task Force on practice guidelines and the Heart 
Rhythm Society. Circulation. 2014; 130: 2071–2104.
 426. Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC Guideline 
for the Management of Patients With Valvular Heart Disease: execu-
tive summary: a report of the American College of Cardiology/
American Heart Association Task Force on Practice Guidelines. 
Circulation. 2014; 129: 2440–2492.
 427. Livhits M, Ko CY, Leonardi MJ, et al. Risk of surgery following recent 
myocardial infarction. Ann Surg. 2011; 253: 857–864.
 428. Palmer SC, Di Micco L, Razavian M, et al. Effects of antiplatelet 
therapy on mortality and cardiovascular and bleeding outcomes in 
persons with chronic kidney disease: a systematic review and meta-
analysis. Ann Int Med. 2012; 156: 445–459.
 429. Wijeysundera DN, Wijeysundera HC, Yun L, et al. Risk of elective 
major noncardiac surgery after coronary stent insertion: a popula-
tion-based study. Circulation. 2012; 126: 1355–1362.
 430. Holcomb CN, Graham LA, Richman JS, et al. The incremental risk 
of noncardiac surgery on adverse cardiac events following coronary 
stenting. J Am Coll Cardiol. 2014; 64: 2730–2739.
 431. Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA Guideline 
Focused Update on Duration of Dual Antiplatelet Therapy in Patients 
With Coronary Artery Disease: A Report of the American College 
© 2020 Wolters Kluwer  S93
of Cardiology/American Heart Association Task Force on Clinical 
Practice Guidelines. J Am Coll Cardiol. 2016; 68: 1082–1115.
 432. Herzog CA. Kidney disease in cardiology. Nephrol Dial Transplant. 
2011; 26: 46–50.
 433. Herzog CA, Ma JZ, Collins AJ. Long-term survival of dialysis patients 
in the United States with prosthetic heart valves: should ACC/AHA 
practice guidelines on valve selection be modified? Circulation. 
2002; 105: 1336–1341.
 434. Navaneethan SD, Roy J, Tao K, et al. Prevalence, Predictors, and 
Outcomes of Pulmonary Hypertension in CKD. J Am Soc Nephrol. 
2016; 27: 877–886.
 435. Stallworthy EJ, Pilmore HL, Webster MW, et al. Do echocardio-
graphic parameters predict mortality in patients with end-stage renal 
disease? Transplantation. 2013; 95: 1225–1232.
 436. National Kidney Foundation. K/DOQI clinical practice guidelines for 
cardiovascular disease in dialysis patients. Am J Kidney Dis. 2005; 
45: S1–153.
 437. Lentine KL, Villines TC, Axelrod D, et al. Evaluation and Management 
of Pulmonary Hypertension in Kidney Transplant Candidates and 
Recipients: Concepts and Controversies. Transplantation. 2017; 
101: 166–181.
 438. de Mattos AM, Siedlecki A, Gaston RS, et al. Systolic dysfunction 
portends increased mortality among those waiting for renal trans-
plant. J Am Soc Nephrol. 2008; 19: 1191–1196.
 439. Solomon SD, Anavekar N, Skali H, et al. Influence of ejection frac-
tion on cardiovascular outcomes in a broad spectrum of heart failure 
patients. Circulation. 2005; 112: 3738–3744.
 440. Yamada S, Ishii H, Takahashi H, et al. Prognostic value of reduced 
left ventricular ejection fraction at start of hemodialysis therapy on 
cardiovascular and all-cause mortality in end-stage renal disease 
patients. Clin J Am Soc Nephrol. 2010; 5: 1793–1798.
 441. Cice G, Ferrara L, D’Andrea A, et al. Carvedilol increases two-
year survivalin dialysis patients with dilated cardiomyopathy: a 
prospective, placebo-controlled trial. J Am Coll Cardiol. 2003; 41: 
1438–1444.
 442. Vahanian A, Alfieri O, Andreotti F, et al. Guidelines on the manage-
ment of valvular heart disease (version 2012): the Joint Task Force on 
the Management of Valvular Heart Disease of the European Society of 
Cardiology (ESC) and the European Association for Cardio-Thoracic 
Surgery (EACTS). Eur J Cardiothorac Surg. 2012; 42: S1–44.
 443. Tang W, McDonald SP, Hawley CM, et al. End-stage renal failure due 
to amyloidosis: outcomes in 490 ANZDATA registry cases. Nephrol 
Dial Transplant. 2013; 28: 455–461.
 444. Sattianayagam PT, Gibbs SD, Pinney JH, et al. Solid organ trans-
plantation in AL amyloidosis. Am J Transplant. 2010; 10: 2124–2131.
 445. Banypersad SM, Moon JC, Whelan C, et al. Updates in cardiac amy-
loidosis: a review. J Am Heart Assoc. 2012; 1: e000364.
 446. Bangalore S, Maron DJ, Fleg JL, et al. International Study of 
Comparative Health Effectiveness with Medical and Invasive 
Approaches-Chronic Kidney Disease (ISCHEMIA-CKD): Rationale 
and design. Am Heart J. 2018; 205: 42–52.
 447. Jones DW, Dansey K, Hamdan AD. Lower Extremity Revascularization 
in End-Stage Renal Disease. Vasc Endovascular Surg. 2016; 50: 
582–585.
 448. Brar A, Jindal RM, Elster EA, et al. Effect of peripheral vascular dis-
ease on kidney allograft outcomes: a study of U.S. Renal data sys-
tem. Transplantation. 2013; 95: 810–815.
 449. Kahn J, Ram LM, Eberhard K, et al. Calcification score evaluation in 
patients listed for renal transplantation. Clin Transplant. 2017; 31.
 450. Chen J, Mohler ER, 3rd, Garimella PS, et al. Ankle Brachial Index 
and Subsequent Cardiovascular Disease Risk in Patients With 
Chronic Kidney Disease. J Am Heart Assoc. 2016; 5: pii: e003339.
 451. Wu SW, Lin CK, Hung TW, et al. Subclinical peripheral arterial dis-
ease in renal transplantation. Am J Med Sci. 2014; 347: 267–270.
 452. Andres A, Revilla Y, Ramos A, et al. Helical computed tomogra-
phy angiography is the most efficient test to assess vascular cal-
cifications in the iliac arterial sector in renal transplant candidates. 
Transplant Proc. 2003; 35: 1682–1683.
 453. Tozzi M, Franchin M, Soldini G, et al. Treatment of aortoiliac occlusive 
or dilatative disease concomitant with kidney transplantation: how 
and when? Int J Surg. 2013; 11 Suppl 1: S115–119.
 454. Matia I, Adamec M, Varga M, et al. Aortoiliac reconstruction with 
allograft and kidney transplantation as a one-stage procedure: long 
term results. Eur J Vasc Endovasc Surg. 2008; 35: 353–357.
 455. Galazka Z, Grochowiecki T, Jakimowicz T, et al. Is severe atheroscle-
rosis in the aortoiliac region a contraindication for kidney transplanta-
tion? Transplant Proc. 2011; 43: 2908–2910.
 456. Gallagher KA, Ravin RA, Schweitzer E, et al. Outcomes and timing of 
aortic surgery in renal transplant patients. Ann Vasc Surg. 2011; 25: 
448–453.
 457. Snyder JJ, Kasiske BL, Maclean R. Peripheral arterial disease and 
renal transplantation. J Am Soc Nephrol. 2006; 17: 2056–2068.
 458. Ro H, Kim AJ, Chang JH, et al. Can Kidney Transplantation Improve 
Arterial Stiffness in End-Stage Renal Patients? Transplant Proc. 
2016; 48: 884–886.
 459. Northcutt A, Zibari G, Tan TW, et al. Does kidney transplantation to 
iliac artery deteriorate ischemia in the ipsilateral lower extremity with 
peripheral arterial disease? Vascular. 2015; 23: 490–493.
 460. Sung RS, Althoen M, Howell TA, et al. Peripheral vascular occlusive 
disease in renal transplant recipients: risk factors and impact on kid-
ney allograft survival. Transplantation. 2000; 70: 1049–1054.
 461. A classification and outline of cerebrovascular diseases. II. Stroke. 
1975; 6: 564–616.
 462. Sanders RD, Bottle A, Jameson SS, et al. Independent preoperative 
predictors of outcomes in orthopedic and vascular surgery: the influ-
ence of time interval between an acute coronary syndrome or stroke 
and the operation. Ann Surg. 2012; 255: 901–907.
 463. Jorgensen ME, Torp-Pedersen C, Gislason GH, et al. Time elapsed 
after ischemic stroke and risk of adverse cardiovascular events and 
mortality following elective noncardiac surgery. JAMA. 2014; 312: 
269–277.
 464. Jonas DE, Feltner C, Amick HR, et al. Screening for asymptomatic 
carotid artery stenosis: a systematic review and meta-analysis for 
the U.S. Preventive Services Task Force. Ann Intern Med. 2014; 161: 
336–346.
 465. Aull-Watschinger S, Konstantin H, Demetriou D, et al. Pre-transplant 
predictors of cerebrovascular events after kidney transplantation. 
Nephrol Dial Transplant. 2008; 23: 1429–1435.
 466. LeFevre ML, Force USPST. Screening for asymptomatic carotid 
artery stenosis: U.S. Preventive Services Task Force recommenda-
tion statement. Ann Intern Med. 2014; 161: 356–362.
 467. Rossitter CW, Vigo RB, Gaber AO, et al. Evaluation of Carotid 
Ultrasonography Screening Among Kidney Transplant Candidates: 
A Single-Center, Retrospective Study. Transplant Direct. 2017; 3: 
e135.
 468. Irazabal MV, Huston J, 3rd, Kubly V, et al. Extended follow-up of 
unruptured intracranial aneurysms detected by presymptomatic 
screening in patients with autosomal dominant polycystic kidney 
disease. Clin J Am Soc Nephrol. 2011; 6: 1274–1285.
 469. Xu HW, Yu SQ, Mei CL, et al. Screening for intracranial aneurysm 
in 355 patients with autosomal-dominant polycystic kidney disease. 
Stroke. 2011; 42: 204–206.
 470. Vlak MH, Algra A, Brandenburg R, et al. Prevalence of unruptured 
intracranial aneurysms, with emphasis on sex, age, comorbidity, 
country, and time period: a systematic review and meta-analysis. . 
Lancet Neurol. 2011; 10: 626–636.
 471. Rozenfeld MN, Ansari SA, Mohan P, et al. Autosomal Dominant 
Polycystic Kidney Disease and Intracranial Aneurysms: Is There an 
Increased Risk of Treatment? AJNR Am J Neuroradiol. 2016; 37: 
290–293.
 472. Chapman AB, Devuyst O, Eckardt KU, et al. Autosomal-dominant 
polycystic kidney disease (ADPKD): executive summary from a 
Kidney Disease: Improving Global Outcomes (KDIGO) Controversies 
Conference. Kidney Int. 2015; 88: 17–27.
 473. Lee VW, Dexter MA, Mai J, et al. KHA-CARI Autosomal Dominant 
Polycystic Kidney Disease Guideline: Management of Intracranial 
Aneurysms. Semin Nephrol. 2015; 35: 612–617.
 474. Schrier RW, Belz MM, Johnson AM, et al. Repeat imaging for intrac-
ranial aneurysms in patients with autosomal dominant polycystic 
kidney disease with initially negative studies: a prospective ten-year 
follow-up. J Am Soc Nephrol. 2004; 15: 1023–1028.
 475. Jiang T, Wang P, Qian Y, et al. A follow-up study of autosomal domi-
nant polycystic kidney disease with intracranial aneurysms using 3.0 
T three-dimensional time-of-flight magnetic resonance angiography. 
Eur J Radiol. 2013; 82: 1840–1845.
 476. Bolton CF, Baltzan MA, Baltzan RB. Effects of renal transplantation 
on uremic neuropathy. A clinical and electrophysiologic study. N Engl 
J Med. 1971; 284: 1170–1175.
 477. Sarkio S, Halme L, Kyllonen L, et al. Severe gastrointestinal compli-
cations after 1,515 adult kidney transplantations. Transpl Int. 2004; 
17: 505–510.
 478. Telkes G, Peter A, Tulassay Z, et al. High frequency of ulcers, not asso-
ciated with Helicobacter pylori, in the stomach in the first year after 
kidney transplantation. Nephrol Dial Transplant. 2011; 26: 727–732.
S94 Transplantation  ■  April 2020  ■ Volume 104  ■  Number 4S www.transplantjournal.com
 479. Logan AJ, Morris-Stiff GJ, Bowrey DJ, et al. Upper gastrointestinal 
complications after renal transplantation: a 3-yr sequential study. 
Clin Transplant. 2002; 16: 163–167.
 480. Troppmann C, Papalois BE, Chiou A, et al. Incidence, complications, 
treatment, and outcome of ulcers of the upper gastrointestinal tract 
after renal transplantation during the cyclosporine era. J Am Coll 
Surg. 1995; 180: 433–443.
 481. Ueda Y, Chiba T. Helicobacter pylori in solid-organ transplant recipi-
ent. Curr Opin Organ Transplant. 2008; 13: 586–591.
 482. Cocchiara G, Romano M, Buscemi G, et al. Advantage of eradica-
tion therapy for Helicobacter pylori before kidney transplantation in 
uremic patients. Transplant Proc. 2007; 39: 3041–3043.
 483. Sarkio S, Rautelin H, Kyllonen L, et al. Should Helicobacter pylori 
infection be treated before kidney transplantation? Nephrol Dial 
Transplant. 2001; 16: 2053–2057.
 484. Coccolini F, Catena F, Di Saverio S, et al. Colonic perforation after 
renal transplantation: risk factor analysis. Transplant Proc. 2009; 41: 
1189–1190.
 485. Oor JE, Atema JJ, Boermeester MA, et al. A systematic review of 
complicated diverticulitis in post-transplant patients. J Gastrointest 
Surg. 2014; 18: 2038–2046.
 486. Klarenbeek BR, Veenhof AA, Bergamaschi R, et al. Laparoscopic 
sigmoid resection for diverticulitis decreases major morbidity rates: 
a randomized control trial: short-term results of the Sigma Trial. Ann 
Surg. 2009; 249: 39–44.
 487. Slakey DP, Johnson CP, Cziperle DJ, et al. Management of severe 
pancreatitis in renal transplant recipients. Ann Surg. 1997; 225: 
217–222.
 488. Graham SM, Flowers JL, Schweitzer E, et al. The utility of prophy-
lactic laparoscopic cholecystectomy in transplant candidates. Ann 
Surg. 1995; 169: 44–48.
 489. Jackson T, Treleaven D, Arlen D, et al. Management of asympto-
matic cholelithiasis for patients awaiting renal transplantation. Surg 
Endosc. 2005; 19: 510–513.
 490. Meka M, Potdar S, Benotti P, et al. Role of ultrasound screening for 
gallbladder disease in pretransplant patients. Am Surg. 2008; 74: 
832–833.
 491. Melvin WS, Meier DJ, Elkhammas EA, et al. Prophylactic cholecys-
tectomy is not indicated following renal transplantation. Am J Surg. 
1998; 175: 317–319.
 492. Brito AT, Azevedo LS, Nahas WC, et al. Cholelithiasis in patients 
on the kidney transplant waiting list. Clinics (Sao Paulo). 2010; 65: 
389–391.
 493. Sarkio S, Salmela K, Kyllonen L, et al. Complications of gallstone 
disease in kidney transplantation patients. Nephrol Dial Transplant. 
2007; 22: 886–890.
 494. Schnitzler F, Friedrich M, Stallhofer J, et al. Solid Organ 
Transplantation in Patients with Inflammatory Bowel Diseases (IBD): 
Analysis of Transplantation Outcome and IBD Activity in a Large 
Single Center Cohort. PLoS One. 2015; 10: e0135807.
 495. Verdonk RC, Dijkstra G, Haagsma EB, et al. Inflammatory bowel dis-
ease after liver transplantation: risk factors for recurrence and de 
novo disease. Am J Transplant. 2006; 6: 1422–1429.
 496. Dvorchik I, Subotin M, Demetris AJ, et al. Effect of liver transplanta-
tion on inflammatory bowel disease in patients with primary scleros-
ing cholangitis. Hepatology. 2002; 35: 380–384.
 497. Haagsma EB, Van Den Berg AP, Kleibeuker JH, et al. Inflammatory 
bowel disease after liver transplantation: the effect of different immu-
nosuppressive regimens. Aliment Pharmacol Ther. 2003; 18: 33–44.
 498. Indriolo A, Ravelli P. Clinical management of inflammatory bowel 
disease in the organ recipient. World J Gastroenterol. 2014; 20: 
3525–3533.
 499. Garrouste C, Anglicheau D, Kamar N, et al. Anti-TNFalpha therapy 
for chronic inflammatory disease in kidney transplant recipients: 
Clinical outcomes. Medicine (Baltimore). 2016; 95: e5108.
 500. Clarke WT, Feuerstein JD. Updates in colorectal cancer screening 
in inflammatory bowel disease. Curr Opin Gastroenterol. 2018; 34: 
208–216.
 501. Farraye FA, Odze RD, Eaden J, et al. AGA medical position statement 
on the diagnosis and management of colorectal neoplasia in inflam-
matory bowel disease. Gastroenterology. 2010; 138: 738–745.
 502. Cairns SR, Scholefield JH, Steele RJ, et al. Guidelines for colorectal 
cancer screening and surveillance in moderate and high risk groups 
(update from 2002). Gut. 2010; 59: 666–689.
 503. Cubiella J, Marzo-Castillejo M, Mascort-Roca JJ, et al. Clinical prac-
tice guideline. Diagnosis and prevention of colorectal cancer. 2018 
Update. Gastroenterol Hepatol. 2018; 41: 585–596.
 504. Eason JD, Gonwa TA, Davis CL, et al. Proceedings of Consensus 
Conference on Simultaneous Liver Kidney Transplantation (SLK). Am 
J Transplant. 2008; 8: 2243–2251.
 505. Phelan PJ, O’Kelly P, Tarazi M, et al. Renal allograft loss in the first 
post-operative month: causes and consequences. Clin Transplant. 
2012; 26: 544–549.
 506. Kujovich JL. Thrombophilia and thrombotic problems in renal trans-
plant patients. Transplantation. 2004; 77: 959–964.
 507. Irish AB, Green FR, Gray DW, et al. The factor V Leiden (R506Q) 
mutation and risk of thrombosis in renal transplant recipients. 
Transplantation. 1997; 64: 604–607.
 508. Vaidya S, Sellers R, Kimball P, et al. Frequency, potential risk 
and therapeutic intervention in end-stage renal disease patients 
with antiphospholipid antibody syndrome: a multicenter study. 
Transplantation. 2000; 69: 1348–1352.
 509. Friedman GS, Meier-Kriesche HU, Kaplan B, et al. Hypercoagulable 
states in renal transplant candidates: impact of anticoagulation upon 
incidence of renal allograft thrombosis. Transplantation. 2001; 72: 
1073–1078.
 510. Esfandiar N, Otukesh H, Sharifian M, et al. Protective effect of hepa-
rin and aspirin against vascular thrombosis in pediatric kidney trans-
plants. Iran J Kidney Dis. 2012; 6: 141–145.
 511. Murashima M, Konkle BA, Bloom RD, et al. A single-center experi-
ence of preemptive anticoagulation for patients with risk factors for 
allograft thrombosis in renal transplantation. Clin Nephrol. 2010; 74: 
351–357.
 512. Dalal A. Organ transplantation and drug eluting stents: Perioperative 
challenges. World J Transplant. 2016; 6: 620–631.
 513. Kolh P, Windecker S, Alfonso F, et al. 2014 ESC/EACTS Guidelines 
on myocardial revascularization: the Task Force on Myocardial 
Revascularization of the European Society of Cardiology (ESC) and 
the European Association for Cardio-Thoracic Surgery (EACTS). 
Developed with the special contribution of the European Association 
of Percutaneous Cardiovascular Interventions (EAPCI). Eur J 
Cardiothorac Surg. 2014; 46: 517–592.
 514. International Myeloma Working Group. Criteria for the classification 
of monoclonal gammopathies, multiple myeloma and related dis-
orders: a report of the International Myeloma Working Group. Br J 
Haematol. 2003; 121: 749–757.
 515. Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International 
Myeloma Working Group updated criteria for the diagnosis of multi-
ple myeloma. Lancet Oncol. 2014; 15: e538–548.
 516. Leung N, Bridoux F, Batuman V, et al. The evaluation of monoclo-
nal gammopathy of renal significance: a consensus report of the 
International Kidney and Monoclonal Gammopathy Research Group. 
Nat Rev Nephrol. 2019; 15: 45–59.
 517. Cowan AJ, Johnson CK, Libby EN. Plasma cell diseases and organ 
transplant: A comprehensive review. Am J Transplant. 2018; 18: 
1046–1058.
 518. Alfano G, Fontana F, Colaci E, et al. Monoclonal Gammopathy of 
Undetermined Significance After Kidney Transplantation: Single-
Center Experience. Transplantation. 2017; 101: e337-e342.
 519. Coco M, Pullman J, Cohen HW, et al. Effect of risedronate on 
bone in renal transplant recipients. J Am Soc Nephrol. 2012; 23: 
1426–1437.
 520. Haas M, Leko-Mohr Z, Roschger P, et al. Zoledronic acid to prevent 
bone loss in the first 6 months after renal transplantation. Kidney Int. 
2003; 63: 1130–1136.
 521. Perez-Saez MJ, Herrera S, Prieto-Alhambra D, et al. Bone density, 
microarchitecture, and material strength in chronic kidney disease 
patients at the time of kidney transplantation. Osteoporos Int. 2017; 
28: 2723–2727.
 522. Naylor KL, Jamal SA, Zou G, et al. Fracture Incidence in Adult Kidney 
Transplant Recipients. Transplantation. 2016; 100: 167–175.
 523. Naylor KL, Li AH, Lam NN, et al. Fracture risk in kidney trans-
plant recipients: a systematic review. Transplantation. 2013; 95: 
1461–1470.
 524. Nikkel LE, Hollenbeak CS, Fox EJ, et al. Risk of fractures after renal 
transplantation in the United States. Transplantation. 2009; 87: 
1846–1851.
 525. Palmer SC, McGregor DO, Strippoli GF. Interventions for preventing 
bone disease in kidney transplant recipients. Cochrane Database 
Syst Rev. 2007: CD005015.
 526. Bouquegneau A, Salam S, Delanaye P, et al. Bone Disease 
after Kidney Transplantation. Clin J Am Soc Nephrol. 2016; 11: 
1282–1296.
© 2020 Wolters Kluwer  S95
 527. Sprague SM, Bellorin-Font E, Jorgetti V, et al. Diagnostic Accuracy 
of Bone Turnover Markers and Bone Histology in Patients With CKD 
Treated by Dialysis. Am J Kidney Dis. 2016; 67: 559–566.
 528. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD 
Update Work Group. KDIGO 2017 Clinical Practice Guideline Update 
for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic 
Kidney Disease–Mineral and Bone Disorder (CKD-MBD). Kidney Int 
Suppl. 2017;7:1–59.
 529. Callender GG, Malinowski J, Javid M, et al. Parathyroidectomy prior to 
kidney transplant decreases graft failure. Surgery. 2017; 161: 44–50.
 530. Parikh S, Nagaraja H, Agarwal A, et al. Impact of post-kidney trans-
plant parathyroidectomy on allograft function. Clin Transplant. 2013; 
27: 397–402.
 531. Cruzado JM, Moreno P, Torregrosa JV, et al. A Randomized 
Study Comparing Parathyroidectomy with Cinacalcet for 
Treating Hypercalcemia in Kidney Allograft Recipients with 
Hyperparathyroidism. J Am Soc Nephrol. 2016; 27: 2487–2494.
 532. Hod T, Riella LV, Chandraker A. Recombinant PTH therapy for severe 
hypoparathyroidism after kidney transplantation in pre-transplant 
parathyroidectomized patients: review of the literature and a case 
report. Clin Transplant. 2015; 29: 951–957.
 533. Cejka D, Haas M. Should teriparatide ever be used for adynamic 
bone disease? Semin Dial. 2011; 24: 431–433.
 534. De Clippel D, Baeten M, Torfs A, et al. Screening for HLA antibodies 
in plateletpheresis donors with a history of transfusion or pregnancy. 
Transfusion. 2014; 54: 3036–3042.
 535. Magee BA, Martin J, Cole MP, et al. Effects of HLA-matched 
blood transfusion for patients awaiting renal transplantation. 
Transplantation. 2012; 94: 1111–1116.
 536. Jia Y, Li W, Liu N, et al. Prevalence of platelet-specific antibodies and 
efficacy of crossmatch-compatible platelet transfusions in refractory 
patients. Transfus Med. 2014; 24: 406–410.
 537. Honger G, Fornaro I, Granado C, et al. Frequency and determinants 
of pregnancy-induced child-specific sensitization. Am J Transplant. 
2013; 13: 746–753.
 538. Geneugelijk K, Honger G, van Deutekom HW, et al. Predicted 
Indirectly Recognizable HLA Epitopes Presented by HLA-DRB1 
Are Related to HLA Antibody Formation During Pregnancy. Am J 
Transplant. 2015; 15: 3112–3122.
 539. Arnold ML, Dechant M, Doxiadis, II, et al. Prevalence and specific-
ity of immunoglobulin G and immunoglobulin A non-complement-
binding anti-HLA alloantibodies in retransplant candidates. Tissue 
Antigens. 2008; 72: 60–66.
 540. Arnold ML, Pei R, Spriewald B, et al. Anti-HLA class II antibodies in 
kidney retransplant patients. Tissue Antigens. 2005; 65: 370–378.
 541. Scornik JC, Kriesche HU. Human leukocyte antigen sensitization 
after transplant loss: timing of antibody detection and implications 
for prevention. Hum Immunol. 2011; 72: 398–401.
 542. Hyun J, Park KD, Yoo Y, et al. Effects of different sensitization events 
on HLA alloimmunization in solid organ transplantation patients. 
Transplant Proc. 2012; 44: 222–225.
 543. Gralla J, Tong S, Wiseman AC. The impact of human leukocyte anti-
gen mismatching on sensitization rates and subsequent retransplan-
tation after first graft failure in pediatric renal transplant recipients. 
Transplantation. 2013; 95: 1218–1224.
 544. Lucia M, Luque S, Crespo E, et al. Preformed circulating HLA-
specific memory B cells predict high risk of humoral rejection in kid-
ney transplantation. Kidney Int. 2015; 88: 874–887.
 545. Mulder A, Kardol MJ, Kamp J, et al. Determination of the frequency 
of HLA antibody secreting B-lymphocytes in alloantigen sensitized 
individuals. Clin Exp Immunol. 2001; 124: 9–15.
 546. Hricik DE, Rodriguez V, Riley J, et al. Enzyme linked immunosorbent 
spot (ELISPOT) assay for interferon-gamma independently predicts 
renal function in kidney transplant recipients. Am J Transplant. 2003; 
3: 878–884.
 547. Bray RA, Nickerson PW, Kerman RH, et al. Evolution of HLA anti-
body detection: technology emulating biology. Immunol Res. 2004; 
29: 41–54.
 548. Tait BD, Hudson F, Brewin G, et al. Solid phase HLA antibody detec-
tion technology--challenges in interpretation. Tissue Antigens. 2010; 
76: 87–95.
 549. Montgomery RA, Leffell MS, Zachary AA. Transplantation of the sen-
sitized patient: histocompatibility testing. Methods Mol Biol. 2013; 
1034: 117–125.
 550. Bachelet T, Martinez C, Del Bello A, et al. Deleterious Impact of 
Donor-Specific Anti-HLA Antibodies Toward HLA-Cw and HLA-DP 
in Kidney Transplantation. Transplantation. 2016; 100: 159–166.
 551. Mierzejewska B, Schroder PM, Baum CE, et al. Early acute anti-
body-mediated rejection of a negative flow crossmatch 3rd kidney 
transplant with exclusive disparity at HLA-DP. Hum Immunol. 2014; 
75: 703–708.
 552. Cippa PE, Gaspert A, Etter C, et al. Late antibody-mediated rejection 
by de novo donor HLA-DP-specific antibody after renal transplanta-
tion: a case report. Hum Immunol. 2014; 75: 462–465.
 553. Jolly EC, Key T, Rasheed H, et al. Preformed donor HLA-DP-specific 
antibodies mediate acute and chronic antibody-mediated rejec-
tion following renal transplantation. Am J Transplant. 2012; 12: 
2845–2848.
 554. Billen EV, Christiaans MH, Doxiadis, II, et al. HLA-DP antibodies 
before and after renal transplantation. Tissue Antigens. 2010; 75: 
278–285.
 555. Cicciarelli J, Helstab K, Mendez R. Flow cytometry PRA, a new test 
that is highly correlated with graft survival. Clin Transplant. 1992; 6: 
159–164.
 556. Pei R, Lee JH, Shih NJ, et al. Single human leukocyte antigen flow 
cytometry beads for accurate identification of human leukocyte anti-
gen antibody specificities. Transplantation. 2003; 75: 43–49.
 557. Zachary AA, Kopchaliiska D, Jackson AM, et al. Immunogenetics 
and immunology in transplantation. Immunol Res. 2010; 47: 
232–239.
 558. Taylor CJ, Kosmoliaptsis V, Summers DM, et al. Back to the future: 
application of contemporary technology to long-standing questions 
about the clinical relevance of human leukocyte antigen-specific 
alloantibodies in renal transplantation. Hum Immunol. 2009; 70: 
563–568.
 559. Zachary AA, Vega RM, Lucas DP, et al. HLA antibody detection and 
characterization by solid phase immunoassays: methods and pit-
falls. Methods Mol Biol. 2012; 882: 289–308.
 560. Haarberg KM, Tambur AR. Detection of donor-specific antibodies in 
kidney transplantation. Br Med Bull. 2014; 110: 23–34.
 561. Pei R, Lee J, Chen T, et al. Flow cytometric detection of HLA anti-
bodies using a spectrum of microbeads. Hum Immunol. 1999; 60: 
1293–1302.
 562. Pei R, Wang G, Tarsitani C, et al. Simultaneous HLA Class I and 
Class II antibodies screening with flow cytometry. Hum Immunol. 
1998; 59: 313–322.
 563. Morales-Buenrostro LE, Terasaki PI, Marino-Vazquez LA, et al. 
“Natural” human leukocyte antigen antibodies found in nonalloim-
munized healthy males. Transplantation. 2008; 86: 1111–1115.
 564. Grenzi PC, de Marco R, Silva RZ, et al. Antibodies against denatured 
HLA class II molecules detected in luminex-single antigen assay. 
Hum Immunol. 2013; 74: 1300–1303.
 565. Cecka JM. Calculated PRA (CPRA): the new measure of sensitiza-
tion for transplant candidates. Am J Transplant. 2010; 10: 26–29.
 566. Tinckam KJ, Liwski R, Pochinco D, et al. cPRA Increases With 
DQA, DPA, and DPB Unacceptable Antigens in the Canadian cPRA 
Calculator. Am J Transplant. 2015; 15: 3194–3201.
 567. Duquesnoy RJ, Awadalla Y, Lomago J, et al. Retransplant candi-
dates have donor-specific antibodies that react with structurally 
defined HLA-DR,DQ,DP epitopes. Transpl Immunol. 2008; 18: 
352–360.
 568. Vaidya S, Hilson B, Sheldon S, et al. DP reactive antibody in a 
zero mismatch renal transplant pair. Hum Immunol. 2007; 68: 
947–949.
 569. Wiebe C, Pochinco D, Blydt-Hansen TD, et al. Class II HLA epitope 
matching-A strategy to minimize de novo donor-specific antibody 
development and improve outcomes. Am J Transplant. 2013; 13: 
3114–3122.
 570. Sapir-Pichhadze R, Tinckam K, Quach K, et al. HLA-DR and -DQ 
eplet mismatches and transplant glomerulopathy: a nested case-
control study. Am J Transplant. 2015; 15: 137–148.
 571. Duquesnoy RJ, Kamoun M, Baxter-Lowe LA, et al. Should HLA mis-
match acceptability for sensitized transplant candidates be deter-
mined at the high-resolution rather than the antigen level? Am J 
Transplant. 2015; 15: 923–930.
 572. Bray RA, Gebel HM. Allele-specific HLA alloantibodies: Implications for 
organ allocation. [Abstract 1306] Am J Transplant. 2005; 5(s11): 488.
 573. Wiebe C, Gibson IW, Blydt-Hansen TD, et al. Rates and determi-
nants of progression to graft failure in kidney allograft recipients 
with de novo donor-specific antibody. Am J Transplant. 2015; 15: 
2921–2930.
 574. Hricik DE, Formica RN, Nickerson P, et al. Adverse Outcomes of 
Tacrolimus Withdrawal in Immune-Quiescent Kidney Transplant 
Recipients. J Am Soc Nephrol. 2015; 26: 3114–3122.
S96 Transplantation  ■  April 2020  ■ Volume 104  ■  Number 4S www.transplantjournal.com
 575. Wiebe C, Gibson IW, Blydt-Hansen TD, et al. Evolution and clinical 
pathologic correlations of de novo donor-specific HLA antibody post 
kidney transplant. Am J Transplant. 2012; 12: 1157–1167.
 576. Bostock IC, Alberu J, Arvizu A, et al. Probability of deceased donor 
kidney transplantation based on % PRA. Transpl Immunol. 2013; 28: 
154–158.
 577. Friedewald JJ, Samana CJ, Kasiske BL, et al. The kidney allocation 
system. Surg Clin North Am. 2013; 93: 1395–1406.
 578. Claas FH, Witvliet MD, Duquesnoy RJ, et al. The acceptable mis-
match program as a fast tool for highly sensitized patients awaiting 
a cadaveric kidney transplantation: short waiting time and excellent 
graft outcome. Transplantation. 2004; 78: 190–193.
 579. Cecka JM, Kucheryavaya AY, Reinsmoen NL, et al. Calculated PRA: 
initial results show benefits for sensitized patients and a reduction in 
positive crossmatches. Am J Transplant. 2011; 11: 719–724.
 580. Leffell MS. The calculated panel reactive antibody policy: an advance-
ment improving organ allocation. Curr Opin Organ Transplant. 2011; 
16: 404–409.
 581. Sapir-Pichhadze R, Tinckam KJ, Laupacis A, et al. Immune 
Sensitization and Mortality in Wait-Listed Kidney Transplant 
Candidates. J Am Soc Nephrol. 2016; 27: 570–578.
 582. Huber L, Lachmann N, Niemann M, et al. Pretransplant virtual PRA 
and long-term outcomes of kidney transplant recipients. Transpl Int. 
2015; 28: 710–719.
 583. Wehmeier C, Honger G, Cun H, et al. Donor Specificity but Not 
Broadness of Sensitization Is Associated With Antibody-Mediated 
Rejection and Graft Loss in Renal Allograft Recipients. Am J 
Transplant. 2017; 17: 2092–2102.
 584. Gonzalez-Galarza FF, Christmas S, Middleton D, et al. Allele fre-
quency net: a database and online repository for immune gene fre-
quencies in worldwide populations. Nucleic Acids Res. 2011; 39: 
D913–919.
 585. Gonzalez-Galarza FF, Takeshita LY, Santos EJ, et al. Allele frequency 
net 2015 update: new features for HLA epitopes, KIR and disease 
and HLA adverse drug reaction associations. Nucleic Acids Res. 
2015; 43: D784–788.
 586. Takeshita LY, Jones AR, Gonzalez-Galarza FF, et al. Allele frequen-
cies database. Transfus Med Hemother. 2014; 41: 352–355.
 587. Takeshita LY, Gonzalez-Galarza FF, dos Santos EJ, et al. A database 
for curating the associations between killer cell immunoglobulin-
like receptors and diseases in worldwide populations. Database 
(Oxford). 2013; bat021; https://doi.org/10.1093/database/bat021.
 588. Giral M, Foucher Y, Dufay A, et al. Pretransplant sensitization against 
angiotensin II type 1 receptor is a risk factor for acute rejection and 
graft loss. Am J Transplant. 2013; 13: 2567–2576.
 589. Taniguchi M, Rebellato LM, Cai J, et al. Higher risk of kidney graft 
failure in the presence of anti-angiotensin II type-1 receptor antibod-
ies. Am J Transplant. 2013; 13: 2577–2589.
 590. Alvarez-Marquez A, Aguilera I, Gentil MA, et al. Donor-specific anti-
bodies against HLA, MICA, and GSTT1 in patients with allograft 
rejection and C4d deposition in renal biopsies. Transplantation. 
2009; 87: 94–99.
 591. Terasaki PI, Ozawa M, Castro R. Four-year follow-up of a prospec-
tive trial of HLA and MICA antibodies on kidney graft survival. Am J 
Transplant. 2007; 7: 408–415.
 592. Zou Y, Stastny P, Susal C, et al. Antibodies against MICA anti-
gens and kidney-transplant rejection. N Engl J Med. 2007; 357: 
1293–1300.
 593. Mizutani K, Terasaki PI, Shih RN, et al. Frequency of MIC antibody 
in rejected renal transplant patients without HLA antibody. Hum 
Immunol. 2006; 67: 223–229.
 594. Praprotnik S, Blank M, Meroni PL, et al. Classification of anti-
endothelial cell antibodies into antibodies against microvascular 
and macrovascular endothelial cells: the pathogenic and diagnostic 
implications. Arthritis Rheum. 2001; 44: 1484–1494.
 595. Zitzner JR, Shah S, Jie C, et al. A prospective study evaluating the 
role of donor-specific anti-endothelial crossmatch (XM-ONE assay) 
in predicting living donor kidney transplant outcome. Hum Immunol. 
2013; 74: 1431–1436.
 596. Xavier P, Aires P, Sampaio S, et al. XM-ONE detection of endothelium 
cell antibodies identifies a subgroup of HLA-antibody negative patients 
undergoing acute rejection. Transplant Proc. 2011; 43: 91–94.
 597. Mizutani K, Terasaki P, Rosen A, et al. Serial ten-year follow-up of 
HLA and MICA antibody production prior to kidney graft failure. Am 
J Transplant. 2005; 5: 2265–2272.
 598. Yell M, Muth BL, Kaufman DB, et al. C1q Binding Activity of De Novo 
Donor-specific HLA Antibodies in Renal Transplant Recipients With 
and Without Antibody-mediated Rejection. Transplantation. 2015; 
99: 1151–1155.
 599. Otten HG, Verhaar MC, Borst HP, et al. Pretransplant donor-specific 
HLA class-I and -II antibodies are associated with an increased risk 
for kidney graft failure. Am J Transplant. 2012; 12: 1618–1623.
 600. Crespo M, Torio A, Mas V, et al. Clinical relevance of pretransplant 
anti-HLA donor-specific antibodies: does C1q-fixation matter? 
Transpl Immunol. 2013; 29: 28–33.
 601. Lowe D, Higgins R, Zehnder D, et al. Significant IgG subclass het-
erogeneity in HLA-specific antibodies: Implications for pathogenic-
ity, prognosis, and the rejection response. Hum Immunol. 2013; 74: 
666–672.
 602. Lefaucheur C, Viglietti D, Bentlejewski C, et al. IgG Donor-
Specific Anti-Human HLA Antibody Subclasses and Kidney 
Allograft Antibody-Mediated Injury. J Am Soc Nephrol. 2016; 27: 
293–304.
 603. Arnold ML, Ntokou IS, Doxiadis, II, et al. Donor-specific HLA anti-
bodies: evaluating the risk for graft loss in renal transplant recipients 
with isotype switch from complement fixing IgG1/IgG3 to noncom-
plement fixing IgG2/IgG4 anti-HLA alloantibodies. Transpl Int. 2014; 
27: 253–261.
 604. Guidicelli G, Guerville F, Lepreux S, et al. Non-Complement-Binding 
De Novo Donor-Specific Anti-HLA Antibodies and Kidney Allograft 
Survival. J Am Soc Nephrol. 2016; 27: 615–625.
 605. Ginevri F, Nocera A, Comoli P, et al. Posttransplant de novo donor-
specific hla antibodies identify pediatric kidney recipients at risk 
for late antibody-mediated rejection. Am J Transplant. 2012; 12: 
3355–3362.
 606. Wiebe C, Gareau AJ, Pochinco D, et al. Evaluation of C1q Status 
and Titer of De Novo Donor-Specific Antibodies as Predictors of 
Allograft Survival. Am J Transplant. 2017; 17: 703–711.
 607. Comoli P, Cioni M, Tagliamacco A, et al. Acquisition of C3d-Binding 
Activity by De Novo Donor-Specific HLA Antibodies Correlates 
With Graft Loss in Nonsensitized Pediatric Kidney Recipients. Am J 
Transplant. 2016; 16: 2106–2116.
 608. Loupy A, Lefaucheur C, Vernerey D, et al. Complement-binding anti-
HLA antibodies and kidney-allograft survival. N Engl J Med. 2013; 
369: 1215–1226.
 609. Tambur AR, Herrera ND, Haarberg KM, et al. Assessing Antibody 
Strength: Comparison of MFI, C1q, and Titer Information. Am J 
Transplant. 2015; 15: 2421–2430.
 610. Gloor JM, DeGoey S, Ploeger N, et al. Persistence of low levels of 
alloantibody after desensitization in crossmatch-positive living-donor 
kidney transplantation. Transplantation. 2004; 78: 221–227.
 611. Stegall MD, Park WD, Larson TS, et al. The histology of solitary renal 
allografts at 1 and 5 years after transplantation. Am J Transplant. 
2011; 11: 698–707.
 612. Gloor JM, Winters JL, Cornell LD, et al. Baseline donor-specific anti-
body levels and outcomes in positive crossmatch kidney transplan-
tation. Am J Transplant. 2010; 10: 582–589.
 613. Ferrari P, de Klerk M. Paired kidney donations to expand the living 
donor pool. J Nephrol. 2009; 22: 699–707.
 614. Ferrari P, Fidler S, Wright J, et al. Virtual crossmatch approach to 
maximize matching in paired kidney donation. Am J Transplant. 
2011; 11: 272–278.
 615. Ferrari P, Woodroffe C, Christiansen FT. Paired kidney donations to 
expand the living donor pool: the Western Australian experience. 
Med J Aust. 2009; 190: 700–703.
 616. Lucan M. Five years of single-center experience with paired 
kidney exchange transplantation. Transplant Proc. 2007; 39: 
1371–1375.
 617. Montgomery RA, Gentry SE, Marks WH, et al. Domino paired kidney 
donation: a strategy to make best use of live non-directed donation. 
Lancet. 2006; 368: 419–421.
 618. Roodnat JI, Zuidema W, van de Wetering J, et al. Altruistic donor 
triggered domino-paired kidney donation for unsuccessful couples 
from the kidney-exchange program. Am J Transplant. 2010; 10: 
821–827.
 619. Roth AE, Sonmez T, Unver MU, et al. Utilizing list exchange and 
nondirected donation through ‘chain’ paired kidney donations. Am J 
Transplant. 2006; 6: 2694–2705.
 620. Waki K, Terasaki PI. Paired kidney donation by shipment of living 
donor kidneys. Clin Transplant. 2007; 21: 186–191.
 621. Ferrari P, Weimar W, Johnson RJ, et al. Kidney paired donation: prin-
ciples, protocols and programs. Nephrol Dial Transplant. 2015; 30: 
1276–1285.
© 2020 Wolters Kluwer  S97
 622. Manook M, Koeser L, Ahmed Z, et al. Post-listing survival for 
highly sensitised patients on the UK kidney transplant waiting list: a 
matched cohort analysis. Lancet. 2017; 389: 727–734.
 623. Orandi BJ, Garonzik-Wang JM, Massie AB, et al. Quantifying the 
risk of incompatible kidney transplantation: a multicenter study. Am 
J Transplant. 2014; 14: 1573–1580.
 624. Montgomery RA, Lonze BE, King KE, et al. Desensitization in HLA-
incompatible kidney recipients and survival. N Engl J Med. 2011; 
365: 318–326.
 625. Marfo K, Lu A, Ling M, et al. Desensitization protocols and their out-
come. Clin J Am Soc Nephrol. 2011; 6: 922–936.
 626. Montgomery RA. Renal transplantation across HLA and ABO anti-
body barriers: integrating paired donation into desensitization proto-
cols. Am J Transplant. 2010; 10: 449–457.
 627. Sivakumaran P, Vo AA, Villicana R, et al. Therapeutic plasma 
exchange for desensitization prior to transplantation in ABO-
incompatible renal allografts. J Clin Apher. 2009; 24: 155–160.
 628. Vo AA, Lukovsky M, Toyoda M, et al. Rituximab and intravenous 
immune globulin for desensitization during renal transplantation. N 
Engl J Med. 2008; 359: 242–251.
 629. Stegall MD, Gloor J, Winters JL, et al. A comparison of plasmapher-
esis versus high-dose IVIG desensitization in renal allograft recipi-
ents with high levels of donor specific alloantibody. Am J Transplant. 
2006; 6: 346–351.
 630. Orandi BJ, Luo X, Massie AB, et al. Survival Benefit with Kidney 
Transplants from HLA-Incompatible Live Donors. N Engl J Med. 
2016; 374: 940–950.
 631. Woodle ES, Shields AR, Ejaz NS, et al. Prospective iterative trial of 
proteasome inhibitor-based desensitization. Am J Transplant. 2015; 
15: 101–118.
 632. Gloor JM, Moore SB, Schneider BA, et al. The effect of antithymo-
cyte globulin on anti-human leukocyte antigen antibody detection 
assays. Transplantation. 2007; 84: 258–264.
 633. Tambur AR, Campbell P, Claas FH, et al. Sensitization in 
Transplantation: Assessment of Risk (STAR) 2017 Working Group 
Meeting Report. Am J Transplant. 2018; 18: 1604–1614.
 634. Tait BD, Susal C, Gebel HM, et al. Consensus guidelines on the 
testing and clinical management issues associated with HLA and 
non-HLA antibodies in transplantation. Transplantation. 2013; 95: 
19–47.
S98 Transplantation  ■  April 2020  ■ Volume 104  ■  Number 4S www.transplantjournal.com
Appendix: Biographic and Disclosure Information
WORK GROUP
 Steven J. Chadban, BMed (hons), 
PhD, FAAHMS, FRACP (Work Group 
Co-Chair), received the University 
Medal for Medicine at the University 
of Newcastle and completed physician 
training in Newcastle, Nephrology 
training and his PhD at Monash, 
Victoria, Australia. Following his 
PhD, Dr. Chadban took a postdoctoral 
position studying immunology at the 
University of Cambridge, UK. He later returned to Monash 
University to run the Transplantation Program from 1999–
2002 before moving to the Royal Prince Alfred Hospital, 
Sydney, Australia, where he is currently area director of renal 
medicine, senior staff nephrologist, professor of medicine 
(nephrology) and leader of the Kidney Node, Charles Perkins 
Centre at the University of Sydney.
Professor Chadban is past-president of the Transplantation 
Society of Australia and New Zealand and councilor of The 
Transplantation Society (Oceania Rep), executive member of 
ANZDATA and a lead investigator in the CARSK and 
AusDiab (Australian Diabetes, Obesity and Lifestyle Study) 
Kidney Studies. Chadban’s lab has been continuously sup-
ported by grant income from National Health and Medical 
Research Council since 2004 and he also advises the govern-
ment as Chair of the Transplant Liason Reference Group 
(Organ and Tissue Authority) and National Vascular Diseases 
Advisory Group/CKD (Australian Institute of Health and 
Welfare). Dr. Chadban is associate editor for Transplantation 
and has authored over 250 publications including in journals 
such as the New England Journal of Medicine, Journal of the 
American Medical Association, Lancet and the Journal of 
Clinical Investigation. He has lectured at numerous national 
and international meetings and his works have been cited 
14,197 times with an H-index of 59. His research interests 
include CKD and ESKD epidemiology; the molecular mecha-
nisms of transplant rejection and CKD, with a focus on innate 
immunity; and improving outcomes for kidney transplant 
recipients through clinical trials. Dr. Chadban reported no rel-
evant financial relationships.
Gregroy A. Knoll, MD, MSc, 
FRCPC (Work Group Co-Chair), is 
head of the Division of Nephrology 
at the Ottawa Hospital and full pro-
fessor of medicine at the University of 
Ottawa, Canada. He currently holds 
the University of Ottawa Chair in 
Clinical Transplantation Research and 
is a senior scientist with the Clinical 
Epidemiology Program of the Ottawa 
Hospital Research Institute. Dr. Knoll 
completed his nephrology fellowship at the University of 
Ottawa followed by a kidney transplant fellowship at the 
University of Alabama at Birmingham. Following this training 
he took further graduate work and received a master’s degree 
in Epidemiology. For over 15 years he was the medical direc-
tor of kidney transplantation at the Ottawa Hospital and he 
assumed his current position as Nephrology Division head in 
2016. Dr. Knoll is a past-president of the Canadian Society of 
Transplantation. His present research interests involve ongo-
ing studies related to cardiac screening in kidney transplant 
candidates, systematic reviews on immunosuppressive strate-
gies, and measuring quality in transplantation. He was the lead 
author on the Canadian Society of Transplantation consensus 
guidelines on eligibility for kidney transplantation and he is 
currently serving as a Work Group member on the KDIGO 
Clinical Practice Guideline Update on Blood Pressure. Grant/
Research Support: Canadian Institutes of Health Research*. 
*monies paid to institution
Curie Ahn, MD, PhD, is a nephrol-
ogist from Seoul, Korea with a special 
interest in transplantation. After grad-
uating from the College of Medicine 
of Seoul National University Hospital 
(SNUH), she was clinically trained 
there as an internist and a nephrol-
ogy specialist. From 1986 to 1988, 
Dr. Ahn worked as a nephrology fel-
low at the University of Cincinnati 
Medical Center. Immediately after 
until 1992, she studied immunology 
at The Scripps Research Institute in 
La Jolla, California as a research fellow.
After returning to Korea, Dr. Ahn began working at her 
alma mater, the College of Medicine of SNUH, as a professor 
of nephrology. Concurrently, she also served as the director of 
the Division of Nephrology, director of the Transplantation 
Center, and director of the Transplantation Research Institute 
of SNUH. Currently, she is the director of the Department of 
Graduate School of Translational Medicine, and director of 
the Designed Animal and Transplantation Research Institute 
in Seoul National University.
Dr. Ahn was the chair of the Korean Society for Transplantation 
and has actively promoted deceased organ transplantation in 
Korea. As a leading core member of the Society, she was instru-
mental in revising the Organ Transplantation Law as well as 
participating in important organizations that promote deceased 
organ donation. As the Chief Executive Officer of the Korean 
Transplantation Registry (KOTRY), she leads the major trans-
plantation cohort project in Korea. Internationally, Dr. Ahn is 
an executive council member of Women in Transplantation 
(WIT) and the Declaration of Istanbul Custodian Group 
(DICG) of the Transplantation Society.
Currently, she is the president of the Korean Xenotransplan-
tation Association (KXA) and a member in the International 
Xenotransplantation Association (IXA). For the past 10 years, 
she has also been actively working in Mongolia and Myanmar 
to advance clinical capacity building in nephrology and trans-
plantation. Dr. Ahn reported no relevant financial relationships.
David A. Axelrod, MD, MBA, 
FACS, has two decades of experi-
ence in transplant clinical leadership, 
business development, health services 
research and economic assessment. He 
currently serves as professor of sur-
gery and surgical director of Kidney, 
Pancreas, and Living Donor Surgery 
at the University of Iowa. In addition, 
he is the chairman of the Standards 
Committee for American Society of 
Transplant Surgeons (ASTS), past 
chairman of the Business Practice 
© 2020 Wolters Kluwer  S99
Committee and creator of the ASTS Leadership Development 
Program. He has also served as the Pancreas Committee 
chairman and counselor for Region 1 for the United Network 
for Organ Sharing. Dr. Axelrod is a nationally recognized 
leader in transplant economics and management. Consultant: 
CareDx. Speaker: CareDx. Stock/Stock Options: CareDx. 
Other: Spouse is employed by CareDx.
Bethany J. Foster, MD, MSCE, 
is the director of the Division 
of Pediatric Nephrology at the 
Montreal Children’s Hospital of the 
McGill University Health Centre and 
a professor of pediatrics at McGill 
University, Canada. She is also a 
clinical epidemiologist and an asso-
ciate member of the Department 
of Epidemiology, Biostatistics and 
Occupational Health at McGill 
University. Her primary research 
interest is in the long-term outcomes of children and young 
adults with kidney transplants. Dr. Foster has been funded 
by Canadian Institutes of Health Research and US National 
Institutes of Health to study immunosuppressive medication 
adherence and graft outcomes in adolescent and young adult 
kidney transplant recipients. Her work has been instrumen-
tal in determining the association between age and graft fail-
ure risk among kidney, liver, and heart transplant recipients. 
She showed that across all three organ groups, late adoles-
cents and young adults have the highest risk for graft loss of 
all ages. Dr. Foster also led the successful TAKE-IT study, a 
multi-center, randomized trial of an intervention to improve 
immunosuppressive medication adherence in adolescents and 
young adults.
Dr. Foster is a member of the Board of Directors of 
the Canadian Society of Transplantation, and a member 
of the Canadian Donation and Transplantation Research 
Program. Dr. Foster reported no relevant financial 
relationships.
Bertram L. Kasiske, MD, FACP, 
obtained his undergraduate training 
at Michigan State University, East 
Lansing, MI, USA. He received his 
medical degree from the University of 
Iowa, Iowa City, IA, USA and com-
pleted an internal medicine residency 
and fellowship training in nephrology 
at Hennepin County Medical Center, 
an affiliate hospital of the University 
of Minnesota in Minneapolis, USA. 
Dr. Kasiske is former deputy direc-
tor of the United States (US) Renal Data System, former 
Editor-in-Chief of the American Journal of Kidney Diseases, 
and former Co-Chair of Kidney Disease: Improving Global 
Outcomes (KDIGO). Dr. Kasiske recently stepped down from 
being director of nephrology at Hennepin County Medical 
Center for 23 years. He was also the director of the Scientific 
Registry of Transplant Recipients (SRTR) for 9 years, and 
still serves as a senior staff member of the SRTR, which is 
a federal registry of solid organ transplants in the US. His 
research interests currently focus on living donors, and he has 
conducted a long term, prospective, controlled study of liv-
ing kidney donors sponsored by the US National Institutes of 
Health. He is also currently conducting a pilot study to estab-
lish a registry of living kidney and living liver donors in the 
US. Grant/Research Support: Health Resources and Services 
Administration, Hennepin Healthcare Research Institute.
Vijay Kher, MD, DM, FAMS, 
FRCPE, FIMAS, is chairman, 
Division of Nephrology & Renal 
Transplant Medicine, Medatna – The 
Medicity, Gurgaon, India and was 
President of the Indian Society of 
Nephrology (2016-2017). Prof. Kher 
has established academic and clinical 
departments of Nephrology at Shere-
Kashmir, Institute of Medical Sciences 
in Srinagar; Sanjay Gandhi Post 
Graduate Institute, Lucknow; Apollo Hospitals, New Delhi; 
Fortis Group of Hospitals NCR, Delhi; and Medanta – the 
Medicity Gurgaon, during the past 30 years.
His research interests include kidney transplantation (clini-
cal immunosuppression, ABO incompatible transplantation, 
paired exchange donation, and cost containment), progres-
sion of kidney disease, acute kidney injury and glomerulone-
phritis. An astute clinician, a teacher par excellence and a keen 
researcher, Prof. Kher combines these assets with a friendly 
and inclusive demeanor to inspire the nephrology fraternity 
in India and abroad by his professional dedication, academic 
excellence and social responsibility.
Dr. Kher has been awarded fellowships by the National 
Academy of Medical Sciences, India; Royal College of 
Physicians, Edinburg; Indian Society of Nephrology and 
received numerous orations from various scientific societies. He 
has published more than 200 papers in peer reviewed journals, 
authored 43 book chapters and edited 12 books. Consultant: 
Biocon Pharmaceuticals, India; Intas Pharmaceuticals, 
India; Novartis, India; Panacea Pharma, India; Roche, 
India; Sanofi Aventis, India; Torrent Pharmaceuticals, India. 
Grant/Research Support: Astellas, India*; Novartis, India*; 
Sanofi Aventis, India*. Expert Testimony/Scientific Adviser: 
Biocon Pharmaceuticals, India; Medtronic, India; Novartis, 
India; Dr. Reddy’s Laboratories, India; Roche, India; Sanofi 
Aventis, India; Torrent Pharmaceuticals, India; Wockhardt, 
India. Speaker: Biocon Pharmaceuticals, India; Intas 
Pharmaceuticals, India; JB Chemicals & Pharmaceuticals, 
India; Johnson and Johnson, India; Novartis, India; Panacea 
Pharma, India; Pfizer, India; Roche, India; Sanofi Aventis, 
India. *monies paid to institution
Deepali Kumar, MD, MSc, FRCPC, 
FAST, is professor of medicine at 
the University of Toronto, Canada. 
She is attending physician in the 
Multi-Organ Transplant Program, 
Transplant Infectious Diseases service 
at the University Health Network. Dr. 
Kumar obtained her medical degree 
from the University of Ottawa and 
completed infectious disease training 
at the University of California-San 
Diego, USA and McMaster University, Canada. She further 
acquired a Masters degree with a focus in transplantation at 
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at the Hospital del Mar, 
Barcelona, Spain, and Professor 
at Universidad Autónoma, 
Barcelona. He is also the chief 
of the Kidney Diseases Research 
Group at the Biomedical 
Research Park in Barcelona.
He undertook his residency at the Department of 
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James R. Rodrigue, PhD, FAST, 
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health services to improve the lives of transplant patients and 
living donors. In 2017, he received the AST’s Clinician of 
Distinction Award in recognition of his outstanding contribu-
tions to clinical transplantation.
Currently, Dr. Rodrigue is principal investigator on five 
federally funded clinical research grants in transplantation. 
He has been primary investigator or co-investigator on over 
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(VCA) Committee (2015-2017), and Living Donor Committee 
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criteria, and pediatric deceased donation.
He is an avid Boston sports fan, loves to golf, and enjoys 
traveling. Speaker: Sanofi.
Dorry L. Segev, MD, PhD, 
is the Marjory K. and Thomas 
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